0001493152-24-014864.txt : 20240416 0001493152-24-014864.hdr.sgml : 20240416 20240416171457 ACCESSION NUMBER: 0001493152-24-014864 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 78 CONFORMED PERIOD OF REPORT: 20231231 FILED AS OF DATE: 20240416 DATE AS OF CHANGE: 20240416 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Bright Green Corp CENTRAL INDEX KEY: 0001886799 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41395 FILM NUMBER: 24848666 BUSINESS ADDRESS: STREET 1: 401 EAST LAS OLAS BLVD. STREET 2: SUITE 1400 CITY: FT. LAUDERDALE STATE: FL ZIP: 33301 BUSINESS PHONE: (201)370-1140 MAIL ADDRESS: STREET 1: 401 EAST LAS OLAS BLVD. STREET 2: SUITE 1400 CITY: FT. LAUDERDALE STATE: FL ZIP: 33301 10-K 1 form10-k.htm
false FY 0001886799 0 149 0001886799 2023-01-01 2023-12-31 0001886799 2023-06-30 0001886799 2024-04-11 0001886799 2023-12-31 0001886799 2022-12-31 0001886799 us-gaap:RelatedPartyMember 2023-12-31 0001886799 us-gaap:RelatedPartyMember 2022-12-31 0001886799 2022-01-01 2022-12-31 0001886799 us-gaap:CommonStockMember 2021-12-31 0001886799 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001886799 us-gaap:RetainedEarningsMember 2021-12-31 0001886799 2021-12-31 0001886799 us-gaap:CommonStockMember 2022-12-31 0001886799 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001886799 us-gaap:RetainedEarningsMember 2022-12-31 0001886799 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001886799 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001886799 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001886799 us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001886799 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-12-31 0001886799 us-gaap:RetainedEarningsMember 2023-01-01 2023-12-31 0001886799 us-gaap:CommonStockMember 2023-12-31 0001886799 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001886799 us-gaap:RetainedEarningsMember 2023-12-31 0001886799 us-gaap:PrivatePlacementMember srt:MaximumMember 2023-02-01 2023-02-01 0001886799 us-gaap:PrivatePlacementMember 2023-02-01 0001886799 us-gaap:CommonStockMember BGXX:AccreditedInvestorAndExistingStockholderMember 2023-05-20 2023-05-21 0001886799 us-gaap:CommonStockMember BGXX:AccreditedInvestorAndExistingStockholderMember 2023-05-21 0001886799 BGXX:AccreditedInvestorAndExistingStockholderMember us-gaap:PrivatePlacementMember 2023-05-21 0001886799 us-gaap:BuildingAndBuildingImprovementsMember 2023-12-31 0001886799 us-gaap:FurnitureAndFixturesMember 2023-12-31 0001886799 srt:MinimumMember 2023-12-31 0001886799 srt:MaximumMember 2023-12-31 0001886799 BGXX:SettlementAndReleaseAgreementMember us-gaap:SubsequentEventMember 2024-03-13 2024-03-13 0001886799 BGXX:AlterolaBiotechIncMember 2022-10-03 0001886799 BGXX:AlterolaBiotechIncMember BGXX:SellersMember 2022-10-03 0001886799 BGXX:AlterolaBiotechIncMember BGXX:SellersMember 2022-10-02 2022-10-03 0001886799 BGXX:SellersMember 2023-12-31 0001886799 BGXX:SellersMember 2022-12-31 0001886799 BGXX:AlterolaBiotechIncMember BGXX:SellersMember us-gaap:SubsequentEventMember 2024-03-13 2024-03-13 0001886799 BGXX:VotingAgreementMember 2023-01-01 2023-12-31 0001886799 BGXX:AlterolaBiotechIncMember 2023-12-31 0001886799 BGXX:AlterolaBiotechIncMember 2023-09-30 0001886799 BGXX:AlterolaBiotechIncMember 2022-12-31 0001886799 BGXX:AlterolaBiotechIncMember 2023-01-01 2023-09-30 0001886799 BGXX:AlterolaBiotechIncMember 2022-01-01 2022-12-31 0001886799 BGXX:AlterolaBiotechIncMember 2021-12-31 0001886799 BGXX:AlterolaBiotechIncMember 2022-01-01 2022-12-31 0001886799 BGXX:AlterolaBiotechIncMember 2022-12-31 0001886799 BGXX:AlterolaBiotechIncMember 2023-01-01 2023-12-31 0001886799 BGXX:VenloStyleGreenHouseMember BGXX:NMMember 2023-12-31 0001886799 BGXX:NMMember 2022-12-31 0001886799 us-gaap:ConstructionInProgressMember 2023-12-31 0001886799 us-gaap:ConstructionInProgressMember 2022-12-31 0001886799 us-gaap:SubsequentEventMember 2024-01-19 2024-01-19 0001886799 BGXX:GrantGreenhouseGrowersIncMember BGXX:RealEstateOptionAgreementOneMember 2020-10-05 2020-10-05 0001886799 BGXX:GrantGreenhouseGrowersIncMember BGXX:RealEstateOptionAgreementOneMember 2020-10-05 2021-06-30 0001886799 BGXX:GrantGreenhouseGrowersIncMember BGXX:RealEstateOptionAgreementOneMember 2021-07-01 2021-12-31 0001886799 BGXX:GrantGreenhouseGrowersIncMember BGXX:RealEstateOptionAgreementOneMember 2022-01-01 2022-01-01 0001886799 BGXX:GrantGreenhouseGrowersIncMember BGXX:RealEstateOptionAgreementOneMember 2022-01-01 0001886799 BGXX:GrantGreenhouseGrowersIncMember BGXX:RealEstateOptionAgreementTwoMember 2020-10-21 2020-10-21 0001886799 BGXX:GrantGreenhouseGrowersIncMember BGXX:RealEstateOptionAgreementTwoMember 2021-01-01 2021-12-31 0001886799 BGXX:GrantGreenhouseGrowersIncMember BGXX:RealEstateOptionAgreementTwoMember 2022-01-01 2022-01-01 0001886799 BGXX:GrantGreenhouseGrowersIncMember BGXX:RealEstateOptionAgreementTwoMember 2022-01-01 0001886799 us-gaap:EquipmentMember 2022-12-31 0001886799 us-gaap:EquipmentMember 2022-01-01 2022-12-31 0001886799 BGXX:UnsecuredLineOfCreditMember BGXX:LDSCapitalLLCMember srt:MaximumMember 2022-06-05 0001886799 BGXX:UnsecuredLineOfCreditMember BGXX:LDSCapitalLLCMember 2022-06-05 0001886799 BGXX:UnsecuredLineOfCreditMember us-gaap:PrimeRateMember BGXX:LDSCapitalLLCMember 2022-06-05 0001886799 BGXX:AmendedUnsecuredLineOfCreditMember 2022-11-14 0001886799 BGXX:UnsecuredLineOfCreditMember BGXX:LDSCapitalLLCMember 2023-01-01 2023-12-31 0001886799 BGXX:UnsecuredLineOfCreditMember BGXX:LDSCapitalLLCMember 2022-01-01 2022-12-31 0001886799 BGXX:UnsecuredLineOfCreditMember BGXX:LDSCapitalLLCMember us-gaap:ConstructionInProgressMember 2023-12-31 0001886799 BGXX:UnsecuredLineOfCreditMember BGXX:LDSCapitalLLCMember 2023-12-31 0001886799 BGXX:UnsecuredLineOfCreditMember BGXX:LDSCapitalLLCMember 2022-12-31 0001886799 2023-02-01 2023-02-01 0001886799 2023-02-06 2023-02-06 0001886799 2023-02-06 0001886799 2023-03-14 2023-03-14 0001886799 2023-08-31 0001886799 2023-08-31 2023-08-31 0001886799 2023-12-01 2023-12-01 0001886799 2023-12-01 0001886799 BGXX:OneAccreditedInvestorMember 2023-02-01 2023-02-28 0001886799 BGXX:OneAccreditedInvestorMember 2023-02-28 0001886799 us-gaap:CommonStockMember BGXX:BoardMemberMember 2023-02-01 2023-02-28 0001886799 us-gaap:CommonStockMember BGXX:BoardMemberMember 2023-02-28 0001886799 2023-02-01 2023-02-28 0001886799 us-gaap:CommonStockMember BGXX:OneAccreditedInvestorMember 2023-03-01 2023-03-31 0001886799 us-gaap:CommonStockMember BGXX:OneAccreditedInvestorMember 2023-03-31 0001886799 us-gaap:CommonStockMember BGXX:ExecutiveChairmanMember 2023-03-01 2023-03-31 0001886799 us-gaap:CommonStockMember BGXX:ExecutiveChairmanMember 2023-03-31 0001886799 us-gaap:CommonStockMember srt:ChiefExecutiveOfficerMember 2023-05-01 2023-05-31 0001886799 us-gaap:CommonStockMember srt:ChiefExecutiveOfficerMember 2023-05-31 0001886799 us-gaap:PrivatePlacementMember 2023-05-01 2023-05-31 0001886799 us-gaap:PrivatePlacementMember 2023-05-31 0001886799 us-gaap:CommonStockMember BGXX:ExecutiveChairmanMember 2023-06-01 2023-06-30 0001886799 us-gaap:CommonStockMember BGXX:ExecutiveChairmanMember 2023-06-30 0001886799 us-gaap:CommonStockMember BGXX:ConsultantMember 2023-07-01 2023-07-31 0001886799 us-gaap:CommonStockMember BGXX:ConsultantMember 2023-07-31 0001886799 2023-09-01 2023-09-30 0001886799 us-gaap:WarrantMember 2023-09-30 0001886799 us-gaap:CommonStockMember 2023-09-30 0001886799 us-gaap:CommonStockMember BGXX:ConsultantMember 2023-09-01 2023-09-30 0001886799 us-gaap:CommonStockMember BGXX:ConsultantMember 2023-09-30 0001886799 us-gaap:CommonStockMember srt:ChiefFinancialOfficerMember 2023-09-01 2023-09-30 0001886799 us-gaap:CommonStockMember srt:ChiefFinancialOfficerMember 2023-09-30 0001886799 us-gaap:CommonStockMember BGXX:ExecutiveChairmanMember 2023-09-01 2023-09-30 0001886799 us-gaap:CommonStockMember BGXX:ExecutiveChairmanMember 2023-09-30 0001886799 us-gaap:CommonStockMember srt:DirectorMember 2023-11-01 2023-11-30 0001886799 us-gaap:CommonStockMember srt:DirectorMember 2023-11-30 0001886799 us-gaap:CommonStockMember BGXX:DirectorOneMember 2023-11-01 2023-11-30 0001886799 us-gaap:CommonStockMember BGXX:DirectorTwoMember 2023-11-01 2023-11-30 0001886799 us-gaap:CommonStockMember BGXX:DirectorThreeMember 2023-11-01 2023-11-30 0001886799 us-gaap:CommonStockMember BGXX:ExecutiveChairmanMember 2023-12-01 2023-12-31 0001886799 us-gaap:CommonStockMember BGXX:ExecutiveChairmanMember 2023-12-31 0001886799 us-gaap:CommonStockMember BGXX:OneAccreditedInvestorMember 2022-01-01 2022-01-31 0001886799 us-gaap:CommonStockMember BGXX:OneAccreditedInvestorMember 2022-01-31 0001886799 us-gaap:CommonStockMember srt:ChiefFinancialOfficerMember 2022-04-01 2022-04-30 0001886799 us-gaap:CommonStockMember srt:ChiefFinancialOfficerMember 2022-04-30 0001886799 us-gaap:CommonStockMember us-gaap:PrivatePlacementMember 2022-04-30 0001886799 us-gaap:CommonStockMember BGXX:SixConsultantsMember 2022-04-01 2022-04-30 0001886799 us-gaap:CommonStockMember BGXX:SixConsultantsMember 2022-04-30 0001886799 us-gaap:CommonStockMember us-gaap:PrivatePlacementMember BGXX:SixConsultantsMember 2022-04-30 0001886799 us-gaap:CommonStockMember BGXX:DirectorsMember 2022-04-01 2022-04-30 0001886799 us-gaap:CommonStockMember BGXX:DirectorsMember 2022-04-30 0001886799 us-gaap:CommonStockMember BGXX:TwoAccreditedInvestorMember 2022-05-01 2022-05-31 0001886799 us-gaap:CommonStockMember BGXX:TwoAccreditedInvestorMember 2022-05-31 0001886799 us-gaap:CommonStockMember BGXX:ConsultantsMember 2022-06-01 2022-06-30 0001886799 us-gaap:CommonStockMember BGXX:ConsultantsMember 2022-06-30 0001886799 us-gaap:WarrantMember 2023-01-01 2023-09-30 0001886799 us-gaap:CommonStockMember srt:ChiefExecutiveOfficerMember 2022-12-01 2022-12-31 0001886799 BGXX:CommonStockOneMember srt:ChiefExecutiveOfficerMember 2022-12-01 2022-12-31 0001886799 BGXX:CommonStockOneMember srt:ChiefExecutiveOfficerMember 2022-12-31 0001886799 BGXX:CommonStockTwoMember srt:ChiefExecutiveOfficerMember 2022-12-01 2022-12-31 0001886799 BGXX:CommonStockTwoMember srt:ChiefExecutiveOfficerMember 2022-12-31 0001886799 BGXX:CommonStockThreeMember srt:ChiefExecutiveOfficerMember 2022-12-01 2022-12-31 0001886799 BGXX:CommonStockThreeMember srt:ChiefExecutiveOfficerMember 2022-12-31 0001886799 us-gaap:PrivatePlacementMember BGXX:SecuritiesPurchaseAgreementMember 2022-09-07 2022-09-07 0001886799 us-gaap:PrivatePlacementMember BGXX:SecuritiesPurchaseAgreementMember 2022-09-07 0001886799 us-gaap:PrivatePlacementMember 2022-09-07 2022-09-12 0001886799 2022-09-07 2022-09-07 0001886799 2022-09-21 2022-09-21 0001886799 2022-09-21 0001886799 BGXX:SecuritiesPurchaseAgreementMember 2023-05-21 0001886799 us-gaap:PrivatePlacementMember 2023-05-22 2023-05-24 0001886799 2023-05-01 2023-05-31 0001886799 us-gaap:PrivatePlacementMember 2022-09-07 0001886799 2022-09-06 0001886799 2022-09-12 0001886799 2022-09-07 2022-09-12 0001886799 us-gaap:WarrantMember us-gaap:PrivatePlacementMember 2023-05-01 2023-05-31 0001886799 us-gaap:WarrantMember us-gaap:PrivatePlacementMember 2023-05-31 0001886799 us-gaap:MeasurementInputExpectedTermMember us-gaap:WarrantMember us-gaap:PrivatePlacementMember 2023-05-31 0001886799 us-gaap:MeasurementInputOptionVolatilityMember us-gaap:WarrantMember us-gaap:PrivatePlacementMember 2023-05-31 0001886799 us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:WarrantMember us-gaap:PrivatePlacementMember 2023-05-31 0001886799 us-gaap:MeasurementInputExpectedDividendRateMember us-gaap:WarrantMember us-gaap:PrivatePlacementMember 2023-05-31 0001886799 us-gaap:WarrantMember us-gaap:PrivatePlacementMember srt:ScenarioForecastMember 2024-05-24 2024-05-24 0001886799 us-gaap:WarrantMember 2023-09-01 2023-09-30 0001886799 us-gaap:MeasurementInputExpectedTermMember us-gaap:WarrantMember 2023-09-30 0001886799 us-gaap:MeasurementInputOptionVolatilityMember us-gaap:WarrantMember 2023-09-30 0001886799 us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:WarrantMember 2023-09-30 0001886799 us-gaap:MeasurementInputExpectedDividendRateMember us-gaap:WarrantMember 2023-09-30 0001886799 us-gaap:WarrantMember 2023-09-01 2023-09-01 0001886799 BGXX:EquityCompensationPlanMember 2023-01-01 2023-12-31 0001886799 BGXX:EquityCompensationPlanMember 2022-01-01 2022-12-31 0001886799 us-gaap:RestrictedStockMember BGXX:EquityCompensationPlanMember 2023-12-31 0001886799 2023-09-20 2023-09-20 0001886799 2023-11-16 2023-11-16 0001886799 us-gaap:CommonStockMember srt:ChiefExecutiveOfficerMember us-gaap:SubsequentEventMember 2024-03-31 2024-03-31 0001886799 srt:ChiefExecutiveOfficerMember us-gaap:SubsequentEventMember 2024-03-31 2024-03-31 0001886799 srt:ChiefExecutiveOfficerMember us-gaap:SubsequentEventMember BGXX:MutualAgreementMember 2024-03-31 2024-03-31 0001886799 us-gaap:DomesticCountryMember 2023-12-31 0001886799 us-gaap:DomesticCountryMember 2022-12-31 0001886799 us-gaap:CommonStockMember BGXX:FormerExecutiveChairmanMember 2023-01-01 2023-12-31 0001886799 us-gaap:CommonStockMember srt:ChiefExecutiveOfficerMember 2023-01-01 2023-12-31 0001886799 us-gaap:CommonStockMember srt:ChiefFinancialOfficerMember 2023-01-01 2023-12-31 0001886799 BGXX:ThreeDirectorsMember 2023-01-01 2023-12-31 0001886799 srt:ChiefExecutiveOfficerMember us-gaap:RestrictedStockMember 2023-01-01 2023-12-31 0001886799 BGXX:ExecutiveChairmanMember us-gaap:AccruedLiabilitiesMember 2023-12-31 0001886799 BGXX:ExecutiveChairmanMember us-gaap:AccruedLiabilitiesMember 2022-12-31 0001886799 us-gaap:SubsequentEventMember us-gaap:CommonStockMember BGXX:FormerInterimChiefExecutiveOfficerMember 2024-02-15 2024-02-15 0001886799 BGXX:FormerChiefExecutiveOfficerMember us-gaap:AccountsPayableMember 2023-12-31 0001886799 srt:ChiefFinancialOfficerMember us-gaap:AccountsPayableMember 2023-12-31 0001886799 srt:ChiefFinancialOfficerMember us-gaap:AccountsPayableMember 2022-12-31 0001886799 srt:ChiefExecutiveOfficerMember us-gaap:AccountsPayableMember 2023-12-31 0001886799 srt:ChiefExecutiveOfficerMember us-gaap:AccountsPayableMember 2022-12-31 0001886799 BGXX:BoardOfDirectorsMember us-gaap:AccountsPayableMember 2023-12-31 0001886799 BGXX:BoardOfDirectorsMember us-gaap:AccountsPayableMember 2022-12-31 0001886799 srt:ChiefExecutiveOfficerMember 2023-01-01 2023-12-31 0001886799 us-gaap:SubsequentEventMember us-gaap:CommonStockMember BGXX:FourConsultantsMember 2024-01-30 2024-01-30 0001886799 us-gaap:SubsequentEventMember us-gaap:CommonStockMember BGXX:FourConsultantsMember 2024-01-30 0001886799 us-gaap:SubsequentEventMember BGXX:OntarioLtdMember 2024-02-07 2024-02-07 0001886799 us-gaap:SubsequentEventMember 2024-02-08 2024-02-08 0001886799 us-gaap:SubsequentEventMember us-gaap:CommonStockMember BGXX:SeparationAgreementMember BGXX:Mr.TerryRafihMember 2024-02-15 2024-02-15 0001886799 us-gaap:SubsequentEventMember us-gaap:CommonStockMember BGXX:SeparationAgreementMember BGXX:Mr.TerryRafihMember 2024-02-15 0001886799 us-gaap:SubsequentEventMember us-gaap:CommonStockMember BGXX:SeparationAgreementMember 2024-02-15 2024-02-15 0001886799 us-gaap:SubsequentEventMember BGXX:CFOAgreementMember BGXX:Mr.ElmasriMember BGXX:TitanAdvisoryServicesLLCMember 2024-03-07 2024-03-07 0001886799 BGXX:CreditAgreementMember us-gaap:SubsequentEventMember 2024-03-14 0001886799 us-gaap:SubsequentEventMember 2024-03-25 2024-03-25 0001886799 us-gaap:SubsequentEventMember BGXX:ExecutiveEmploymentAgreementMember 2024-10-02 2024-10-02 0001886799 us-gaap:SubsequentEventMember BGXX:ExecutiveEmploymentAgreementMember 2024-10-03 2025-10-02 0001886799 us-gaap:SubsequentEventMember BGXX:ExecutiveEmploymentAgreementMember 2025-10-03 2026-10-02 0001886799 us-gaap:RestrictedStockMember us-gaap:SubsequentEventMember 2024-03-31 0001886799 us-gaap:SubsequentEventMember BGXX:ExecutiveEmploymentAgreementMember 2024-03-31 2024-03-31 0001886799 us-gaap:SubsequentEventMember BGXX:ExecutiveEmploymentAgreementMember us-gaap:RestrictedStockUnitsRSUMember 2024-03-31 2024-03-31 0001886799 us-gaap:SubsequentEventMember BGXX:ExecutiveEmploymentAgreementAgreementMember 2024-04-02 2024-04-02 0001886799 us-gaap:SubsequentEventMember BGXX:ExecutiveEmploymentAgreementAgreementMember 2024-03-31 2024-03-31 0001886799 us-gaap:SubsequentEventMember 2024-04-05 2024-04-05 0001886799 us-gaap:SubsequentEventMember 2024-04-09 2024-04-09 0001886799 us-gaap:SubsequentEventMember 2024-04-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares utr:acre xbrli:pure

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-K

 

(Mark One)

☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the fiscal year ended December 31, 2023

 

OR

 

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
   
  FOR THE TRANSITION PERIOD FROM                     TO                     

 

Commission File Number: 001-41395

 

BRIGHT GREEN CORPORATION

(Exact name of Registrant as specified in its Charter)

 

Delaware   83-4600841

(State or other jurisdiction of

incorporation or organization)

  

(I.R.S. Employer

Identification No.)

 

1033 George Hanosh Boulevard

Grants, NM

   87020
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (833) 658-1799

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common stock, $0.0001 par value per share   BGXX   The Nasdaq Stock Market LLC

 

Securities registered pursuant to Section 12(g) of the Act: None

 

Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒

 

Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes ☐ No ☒

 

Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐ Accelerated filer ☐
Non-accelerated filer ☒ Smaller reporting company ☒
    Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐

 

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐

 

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

 

The aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant, based on the closing price of the shares of common stock on The Nasdaq Stock Market on June 30, 2023, was $75,060,837.

 

The number of shares of the registrant’s common stock outstanding as of April 11, 2024, was 190,166,318.

 

Documents Incorporated by Reference: Certain portions of the registrant’s definitive Proxy Statement for its 2024 Annual Meeting of Stockholders are incorporated by reference into Items 10, 11, 12, 13 and 14 of Part III of this Annual Report on Form 10-K.

 

 

 

 
 

 

Table of Contents

 

    Page
  References to Bright Green ii
  Special Note Regarding Forward-Looking Statements ii
  Trademarks and Tradenames iii
  Market Data and Forecasts iii
PART I    
Item 1. Business 1
Item 1A. Risk Factors 15
Item 1B. Unresolved Staff Comments 40
Item 1C. Cybersecurity 41
Item 2. Properties 41
Item 3. Legal Proceedings 42
Item 4. Mine Safety Disclosures 42
     
PART II    
Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 43
Item 6. [Reserved] 43
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations 43
Item 7A. Quantitative and Qualitative Disclosures about Market Risk 49
Item 8. Financial Statements and Supplementary Data 49
Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 49
Item 9A. Controls and Procedures 49
Item 9B. Other Information 51
Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 51
     
PART III    
Item 10. Directors, Executive Officers and Corporate Governance 52
Item 11. Executive Compensation 52
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 52
Item 13. Certain Relationships and Related Transactions, and Director Independence 52
Item 14. Principal Accountant Fees and Services 52
     
PART IV    
Item 15. Exhibits, Financial Statement Schedules 53
Item 16. Form 10-K Summary 55

 

i
 

 

References to Bright Green

 

Unless otherwise indicated in this Annual Report on Form 10-K (this “Annual Report”), “Bright Green Corporation,” “Bright Green,” “BGC,” “the Corporation,” “the Company,” “we,” “us” and “our” refer to Bright Green Corporation and its consolidated subsidiary.

 

Special Note Regarding Forward-Looking Statements

 

This Annual Report and the documents incorporated by reference herein may contain “forward-looking statements” within the meaning of the federal securities laws made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth below under Part I, Item 1A, “Risk Factors” in this Annual Report. Except as required by law, we assume no obligation to update these forward-looking statements, whether as a result of new information, future events or otherwise. These statements, which represent our current expectations or beliefs concerning various future events, may contain words such as “may,” “will,” “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate” or other words indicating future results, though not all forward-looking statements necessarily contain these identifying words. Such statements may include, but are not limited to, statements concerning the following:

 

  ● the initiation, design, cost, timing, progress and results of, and our expected ability to undertake certain activities and accomplish our goals;
  ● the likelihood or timing of any regulatory approval;
  ● our ability to successfully commercialize, and our expectations regarding commercial potential with respect to, our products;
  ● the rate and degree of market acceptance of our products;
  ● the size and growth potential of the markets for our products, and our ability to serve those markets;
  ● our ability to obtain and maintain intellectual property protection;
  ● interactions with regulatory authorities in the United States and foreign countries;
  ● our ability to attract and retain experienced and seasoned scientific and management professionals to lead the Company;
  ● the performance of our third-party suppliers and manufacturers, including our ability to scale-up manufacturing levels as necessary;
  ● our ability to attract collaborators with relevant development, regulatory and commercialization expertise;
  ● future activities to be undertaken by our strategic alliance partners, collaborators and other third parties;
  ● our ability to develop sales and marketing capabilities, whether alone or with potential future collaborators;
  ● our ability to avoid, settle or be victorious at costly litigation with shareholders, former executives or others, should these situations arise;
  ● our ability to obtain and deploy funding for our operations and to efficiently use our financial and other resources;
  ● our ability to maintain our listing on The Nasdaq Capital Market;
  ● our ability to continue as a going concern; and
  ● the accuracy of our estimates regarding future expenses, future revenues, capital requirements and need for additional financing.

 

ii
 

 

Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results or performance to differ materially from those projected. These statements are only current predictions and are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from those anticipated by the forward-looking statements. In addition, historic results of scientific research, preclinical and clinical trials do not guarantee that future research or trials will suggest the same conclusions, nor that historic results referred to herein will be interpreted the same in light of additional research, preclinical and clinical trial results. The forward-looking statements contained in this Annual Report are subject to risks and uncertainties, including those discussed in our other filings with the United States Securities and Exchange Commission (the “SEC”). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.

 

Trademarks and Tradenames

 

The Bright Green logo and other trademarks of Bright Green appearing in this Annual Report are the property of Bright Green. All other trademarks, service marks and trade names in this Annual Report are the property of their respective owners. Solely for convenience, trademarks and trade names referred to in this report may appear without the ® or ™ symbols.

 

Market Data and Forecasts

 

Unless otherwise indicated, information in this Annual Report concerning economic conditions, our industry, and our markets, including our general expectations and competitive position, market opportunity and market size, is based on a variety of sources, including information from independent industry analysts and publications, as well as our own estimates and research. Our estimates are derived from industry and general publications, studies and surveys conducted by third-parties, as well as data from our own internal research. These publications, studies and surveys generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information, and we have not independently verified industry data from such third-party sources. While we believe our internal research is reliable and that our internal estimates are reasonable, such research has not been verified by any independent source and our internal estimates are based on our good faith beliefs as of the respective dates of such estimates. We are responsible for all of the disclosure in this Annual Report.

 

iii
 

 

PART I

 

Item 1. Business.

 

Our Mission and Vision

 

Bright Green’s mission is to be the premier federally-authorized provider of plant-and fungi-based Active Pharmaceutical Ingredients (APIs) in North America. Our vision is to improve the quality of life across a broad spectrum of demographics through the opportunities presented by medicinal applications of plant-based products. Our Company’s focus is on sustainability, high-tech agriculture, and unlocking the potential for domestic production of plant-based medicines in the U.S. We plan to conduct significant research and development into the opportunities presented by medicinal applications of plant-based therapies, alongside human hormone replacement therapies and anti-aging applications. Our developments and products reflect our commitment to healthcare, reasonable costs for medicines, and sustainability.

 

Overview

 

We are a first-mover in the U.S. federally-authorized cannabis space. BGC is one of a few companies who have received from the U.S. Drug Enforcement Administration (the “DEA”), a federal controlled substances registration for the bulk manufacturing of cannabis under DEA Registration No. RB0649383 (the “DEA Registration”), which allows the Company to produce and export federally legal cannabis, cannabis extracts, and tetrahydrocannabinol in the U.S. We received the DEA Registration on April 28, 2023, pursuant to the Memorandum of Agreement (the “MOA”) with the DEA entered into on April 27, 2023, which replaced the 2021 Memorandum of Agreement (the “2021 MOA”) (DEA Document Control Number W20078135E). In May 2023, we received a second DEA Registration for Importing Schedule I Controlled Substances under DEA Registration No. RB0650754.

 

Unlike state-licensed cannabis companies who engage in commercial sales to consumers, and whose businesses are legal under state law but not federal law, subject to the milestones and requirements set forth herein, we are authorized by the federal government to sell cannabis commercially for research and manufacturing purposes, export cannabis for international cannabis research purposes, and sell cannabis to DEA-registered pharmaceutical companies for the production of medical cannabis products and preparations. Our business activities under the DEA Registration are subject to applicable federal law and regulations and to our obligations under the MOA we entered into with the DEA. Our DEA Registration is valid through July 31, 2024. For our cannabis business line, we plan to focus on the development of cannabis strains and sales of cannabis and hemp products with high contents of CBN (cannabinol) and CBG (cannabigerol).

 

In addition to research and pharmaceutical supply sales, Bright Green will be able to sell certain cannabinoids, such as CBN (cannabinol) and CBG (cannabigerol) as hemp isolates or extracts, and plans to sell CBN and CBG hemp products to consumers where such products are fully legal under all applicable laws. On August 9, 2022, the DEA confirmed to BGC that cannabinoids, including, but not limited to CBN/CBG, which meet the definition of “hemp” by having a Delta-9-tetrahydrocannabinol concentration of not more than 0.3 percent on a dry weight basis, are outside of the DEA’s jurisdiction because they are not controlled under the CSA. Hemp and hemp products were made legal by the Agriculture Improvement Act of 2018 (the “2018 Farm Bill”), which has been codified in 21 U.S.C. § 802(16)(B)(i), and 7 U.S.C. § 1639o. This hemp product business line will be in addition to our research and pharmaceutical cannabis activities conducted under the DEA Registration.

 

1
 

 

In addition to hemp and cannabis, we plan to manufacture additional plant-based medicines derived from controlled substance plants and fungi, including but not limited to, psilocybin, peyote cactus, and opium poppy as part of our “Drugs Made in America” strategy. In February 2024, we received approval from the New Mexico Board of Pharmacy to produce additional Schedule I and Schedule II controlled substances at our Grants, NM facility (NM Board of Pharmacy License Nos. CS02324187 and WD20220144). We have applied for an additional DEA Bulk Manufacturing Registration for these additional Schedule I and Schedule II controlled substances. Our decision to expand beyond cannabis to other plant-based medicines is in response to increased demand for additional controlled substances, the growing need to bolster domestic supply and production of plant based medicines, and the DEA’s recent decision to increase quotas for certain psychedelic controlled substances. Psilocybin, in particular, has received significant media attention in recent years, and clinical trials on the drug’s potential are underway at the Johns Hopkins Center for Psychedelic & Consciousness Research, the University of California, New York University, the University of Michigan, Yale University, and the Usona Institute, among others. Additionally, in July 2023, the American Medical Association (“AMA”) published language for new Current Procedural Terminology (“CPT”) III codes for psychedelic therapies. The codes went into effect on January 1, 2024. These new CPT codes will facilitate reimbursement and access to FDA-approved psychedelic therapies in the U.S. While no psychedelic-assisted therapy has yet been approved by the FDA, several potential new drugs are in various phases of clinical trials with the potential for at least one approval in 2024. The additional DEA Bulk Manufacturing Registration that Bright Green is seeking will allow us to supply the growing demand for psychedelic and plant-based medicine research, as well as to produce Active Pharmaceutical Ingredients (“APIs”) for a number of key pharmaceutical drugs. Given the recent prescription drug shortages experienced both in the U.S. and in other countries, our additional approval would allow us to meet U.S. demand for these drugs and contribute a consistent domestic supply of these drugs both for API and for research purposes.

 

Because cannabis, and the other future controlled substances we have applied for DEA Registration to manufacture, are still Schedule I and Schedule II controlled substances in the U.S., such substances have been historically under-researched. Though the majority of Americans now live in states where cannabis is legal, the full potential of the cannabis plant (and other controlled substance plants) for medicinal use remains understudied due to limited access to federally-approved cannabis and other controlled substances. The DEA recently issued a call for more cannabis research supply based on the increased demand for cannabis research in the U.S. As described herein, on April 28, 2023, we received the DEA Registration, which allows us to produce federally legal cannabis, cannabis extracts, and tetrahydrocannabinol and to sell legally within the U.S. to licensed researchers and pharmaceutical companies, in addition to qualifying us to export cannabis internationally. In January 2024, the DEA increased its quotas not only for cannabis but also for psilocybin and other psychedelics to meet medical and scientific needs. Our plan to expand our business to include additional controlled substances is in line with our Company’s mission and is in response to increased demand for these historically understudied plant medicines.

 

BGC must comply with the terms agreed upon pursuant to the MOA which include: submitting an Individual Procurement Quota on or before April 1 of each year utilizing DEA Form 250; submitting an Individual Manufacturing Quota on or before May 1 of each year utilizing DEA Form 189; collecting samples of cannabis and distributing them to DEA-registered analytical laboratories for chemical analysis during the pendency of cultivation and prior to the DEA’s taking possession of the cannabis grown; providing the DEA with 15-day advance written notification, via email, of its intent to harvest cannabis; following the DEA’s packaging, labeling, storage and transportation requirements; distributing DEA’s stocks of cannabis to buyers who entered into bona fide supply agreements with the Company; providing the DEA with 15-day advance written notification of its intent to distribute cannabis; and invoicing the DEA for harvested cannabis that it intends to sell to the DEA.

 

Having received our DEA Registration for Bulk Manufacturing of cannabis, we are permitted to cultivate and manufacture cannabis, supply cannabis researchers in the U.S. and globally, and produce cannabis for use in pharmaceutical production of prescription medicines within the U.S. Our DEA Registration permits our cannabis activities under federal law, which sets BGC apart from most other U.S. cannabis companies.

 

We have assembled an experienced team of medical professionals and researchers, international horticultural growers and experts, and construction and cannabis production professionals, which we believe position us as a future industry leader in the production of plant-based medicines.

 

2
 

 

Background

 

BGC owns a 70-acre parcel of land on agricultural property, which includes an existing 22-acre greenhouse structure. The Company also owns a 40-acre parcel of land nearby, and holds options for two additional 300-acre properties which are adjacent to the owned properties (one is known as the “Candelaria” property, and the other is known as the “Azuz” property).

 

We are engaged in a phased, modular development process consisting of the following:

 

  ● renovation of BGC’s existing 22-acre production facility;
     
  ● development of a 118-acre state-of-the-art agricultural manufacturing and research facility; and
     
  ● future greenhouse developments.

 

When completed, we believe the project will be one of the nation’s largest federally authorized manufacturing and research facilities for plant-based therapies, supplying researchers across the United States and internationally with high-quality controlled substances. The facility will be capable of producing up to approximately 100,000 grams of cannabis resin per day with a concentration of a minimum of 85% useful cannabinoids.

 

Phase 1 of the project consists of the renovation of BGC’s existing 22-acre production facility to process medicinal plants.

 

We are in the process of completing construction of the 22-acre existing greenhouse to comply with the requirements for Schedule I and Schedule II plant based drugs. Within the first 10-acres of the existing greenhouse, we will include a two-acre university greenhouse (the “University Greenhouse”) to house our cannabis research, development, cultivation and manufacturing operations.

 

In addition to the existing greenhouse, we plan to construct two new 57-acre greenhouses, one on the Candelaria property and one on the Azuz property. We have engaged Dalsem Complete Greenhouse Projects, B.V. (“Dalsem”) and Universal FAB to complete the construction of these facilities and have negotiated an agreement with them, which our legal team is drafting.

 

BGC will leverage automation throughout the facility to ensure that all of BGC’s processes are reliable and consistent, including the Visser transplanter robot or Visser potting robot, and automated growing systems. Additionally, we are exploring the use of artificial intelligence in greenhouse growing and for use in moderating temperature, climate, and growing conditions. New Mexico’s uniquely predictable climate and abundant sunshine make it an ideal setting for cultivation of cannabis and other medicinal plants in a greenhouse. BGC will use state-of-the-art technology to cultivate controlled substances plants and fungi in an efficient, standardized, and cost-effective way. The technologies specific to our planned greenhouses include:

 

  ● technologically advanced greenhouse design, which allows for maximum environmental control, cost-efficiency, and a low carbon footprint;
  ● environmentally sustainable cultivation methodology and practices in harmony with New Mexico’s unique climate, using naturally available resources;
  ● cultivation at a large scale to provide consistent, secure supply for researchers and the pharmaceutical industry;
  ● a patented air ventilation system, which uses ambient physical properties to generate optimal indoor conditions based upon the data driven growing strategy, with minimum use of energy, which in turn enables the highest yield and quality of crop in the shortest time;
  ● ebb-flood irrigation to enable the use of mildew resistant cultivars;
  ● fully-implemented pest/disease scouting system;
  ● controlled output through Pharma grade drying and extraction;

 

3
 

 

  ● extraction and separation techniques allowing for specific combinations of cannabinoids and other properties from cannabis for targeted therapeutics; and
  ● tamper-proof track & trace and record keeping system.

 

Our agricultural property has adequate utilities and water and is ideally situated to cultivate and process controlled substance plants in harmony with the surrounding environment, using the most advanced technology. We intend to power the newly constructed greenhouses using solar power. The result will be consistent, pure, high-quality cannabis, cannabis extracts, and other controlled substances that will provide consistent, safe inventory for researchers around the nation.

 

Planned Business Lines

 

Domestic Cannabis for U.S. Researchers and Registered Manufacturers

 

We plan to sell cannabis to research institutions, pursuant to our DEA Registration. Sales of THC cannabis products will be made only via bona fide supply agreements from existing DEA registrants, and will not be sold directly to consumers under current scheduling rules.

 

Our DEA Registration permits us to supply DEA-registered research institutions with cannabis that contains high levels of THC. Additionally, we plan to conduct in-house research at our own facilities and have submitted an application to become a DEA Schedule I Controlled Substance Registered Researcher. Our DEA Registration will also allow us to provide our products to in-house researchers, which we believe will allow us to conduct cutting edge research into plant-based therapies using cannabis. We have been granted several patents for cannabis based products. See “Business-Intellectual Property”.

 

Given the competitiveness of the process to obtain a DEA Registration to cultivate and process cannabis, and the continued federal illegality of cannabis in the U.S., we believe we will be uniquely positioned to capture significant parts of the cannabis research supply market. The market for clinical research has grown dramatically over the past decades, and we project cannabis research to take a similar trajectory.

 

Cannabis for International Export

 

Our DEA Registration allows us to export cannabis to researchers internationally. Given our state-of-the-art facility in development, as well as the cannabis manufacturing expertise of our team, the unique climate of New Mexico and its suitability for a cannabis crop, we anticipate significant demand for our high-quality cannabis products from international markets.

 

Cannabis for U.S. Pharmaceutical Production - CBN and CBG

 

Our DEA Registration permits us, subject to requisite terms and conditions, to sell cannabis to DEA-registered pharmaceutical companies to produce medicinal cannabis or cannabis preparations, and we can also sell CBN and CBG to other companies developing products. There is significant potential for revenue from pharmaceutical companies that currently manufacture or desire to manufacture drugs containing cannabis extracts, either on an over-the-counter or on a prescription basis, and we anticipate a significant demand for CBN and CBG for the development of other products.

 

CBG and CBN are cannabinoids, like CBD, which can be extracted from the cannabis plant. The CBG and CBN extracts that we plan to produce would be sold to pharmaceutical companies and other market participants. We are in preliminary discussions with several pharmaceutical companies in connection with proposed supply contracts for CBN and CBG high-grade oil extracts, to be used in healthcare, hormone balance and anti-aging studies. We plan to distinguish ourselves by focusing on the CBN and CBG cannabinoids, which offer alternative health and wellness benefits to CBD. By focusing on cannabis-derived CBN and CBG rather than hemp-derived CBD, we will leverage the potential growth opportunity offered by these alternative compounds. The cannabis plant contains hundreds of cannabinoids and other compounds, and due to the ongoing federal illegality, severely restricting research on these components, many believe that there is health and wellness potential in some of these plant derivatives that has not yet been studied.

 

4
 

 

On August 9, 2022, the DEA confirmed to BGC that cannabinoids, including, but not limited to CBN and CBG, which meet the definition of “hemp” by having a Delta-9-tetrahydrocannabinol concentration of not more than 0.3 percent on a dry weight basis, are outside of the DEA’s jurisdiction because they are not controlled under the CSA. Hemp and hemp products were made legal by the 2018 Farm Bill, which has been codified in 21 U.S.C. § 802(16)(B)(i), and 7 U.S.C. § 1639o. This hemp product business line will be in addition to our research and pharmaceutical cannabis sales conducted under the DEA Registration for the Bulk Manufacturing.

 

FDA Supply

 

The U.S. Food and Drug Administration (the “FDA”) has stated that it recognizes that there is significant interest in the development of therapies and other consumer products derived from cannabis. The FDA has stated that it is committed to protecting the public health while also taking steps to improve the efficiency of regulatory pathways for the lawful marketing of appropriate cannabis and cannabis-derived products. The FDA has stated that it is working to answer questions about the science, safety, and quality of products containing cannabis and cannabis-derived compounds. BGC will be well-positioned to act as a partner to the FDA as it advances these efforts, and we will be one of the few federally registered suppliers of cannabis available to the FDA for any of its research or exploration efforts in the space. As noted elsewhere, it is also possible that the FDA may move forward with regulating cannabis products, which could materially affect our business plan depending on what the future regulatory requirements would be. Moreover, there is no guarantee that the FDA will find our products safe or effective or grant us the required approvals under the FDCA, which may inhibit our business prospects even in the case that the federal government were to legalize cannabis.

 

CBG and CBN Hemp Products to Consumers

 

We plan to sell high-grade CBN and CBG cannabis-derived, hemp isolate products directly to consumers. On August 9, 2022, the DEA confirmed to BGC that cannabinoids, including, but not limited to CBN/CBG, which meet the definition of “hemp” by having a Delta-9-tetrahydrocannabinol concentration of not more than 0.3 percent on a dry weight basis, are outside of the DEA’s jurisdiction because they are not controlled under the CSA. Hemp and hemp products were made legal by the 2018 Farm Bill, which has been codified in 21 U.S.C. § 802(16)(B)(i), and 7 U.S.C. § 1639o. This hemp product business line will be in addition to our research and pharmaceutical cannabis sales conducted under our DEA Registration.

 

“Drugs Made in America” Plant-Based Controlled Substances for U.S. Researchers and Registered Manufacturers

 

We are seeking an additional DEA Registration to Bulk Manufacture additional Schedule I and Schedule II controlled substances as part of our “Drugs Made in America” strategy. We have already secured State of New Mexico Board of Pharmacy approval for production of these additional controlled substances, and have submitted our application to DEA for Registration for Bulk Manufacturing of these additional substances. Prior to commencing these operations for the new controlled substances, we will need DEA’s approval. Sales of these controlled substance products will be made only via bona fide supply agreements from existing DEA registrants. Our additional DEA Registration would permit us to supply DEA-registered research institutions investigating the medicinal and therapeutic potential of plant- and fungi-derived controlled substances. The market for clinical research for psychedelic and plant-based drugs has grown significantly over the past decades, and our planned business line would meet this new demand.

 

BGC has applied for DEA Registration to Bulk Manufacture the following controlled substances as part of our “Drugs Made in America” plan:

 

Schedule I

 

●Ibogaine;
●Mescaline;
●Morphine-N-oxide;
●Morphine Methylbromide;
●Morphine Methylsulfonate;
●Peyote;
●Psilocybin; and
●Psilocyn.

 

Schedule II

 

●Morphine;
●Opium Poppy;
●Poppy Straw;
●Raw Opium;
●Opium Extracts;
●Oxycodone;
●Powdered Opium;
●Granulated Opium;
●Tincture of Opium;
●Opium Fluid Extracts;
●Poppy Straw Concentrate;
●Opium combination product; and
 ●Thebaine.

 

Production Capabilities

 

BGC has adopted a phased approach to increase production on its site in Grants, New Mexico. In the first phase, the existing 22-acre Venlo greenhouse has been renovated, subject to additional construction needed to comply with the requirements for Schedule I and Schedule II plant based drugs. and an initial 10-acres will be prepared for operations. The University Greenhouse will be contained within those first 10-acres. Subsequently, both of the two larger greenhouses will be built in Phase 2.

 

5
 

 

Timeline

 

We are in process of completing construction on the existing 22-acre Venlo greenhouse to comply with the requirements for Schedule I and Schedule II plant based drug manufacture pursuant to the DEA Registration. The University Greenhouse will be located within the first 10-acres of the existing Venlo greenhouse and the 10-acre facility will provide the initial supply of cannabis and cannabis extracts. Our first harvest will be complete approximately two months from the first planting. We plan to implement a phased approach to the build out of Phase 1 and Phase 2 and to plant intermittently as phases of each greenhouse reach completion. The addition of the “Drugs Made in America” plan controlled substances, contingent upon receiving all necessary approvals, will be built out modularly in response to demand for particular controlled substances.

 

Based on the targeted production plan, BGC will have capacity for the following outputs once all of the greenhouse facilities are complete:

 

  ● 50,000 cannabis plants in the facility at all times and at different maturity levels;
  ● annual harvested plants approximately 300,000 (multiple harvests per year); and
  ● capacity to process 5,000 lbs. of plant material per day, using supercritical CO2 extraction.

 

BGC plans to cultivate cannabis and focus on the production of dried flower, and oils and marijuana extracts. BGC may also produce edibles which contain extracts, if permitted by DEA regulations and requested by customers. In addition to cannabis, we will have a separate area for controlled substance cactus cultivation, and a separate controlled area for mushroom propagation. Each controlled substance will have a separate area for propagation or cultivation.

 

The BGC process draws on expertise from Controlled Environmental Agriculture Design, by Larssen (“Larssen”), who have completed over 50 fully legal cannabis projects in jurisdictions throughout the world, including Canada, Australia and Denmark. BGC is in discussions to enter into a supply agreement with cannabis tissue supplier Nordic Supreme. Following execution of a definitive supply agreement, Nordic Supreme will supply BGC with proven cannabis genetics from their facilities in Denmark.

 

BGC will engage Larssen for consulting and the development of best practices for our cultivation and manufacturing operations. Larssen will provide BGC with technical design services related to the greenhouse retrofit and construction in Grants, New Mexico. The scope of our engagement with Larssen will be tailored to support and complement Dalsem and Universal FAB. Larssen consulted on the retrofit for the existing 22-acre greenhouse and will consult on the Dalsem build of the two new greenhouses. Larssen will then implement a Quality Management System, along with the applicable documents, forms, logbooks, and SOPs required to achieve GACP/GMP and DEA compliance.

 

Dalsem and Universal FAB will be BGC’s principal suppliers of the greenhouse building materials which will include hot dipped galvanized steel, aluminum system profiles for the outside cladding and horticultural glass as covering. Dalsem and Universal FAB will also provide irrigation building materials and components for building the Visser Transplanter. There could be price fluctuations for these materials depending on the cost of raw materials like steel, glass, and aluminum. PlantLogic will supply plastic pots and water collection for the coco peat insert material to grow plants, and Fertoz will provide organic soil for our facility. Octillo Lumber supplied the steel mesh, and barbed wire for the property’s perimeter fence.

 

Intellectual Property

 

BGC holds four issued patents, and other approved patent applications, applications pending review and applications submitted for review. The patents held by the Company are: Patent No. 10,668,045 for topical massage oil and cream containing CBD, CBN, Curcumin and Boswellia Resin; Patent No. 10,946,307 Extraction of Cannabinoids, Curcuminoids and Ginsenosides; Patent No. 10,946,308 Enzymatic Method for Extraction and Purification of Phytocannabinoids; and Patent No. 11,197,833 Fortified CBD oil for treatment of PTSD.

 

6
 

 

Patents Issued

 

Patent Name  Type of Patent Protection (composition of matter, method, or use)  Patent Number  Expiration Date  Jurisdiction
Topical massage oil and cream containing CBD, CBN, Curcumin and Boswella Resin  Method & Composition  10,668,045  7/12/2039  U.S.
Extraction of Cannabinoids, Curcuminoids and Ginsenosides  Method  10,946,307  7/12/2039  U.S.
Enzymatic Method for Extraction and Purification of Phytocannabinoids  Method  10,946,308  7/12/2039  U.S.
Fortified CBD oil for treatment of PTSD  Method  11,197,833  7/12/2039  U.S.

 

Patent Applications Submitted

 

Patent Application Name  Type of Patent Protection (composition of matter, method, or use)  Patent Application Number  Patent Application Filing Date  Jurisdiction
Fortified CBD oil for Treatment of PTSD  Composition  17/523,464  November 10, 2021  U.S.
Dissolution of Curcuminoids from Turmeric in Cannabis oil  Method & Composition  63/279,396  November 15, 2021  U.S.
Fortified cannabis oil and beverages containing cannabis oil and curcuminoids  Method  63/279,406  November 15, 2021  U.S.
Fortified Cannabis Oil Topical Preparations for Dermal (Skin) Health  Method  63/279,413  November 15, 2021  U.S.
Chromatographic separation of THC, CBD and other cannabinoids  Method  63/279,419  November 15, 2021  U.S.
Cannabinoid Mixture  Method & Composition  63/279,369  November 15, 2021  U.S.
Chromatographic separation of THC, CBD and other cannabinoids  Method  63/279,428  November 15, 2021  U.S.
Method for enriching Cannabinol (CBN) in Cannabis oil  Method  63/279,442  November 15, 2021  U.S.
Generation of new varieties of cannabis by ethyl methane sulfonate (EMS) Mutagenesis of cannabis seeds  Method  63/279,446  November 15, 2021  U.S.
Selection of new varieties of cannabis through somatic embryogenesis  Method  63/279,451  November 15, 2021  U.S.
Fortified cannabis oil for treating sleep disorders  Method  63/279,456  November 15, 2021  U.S.
Selection of New Varieties of Cannabis Plants expressing Cannabinoids by Cell Culture  Method  16/594,714  December 2022  U.S.

 

7
 

 

Current Licenses Held

 

DEA Registration

 

In April 2023, BGC received its DEA Registration for Schedule I Controlled Substances Bulk Manufacturing of Cannabis. The Company’s DEA Registration Number is RB0649383. The expiration date of the DEA Registration is 7/31/2024. In April 2023, BGC also entered into a new MOA, governing the terms of its cannabis activities. Previously, the Company had entered into an MOA with DEA in 2021 which was subsequently updated this year with similar terms. The newer MOA includes an Addendum stating certain conditions for the Company’s hemp activities, and also specifies that the Company’s hemp activities are not subject to the terms or requirements of the MOA.

 

The MOA with the DEA is effective for a one-year term, renewable for up to four additional one-year terms.

 

In May 2023, BGC received a second DEA Registration for Importing Schedule I Controlled Substances (DEA Reg. No. RB0650754).

 

Current Licenses

 

As described above, BGC holds two DEA Registrations: in April 2023, BGC received its DEA Registration for Schedule I Controlled Substances Bulk Manufacturing (DEA Reg. No. RB0649383). In May 2023, BGC received a second DEA Registration for Importing Schedule I Controlled Substances (DEA Reg. No. RB0650754).

 

On July 23, 2020, BGC received approval from the State of New Mexico Board of Pharmacy to conduct Controlled Substances Manufacturing of Cannabis Products in the state, pursuant to receiving approval from the DEA to do so. License No. CS00229100 expires on 7/31/2024. On March 23, 2023 we were notified that the Board of Pharmacy no longer has jurisdiction over cannabis in New Mexico.

 

BGC holds a State of New Mexico Department of Agriculture 2023 Continuous Hemp Commercial Production License, CHPL-02-2024, USDA License No. 35-0045, which was issued on 2/16/2024 and expires 1/31/2025.

 

BGC holds a State of New Mexico Cannabis Control Division, Cannabis Research Laboratory License. No. CCD-2023-RSCH-001, which was issued on 3/23/2023, and expired on 3/23/2024. The Company is in the process of renewing this license.

 

BGC also holds State of New Mexico Board of Pharmacy Controlled Substance licenses for additional Schedule I and Schedule II Controlled Substances: a Controlled Substance Facility License, No. CS02324187, which expires on 5/2/2024, and a Controlled Substance Wholesaler License, No. WD20220144, which expires on 5/2/2024.

 

Industry Overview

 

US Market Overview

 

The U.S. cannabis industry is undergoing rapid growth and change, particularly with the recent opening of opportunities for federally sanctioned research on cannabis in partnership with the DEA, as well as the federal legalization of hemp, and corresponding state and federal hemp research programs.

 

BGC plans to operate in the U.S. market for federally sanctioned cannabis - as a supplier of cannabis for research or DEA Registered Manufacturing purposes, and as a researcher itself. Importantly, all of BGC’s proposed activities will comply with all existing or future federal and state regulations.

 

8
 

 

Legal Background - Cannabis

 

Thirty-nine U.S. states, the District of Columbia, Puerto Rico and Guam have legalized some form of whole-plant cannabis cultivation, sales and use for certain medical purposes (medical states). Twenty-two of those states and the District of Columbia and Northern Mariana have also legalized cannabis for adults for non-medical purposes (sometimes referred to as adult use). Under U.S. federal law, however, those activities are illegal. Cannabis, other than hemp (defined by the U.S. government as Cannabis sativa L. with a THC concentration of not more than 0.3% on a dry weight basis), is a Schedule I controlled substance under the U.S. Controlled Substances Act (21 U.S.C. § 801, et seq.) (the “CSA”). Even in states or territories that have legalized cannabis to some extent, the cultivation, possession, and sale of cannabis in-state or where those activities are deemed involved in interstate commerce, all violate the CSA and are punishable by imprisonment, substantial fines and forfeiture. Moreover, individuals and entities may violate federal law if they aid and abet another in violating the CSA, or conspire with another to violate the law, and violating the CSA is a predicate for certain other crimes, including money laundering laws and the Racketeer Influenced and Corrupt Organizations Act. The U.S. Supreme Court has ruled that the federal government has the authority to regulate and criminalize the sale, possession and use of cannabis, even for individual medical purposes, regardless of whether it is legal under state law.

 

While the United States Department of Justice (“DOJ”), including the U.S. Attorneys Offices through the U.S., has not enforced those laws against companies complying with state cannabis laws, it retains the authority to do so, and as such the likelihood of any future adverse enforcement against companies complying with state cannabis laws remains uncertain. In 2018, then U.S. Attorney General Jefferson Sessions rescinded the DOJ’s previous guidance (the Cole Memo, dated August 29, 2013) that had given federal prosecutors discretion not to enforce federal law in states that legalized cannabis, as long as the state’s legal regime adequately addressed specified federal priorities. The Sessions memo stated that each U.S. Attorney’s Office should follow established principles that govern all federal prosecutions when deciding which cannabis activities to prosecute. Since the Sessions memo was issued nearly five years ago, U.S. Attorneys have not targeted state law compliant entities. The policy of not prosecuting companies complying with state cannabis laws is likely to continue under current U.S. Attorney General Merrick Garland. In April 2022, Attorney General Garland reiterated that prosecuting the possession of cannabis is “not an efficient use” of federal resources, especially “given the ongoing opioid and methamphetamine epidemic[s]” facing the nation. Recent statements made by Garland suggest that the DOJ may issue further guidance on cannabis enforcement, though the timing of such guidance remains unknown. In March 2023, Garland testified in a Congressional hearing that the DOJ was continuing its work on a new memorandum regarding cannabis enforcement. He stated that the policy will be “very close to what was done in the Cole memorandum” but was yet to be finalized. While these statements are not promises to avoid federal interference with state cannabis laws, and do not amount to desuetude, it does signal that the enforcement priorities of DOJ lie elsewhere. Notwithstanding the comments made by the Attorney General, there is no guarantee that the current presidential administration will not change its stated policy regarding the low-priority enforcement of U.S. federal cannabis laws that conflict with state laws. The current administration could reverse course and decide to enforce U.S. federal cannabis laws vigorously, or a future administration could do so.

 

Since 2014, versions of the U.S. omnibus spending bill have included a provision prohibiting the DOJ, which includes the DEA, from using appropriated funds to prevent states from implementing their medical-use cannabis laws. In USA vs. McIntosh, the U.S. Court of Appeals for the Ninth Circuit held that the provision prohibits the DOJ from spending funds to prosecute individuals who engage in conduct permitted by state medical-use cannabis laws and who strictly comply with such laws. However, the court noted that, if the spending bill provision were not continued, prosecutors could enforce against conduct occurring during the statute of limitations even while the provision was previously in force. Other courts that have considered the issue have ruled similarly. This affords some extra protection for medical cannabis businesses, but does not apply to adult use businesses. Furthermore, any change in the federal government’s enforcement posture with respect to state-licensed cannabis sales, including the enforcement postures of individual federal prosecutors, is still a possibility.

 

Despite the ongoing federal illegality of cannabis, the DEA authorizes certain institutions to conduct research using cannabis, and recently expanded those efforts. Between January 2017 and January 2019, the DEA’s projections for federally approved cannabis research projects increased dramatically, and as a result, the DEA more than quadrupled its production quota. In that time, the number of federally registered cannabis researchers increased by more than 40 percent, from 384 to 542. Subsequently, the DEA announced that it would, for the first time in decades, open up opportunities for additional cultivators to supply cannabis for this research.

 

9
 

 

On August 26, 2019, the DEA announced that it will further facilitate and expand scientific and medical research for cannabis in the United States, including registering additional entities to produce cannabis for researchers, to increase the amount and variety of cannabis available for research. The DEA intends this to “facilitate research, advance scientific understanding about the effects of marijuana, and potentially aid in the development of safe and effective drug products that may be approved for marketing by the Food and Drug Administration.” In other words, the U.S. government believes that cannabis research is in the public’s interest. Furthermore, this public statement acknowledges the possibility that medical cannabis or related products may, in the future, require FDA approval and come under the FDA’s FDCA jurisdiction. However, there is no guarantee that the FDA will find our products safe or effective or grant us the required approvals under the FDCA. Additionally, the costs of compliance with any future FDA requirements are unknown and our ability to meet those requirements is also unknown, which may increase our operating costs and inhibit our business prospects even in the case that the federal government were to legalize cannabis.

 

On December 18, 2020, the DEA finalized new regulations pertaining to applications by entities seeking to become registered with the DEA to grow cannabis as bulk manufacturers for authorized purposes. Under these and other applicable regulations, applicants are responsible for demonstrating they have met various requirements, including requirements to possess appropriate state authority, document that their customers are licensed to perform research, and employ adequate safeguards to prevent diversion.

 

On May 14, 2021, the DEA announced that MOAs were provided to an unspecified and unnamed number of companies to collaborate with the DEA “to facilitate the production, storage, packaging, and distribution of marijuana under the new regulations as well as other applicable legal standards and relevant laws.” To the extent these memorandums of agreement are finalized, DEA anticipates issuing DEA Registrations to these manufacturers. Each applicant will then be authorized to cultivate cannabis - up to an allotted quota - in support of the more than 575 DEA-licensed researchers across the nation. As individual manufacturers are granted DEA registrations, that information will be made available on DEA’s Diversion Control website. As of April 11, 2024, eight companies have been granted DEA Registration to bulk manufacture cannabis.

 

In addition to anticipated expenses related to the DEA, we face expected costs related to compliance with existing environmental and other regulations at the local, state, and federal level, as well as future environmental or other regulations.

 

Recent Federal Cannabis Bills

 

Industry observers were hopeful that a Democrat-controlled House and Senate, along with a Biden presidency, would increase the chances of federal legalization of cannabis or some piecemeal policy reform. During his campaign, President Biden promised federal reform on cannabis, including decriminalization generally. In 2022, President Biden signed into law the Medical Marijuana and Cannabidiol Research Expansion Act, a bill aimed at easing restrictions on cannabis research — bipartisan legislation which is the first standalone cannabis reform bill to pass both the House and Senate. Additionally, on October 6, 2022, President Biden issued a presidential proclamation pardoning federal convictions for simple marijuana possession offenses, encouraging state governors to do the same on the state level where permissible, and requesting that the Secretary of Health and Human Services and the Attorney General initiate an administrative process to review cannabis’s Schedule I classification under the CSA. This process could, but is not guaranteed to, change the legal status of cannabis on a federal level. Regardless of the ultimate outcome on CSA scheduling, both actions represent significant milestones in the evolution of federal cannabis policy.

 

10
 

 

While the timing of federal reform is unknown, there is bipartisan support for cannabis reform on the federal level. Members of the U.S. Congress from the Democratic and Republican parties have introduced bills to end the federal cannabis prohibition, by de-scheduling cannabis completely and regulating it. In the 117th Congress, Senators Cory Booker (D-NJ), Ron Wyden (D-OR), and Chuck Schumer (D-NY) filed the Cannabis Administration And Opportunity Act, a bill that would regulate cannabis and expunge prior cannabis convictions; and Rep. Nancy Mace (R-SC) filed the States Reform Act, which would repeal the federal prohibition of and further regulate cannabis on the federal level. This session has seen additional incremental reform bills, including a bill that would direct the Attorney General of the United States to amend the CSA to move cannabis from Schedule I to Schedule III of the Act (the “Marijuana 1 to 3 Act”), and a bill to allow medical cannabis patients to purchase and possess firearms (the “Second Amendment Protection Act”). In the 118th Congress, a new bipartisan SAFE Banking Act was introduced into the Senate (H.R. 2891), which would bar federal regulators from taking several punitive steps against banks or financial services providers to state-legal cannabis businesses. While the timing of federal reform remains unknown, it is expected that federal policy on cannabis will continue becoming more, rather than less, permissive, and legislative efforts to legalize cannabis or cannabis banking at the national level are likely to continue in 2024.

 

Future pathways to, and chances of, federal legalization or even further reform benefiting the state regulated, but federally illegal operators remain uncertain and speculative. Regardless of the future status of federal legalization of cannabis, there are already tremendous opportunities for fully legal medical cannabis researchers, suppliers, and product developers.

 

On August 29, 2023, the Department of Health and Human Services (“HHS”) issued a letter to the Drug Enforcement Administration (“DEA”) recommending that cannabis be reclassified as a Schedule III controlled substance under the CSA. If the DEA chooses to reschedule cannabis pursuant to the HHS recommendation, the full implications are currently unknown. The DEA’s decision to reclassify cannabis would neither legalize nor likely eliminate current state cannabis programs. Under schedule III, cannabis would remain a controlled substance and state-legal programs would continue to operate outside of federally legal channels particularly because no state operator currently holds a DEA registration to manufacture or dispense cannabis. Additionally, states (and potentially federal agencies) may take rescheduling of cannabis as an opportunity to update their laws in manners that are favorable or unfavorable to us. However, some fear that the DEA or FDA may impose additional requirements or begin to target enforcement on state cannabis programs in the event of a rescheduling event.

 

Market Growth

 

In the medical market, the demand for cannabis for research is likely to increase significantly over the next few years and decades, due to the increasing number of states legalizing cannabis and the strong public support for cannabis legalization. By 2025, 5.4 million Americans, or 2.4% of U.S. adults, are predicted to be registered patients in medical cannabis states, according to a report by New Frontier Data (“New Frontier”). New Frontier also projects that the medical cannabis market will nearly double to over $16 billion in that time, taking into account more geographies within the U.S. legalizing cannabis, which will lead to market expansion, the normalization of cannabis which will increase the number of consumers, and medical cannabis patients turning to cannabis as an alternative to prescription drugs. The global medical cannabis market is projected to reach $87.4 billion by 2027, according to Global Market Insights (“GMI”). The DEA’s aggregate production quotas for cannabis are 6,675 kg in 2024 for dried flower (an estimated $73 million market) and 1,000 kg for cannabis extract (an estimated $100 million market). These aggregate production quotas are expected to continue increasing to meet increasing demand for cannabis research in the U.S. In addition to government funding, some institutions are already receiving private investment in cannabis research. For example, Harvard and MIT received a $9 million donation to fund research into cannabis’ influence on brain health and behavior. Additionally, CB2 insights has noted that average prescriptions for qualifying conditions such as chronic pain, PTSD, sleep disorders, epilepsy and anxiety saw a decline in 11% in favor of medical cannabis replacement leading the analysts to estimate that more than $4 billion in sales that currently go to pharmaceutical products could be redirected towards medical cannabis. Further research on cannabis legalization and its impact on public health are needed and are likely to take place over the coming years, as the DEA has recognized the increased need for cannabis related research. Our “Drugs Made in America” plan includes a number of opioids, in addition to cannabis production, the combined market for cannabis and opium APIs is projected to reach $11.66 billion by 2030, with a CAGR of 13.9% according to Coherent Market Insights.

 

In 2021, large pharmaceutical companies in the U.S. spent $102.3 billion on drug research and development, and the number has continued to increase each year. The private research market, like the federal DEA research program, has an interest in investigating the uses and risk of cannabis and hemp derivatives, not only in states that have legalized medical cannabis, but also in anticipation of potential full legalization. Research topics of interest include:

 

  ● therapeutic benefits and risks of cannabis for common conditions for military veterans, including PTSD and chronic pain;
     
  ● therapeutic benefits and risks of cannabis for opioid addiction treatment, as well as other medical conditions and disabilities;

 

11
 

 

  ● cognitive effects of THC use in the developing brain of adolescents;
     
  ● prevention of and treatment for cannabis use disorder;
     
  ● effects of different levels of THC potency levels;
     
  ● accurate roadside testing to detect driving while impaired with cannabis and related topics;
     
  ● availability of inaccurately labeled and adulterated cannabis;
     
  ● effective cannabis packaging requirements for consumer and child safety;
     
  ● effect of cannabis legalization on workplace testing and workplace safety for safety-sensitive jobs, including the use of synthetic THC;
     
  ● effect of cannabis use on mental health and addiction;
     
  ● effect of cannabinoids on immunological responses against bacterial or viral infections.

 

Regarding the cannabis market generally, the industry is large and is growing. In 2020, there were $17.5 billion in annual industry sales, a 46% increase from 2019. As of May 2021, capital raises in cannabis reached $6 billion, signaling increased confidence in projections of aggressive cannabis market growth. According to a report by New Frontier Data, the U.S. legal cannabis market is predicted to more than double by 2025, reaching $41.5 billion in sales, and producing a 21% compound annual growth rate (“CAGR”). Therefore, BGC will be entering a sizeable market with the first-mover advantage of a federally compliant business as cannabis enters a new stage of growth and development, once it obtains authorization from the DEA to begin operations. In addition to the cannabis market, BGC will be entering a larger API market via our “Drugs Made in America” plan.

 

Human Capital Resources

 

As of December 31, 2023, we had 5 full-time employees and contractors and 3 part-time contractors. We consider our relationship with our employees to be good. We emphasize several measures and objectives in managing its human capital assets, including, among others, (i) employee safety and wellness, (ii) talent acquisition and retention, (iii) employee engagement, development and training, (iv) diversity and inclusion and (v) compensation. These targeted ideals may include annual bonuses, stock-based compensation awards, a 401(k) plan with employee matching opportunities, healthcare, and insurance benefits, health savings and flexible spending accounts, paid time off, family leave, family care resources, and/or employee assistance programs. We also provide our employees with access to various innovative, flexible, and convenient health and wellness programs. We designed these programs to support employees’ physical and mental health by providing tools and resources to improve or maintain their health status and encourage engagement in healthy behaviors.

 

Facilities

 

The following table sets forth the Company’s owned and leased physical properties as of December 31, 2023, which include corporate offices, cultivation and production facilities (operating and under construction). In addition to the currently owned and leased property, the Company holds two options, each for the purchase of 300 acres of land in Grants, New Mexico.

 

Property Type   Owned/Leased   County   State
Agricultural Property - 40 acres   Owned   Cibola   New Mexico
Agricultural Property - 70 acres   Owned   Cibola   New Mexico
Office   Leased   Broward   Florida

 

As of December 31, 2023, we notified the land owners of our intention to exercise the two options and are in process of negotiating final terms of acquisition, which are pending financing. 

 

12
 

 

Competition

 

We will face intense competition from the illicit market as well as other more regulated companies, some of which may have longer operating histories and more financial resources and manufacturing and marketing experience. Our “Drugs Made in America” plan faces intense competition from the international global pharmaceutical market, and from other countries which currently lead API export for some of these substances (for example Tasmania, the world’s leading supplier of legal opioids). Additionally, with potential consolidation in the cannabis industry, we could face increased competition by larger and better financed competitors.

 

Growers of cannabis and retailers operating in the illicit market continue to hold significant market share in the United States and are effectively competitors to our business. Illicit market participants divert customers away through product offering, price point, anonymity and convenience.

 

Outdoor cultivation also significantly reduces the barrier to entry by reducing the start-up capital required for new entrants in the cannabis industry. It may also ultimately lower prices as capital expenditure requirements related to growing outside are typically much lower than those associated with indoor growing. Further, the licensed outdoor cultivation capacity is extremely large. While outdoor cultivation is almost exclusively extraction grade, its presence in the market will have a negative effect on pricing of extraction grade wholesale cannabis.

 

Competition is also based on product innovation, product quality, price, brand recognition and loyalty, effectiveness of marketing and promotional activity, the ability to identify and satisfy consumer preferences, as well as convenience and service.

 

Internationally, cannabis companies are limited to those countries which have legalized aspects of the cultivation, distribution, sale or use of cannabis. The barrier to entry for competitors in these is significantly influenced by the national regulatory landscape with respect to cannabis and the economic climate subsisting in each region.

 

We expect more countries to pass regulation allowing for the use of medical and/or recreational cannabis. While expansion of the global cannabis market will provide more opportunities to grow our international business, we also expect to experience increased global competition.

 

Bright Green EB-5 Program 

 

On February 1, 2023, we initiated a private placement offering of our common stock, only to accredited or qualified institutional investors, in reliance upon Rule 506, Regulation D promulgated under the Securities Act, pursuant to the U.S. government’s EB-5 immigrant investor program. As of May 25, 2023, we have sold 44,010 shares of common stock at $39.99 per share, receiving proceeds of $1.76 million, inclusive of $160,000 of administrative fees payable by the investor.

 

On March 29, 2024, we modified our private placement offering, to authorize 20,000,000 shares to be sold at $2.00 per share pursuant to the U.S. government’s EB-5 immigrant investor program. This private placement offering allows for 50 investors to participate in the offering by making an $800,000 in exchange for 200,000 shares of common stock. The EB-5 investment project application on file with United States Citizenship and Immigration Services (“USCIS”) projects the creation of enough jobs in a designated rural area to support up to 573 investors.

 

13
 

 

Corporate History

 

BGC was incorporated on April 16, 2019 under the Delaware General Corporation Law (the “DGCL”). On May 28, 2019, BGC entered into a merger agreement (the “BGGI Agreement”) with Bright Green Grown Innovation LLC, a limited liability company (“BGGI”), whereby BGC issued to BGGI an aggregate of 123,589,000 shares of common stock (the “BGGI Merger”). In connection with the BGGI Merger, BGC acquired two parcels of land, consisting of one 70-acre parcel and one 40-acre parcel, and a completed greenhouse structure in Grants, New Mexico. Lynn Stockwell received 18,000,000 shares for the 70-acre parcel including the Greenhouse. She additionally received 9,500 shares for the 40 acre parcel. Share certificates were issued accordingly.

 

BGC entered into an agreement and plan of merger with Grants Greenhouse Growers, Inc., a New Mexico corporation (“GGG”) on October 30, 2020 (the “GGG Agreement”), whereby BGC issued to GGG an aggregate of 1,000,000 shares of common stock (the “GGG Merger”). In connection with the GGG Merger, BGC received an option to purchase approximately 505 acres of land near BGC’s Grants, New Mexico property at the purchase price of $5,000 per acre.

 

BGC entered into an agreement and plan of merger (the “Naseeb Agreement”) with Naseeb Inc. (“Naseeb”) on November 10, 2020, whereby BGC issued to Naseeb an aggregate of 10,000,000 shares of common stock (the “Naseeb Merger”). In connection with the Naseeb Merger, BGC received certain intangible property, including rights to certain patents and patent applications, licenses to operate cultivation facilities, and rights to additional licenses if-and-when issued.

 

On May 17, 2022, we completed a direct listing of our common stock (the “Direct Listing”), on the Nasdaq Capital Market (“Nasdaq”) under the symbol “BGXX.” We incurred fees related to financial advisory service, audit, and legal expenses in connection with the Direct Listing and incurred approximately $2.4 million in general and administrative expenses during the period ended March 31, 2023. In addition, in connection with the Direct Listing, and pursuant to a financial advisory agreement by and between the Company and EF Hutton, division of Benchmark Investments, LLC (the “Advisor Agreement”) dated April 8, 2022, on June 3, 2022, we issued representatives and affiliates of the Advisor and related parties, an aggregate of 787,245 shares of common stock, and representatives of Entoro Securities LLC (“Entoro”) an aggregate of 787,245 shares of common stock.

 

Available Information

 

Our principal executive offices are located at 1033 George Hanosh Boulevard, Grants, NM 87020, and our telephone number is (833) 658-1799. Our corporate website address is https://brightgreen.us. Information contained on or accessible through our website is not a part of this Annual Report and should not be considered to be part thereof. The public may read and copy any materials that we file with the Securities and Exchange Commission (the “SEC”) electronically through the SEC website (www.sec.gov). The information contained on the SEC’s website is not incorporated by reference into this Annual Report and should not be considered to be part thereof. We also provide access without charge to all of our SEC filings, including copies of this Annual Report, Quarterly Reports on Form 10-Q, Annual Reports on Form 10-K, Current Reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act, as soon as reasonably practicable after filing or furnishing, on our website.

 

14
 

 

Item 1A. Risk Factors.

 

Investing in our securities involves a high degree of risk. Before you make a decision to buy our securities, in addition to the risks and uncertainties discussed above under “Special Note Regarding Forward-Looking Statements,” you should carefully consider the risks and uncertainties described below together with all of the other information contained in this Annual Report, including our consolidated financial statements and related notes included at the end of this Annual Report and in the section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” If any of the events or developments described below were to occur, our business, prospects, operating results and financial condition could suffer materially, the trading price of our securities could decline and you could lose all or part of your investment. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently believe to be immaterial may also adversely affect our business.

 

Risk Factors Summary 

 

Below is a summary of material factors that make an investment in our securities speculative or risky. Importantly, this summary does not address all of the risks and uncertainties that we face. You should carefully consider the full risk factor disclosure outlined in this Annual Report, in addition to the other information herein, including the section of this Annual Report titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and our consolidated financial statements and related notes.

 

  ● We have a relatively limited history of operations, a history of losses, and our future earnings, if any, and cash flows may be volatile, resulting in uncertainty about our prospects;
  ● We had negative operating cash flow for the year ended December 31, 2023 and December 31, 2022;
  ● We are highly dependent on our management team, certain members of our board of directors and advisors, and the loss of our executive officers, non-executive directors or other key advisors or service providers could harm our ability to implement our strategies, impair our relationships with clients and adversely affect our business, results of operations and growth prospects;
  ● Our plan to expand our product offerings and sales channels might not be successful, and implementation of these plans might divert our operational, managerial and administrative resources, which could impact our competitive position;
  ● We are in discussions to consummate arrangements with certain service providers, and if these arrangements do not materialize, or materialize on terms that are not favorable to the Company, it could materially adversely affect our business, financial condition, results of operations, cash flows and day-to-day operations;
  ● We have identified a material weakness in our internal control over financial reporting and determined that our disclosure controls and procedures were ineffective as of June 30, 2022, as a result of the restatement of our unaudited financial information as of and for the quarter ended June 30, 2022. We have strengthened our review controls around the issuance of shares of common stock and the recording of the associated expense by adding an additional reviewer to the review process. Although our Chief Executive Officer and Chief Financial Officer have concluded that the Company’s disclosure controls and procedures were effective as of December 31, 2023, we may, in the future, identify additional material weaknesses or otherwise fail to maintain an effective system of internal control over financial reporting or adequate disclosure controls and procedures, which may result in material errors in our financial statements or cause us to fail to meet our period reporting obligations; 
  ● Cannabis and other controlled substances are highly regulated at the federal and state level, and authorizations for the production of cannabis for research are still in the early stages;
  ● A denial of, or significant delay in obtaining, or any interruption of required government authorizations to grow cannabis or other controlled substances for federally sanctioned purposes would likely significantly, negatively impact us;
  ● The U.S. wholesale market for cannabis and other controlled substances for research is of unknown size and is difficult to forecast;

 

15
 

 

  ● FDA regulation of cannabis could negatively affect the cannabis industry, which would directly affect our financial condition;
  ● Research in the United States, Canada and other countries on the medical benefits, viability, safety, efficacy and dosing of cannabis or isolated cannabinoids, as well as other controlled substances, may cause adverse effects on our operations;
  ● The very dynamic nature of the laws and regulations affecting the cannabis market (including the Rescheduling of cannabis under the Controlled Substances Act), the federal authorization of cannabis for research, or the state-regulated cannabis industry could materially adversely affect our proposed operations, and we cannot predict the impact that future laws or regulations may have on us;
  ● The uncertainties around funding, construction, and growing an agricultural crop pose risks to our business;
  ● The cannabis industry is subject to the risks inherent in an agricultural business, including environmental factors and the risk of crop failure;
  ● We are subject to environmental regulations and laws, and failure to timely or completely comply with such regulations and laws, or failure to obtain or maintain applicable licenses, may adversely affect our business;
  ● The growth of our business continues to be subject to new and changing federal, state, and local laws and regulations;
   ● We are subject to risks, including delays, from our ongoing and future construction projects, which may result from reliance on third parties, delays relating to material delivery and supply chains, and fluctuating material prices, among other factors;
  ● Our planned future sale of controlled substance products could expose us to significant product liability risks;
  ● We will need to raise substantial additional funds in the future, which funds may not be available or, if available, may not be available on acceptable terms;
  ● There is no guarantee that we will be able to continue to raise funds through our EB-5 Program, if and when such program receives the requisite regulatory approvals;
  ● We are dependent on our banking relations, and while we currently have a stable banking relationship and operate in compliance with all applicable laws, we could have difficulty accessing or consistently maintaining banking or other financial services due to banks’ risk aversion toward serving even legal parts of the cannabis industry;
  ● We may engage in future acquisitions or strategic transactions, which may require us to seek additional financing or financial commitments, increase our expenses and/or present significant distractions to our management;
  ● We are subject to risks related to information technology systems, including cyber-security risks; successful cyber-attacks or technological malfunctions can result in, among other things, financial losses, the inability to process transactions, the unauthorized release of confidential information and reputational risk, all of which would negatively impact our business, financial condition or results of operations;
  ● Our common stock has a limited trading history and an active trading market may not develop or continue to be liquid, and the market price of our shares of common stock may be volatile;
  ● The market price of our common stock has been extremely volatile and may continue to be volatile due to numerous circumstances beyond our control;
  ● You may be diluted by issuances of preferred stock or additional common stock in connection with our incentive plans, acquisitions or otherwise; future sales of such shares in the public market, or the expectations that such sales may occur, could lower our stock price;
  ● The future exercise of registration rights may adversely affect the market price of our common stock;

 

16
 

 

  ● If securities or industry analysts do not publish research or reports about our business, or if they downgrade their recommendations regarding our common stock, its trading price and volume could decline;
  ● We are an “emerging growth company,” and our election to comply with the reduced disclosure requirements as a public company may make our common stock less attractive to investors;
  ● Provisions of our amended and restated certificate of incorporation and bylaws may delay or prevent a take-over that may not be in the best interests of our stockholders;
  ● The requirements of being a public company may strain our resources, divert management’s attention and affect our ability to attract and retain executive management and qualified board members;
  ● Our failure to meet the continuing listing requirements of Nasdaq could result in a de-listing of our securities;
  ● If we cannot continue to satisfy the rules of Nasdaq, our securities may be delisted, which could negatively impact the price of our securities and your ability to sell them;
  ● Your ownership interest will be diluted and our stock price could decline when we issue additional shares of common stock; and
  ● We have issued warrants and may continue to issue additional securities in the future. The exercise of these warrants and the sale of the common stock issuable thereunder may dilute your percentage ownership interest and may also result in downward pressure on the price of our common stock.

 

Risks Related to our Business and Operations - General Risks

 

We have a relatively limited history of operations, a history of losses, and our future earnings, if any, and cash flows may be volatile, resulting in uncertainty about our prospects.

 

Our lack of a significant history and the evolving nature of the market in which we operate make it likely that there are risks inherent to our business that are yet to be recognized by us or others, or not fully appreciated, and that could result in us suffering further losses. As a result of the foregoing, and concerns regarding the economic impact from COVID-19, an investment in our securities necessarily involves uncertainty about the stability of our operating results or results of operations.

 

We had negative operating cash flow for the years ended December 31, 2023 and December 31, 2022.

 

We had negative operating cash flow of $2,455,612 in the year ended December 31, 2023, and a negative operating cash flow of $2,265,770 for the year ended December 31, 2022. To the extent that we have negative operating cash flow in future periods, we may need to allocate a portion of our cash reserves to fund such negative cash flow. We may also be required to raise additional funds through the issuance of equity or debt securities. There can be no assurance that we will be able to generate positive cash flow from our operations, that additional capital or other types of financing will be available when needed or that these financings will be on terms favorable to us.

 

We have not based our financial projections or valuation on actual operations.

 

Our pre-operational stage precludes us from providing financial information based on actual operations. Current financial projections are based on assumptions concerning future operations that we believe are reasonable but may prove incorrect. Because actual conditions will differ from those assumptions, and the differences may be material, we cannot assure you that these projections will prove accurate and caution you against excessive reliance on them in deciding whether to invest in our equity securities. Any increase in our costs or decrease in our revenues could affect your ability to receive a return on your investment.

 

17
 

 

We are highly dependent on our management team, certain members of our board of directors and advisors, and the loss of our executive officers, non-executive directors or other key advisors or service providers could harm our ability to implement our strategies, impair our relationships with clients and adversely affect our business, results of operations and growth prospects.

 

Our success depends, to a large degree, on the skills of our management team and our ability to retain, recruit and motivate key officers and employees. Our active senior executive leadership team has significant experience, and their knowledge and relationships would be difficult to replace. Leadership changes will occur from time to time, and we cannot predict whether significant resignations will occur or whether we will be able to recruit additional qualified personnel. Competition for senior executives and skilled personnel in the horticulture industry is intense, which means the cost of hiring, paying incentives and retaining skilled personnel may continue to increase.

 

We need to continue attracting and retaining key personnel and recruiting qualified individuals to succeed existing key personnel to ensure the continued growth and successful operation of our business. In addition, as a provider of custom-tailored horticulture solutions, we must attract and retain qualified personnel to continue to grow our business, and competition for such personnel can be intense. Our ability to effectively compete for senior executives and other qualified personnel by offering competitive compensation and benefit arrangements may be restricted by cash flow and other operational restraints. The loss of the services of any senior executive or other key personnel, or the inability to recruit and retain qualified personnel in the future, could have a material adverse effect on our business, financial condition or results of operations. In addition, to attract and retain personnel with appropriate skills and knowledge to support our business, we may offer a variety of benefits, which could reduce our earnings or have a material adverse effect on our business, financial condition or results of operations.

 

Our insurance may not adequately cover our operating risk.

 

We have insurance to protect our assets, operations and employees. While we believe our insurance coverage addresses all material risks to which we are exposed and is adequate and customary in our current state of operations, such insurance is subject to coverage limits and exclusions and may not be available for the risks and hazards to which we are exposed. In addition, no assurance can be given that such insurance will be adequate to cover our liabilities or will be generally available in the future or, if available, that premiums will be commercially justifiable. If we were to incur substantial liability and such damages were not covered by insurance or were in excess of policy limits, or if we were to incur such liability at a time when we are not able to obtain liability insurance, our business, results of operations and financial condition could be materially adversely affected.

 

We may have difficulty obtaining insurance at economically viable rates.

 

Our lack of operating history in an emerging area, and our plan to grow cannabis, even legally under all applicable laws, may make it difficult to obtain insurance policies at rates competitive with rates for other crops. Insurance that is otherwise readily available, such as workers’ compensation, general liability, title insurance and directors’ and officers’ insurance, is more difficult for us to find and more expensive because of our involvement in emerging areas as well as our cultivation, processing, and sale of cannabis, albeit legally under both state and federal laws. There are no guarantees that we will be able to find insurance coverage at otherwise competitive, or even economically viable terms.

 

Changes in accounting standards and subjective assumptions, estimates and judgments by management related to complex accounting matters could significantly affect our financial results.

 

U.S. GAAP and related pronouncements, implementation guidelines and interpretations with regard to a wide variety of matters that are relevant to our business, such as, but not limited to, revenue recognition, stock-based compensation, trade promotions, and income taxes, are highly complex and involve many subjective assumptions, estimates and judgments by our management. Changes to these rules or their interpretation or changes in underlying assumptions, estimates or judgments by our management could significantly change our reported results

 

18
 

 

We could be adversely affected by declines in discretionary consumer spending, consumer confidence and general and regional economic conditions.

 

Our success depends to a significant extent on discretionary consumer spending, which is heavily influenced by general economic conditions and the availability of discretionary income. We believe the cannabis markets are heavily reliant on discretionary consumer spending. The current economic environment as a result of COVID-19, coupled with high volatility and uncertainty as to the future global economic landscape, may have an adverse effect on consumers’ discretionary income and consumer confidence. Future volatile, negative, or uncertain economic conditions and recessionary periods or periods of significant inflation may adversely impact consumer spending on our products and services, which would materially adversely affect our business, financial condition and results of operations. Such effects can be especially pronounced during periods of economic contraction or slow economic growth.

 

Our plan to expand our product offerings and sales channels might not be successful, and implementation of these plans might divert our operational, managerial and administrative resources, which could impact our competitive position.

 

BGC’s success and the planned growth and expansion of the business depends on their products and services achieving greater and broader acceptance, resulting in a larger customer base, and on the expansion of its operations into new markets. However, there can be no assurance that customers will purchase its products and/or services, or that they will be able to continually expand their customer base. Additionally, if they are unable to effectively market or expand their product and/or service offerings, we will be unable to grow and expand our business or implement our business strategy.

 

BGC’s ability to grow its existing brand and develop or identify new growth opportunities depends in part on its ability to appropriately identify, develop and effectively execute strategies and initiatives. Failure to effectively identify, develop and execute strategies and initiatives may lead to increased operating costs without offsetting benefits and could have a material adverse effect on our results of operations. These plans involve various risks discussed elsewhere in these risk factors, including:

 

  ●

we may not receive all the required government authority renewals or authorizations needed to realize our plans;

     
  ● implementation of these plans may be delayed or may not be successful;
     
  ● if BGC’s expanded product offerings and sales channels fail to maintain and enhance our distinctive brand identity, our brand image may be diminished, and our sales may decrease; and
     
  ● implementation of these plans may divert management’s attention from other aspects of our business and place a strain on our management, operational and financial resources, as well as our information systems.

 

In addition, BGC’s ability to successfully carry out our plans to expand its product offerings may be affected by, among other things, laws and regulations pertaining to cannabis use and controlled substances research, economic and competitive conditions, changes in consumer spending patterns and consumer preferences. BGC’s expansion plans could be delayed or abandoned, could cost more than anticipated and could divert resources from other areas of our business, any of which could impact its competitive position and reduce our revenue and profitability.

 

19
 

 

We are in discussions to consummate arrangements with certain service providers, and if these arrangements do not materialize, or materialize on terms that are not favorable to the Company, it could materially adversely affect our business, financial condition, results of operations, cash flows and day-to-day operations.

 

We are in discussions to consummate arrangements with certain service providers. Any agreement we plan to enter into with a third party may not materialize, or, may not be on favorable terms, and the expected benefits and growth from these agreements may not materialize as planned. If we fail to enter into agreements with such service providers, or enter into agreements that are not on favorable terms to the Company, it could materially adversely affect our business, financial condition, results of operations, cash flows and day-to-day operations.

 

We have identified a material weakness in our internal control over financial reporting and determined that our disclosure controls and procedures were ineffective as of June 30, 2022, as a result of the restatement of our unaudited financial information as of and for the quarter ended June 30, 2022. We have strengthened our review controls around the issuance of shares of common stock and the recording of the associated expense by adding an additional reviewer to the review process. Although our Chief Executive Officer and Chief Financial Officer have concluded that the Company’s disclosure controls and procedures were effective as of December 31, 2023, we may, in the future, identify additional material weaknesses or otherwise fail to maintain an effective system of internal control over financial reporting or adequate disclosure controls and procedures, which may result in material errors in our financial statements or cause us to fail to meet our period reporting obligations .

 

Under the supervision and with the participation of our management, including our former Interim Chief Executive Officer and Chief Financial Officer, we conducted an assessment of the effectiveness of our internal control over financial reporting as of June 30, 2022. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material error in our annual or interim financial statements will not be prevented or detected on a timely basis. In Management’s Report on Internal Control over Financial Reporting included in our quarterly report on Form 10-Q for the quarter ended June 30, 2022 filed August 12, 2022, our management previously concluded that we maintained effective internal control over financial reporting as of June 30, 2022. Our management subsequently concluded that a material weakness existed and our internal control over financial reporting was not effective as of June 30, 2022. This determination was made as a result of a recording error of the fair value of shares of common stock we issued for services in June 2022. Such shares have a fair value of $8.00 per share, the price of our common stock at the time of our Direct Listing, but were initially recorded at a fair value of $4.00 per share. With this error being corrected in amendment no. 1 to our quarterly report on Form 10-Q for the period ended June 30, 2022, net loss increased by $6,297,960. We have strengthened our review controls around the issuance of shares of common stock and the recording of the associated expense by adding an additional reviewer to the review process. The Company continues to evaluate and implement procedures as deemed appropriate to enhance our disclosure controls.

 

If we identify new material weaknesses in our internal control over financial reporting, if we are unable to assert that our internal control over financial reporting is effective, or if our independent registered public accounting firm is unable to express an opinion as to the effectiveness of our internal control over financial reporting, we may be late with the filing of our periodic reports, investors may lose confidence in the accuracy and completeness of our financial reports and the market price of our common stock could be negatively affected. As a result of such failures, we could also become subject to investigations by the stock exchange on which our securities are then listed, the SEC, or other regulatory authorities, and become subject to litigation from investors and stockholders, which could harm our reputation, financial condition or divert financial and management resources from our core business, and would have a material adverse effect on our business, financial condition and results of operations.

 

We are at risk of cyber-attacks or other security breaches that could compromise sensitive business information, undermine our ability to operate effectively and expose us to liability, which could cause our business and reputation to suffer.

 

Increasingly, companies are subject to a wide variety of attacks on their networks on an ongoing basis. In addition to traditional computer “hackers” malicious code (such as viruses and worms), phishing attempts, employee theft or misuse, and denial of service attacks, sophisticated nation-state and nation-state supported actors engage in intrusions and attacks (including advanced persistent threat intrusions) and add to the risks to internal networks, cloud deployed enterprise and customer-facing environments and the information they store and process. Despite significant efforts to create security barriers to such threats, it is virtually impossible for us to entirely mitigate these risks. We, and our third-party software and service providers, may face security threats and attacks from a variety of sources.

 

20
 

 

As part of our business, we store our data, including intellectual property, and certain data about our employees, customers and vendors in our information technology systems. Our security measures may be breached as a result of third-party action, including intentional misconduct by computer hackers, employee error, malfeasance or otherwise. Third parties may attempt to fraudulently induce employees or customers into disclosing sensitive information such as usernames, passwords, or other information to gain access to our customers’ data or our data, including our intellectual property and other confidential business information, or our information technology systems. In addition, given their size and complexity, our information systems could be vulnerable to service interruptions or to security breaches from inadvertent or intentional actions by our employees, third-party vendors and/or business partners, or from cyber-attacks by malicious third parties attempting to gain unauthorized access to our products, systems or confidential information.

 

If a third party gained unauthorized access to our data, including any data regarding our employees, customers or vendors, the security breach could expose us to risks. Such unauthorized access and a failure to effectively recover from breaches could compromise confidential information, disrupt our business, harm our reputation, result in the loss of customer confidence, business and assets (including trade secrets and other intellectual property), result in regulatory proceedings and legal claims, and have a negative impact on our financial results.

 

Risks Related to our Business and Operations - Required DEA Authority To Grow and Process Controlled Substances

 

Controlled Substances are highly regulated at the federal and state level, and authorizations for the production of cannabis for research and other controlled substances are still in the early stages.

 

Cannabis, other than hemp, is a Schedule I controlled substance under the CSA. Even in states or territories that have legalized cannabis to some extent, the cultivation, possession, and sale of cannabis all remain violations of federal law that are punishable by imprisonment, substantial fines and forfeiture. While cannabis remains a federally illegal Schedule I drug under the CSA, there is a limited exemption under which cannabis can be grown or manufactured for uses in federally sanctioned research. To become an authorized cannabis supplier or researcher in the United States, one must obtain a registration from the DEA and meet certain requirements imposed by the DEA, which are required by the DEA to comply with federal statutes and international treaty law. The registration process to manufacture controlled substances is codified under 21 U.S.C. § 823. It requires that the Attorney General determine whether registrations are in the public interest. To do so, the Attorney General is directed to consider multiple public interest factors, including “compliance with applicable State and local law.”

 

The University of Mississippi, pursuant to a contractual agreement with National Institute on Drug Abuse (“NIDA”), was the only federally authorized cannabis producer in the United States for years. In the face of unprecedented demand for cannabis manufacture for research necessitating more suppliers, the program at the University of Mississippi has faced significant criticism for its poor quality flower, mold issues, and limited availability of strains with levels of THC and CBD comparable to commercial cannabis products.

 

21
 

 

In recent years, the federal government has acknowledged the need for new suppliers. During his confirmation hearings in 2019, Attorney General Barr testified that he supported authorizing more facilities to cultivate cannabis in the U.S. for research purposes. In January 2020, a senior policy advisor for the DEA, Matthew J. Strait, testified before the House Energy and Commerce Committee regarding the DEA’s progress to date. Mr. Strait acknowledged concerns about the limited supply of research-grade cannabis and the lack of chemical diversity in the plants cultivated in Mississippi. He outlined the DEA’s various steps in the past few years to expand cannabis research and manufacturing capacity, including:

 

  ● In December 2015, the DEA announced to all existing Schedule I researchers that it was easing the requirements for obtaining a modification of their existing registration for those who wished to conduct research on cannabidiol (CBD).
  ● In early 2018, the DEA announced that it had developed and implemented an online portal for researchers to safely and securely submit their qualifications, research protocol and institutional approvals for a proposed Schedule I research registration thereby streamlining the acquisition of information necessary to process each application. Presently, the average time it takes for DEA and the FDA to review/approve an application is 52 days.
  ● On the manufacturing side, between 2017 and 2022, the DEA increased the aggregate production quota for cannabis by 575%, from 472 kg in 2017 to 3,200 kg in 2022. The increase has directly supported NIDA’s provision of various strains of cannabis to researchers in the United States.

 

In addition to these efforts, in 2016, the DEA began accepting new research cultivation applications under regulations developed by the Obama administration. However, no decisions were made on those applications, and, in August 2019, the DEA issued a notice to the pending applicants, stating that it would promulgate new regulations to govern the program of growing “marihuana” for scientific and medical research prior to issuing any registrations. During his testimony, Mr. Strait explained that the DEA is “actively taking steps to expand” the number of registered growers, and had recently sent draft regulations to facilitate licensing additional growers to the Office of Management and Budget.

 

Those draft regulations were published in late March 2020. Under the proposed regulations, the DEA will maintain sole ownership of all cannabis produced under the program, requiring growers to notify the DEA of an upcoming harvest up to four months’ in advance, or at a minimum, 15 days before a harvest. The DEA currently has roughly thirty-five outstanding applications for research cannabis cultivation licenses, and the agency said it expects to approve approximately five to thirteen suppliers once the rules are finalized after a public comment period, which has ended. The proposed rule provides that, with a limited exception, applications accepted for filing after the date the final rule becomes effective will not be considered pending until all applications accepted for filing on or before the date the final rule becomes effective have been granted or denied by the Administrator.

 

On December 18, 2020, the DEA finalized new regulations pertaining to applications by entities seeking to become registered with the DEA to grow cannabis as bulk manufacturers for research purposes and provide cannabis to other DEA registered manufacturers. Under these and other applicable regulations, applicants are responsible for demonstrating that they have met various requirements, including requirements to possess appropriate state authority, document that their customers are licensed to perform research, and employ adequate safeguards to prevent diversion. The DEA has registered a limited number of additional bulk manufacturers for the U.S. wholesale market for cannabis for research.

 

On May 14, 2021, the DEA announced that it planned to provide memorandums of agreement to an unspecified and unnamed number of companies to collaborate with the DEA “to facilitate the production, storage, packaging, and distribution of marijuana under the new regulations as well as other applicable legal standards and relevant laws.” The DEA’s final rule on the topic estimated that it would award licenses to between three and fifteen companies. To the extent these memorandums of agreement are finalized, the DEA anticipates issuing DEA registrations to these manufacturers. Each applicant will then be authorized to cultivate cannabis – up to an allotted quota – in support of the more than 575 DEA-licensed researchers across the nation. As of 2024, the DEA lists eight DEA-Registered cannabis manufacturers on its website. As individual manufacturers are granted DEA registrations, that information will be made available on DEA’s Diversion Control website. While other controlled substances the Company seeks DEA Registration for have not been as limited as cannabis for research, many are substances that have been historically understudied, and DEA has increased quotas for production of these substances due to increased research demand (for example, psilocybin and ibogaine). For both cannabis under the DEA program and for these other substances, the programs are either new or recently expanded due to research demand.

 

22
 

 

A denial of, or significant delay in obtaining, or any interruption of required government authorizations to grow cannabis and/or manufacture other controlled substances for federally sanctioned purposes would likely significantly, negatively impact us.

 

Our business plan depends heavily on receiving and maintaining the necessary state and federal authorizations to research cannabis and to grow cannabis, as well as to manufacture other controlled substances, for federally sanctioned research. Bright Green may not commence cannabis growing operations until both the State of New Mexico and the federal government, in particular the DEA, have signed off that Bright Green has met its obligations under state law and the MOA and is compliance with all applicable regulations. The same restriction applies to any expansion plans related to additional controlled substances as part of our “Drugs Made in America” plan. While the DEA has registered the Company to cultivate and manufacture cannabis, the registration is subject to an upcoming renewal in July 2024, and there is no guarantee that we will receive such renewal. We have not yet received DEA Registrations for the additional controlled substances that are part of our “Drugs Made in America” plan. The DEA’s denial of any authorizations or any delay in granting the authorization or renewal could have a significantly negative impact on our business plans, operations and financial results.

 

For the DEA Registration for bulk manufacturing of cannabis, BGC must comply with all terms agreed to in the MOA which include:

 

  ● submitting an Individual Procurement Quota on or before April 1 of each year utilizing DEA Form 250;
  ● submitting an Individual Manufacturing Quota on or before May 1 of each year utilizing DEA Form 189;
  ● collecting samples of cannabis and distributing them to DEA-registered analytical laboratories for chemical analysis during the pendency of cultivation and prior to the DEA’s taking possession of the cannabis grown;
  ● providing the DEA with 15-day advance written notification, via email, of its intent to harvest cannabis;
  ● following the DEA’s packaging, labeling, storage and transportation requirements;
  ● distributing DEA’s stocks of cannabis to buyers who entered into bona fide supply agreements with the Company; providing the DEA with 15-day advance written notification of its intent to distribute cannabis; and
  ● invoicing the DEA for harvested cannabis that it intends to sell to the DEA.

 

Furthermore, unless terminated for cause by the DEA, the MOA for the bulk manufacturing of cannabis is effective for an initial one-year term from its effective date, subject to automatic renewal for up to four additional one-year terms. There is no guarantee, however, that the needed authorizations will be obtained in the first place, or subsequently renewed at the one year or subsequent renewal terms. The authorizations for the “Drugs Made in America” controlled substances are pending.

 

Changes in the competitive landscape for cannabis and other controlled substances for federally sanctioned research could significantly, negatively impact us.

 

If the DEA awards additional Federal Registrations to grow cannabis for federally sanctioned research it would limit our competitive advantage. This would have a negative impact on our business plans, operations and financial results.

 

The U.S. wholesale market for cannabis and other controlled substances for research is of unknown size and is difficult to forecast.

 

BGC plans to operate in a novel market which currently only has seven other participants. The extent to which the DEA will expand the current cannabis research program, and the supply that the DEA will require from bulk manufacturers to furnish researchers with cannabis is unknown and unprecedented. Because this market is new and novel, there are risks to predicting the market size and the resulting revenue BGC will obtain from government contracts to supply cannabis researchers, should the DEA registration be obtained, and any such projections may prove inaccurate. The market for some of the other controlled substances that are part of our “Drugs Made in America” plan, is similarly novel and undeveloped, for example for psilocybin, ibogaine, mescaline, and other controlled substances.

 

We may not develop as many cannabis or controlled substances products or a crop of the consistency, quantity, or quality that we expect, which could have a negative adverse effect on our business plan and profitability.

 

Our success depends on our ability to attract and retain research and pharmaceutical customers, but we face competition in obtaining customers for our cannabis materials and products. There are many factors that could impact our ability to attract and retain customers, including our ability to successfully compete based on price, produce high quality or consistent crops, continually produce desirable and effective APIs and products that are superior to others in the market, and the successful implementation of our customer acquisition plan and the continued growth in the aggregate number of potential customers. Competition for customers may result in increasing our costs while also lowering the market prices for our products, and reduce our profitability. If we are not successful in attracting and retaining customers, we may fail to be competitive or achieve profitability or sustain profitability over time.

 

23
 

 

As a result of changing customer preferences, even among research or pharmaceutical customers, many products attain financial success for a limited period of time.

 

Even if we are successful in introducing new products, a failure to gain consumer acceptance or to update products with compelling attributes could cause a decline in our products’ popularity that could reduce revenues and harm our business, operating results and financial condition. Failure to introduce new products or product types and to achieve and sustain market acceptance could result in our being unable to meet consumer preferences and generate revenue, which would have a material adverse effect on our profitability and financial results from operations.

 

FDA regulation of cannabis could negatively affect the cannabis industry, which would directly affect our financial condition.

 

Should the federal government legalize cannabis, it is possible that the FDA would seek to regulate it under the Food, Drug and Cosmetics Act. After the U.S. government removed hemp and its extracts from the CSA as part of the Agriculture Improvement Act of 2018, the FDA Commissioner Scott Gottlieb issued a statement reminding the public of the FDA’s continued authority “to regulate products containing cannabis or cannabis-derived compounds under the Federal Food, Drug and Cosmetic Act and section 351 of the Public Health Service Act.” He also reminded the public that “it’s unlawful under the FDCA to introduce food containing added cannabidiol (“CBD”) or tetrahydrocannabinol (“THC”) into interstate commerce, or to market CBD or THC products, as, or in, dietary supplements, regardless of whether the substances are hemp-derived,” and regardless of whether health claims are made, because CBD and THC entered the FDA testing pipeline as the subject of public substantial clinical investigations for GW Pharmaceuticals’ Sativex (THC and CBD) and Epidiolex (CBD). Gottlieb’s statement added that, prior to introduction into interstate commerce, any cannabis product, whether derived from hemp or otherwise, marketed with a disease claim (e.g., therapeutic benefit, disease prevention, etc.) must first be approved by the FDA for its intended use through one of the drug approval pathways.

 

The FDA has sent numerous warning letters to sellers of CBD products making health claims. The FDA could turn its attention to the cannabis industry at large. In addition to requiring FDA approval of cannabis products marketed as drugs, the FDA could issue rules and regulations including certified good manufacturing practices related to the growth, cultivation, harvesting and processing of cannabis. It is also possible that the FDA would require that facilities where cannabis is grown register with the FDA and comply with certain federally prescribed regulations. Cannabis facilities are currently regulated by state and local governments. In the event that some or all of these federal enforcement and regulations are imposed, we do not know what the impact would be on our operations, including what costs, requirements and possible prohibitions may be enforced. If we are unable to comply with the regulations or registration as prescribed by the FDA, we may be unable to continue to operate our business in its proposed form or at all. There is no guarantee that cannabinoid products that may not be fully legal now will be able to be legally commercialized in the future or that Bright Green’s products or operations will meet any new FDA regulations or interpretations of the law, which could inhibit Bright Green’s business prospects even in the case that the federal government were to legalize cannabis.

 

Due to the FDA’s position on CBD, and because we are committed to complying with both state and federal laws, any legal restriction on the sale of products that containing extracts of cannabis could limit the legally accessible CBD/legal cannabinoid market for our proposed products.

 

24
 

 

Additionally, the FDA may, in the future, decide to regulate cannabis products, which could significantly accelerate or stall the development and sale of cannabis-based products. Currently, there is uncertainty regarding the FDA’s path forward regarding cannabis. If the FDA were to regulate cannabis, it is possible that it would distinguish between DEA-approved facilities like Bright Green’s, and commercial cannabis retailers selling directly to consumers in state-legal markets. Because Bright Green’s products are not going directly to consumers, and would only reach consumers via a prescription drug that has undergone FDA clinical trials and safety testing, it is likely that the majority of the FDA’s regulation would affect state-legal cannabis operators more so than Bright Green. However, the effect of future FDA regulation on cannabis remains uncertain and could also have an adverse effect on our business operations, operating costs, and performance. Moreover, there is no guarantee that the FDA will find our products safe or effective or grant us the required approvals under the FDCA, which may inhibit our business prospects even in the case that the federal government were to legalize cannabis, and could also create unforeseen costs created by requirements to comply with the FDCA. The same risks that apply to cannabis would also apply to many of our “Drugs Made in America” controlled substances should the FDA seek to regulate them.

 

Research in the United States, Canada and other countries on the medical benefits, viability, safety, efficacy and dosing of cannabis, isolated cannabinoids, and other controlled substances may cause adverse effects on our operations.

 

Historically stringent regulations related to cannabis and other Schedule I and Schedule II controlled substances have made conducting medical and academic studies challenging. Many statements concerning the potential medical benefits of cannabinoids are based on published articles and reports, and as a result, such statements are subject to the experimental parameters, qualifications and limitations in the studies that have been completed. Future research and clinical trials may draw different or negative conclusions regarding the medical benefits, viability, safety, efficacy, dosing or other facts and perceptions related to medical cannabis, and other controlled substances which have been similarly understudied, which could adversely affect social acceptance of cannabis and the demand for their products.

 

There can be no assurance that future scientific research, findings, regulatory proceedings, litigation, media attention, or other research findings or publicity will be favorable to the cannabis market or any particular controlled substance product or will be consistent with earlier publicity. Adverse future scientific research reports, findings and regulatory proceedings that are, or litigation, media attention or other publicity that is, perceived as less favorable than, or that questions, earlier research reports, findings or publicity (whether or not accurate or with merit) could result in a significant reduction in the demand for the cannabis products of a portfolio company. Further, adverse publicity reports or other media attention regarding the safety, efficacy and quality of cannabis (or other controlled substances we seek to produce, such as psilocybin), or our products specifically, or associating the consumption of cannabis or other controlled substances with illness or other negative effects or events, could adversely affect our business. This adverse publicity could arise even if the adverse effects associated with cannabis or other controlled substances products resulted from consumers’ failure to use such products legally, appropriately or as directed.

 

The very dynamic nature of the laws and regulations affecting the cannabis market, the federal authorization of cannabis for research, or the state-regulated cannabis industry could materially adversely affect our proposed operations, and we cannot predict the impact that future laws or regulations may have on us.

 

Local, state and federal cannabis laws and regulations have been evolving rapidly and are subject to varied interpretations, which could require us to incur substantial costs associated with compliance or alter our business plan and could negatively impact our business plan or business. We can know neither the nature of any future laws, regulations, interpretations or applications nor the effect additional governmental regulations or administrative policies and procedures, when and if promulgated, could have on our business. For example, if cannabis is no longer illegal under federal law, and depending on future laws or guidance on cannabis for research, we may experience a significant increase in competition. Accordingly, any change in these laws or regulations, changes in their interpretation, or newly enacted laws or regulations and any failure by us to comply with these laws or regulations could require changes to certain of our business practices, negatively impact our operations, cash flow or financial condition, impose additional costs on us or otherwise adversely affect our business.

 

25
 

 

Operating in a highly regulated business requires significant resources.

 

We intend to operate in a highly regulated business. As a result, we expect a significant amount of our management’s time and external resources to be used to comply with the laws, regulations and guidelines that impact our business, and changes thereto, and such compliance may place a significant burden on our management and other resources.

 

Additionally, we may be subject to a variety of laws, regulations and guidelines in each of the jurisdictions in which we distribute cannabis and where we plan to distribute other controlled substances, which may differ among these various jurisdictions. Complying with multiple regulatory regimes will require additional resources and may impede our ability to expand into certain jurisdictions. For example, even if cannabis were to become legal under U.S. federal law, companies operating in the cannabis industry would have to comply with all applicable state and local laws, which may vary greatly between jurisdictions, increasing costs for companies that operate in multiple jurisdictions.

 

The uncertainties around funding, construction, and growing an agricultural crop pose risks to our business.

 

Our planned operations are contingent on completion of raising significant additional funding for the construction of certain facilities in Grants, New Mexico. We need significant additional capital to build out the properties, and the timing and terms of obtaining that capital are uncertain. It is also possible that we may not be able to raise the capital required for our construction plans.

 

Delays in obtaining the capital, onerous terms for the capital, or a failure to raise the significant capital required could have a material, negative impact on business or plans of operations. Furthermore, we will be an agricultural supplier and will be subject to agricultural risks related to issues such as climate change, natural disasters or pests. In particular, there could be difficulties with the first crop or harvest in any new facility.

 

The cannabis industry is subject to the risks inherent in an agricultural business, including environmental factors and the risk of crop failure.

 

The growing of cannabis is an agricultural process. The same applies to cultivating or propagating other controlled substances. As such we are subject to the risks inherent to an the agricultural business, including risks of crop failure presented by weather, climate change, water scarcity, fires, insects, plant diseases and similar agricultural risks. Although some cannabis production is conducted indoors under climate-controlled conditions, cannabis continues to be grown outdoors, and in our case, in greenhouses using natural light, which is susceptible to climate change, and there can be no assurance that artificial or natural elements, such as insects and plant diseases, will not entirely interrupt production activities or have an adverse effect on the production of cannabis and, accordingly, our operations, which could have an adverse effect on our business, financial condition and results of operations.

 

We may be vulnerable to rising energy costs, and an increase or volatility in energy prices may adversely affect our business and results of operations.

 

Cannabis and controlled substances growing operations consume considerable energy, which makes us vulnerable to rising energy costs and/or the availability of stable energy sources. Accordingly, rising or volatile energy costs or the inability to access stable energy sources may have a material adverse effect on our business, financial condition and results of operations.

 

26
 

 

We are subject to environmental regulations and laws, and failure to timely or completely comply with such regulations and laws, or failure to obtain or maintain applicable licenses, may adversely affect our business.

 

Cultivation and production activities may be subject to licensing requirements relating to environment regulation. Environmental legislation and regulations are evolving in such a manner that may result in stricter standards and enforcement, larger fines and liability and potentially increased capital expenditures and operating costs. The application of environmental laws to our business may cause us to increase the costs of our cultivation, production or scientific activities. Unanticipated licensing delays can result in significant delays and expenses related to compliance with new environmental regulations, and cost overruns in our business and could affect our financial condition and results of operations. There can be no assurance that these delays will not occur.

 

The growth of our business continues to be subject to new and changing federal, state, and local laws and regulations.

 

Continued development of the cannabis industry is dependent upon further legalization of cannabis at the state level, and a number of factors could slow or halt progress in this area, even where there is public support for legislative action. Any delay or halt in the passing or implementation of legislation legalizing cannabis use, or its cultivation, manufacturing, processing, transportation, distribution, storage and/or sale, or the re-criminalization or restriction of cannabis at the state level, could negatively impact our business, even though we are primarily regulated by the DEA. Additionally, changes in applicable federal, state, and local regulations, including zoning restrictions, environmental requirements, FDA compliance, security requirements, or permitting requirements and fees, could restrict the products and services we may offer or impose additional compliance costs on us. Violations of applicable laws, or allegations of such violations, could disrupt our business and result in a material adverse effect on our operations. We cannot predict the nature of any future laws, regulations, interpretations or applications, including local, state, federal, or environmental, and it is possible that regulations may be enacted in the future that will be materially adverse to our business or which would have materially significant costs of compliance which could negatively impact our business.

 

We are subject to risks, including delays, from our ongoing and future construction projects, which may result from reliance on third parties, delays relating to material delivery and supply chains, and fluctuating material prices, among other factors.

 

We are subject to several risks in connection with the construction of our projects, including the availability and performance of engineers and contractors, suppliers and consultants, the availability of funding, and the receipt of required governmental approvals, licenses and permits, and the projected timeline for construction, which could change due to delays. Any delay in the performance of any one or more of the contractors, suppliers, consultants or other persons on which we are dependent in connection with our construction activities, a delay in or failure to receive or renew the required governmental approvals, licenses and permits in a timely manner or on reasonable terms, or a delay in or failure in connection with the completion and successful operation of the operational elements in connection with construction could delay or prevent the construction of the additional phases of the facilities as planned. There can be no assurance that current or future construction plans implemented by us will be successfully completed on time, within budget and without design defect, that the necessary personnel and equipment will be available in a timely manner or on reasonable terms to complete construction projects successfully, that we will be able to obtain all necessary governmental approvals, licenses and permits, or that the completion of the construction, the start-up costs and the ongoing operating costs will not be significantly higher than anticipated by us. Any of the foregoing factors could adversely impact our operations and financial condition.

 

The costs to procure such materials and services to build new facilities may fluctuate widely based on the impact of numerous factors beyond our control including, international, economic and political trends, foreign currency fluctuations, expectations of inflation, global or regional consumptive patterns, speculative activities and increased or improved production and distribution methods.

 

27
 

 

Global demand on shipping and transport services may cause us to experience delays in the future, which could impact our ability to obtain materials or build our facilities in a timely manner. These factors could otherwise disrupt our operations and could negatively impact our business, financial condition and results of operations.

 

Logistical problems, unexpected costs, and delays in facility construction, which we cannot control, can cause prolonged disruption to or increased costs of third-party transportation services used to ship materials, which could negatively affect our facility building schedule, and more generally our business, financial condition, results of operations and prospects. If we experience significant unexpected delays in construction, we may have to delay or limit our production depending on the timing and extent of the delays, which could harm our business, financial condition and results of operation.

 

Product recalls could adversely affect our business.

 

Our products could become subject to recall or return for various reasons, including product defects, such as contamination, unintended harmful side effects or interactions with other substances, packaging safety and inadequate or inaccurate labeling disclosure. If any of our products are recalled due to an alleged product defect, regulatory requirements or for any other reason, we could be required to incur the unexpected expense of the recall and any legal proceedings that might arise in connection with the recall. We may lose a significant amount of sales and may not be able to replace those sales at an acceptable margin or at all. In addition, a product recall may require significant management attention. Recall of products could lead to adverse publicity, decreased demand for our products and could have significant reputational and brand damage. Although we have detailed procedures in place for testing finished products, there can be no assurance that any quality, potency or contamination problems will be detected in time to avoid unforeseen product recalls, regulatory action or lawsuits. A recall for any of the foregoing reasons could lead to decreased demand for our products and could have a material adverse effect on our results of operations and financial condition. Additionally, product recalls may lead to increased scrutiny of our operations by health authorities or regulatory agencies where the Company operates or products are sold, requiring further management attention and potential legal fees and other expenses.

 

Our planned future sale of cannabis and controlled substances products could expose us to significant product liability risks.

 

We may be subject to various product liability claims, including, among others, that our products caused injury or illness, include inadequate instructions for use or include inadequate warnings concerning possible side effects or interactions with other substances. A product liability claim or regulatory action against us could result in increased costs, could adversely affect our reputation with our clients and consumers generally, and could have a material adverse effect on our business, financial condition and results of operations. There can be no assurances that we will be able to obtain or maintain product liability insurance on acceptable terms or with adequate coverage against potential liabilities. Such insurance is expensive and may not be available in the future on acceptable terms, or at all. The inability to obtain sufficient insurance coverage on reasonable terms or to otherwise protect against potential product liability claims could prevent or inhibit the commercialization of our potential products.

 

Recent Enforcement by U.S. Customs and Border Protection (CBP) against State Legal Cannabis in New Mexico Could Disrupt Transport of Our Products and Reduce Our Profitability

 

Recently, U.S. Customs and Border Protection (“CBP”) has conducted several seizures of state-legal cannabis products at interior checkpoints in New Mexico, around the Las Cruces area. These seizures have involved detaining industry workers, confiscating hundreds of pounds of cannabis, and disrupting the transportation of products from southern New Mexico to testing facilities and retailers in the central and northern parts of the state. This may represent a policy change at CBP that is inconsistent with current federal non-enforcement of state-legal operations, and has raised concerns among industry stakeholders and state lawmakers. While our Company’s cannabis products are federally legal, unlike state-legal cannabis that has been seized by CBP in New Mexico, the confusion around the laws by a government agency like CBP could still result in our product being seized, or the transport of our product being disrupted. The loss of product due to a seizure by CBP could interrupt our business and cause us to lose profitability, particularly if it is a key shipment that is disrupted by CBP intervention. Additionally, a seizure of our legal products would require significant management attention and potential legal fees and other expenses.

 

A significant failure or deterioration in our quality control systems could have a material adverse effect on our business and operating results.

 

The quality and safety of our products are critical to the success of our business and operations. As such, it is imperative that our (and our service providers’) quality control systems operate effectively and successfully. Quality control systems can be negatively impacted by the design of the quality control systems, the quality training programs and adherence by employees to quality control guidelines. Although we strive to ensure that all of our service providers have implemented and adhere to high-quality control systems, any significant failure or deterioration of such quality control systems could have a material adverse effect on our business and operating results.

 

28
 

 

We are subject to liability arising from any fraudulent or illegal activity by our employees, contractors and consultants.

 

We are exposed to the risk that our employees, independent contractors and consultants may engage in fraudulent or other illegal activity. Misconduct by these parties could include intentional, reckless, or negligent conduct or disclosure of unauthorized activities to us that violate (i) government regulations, (ii) manufacturing standards, (iii) federal, state and provincial healthcare fraud and abuse laws and regulations, or (iv) laws that require the true, complete and accurate reporting of financial information or data. It is not always possible for us to identify and deter misconduct by our employees and other third parties, and the precautions taken by us to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any actions are brought against us, including by former employees, independent contractors or consultants, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of civil, criminal and administrative penalties, damages, monetary fines, contractual damages, reputational harm, diminished profits and future earnings, and the curtailment of our operations, any of which would have an adverse effect on our business, financial condition and results from operations.

 

We will need to raise substantial additional funds in the future, which funds may not be available or, if available, may not be available on acceptable terms.

 

Designing and constructing cultivation, processing and distribution facilities and cultivating and producing cannabis and other controlled substances is expensive. Changing circumstances may cause us to consume capital more rapidly than we currently anticipate. For example, we may incur costs for the design and construction of cultivation, processing and dispensary facilities that greatly exceed our current budget for such projects. Alternatively, we may identify opportunities to acquire additional cannabis licenses or other controlled substances licenses that we believe would be beneficial to us. The acquisition of such licenses, and the cost of acquiring the related cultivation, processing or distribution facilities or, if not in existence or completed, the design and construction of such facilities may require substantial capital. In such events, we may need to raise additional capital to fund the completion of any such projects.

 

Furthermore, the cannabis industry is in its early stages and it is likely that we and our competitors will seek to introduce new products in the future which may include new genetic formulations. In attempting to keep pace with any new market developments, we will need to expend significant amounts of capital to successfully develop and generate revenues from new products, including new genetic formulations. We may also be required to obtain additional regulatory approvals from applicable authorities based on the jurisdictions in which we plan to distribute our products, which may take significant time. We may not be successful in developing effective and safe new products, bringing such products to market in time to be effectively commercialized or obtaining any required regulatory approvals, which together with capital expenditures made in the course of such product development and regulatory approval processes, may have a material adverse effect on our business, financial condition and results of operations.

 

29
 

 

We may need to raise additional funds in the future to support our operations. If we are required to secure additional financing, such additional fundraising efforts may divert our management from our day-to-day activities, and we may be required to:

 

  ● significantly delay, scale back or discontinue the design and construction of any cultivation, processing and dispensary facilities for which we are awarded licenses or
  ● relinquish any cultivation, processing and dispensary licenses that we are awarded, or sell any cultivation, processing or distribution facilities that we are designing and constructing.

 

If we are required to conduct additional fundraising activities and we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may be prevented from executing upon our business plan. This would have a material adverse effect on our business, financial condition and results of operations.

 

There is no guarantee that we will be able to continue to raise funds through our EB-5 Program, if and when such program receives requisite regulatory approvals.

 

On February 1, 2023, we initiated our EB-5 Program, whereby we may issue up to an aggregate of 12,609,152 shares of common stock to accredited or institutional investors, at a price of $39.99 per share. As of the date of this Annual Report, we have issued an aggregate of 44,010 shares.

 

On March 29, 2024, we modified our private placement offering authorizing 20,000,000 shares to be sold at $2.00 per share pursuant to the U.S. government’s EB-5 immigrant investor program.

 

There is no guarantee that we will raise sufficient funds under the EB-5 Program to avoid the need for parallel fundraising activities. If we are required to conduct additional fundraising activities and we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may be prevented from executing upon our business plan. This would have a material adverse effect on our business, financial condition and results of operations. See “Item 1A. Risk Factors – We will need to raise substantial additional funds in the future, which funds may not be available or, if available, may not be available on acceptable terms”, and “Item 1. Business – Bright Green EB-5 Program” for more information.

 

We are dependent on our banking relations, and while we currently have a stable banking relationship and operate in compliance with all applicable laws, we could have difficulty accessing or consistently maintaining banking or other financial services due to banks’ risk aversion toward serving even legal parts of the cannabis industry.

 

We are dependent on the banking industry to support the financial functions of our company. Our business operating functions including payroll for our employees and other expenses and transactions which are reliant on traditional banking. Additionally, we anticipate that our clients will pay us via wire transfer to our bank accounts, or via checks that we deposit into our banks. We require access to banking services for both us and our clients to receive payments in a timely manner. Lastly, to the extent we rely on any lines of credit, these could be affected by our relationships with financial institutions and could be jeopardized if we lose access to a bank account.

 

30
 

 

Important components of our offerings depend on client accounts and relationships, which in turn depend on banking functions. Most federal and federally-insured state banks currently do not serve businesses that grow and sell cannabis products under state laws on the stated ground that growing and selling cannabis is illegal under federal law, even though the Treasury Department’s Financial Crimes Enforcement Network (“FinCEN”), issued guidelines to banks in February 2014 that clarified how financial institutions can provide services to cannabis-related businesses, consistent with financial institutions’ obligations under the Bank Secrecy Act. The continued uncertainty surrounding financial transactions related to federally-illegal cannabis activities and the subsequent risks this uncertainty presents to financial institutions may result in their discontinuing services to the cannabis industry or limit their ability to provide services to the cannabis industry or even federally-legal cannabis businesses like ours, because of the misperception that we are a cannabis business like federally illegal ones are. While we are not transacting in any way with non-federally legal cannabis, it is possible that banks could view us as a risk because of our association with cannabis or a misunderstanding of our legal status.

 

While our business is federally legal and complies with the CSA, it is possible we could still face banking difficulties. Banks have and may continue to consider us to be part of the cannabis industry that is subject to banking restrictions. If we were to lose any of our banking relationships or fail to secure additional banking relationships in the future, we could experience difficulty and incur increased costs in the administration of our business, paying our employees, accepting payments from clients, each of which may adversely affect our reputation or results of operations. Additionally, the closure of many or one of our bank accounts due to a bank’s reluctance to provide services to a cannabis business, even though we are operating legally under U.S. law, would require significant management attention from us and could materially adversely affect our business and operations.

 

31
 

 

We may engage in future acquisitions or strategic transactions, which may require us to seek additional financing or financial commitments, increase our expenses and/or present significant distractions to our management.

 

In the event we engage in an acquisition or strategic transaction, we may need to acquire additional financing (particularly, if the acquired entity is not cash flow positive or does not have significant cash on hand). Obtaining financing through the issuance or sale of additional equity and/or debt securities, if possible, may not be at favorable terms and may result in additional dilution to our current stockholders. Additionally, any such transaction may require us to incur non-recurring or other charges, may increase our near and long-term expenditures and may pose significant integration challenges or disrupt our management or business, which could adversely affect our operations and financial results. For example, an acquisition or strategic transaction may entail numerous operational and financial risks, including the risks outlined above and additionally:

 

  ● exposure to unknown liabilities;
  ● disruption of our business and diversion of our management’s time and attention in order to develop acquired products or technologies;
  ● higher than expected acquisition and integration costs;
  ● write-downs of assets or goodwill or impairment charges;
  ● increased amortization expenses;
  ● difficulty and cost in combining the operations and personnel of any acquired businesses with our operations and personnel;
  ● impairment of relationships with key suppliers or customers of any acquired businesses due to changes in management and ownership; and
  ● inability to retain key employees of any acquired businesses.

 

Accordingly, although there can be no assurance that we will undertake or successfully complete any transactions of the nature described above, and any transactions that we do complete could have a material adverse effect on our business, results of operations, financial condition and prospects.

 

Risks Related to our Business and Operations - Intellectual Property

 

We may be forced to litigate to defend our intellectual property rights, or to defend against claims by third parties against us relating to intellectual property rights.

 

We may be forced to litigate to enforce or defend our intellectual property rights, to protect our trade secrets or to determine the validity and scope of other parties’ proprietary rights. Any such litigation could be very costly and could distract our management from focusing on operating our business. The existence and/or outcome of any such litigation could harm our business.

 

We are subject to risks related to information technology systems, including cyber-security risks; successful cyber-attacks or technological malfunctions can result in, among other things, financial losses, the inability to process transactions, the unauthorized release of confidential information and reputational risk, all of which would negatively impact our business, financial condition or results of operations.

 

Our use of technology is critical to our continued operations. We are susceptible to operational, financial and information security risks resulting from cyber-attacks or technological malfunctions. Successful cyber-attacks or technological malfunctions affecting us or our service providers can result in, among other things, financial losses, the inability to process transactions, the unauthorized release of confidential or proprietary information and reputational risk. As cybersecurity threats continue to evolve, we may be required to use additional resources to continue to modify or enhance protective measures or to investigate security vulnerabilities, which could have a material adverse effect on our business, financial condition or results of operations.

 

32
 

 

We are reliant on our intellectual property; failure to protect our intellectual property could negatively affect our business, financial condition or results of operations.

 

Our success will depend in part on our ability to use and develop new extraction technologies, know-how and new strains of cannabis. We may be vulnerable to competitors who develop competing technology, whether independently or as a result of acquiring access to the proprietary products and trade secrets of acquired businesses. In addition, effective future patent, copyright and trade secret protection may be unavailable or limited in the U.S. due to federal illegality or in foreign countries and may be unenforceable under the laws of some jurisdictions. Failure to adequately maintain and enhance protection over our proprietary techniques and processes, as well as over our unregistered intellectual property, including policies, procedures and training manuals, could have a material adverse effect on our business, financial condition or results of operations.

 

Risks Related to Ownership of Our Common Stock

 

Our common stock has a limited trading history and an active trading market may not develop or continue to be liquid, and the market price of our shares of common stock may be volatile.

 

Our common stock is listed and traded on Nasdaq. Prior to the listing on Nasdaq, there had not been a public market for our common stock, and an active market for our common stock may not develop or be sustained, which could depress the market price of our securities and could affect the ability of our stockholders to sell our common stock at favorable prices. In the absence of an active public trading market, investors may not be able to liquidate their investments in our shares of common stock. An inactive market may also impair our ability to raise capital by selling our common stock or equity-linked securities, our ability to motivate our employees through equity incentive awards and our ability to acquire other companies, products or technologies by using our common stock or equity-linked securities consideration. Further, the market price of our common stock has been and may continue to be, volatile. Between May 17, 2022, the date our common stock began trading on Nasdaq, and April 11, 2024, the market price of our common stock ranged from a high of $58.00 on May 18, 2022 to a low of $0.1501 on February 13, 2024.

 

The market price of our common stock has been extremely volatile and may continue to be volatile due to numerous circumstances beyond our control.

 

The market price of our common stock has fluctuated, and may continue to fluctuate, widely, due to many factors, some of which may be beyond our control. These factors include, without limitation:

 

  ● “short squeezes”;
  ● comments by securities analysts or other third parties, including blogs, articles, message boards and social and other media;
  ● an increase or decrease in the short interest in our common stock ;
  ● actual or anticipated fluctuations in our financial and operating results;
  ● risks and uncertainties associated with events and macroeconomics events such as the ongoing COVID-19 pandemic, fluctuations in U.S. interest rates and rapid inflation; and
  ● overall general market fluctuations.

 

Publicly traded companies’ stock prices in general, and our stock price in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of those companies and our company. For example, between May 17, 2022, the date our common stock began trading on Nasdaq, and April 11, 2024, the market price of our common stock ranged from a high of $58.00 on May 18, 2022 to a low of 0.1501 on February 13, 2024. These broad market fluctuations may adversely affect the trading price of our common stock. In particular, a proportion of our common stock has been, and may continue to be, traded by short sellers which may put pressure on the supply and demand for our common stock, further influencing volatility in the market price. Additionally, these and other external factors have caused, and may continue to cause, the market price and demand of our common stock to fluctuate, which may limit or prevent investors from readily selling their shares of common stock and may otherwise negatively affect the liquidity of our common stock.

 

33
 

 

A “short squeeze” due to a sudden increase in demand for shares of our common stock could lead to extreme price volatility in shares of our common stock.

 

Investors may purchase shares of our common stock to hedge existing exposure or to speculate on the price of our common stock. Speculation of the price of our common stock may lead to long and short exposures. To the extent aggregate short exposure exceeds the number of shares of our common stock available for purchase on the open market, investors with short exposure may have to pay a premium to repurchase shares of our common stock for delivery to lenders of our common stock. Those repurchases may in turn, dramatically increase the price of our common stock until additional shares of our common stock are available for trading or borrowing. This is often referred to as a “short squeeze.” A proportion of our common stock has been, and may continue to be, traded by short sellers which may increase the likelihood that our common stock will be the target of a short squeeze. A short squeeze could lead to volatile price movements in shares of our common stock that are unrelated or disproportionate to our operating performance and, once investors purchase the shares of our common stock necessary to cover their short positions, the price of our common stock may rapidly decline. Investors that purchase shares of our common stock during a short squeeze may lose a significant portion of their investment.

 

You may be diluted by issuances of preferred stock or additional common stock in connection with our incentive plans, acquisitions or otherwise; future sales of such shares in the public market, or the expectations that such sales may occur, could lower our stock price.

 

Our certificate of incorporation, as amended and restated, authorizes us to issue up to 500,000,000 shares of common stock and up to 10,000,000 shares of preferred stock. Additionally, our amended and restated certificate of incorporation which authorizes us to issue shares of common stock and options, rights, warrants and appreciation rights relating to our common stock for the consideration and on the terms and conditions established by our Board of Directors (the “Board”), in its sole discretion. We could issue a significant number of shares of common stock in the future in connection with investments or acquisitions. Any of these issuances could dilute our existing stockholders, and such dilution could be significant. Moreover, such dilution could have a material adverse effect on the market price for the shares of our common stock.

 

The future issuance of shares of preferred stock with voting rights may adversely affect the voting power of the holders of shares of our common stock, either by diluting the voting power of our common stock if the preferred stock votes together with the common stock as a single class, or by giving the holders of any such preferred stock the right to block an action on which they have a separate class vote, even if the action were approved by the holders of our shares of our common stock.

 

The future issuance of shares of preferred stock with dividend or conversion rights, liquidation preferences or other economic terms favorable to the holders of preferred stock could adversely affect the market price for our common stock by making an investment in the common stock less attractive. For example, investors in the common stock may not wish to purchase common stock at a price above the conversion price of a series of convertible preferred stock because the holders of the preferred stock would effectively be entitled to purchase common stock at the lower conversion price, causing economic dilution to the holders of common stock.

 

On December 12, 2022, our stockholders approved the Bright Green Corporation 2022 Omnibus Equity Compensation Plan (the “Plan”). An aggregate of 13,547,384 shares of common stock are reserved for issuance under the Plan, and awards under the Plan may come in the form of options (including non-qualified options and incentive stock options), SARs, restricted shares, performance shares, deferred stock, restricted stock units, dividend equivalents, bonus shares or other stock-based awards .

 

The future exercise of registration rights may adversely affect the market price of our common stock.

 

Certain of our stockholders have registration rights for restricted securities. In addition, certain registration rights holders can request underwritten offerings to sell their securities. These sales, or the perception in the market that the holders of a large number of shares intend to sell shares, could reduce the market price of our common stock.

 

34
 

 

We do not anticipate paying any cash dividends on our common stock in the foreseeable future.

 

We currently intend to retain our future earnings, if any, for the foreseeable future, to fund the development and growth of our business. We do not intend to pay any dividends to holders of our common stock in the foreseeable future. Any decision to declare and pay dividends in the future will be made at the discretion of our Board taking into account various factors, including our business, operating results and financial condition, current and anticipated cash needs, plans for expansion, any legal or contractual limitations on our ability to pay dividends under our loan agreements or otherwise. As a result, if our Board does not declare and pay dividends, the capital appreciation in the price of our common stock, if any, will be your only source of gain on an investment in our common stock, and you may have to sell some or all of your common stock to generate cash flow from your investment.

 

If securities or industry analysts do not publish research or reports about our business, or if they downgrade their recommendations regarding our common stock, its trading price and volume could decline.

 

We expect the trading market for our common stock to be influenced by the research and reports that industry or securities analysts publish about us, our business or our industry. As a new public company, we do not currently have and may never obtain research coverage by securities and industry analysts. If no securities or industry analysts commence coverage of our company, the trading price for our stock may be negatively impacted. If we obtain securities or industry analyst coverage and if one or more of these analysts cease coverage of our company or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline and our common stock to be less liquid. Moreover, if one or more of the analysts who cover us downgrades our stock or publishes inaccurate or unfavorable research about our business, or if our results of operations do not meet their expectations, our stock price could decline.

 

We are an “emerging growth company,” and our election to comply with the reduced disclosure requirements as a public company may make our common stock less attractive to investors.

 

For so long as we remain an “emerging growth company” as defined in the JOBS Act, we may take advantage of certain exemptions from various requirements that are applicable to public companies that are not “emerging growth companies,” including not being required to comply with the independent auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002 (the “Sarbanes-Oxley Act”), reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, being required to provide fewer years of audited financial statements, and exemptions from the requirements of holding a non-binding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. We may lose our emerging growth company status and become subject to the SEC’s internal control over financial reporting management and auditor attestation requirements. If we are unable to certify the effectiveness of our internal controls, or if our internal controls have a material weakness, we could be subject to regulatory scrutiny and a loss of confidence by stockholders, which could harm our business and adversely affect the market price of our common stock.

 

We will cease to be an “emerging growth company” upon the earliest to occur of: (i) the last day of the fiscal year in which we have more than $1.235 billion in annual revenue; (ii) the date we qualify as a large accelerated filer, with at least $700 million of equity securities held by non-affiliates; (iii) the date on which we have, in any three-year period, issued more than $1.0 billion in non-convertible debt securities; and (iv) the last day of the fiscal year following the fifth anniversary of becoming a public company. As an emerging growth company, we may choose to take advantage of some but not all of these reduced reporting burdens. Accordingly, the information we provide to our stockholders may be different than the information you receive from other public companies in which you hold stock. In addition, the JOBS Act also provides that an “emerging growth company” can take advantage of an extended transition period for complying with new or revised accounting standards.

 

35
 

 

We have elected to take advantage of this extended transition period under the JOBS Act. As a result, our operating results and financial statements may not be comparable to the operating results and financial statements of other companies who have adopted the new or revised accounting standards. It is possible that some investors will find our common stock less attractive as a result, which may result in a less active trading market for our common stock and higher volatility in our stock price.

 

We are a “smaller reporting company,” and our election to comply with the reduced disclosure requirements as a public company may make our common stock less attractive to investors.

 

For so long as we remain a smaller reporting company, we are permitted and intend to rely on exemptions from certain disclosure and other requirements that are applicable to other public companies that are not smaller reporting companies, such as providing only two years of audited financing statements. We may continue to be a smaller reporting company if either (i) the market value of our stock held by non-affiliates is less than $250 million measured on the last business day of our second fiscal quarter or (ii) our annual revenue is less than $100 million during the most recently completed fiscal year and the market value of our stock held by non-affiliates is less than $700 million measured on the last business day of our second fiscal quarter.

 

If we are a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. It is possible that some investors will find our common stock less attractive as a result, which may result in a less active trading market for our common stock and higher volatility in our stock price.

 

Provisions of our amended and restated certificate of incorporation and bylaws may delay or prevent a take-over that may not be in the best interests of our stockholders.

 

Provisions of our amended and restated certificate of incorporation and bylaws may be deemed to have anti-takeover effects, which include when and by whom special meetings of our stockholders may be called, and may delay, defer or prevent a takeover attempt.

 

In addition, our amended and restated certificate of incorporation authorizes the issuance of shares of preferred stock which will have such rights and preferences determined from time to time by our Board. Our Board may, without stockholder approval, issue additional preferred shares with dividends, liquidation, conversion, voting or other rights that could adversely affect the voting power or other rights of the holders of our common stock.

 

The choice of forum provision in our amended and restated bylaws, could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or colleagues.

 

Our amended and restated bylaws, provide that, unless we consent in writing to the selection of an alternative forum, the sole and exclusive forum for any derivative action or proceeding brought on behalf of us, any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers or other employees to us or our stockholders, any action asserting a claim arising pursuant to any provision of the DGCL, or any action asserting a claim governed by the internal affairs doctrine, shall be a state or federal court located within the state of Delaware, in all cases subject to the court’s having personal jurisdiction over the indispensable parties named as defendants. The choice of forum provisions may limit a stockholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other colleagues, which may discourage such lawsuits against us and our directors, officers and other colleagues. Alternatively, if a court were to find such choice of forum provisions to be inapplicable or unenforceable in an action, including but not limited to claims brought in connection with the Securities Act of 1934, as amended (the “Securities Act”), or Exchange Act, we may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect our business and financial condition. Investors are unable to waive compliance with U.S. federal securities laws and the rules and regulations thereunder.

 

36
 

 

The forum selection provision is intended to apply “to the fullest extent permitted by applicable law,” subject to certain exceptions. Section 27 of the Exchange Act creates exclusive federal jurisdiction over all suits brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder. As a result, the exclusive forum provision will not apply to suits brought to enforce any duty or liability created by the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction. In addition, the exclusive forum provision will not apply to actions brought under the Securities Act, or the rules and regulations thereunder.

 

This choice of forum provision may limit a stockholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or any of our directors, officers, other employees or stockholders, which may discourage lawsuits with respect to such claims. As such, stockholders of the Company seeking to bring a claim regarding the internal affairs of the Company may be subject to increased costs associated with litigating in Delaware as opposed to their home state or other forum, precluded from bringing such a claim in a forum they otherwise consider to be more favorable, and discouraged from bringing such claims as a result of the foregoing or other factors related to forum selection. Alternatively, if a court were to find the choice of forum provision contained in our amended and restated bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could harm our business, operating results and financial condition.

 

The requirements of being a public company may strain our resources, divert management’s attention and affect our ability to attract and retain executive management and qualified board members.

 

As a public company, we are subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act, the Dodd-Frank Act, and other applicable securities rules and regulations. Compliance with these rules and regulations involves significant legal and financial compliance costs, may make some activities more difficult, time-consuming or costly and may increase demand on our systems and resources, particularly after we are no longer an “emerging growth company,” as defined in the JOBS Act. The Exchange Act requires, among other things, that we file annual, quarterly and current reports with respect to our business and operating results. The Sarbanes-Oxley Act requires, among other things, that we maintain effective disclosure controls and procedures and internal control over financial reporting. In order to maintain and, if required, improve our disclosure controls and procedures and internal control over financial reporting to meet this standard, significant resources and management oversight may be required. As a result, management’s attention may be diverted from other business concerns, which could adversely affect our business and operating results. We may need to hire more employees in the future or engage outside consultants, which will increase our costs and expenses.

 

In addition, changing laws, regulations and standards relating to corporate governance and public disclosure are creating uncertainty for public companies, increasing legal and financial compliance costs and making some activities more time-consuming. These laws, regulations and standards are subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as regulatory and governing bodies provide new guidance. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. We intend to invest resources to comply with evolving laws, regulations and standards, and this investment may result in increased general and administrative expenses and a diversion of management’s time and attention from revenue-generating activities to compliance activities. If our efforts to comply with new laws, regulations and standards differ from the activities intended by regulatory or governing bodies due to ambiguities related to their application and practice, regulatory authorities may initiate legal proceedings against us, and our business may be adversely affected.

 

37
 

 

However, for as long as we remain an “emerging growth company,” we may take advantage of certain exemptions from various reporting requirements that are applicable to public companies that are not “emerging growth companies” including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. We may take advantage of these reporting exemptions until we are no longer an “emerging growth company.” We would cease to be an “emerging growth company” upon the earliest of: (i) the last day of the fiscal year following the fifth anniversary the last day of the fiscal year ending after the fifth anniversary of the listing of our common stock on Nasdaq; (ii) the first fiscal year after our annual gross revenues are $1.235 billion or more; (iii) the date on which we have, during the previous three-year period, issued more than $1.0 billion in non-convertible debt securities; or (iv) as of the end of any fiscal year in which the market value of the common stock held by non-affiliates exceeded $700 million as of the end of the second quarter of that fiscal year.

 

As a result of disclosure of information in this Annual Report and in filings required of a public company, our business and financial condition are highly visible, which may result in threatened or actual litigation, including by competitors and other third parties. If such claims are successful, our business and operating results could be adversely affected, and even if the claims do not result in litigation or are resolved in our favor, these claims, and the time and resources necessary to resolve them, could divert the resources of our management and adversely affect our business and operating results.

 

We are subject to additional regulatory burdens as a public company.

 

We are required to operate, maintain and oversee financial management control systems to manage our obligations as a public company listed on Nasdaq and registered with the SEC. These areas include corporate governance, corporate controls, disclosure controls and procedures and financial reporting and accounting systems. We expended significant resources to improve these systems in preparation for becoming a public company, and continue to review and improve these systems, but we cannot assure holders of our common stock that these and other measures we might take will be sufficient to allow us to satisfy our obligations as a public company. In addition, compliance with reporting and other requirements applicable to public companies listed on Nasdaq create additional costs for us and require management’s time and attention. We cannot predict the amount of the additional costs that we might incur, the timing of such costs or the impact that management’s attention to these matters will have on our business.

 

Our failure to meet the continuing listing requirements of Nasdaq could result in a de-listing of our securities.

 

On August 16, 2023, we received a written notification (the “Notice Letter”) from Nasdaq indicating that we were not in compliance with Nasdaq Listing Rule 5550(a)(2), as the closing bid price for our common stock was below the $1.00 per share requirement for the last 30 consecutive business days (the “Bid Price Rule”). The Notice Letter stated that we have 180 calendar days, or until February 12, 2024, to regain compliance with the minimum bid price requirement.

 

On February 13, 2024, we received notice (the “Approval”) from Nasdaq that the Company has been granted an additional 180-day grace period, or until August 12, 2024, to regain compliance with the Bid Price Rule. To regain compliance with the Bid Price Rule and qualify for continued listing on the Nasdaq Capital Market, the minimum bid price per share of the Company’s common stock must be at least $1.00 for at least 10 consecutive business days on or prior to August 12, 2024. If the Company fails to regain compliance during the additional compliance period, then Nasdaq will notify the Company of its determination to delist the Company’s common stock, at which point the Company would have an opportunity to appeal the delisting determination to a Nasdaq Listing Qualifications Panel (the “Panel”), but there can be no assurance that the Panel would grant the Company’s request for continued listing. As a condition of the Approval imposed by Nasdaq Listing Rule 5810(c)(3)(a), the Company notified Nasdaq that it would seek to implement a reverse stock split, if necessary, to regain compliance with the Bid Price Rule.

 

38
 

 

If we fail to satisfy the continuing listing requirements of such as minimum closing bid price requirements, as discussed above, the corporate governance, or stockholders’ equity or minimum closing bid price requirements, Nasdaq may take steps to delist our common stock. Such a delisting would likely have a negative effect on the price of our common stock and would impair our stockholders’ ability to sell or purchase our common stock. In the event of a delisting, we would likely take actions to restore our compliance with Nasdaq’s listing requirements, but we can provide no assurance that any such action taken by us would allow our common stock to become listed again, stabilize the market price or improve the liquidity of our securities, prevent our common stock from dropping below the Nasdaq minimum bid price requirement or prevent future non-compliance with Nasdaq’s listing requirements.

 

We may be exposed to currency fluctuations.

 

Although our revenues and expenses are expected to be predominantly denominated in U.S. dollars, we may be exposed to currency exchange fluctuations. Recent events in the global financial markets have been coupled with increased volatility in the currency markets. Fluctuations in the exchange rate between the U.S. dollar and the currency of other regions in which we may operate or have customers may have a material adverse effect on our business, financial condition and operating results. We may, in the future, establish a program to hedge a portion of our foreign currency exposure with the objective of minimizing the impact of adverse foreign currency exchange movements. However, even if we develop a hedging program, there can be no assurance that it will effectively mitigate currency risks.

 

Shares eligible for future sale may have adverse effects on our share price.

 

Sales of substantial amounts of shares or the perception that such sales could occur may adversely affect the prevailing market price for our shares. We may issue additional shares in subsequent public offerings or private placements to make new investments or for other purposes. Therefore, it may not be possible for existing shareholders to participate in such future share issuances, which may dilute the existing shareholders’ interests in us.

 

If we cannot continue to satisfy the rules of Nasdaq, our securities may be delisted, which could negatively impact the price of our securities and your ability to sell them.

 

Even though our common stock is listed on Nasdaq, we cannot assure you that our common stock will continue to be listed on Nasdaq.

 

We are required to comply with certain rules of Nasdaq, including those regarding minimum shareholders’ equity, minimum share price, minimum market value of publicly held shares, and various additional requirements. We may not be able to continue to satisfy these requirements and applicable rules. If we are unable to satisfy Nasdaq criteria for maintaining our listing, our securities could be subject to delisting.

 

If Nasdaq delists our securities from trading, we could face significant consequences, including:

 

  ● a limited availability for market quotations for our securities;
     
  ● reduced liquidity with respect to our securities;

 

39
 

 

  ● a determination that our common stock is a “penny stock,” which will require brokers trading in our common stock to adhere to more stringent rules and possibly result in a reduced level of trading activity in the secondary trading market for our common stock ;
     
  ● limited amount of news and analyst coverage; and
     
  ● a decreased ability to issue additional securities or obtain additional financing in the future.

 

Investment in our common stock is speculative and involves a high degree of risk. You may lose your entire investment.

 

There is no guarantee that the common stock will earn any positive return in the short term or long term. A holding of our common stock is speculative and involves a high degree of risk and should be undertaken only by holders whose financial resources are sufficient to enable them to assume such risks and who have no need for immediate liquidity in their investment. A holding of our common stock is appropriate only for holders who have the capacity to absorb a loss of some or all of their holdings.

 

Your ownership interest will be diluted and our stock price could decline when we issue additional shares of common stock.

 

We expect to issue from time to time in the future additional shares of common stock or securities convertible into, or exercisable or exchangeable for, shares of common stock in connection with possible financings, acquisitions, equity incentives for employees or otherwise. Any such issuance could result in substantial dilution to existing shareholders and cause the trading price of the common stock to decline.

 

Under our EB-5 Program, as modified on March 29, 2024, we may issue up to an aggregate of 20,000,000 shares of common stock.

 

We have issued warrants and may continue to issue additional securities in the future. The exercise of these warrants and the sale of the common stock issuable thereunder may dilute your percentage ownership interest and may also result in downward pressure on the price of our common stock.

 

As of December 31, 2023, we have issued and have outstanding warrants to purchase (i) 9,323,810 shares of common stock initially exercisable at a price of $1.05 per share, subject to adjustment as described therein, and has since been reduced to $0.95 per share as a result of the May 2023 modification, (ii) 3,684,210 shares of common stock at an exercise price of $0.95 per share, and (iii) 2,827,960 shares of common stock at an exercise price of $3.00, subject to adjustment as described therein. Because the market for our common stock may be thinly traded, the sales and/or the perception that those sales may occur, could adversely affect the market price of our common stock. Furthermore, the mere existence of a significant number of shares of common stock issuable upon exercise of our outstanding securities may be perceived by the market as having a potential dilutive effect, which could lead to a decrease in the price of our common stock.

 

Item 1B. Unresolved Staff Comments.

 

Not Applicable.

 

40
 

 

Item 1C. Cybersecurity.

 

We operate in the cannabis sector, which is subject to various cybersecurity risks that could adversely affect our business, financial condition, and results of operations, including theft; fraud; extortion; harm to employees or customers; violation of privacy laws and other litigation and legal risk; and reputational risk. We recognize the importance of assessing, identifying, and managing material risks associated with cybersecurity threats. Both our executive management team and our board of directors are involved in the assessment, identification, and management of such risks, including prevention, mitigation, detection, and remediation of cybersecurity incidents.

 

Our executive management team is responsible for day-to-day assessment, identification and management of material risks from cybersecurity threats, including the prevention, mitigation, detection, and remediation of cybersecurity incidents. The executive management team monitors current events in order to remain aware of current cybersecurity threats and is informed of cybersecurity incidents as they arise by our frontline personnel.

 

Our board of directors is responsible for oversight of risks from cybersecurity threats in conjunction with our executive management team. Our board of directors receives updates from our management team with respect to risks from cybersecurity threats and are notified of any new significant cybersecurity threats or incidents as they arise. Additionally, our board of directors considers risks from cybersecurity threats as part of its overall assessment of risk management, including its general oversight of the Company’s business strategy, risk management policies, and financials.

 

To date, no cybersecurity incident (or aggregation of incidents) or cybersecurity threat has materially affected our business strategy, results of operations or financial condition, and we are not aware of any cybersecurity incidents that are reasonably likely to materially affect the Company, including our business strategy, results of operations, or financial condition. For further information regarding the risks associated with cybersecurity incidents, see “Risk Factors-Our business and operations would suffer in the event of computer system failures, cyber-attacks or deficiencies in our cyber-security or those of third-party providers” in Item 1A of this Annual Report on Form 10-K.

 

Item 2. Properties.

 

The following table sets forth the Company’s owned and leased physical properties as of December 31, 2023, which include corporate offices, cultivation and production facilities (operating and under construction). In addition to the currently owned and leased property, the Company holds two options, each for the purchase of 300 acres of land in Grants, New Mexico.

 

Property Type   Owned/Leased   County   State
Agricultural Property – 40 acres   Owned   Cibola   New Mexico
Agricultural Property – 70 acres   Owned   Cibola   New Mexico
Office   Leased   Broward   Florida

 

As of December 31, 2023, we notified the land owners of our intention to exercise the two options and are in process of negotiating final terms of acquisition, which is contingent on financing.  

 

41
 

 

Corporate Headquarters

 

Our principal executive offices are located at 1033 George Hanosh Boulevard Grants, NM 87020, and our telephone number is (833) 658-1799. The Company believes that its existing facilities and other available properties will be sufficient for its needs for the foreseeable future.

 

Item 3. Legal Proceedings.

 

From time to time, we may be involved in legal proceedings arising from the normal course of business activities. Defending such proceedings is costly and can impose a significant burden on management and employees. The results of any current or future litigation cannot be predicted with certainty, and regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors. Other than as set forth below, we are not presently a party to any litigation the outcome of which, if determined adversely to us, would in our estimation, have a material adverse effect on our business, operating results, cash flows or financial condition.

 

  ● Bright Green Corporation v. John Fikany, D-1333-CV-202000231, State of New Mexico, County of Cibola, Thirteenth Judicial District. On October 23, 2020, the Company filed a complaint for declaratory judgment against a consultant of the Bright Green Group of Companies, an entity unrelated to the Company, to determine if defendant is entitled to 5,000,000 shares of the Company’s common stock, based on a failure to fulfil agreed upon conditions precedent to earning such shares from the Company. Defendant counterclaimed and filed a third-party claim against Lynn Stockwell, founder and a director of the Company, and Ms. Stockwell’s husband, for claims including wrongful termination and breach of contract. The Company denies defendants allegations and have set forth arguments refuting defendant’s counterclaims and third-party claims. The trial date for the case has been scheduled for April 22, 2024.
     
  ● Bright Green Corporation v. Jerry Capussi, D-1333-CV-202000252, State of New Mexico, County of Cibola, Thirteenth Judicial District. On November 16, 2020, the Company and defendant, a former consultant of Sunnyland Farms Inc, an entity unrelated to the Company, each filed claims for declaratory judgment seeking to determine by court order whether defendant is entitled to (i) shares of common stock in the Company (amounting to no more than 108,000 shares) or (ii) fair market value of defendant’s equity ownership of BGGI. The lawsuit is in early discovery stages, and we are preparing arguments for a summary judgment motion. There are no claims for specific monetary liability against either party.

 

Item 4. Mine Safety Disclosures.

 

Not Applicable.

 

42
 

 

PART II

 

Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.

 

Market Information

 

Our common stock is listed on Nasdaq under the symbol “BGXX”. On April 11, 2024, the closing price of our common stock was $0.24 per share.

 

Holders of Our common stock

 

As of April 11, 2024, we had 100 holders of record of our common stock. Certain shares are held in “street” name and accordingly, the number of beneficial owners of such shares is not known or included in the foregoing number. This number of holders of record also does not include stockholders whose shares may be held in trust by other entities.

 

Dividend Policy

 

Since our inception, we have not paid any dividends on our common stock, and we currently expect that, for the foreseeable future, all earnings, if any, will be retained for use in the development and operation of our business. In the future, our Board may decide, at its discretion, whether dividends may be declared and paid to holders of our common stock.

 

Securities Authorized for Issuance Under Equity Compensation Plans

 

The information required by Item 5 of Form 10-K regarding equity compensation plans is incorporated herein by reference to Item 12 of Part III of this Annual Report.

 

Recent Sales of Unregistered Securities

 

All sales of unregistered securities by us during the year ended December 31, 2023 have been included previously in a Quarterly Report on Form 10-Q or in a Current Report on Form 8-K.

 

Purchases of Equity Securities by the Issuer and Affiliated Purchasers

 

None.

 

Item 6. [Reserved].

 

Not Applicable.

 

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

 

You should read the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and the accompanying notes included in Part II, Item 8 of this Annual Report. Some of the information contained in this discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. As a result of many factors, including those factors set forth in the section titled “Risk Factors,” our actual results could differ materially from those discussed in or implied by these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in the section titled “Risk Factors.” Please also refer to the section titled “Special Note Regarding Forward-Looking Statements.”

 

43
 

 

Overview

 

We are a first-mover in the U.S. federally-authorized cannabis space. BGC is one of a few companies who have received from the U.S. Drug Enforcement Administration (the “DEA”), a federal controlled substances registration for the bulk manufacturing of cannabis under DEA Registration No. RB0649383 (the “DEA Registration”), which allows the Company to produce and export federally legal cannabis, cannabis extracts, and tetrahydrocannabinol in the U.S. We received the DEA Registration on April 28, 2023, pursuant to the Memorandum of Agreement (the “MOA”) with the DEA entered into on April 27, 2023, which replaced the 2021 Memorandum of Agreement (the “2021 MOA”) (DEA Document Control Number W20078135E). In May 2023, we received a second DEA Registration for Importing Schedule I Controlled Substances under DEA Registration No. RB0650754.

 

Unlike state-licensed cannabis companies who engage in commercial sales to consumers, and whose businesses are legal under state law but not federal law, subject to the milestones and requirements set forth herein, we are authorized by the federal government to sell cannabis commercially for research and manufacturing purposes, export cannabis for international cannabis research purposes, and sell cannabis to DEA-registered pharmaceutical companies for the production of medical cannabis products and preparations. Our business activities under the DEA Registration are subject to applicable federal law and regulations and to our obligations under the MOA we entered into with the DEA. Our DEA Registration is valid through July 31, 2024. For our cannabis business line, we plan to focus on the development of cannabis strains and sales of cannabis and hemp products with high contents of CBN (cannabinol) and CBG (cannabigerol).

 

In addition to research and pharmaceutical supply sales, Bright Green will be able to sell certain cannabinoids, such as CBN (cannabinol) and CBG (cannabigerol) as hemp isolates or extracts, and plans to sell CBN and CBG hemp products to consumers where such products are fully legal under all applicable laws. On August 9, 2022, the DEA confirmed to BGC that cannabinoids, including, but not limited to CBN/CBG, which meet the definition of “hemp” by having a Delta-9-tetrahydrocannabinol concentration of not more than 0.3 percent on a dry weight basis, are outside of the DEA’s jurisdiction because they are not controlled under the CSA. Hemp and hemp products were made legal by the Agriculture Improvement Act of 2018 (the “2018 Farm Bill”), which has been codified in 21 U.S.C. § 802(16)(B)(i), and 7 U.S.C. § 1639o. This hemp product business line will be in addition to our research and pharmaceutical cannabis activities conducted under the DEA Registration.

 

In addition to hemp and cannabis, we plan to manufacture additional plant-based medicines derived from controlled substance plants and fungi, including but not limited to, psilocybin, peyote cactus, and opium poppy as part of our “Drugs Made in America” strategy. In February 2024, we received approval from the New Mexico Board of Pharmacy to produce additional Schedule I and Schedule II controlled substances at our Grants, NM facility (NM Board of Pharmacy License Nos. CS02324187 and WD20220144). We have applied for an additional DEA Bulk Manufacturing Registration for these additional Schedule I and Schedule II controlled substances. Our decision to expand beyond cannabis to other plant-based medicines is in response to increased demand for additional controlled substances, the growing need to bolster domestic supply and production of plant based medicines, and the DEA’s recent decision to increase quotas for certain psychedelic controlled substances. Psilocybin, in particular, has received significant media attention in recent years, and clinical trials on the drug’s potential are underway at the Johns Hopkins Center for Psychedelic & Consciousness Research, the University of California, New York University, the University of Michigan, Yale University, and the Usona Institute, among others. Additionally, in July 2023, the American Medical Association (“AMA”) published language for new Current Procedural Terminology (“CPT”) III codes for psychedelic therapies. The codes went into effect on January 1, 2024. These new CPT codes will facilitate reimbursement and access to FDA-approved psychedelic therapies in the U.S. While no psychedelic-assisted therapy has yet been approved by the FDA, several potential new drugs are in various phases of clinical trials with the potential for at least one approval in 2024. The additional DEA Bulk Manufacturing Registration that Bright Green is seeking will allow us to supply the growing demand for psychedelic and plant-based medicine research, as well as to produce Active Pharmaceutical Ingredients (“APIs”) for a number of key pharmaceutical drugs. Given the recent prescription drug shortages experienced both in the U.S. and in other countries, our additional approval would allow us to meet U.S. demand for these drugs and contribute a consistent domestic supply of these drugs both for API and for research purposes.

 

44
 

 

Because cannabis, and the other future controlled substances we have applied for DEA Registration to manufacture, are still Schedule I and Schedule II controlled substances in the U.S., they have been historically under-researched. Though the majority of Americans now live in states where cannabis is legal, the full potential of the cannabis plant (and other controlled substance plants) for medicinal use remains understudied due to limited access to federally-approved cannabis and other controlled substances. The DEA recently issued a call for more cannabis research supply based on the increased demand for cannabis research in the U.S. As described herein, on April 28, 2023, we received the DEA Registration, which allows us to produce federally legal cannabis, cannabis extracts, and tetrahydrocannabinol and to sell legally within the U.S. to licensed researchers and pharmaceutical companies, in addition to qualifying us to export cannabis internationally. In January 2024, the DEA increased its quotas not only for cannabis but also for psilocybin and other psychedelics to meet medical and scientific needs. Our plan to expand our business to include additional controlled substances is in line with our Company’s mission and is in response to increased demand for these historically understudied plant medicines.

 

BGC must comply with the terms agreed upon pursuant to the MOA which include: submitting an Individual Procurement Quota on or before April 1 of each year utilizing DEA Form 250; submitting an Individual Manufacturing Quota on or before May 1 of each year utilizing DEA Form 189; collecting samples of cannabis and distributing them to DEA-registered analytical laboratories for chemical analysis during the pendency of cultivation and prior to the DEA’s taking possession of the cannabis grown; providing the DEA with 15-day advance written notification, via email, of its intent to harvest cannabis; following the DEA’s packaging, labeling, storage and transportation requirements; distributing DEA’s stocks of cannabis to buyers who entered into bona fide supply agreements with the Company; providing the DEA with 15-day advance written notification of its intent to distribute cannabis; and invoicing the DEA for harvested cannabis that it intends to sell to the DEA.

 

Having received our DEA Registration for the Bulk Manufacturing of cannabis, we are permitted to cultivate and manufacture cannabis, supply cannabis researchers in the U.S. and globally, and produce cannabis for use in pharmaceutical production of prescription medicines within the U.S. Our DEA Registration permits our cannabis activities under federal law, which sets BGC apart from most other U.S. cannabis companies.

 

We have assembled an experienced team of medical professionals and researchers, international horticultural growers and experts, and construction and cannabis production professionals, which we believe position us as a future industry leader in the production of plant-based medicines.

 

Recent Developments

 

Key Factors Affecting Our Results of Operations and Future Performance

 

We believe that our financial performance has been, and in the foreseeable future will continue to be, primarily driven by multiple factors as described below, each of which presents growth opportunities for our business. These factors also pose important challenges that we must successfully address in order to sustain our growth and improve our results of operations. Our ability to successfully address these challenges is subject to various risks and uncertainties, including those described in Part I, Item 1A of this Annual Report.

 

45
 

 

Results of Operations

 

Year Ended December 31, 2023, Compared to Year Ended December 31, 2022

 

Revenue:

 

We are a start-up company and have not generated any revenues for the year ended December 31, 2023 and 2022. We can provide no assurance that we will generate sufficient revenues from our intended business operations to sustain a viable business operation.

 

Operating Expenses:

 

We incurred operating expenses in the amount of $8,891,380 for the year ended December 31, 2023, as compared with $27,313,922 for the same period ended December 31, 2022. Our operating expenses for all periods consisted entirely of general and administrative expenses and depreciation. The detail by major category within general and administrative expenses for the year ended December 31, 2023 and 2022 is reflected in the table below.

 

   For the year ended 
   2023   2022 
         
Stock-based compensation  $3,829,218   $18,833,781 
Professional fees   2,896,749    6,260,289 
Officer salaries   666,136    696,614 
Other expenses   401,491    125,361 
Insurance   139,291    145,993 
Licenses   90,630    87,304 
Travel   78,422    232,794 
Property taxes   56,941    58,054 
Office salaries   50,128    52,358 
Advertising   43,867    78,193 
Land option   -    38,500 
Total general and administrative expenses  $8,252,873   $26,609,241 
Depreciation   638,507    704,681 
Total operating expenses  $8,891,380   $27,313,922 

 

Our general and administrative expenses decreased by $18,356,368 for the year ended December 31, 2023, as compared to December 31, 2022, and was primarily due to decreased spending on stock-based compensation to executives and consultants, and professional fees associated with our direct listing in May 2022.

 

We expect our general and administrative expenses to increase in future quarters as we continue with our SEC reporting obligations and the increased expenses associated with increased operational activity, which is expected for the balance of the year.

 

Liquidity and Capital Resources

 

As of December 31, 2023, the Company had cash of $10,059 compared to $414,574 as of December 31, 2022. The decrease of 404,515 in cash was mainly attributable to the use of funds for the construction in progress, deposits for equipment, and the costs associated with the Company’s SEC filings. This was partly offset by cash received from the sales of the Company’s common stock of $3,104,750, $880,000 through the sales of the Company’s common stock from the Company’s EB-5 Program, $210,000 from the exercise of warrants, and $200,000 from a draw on the line of credit.

 

46
 

 

Since its inception, the Company has incurred net losses and funded its operations primarily through the issuance of equities, an advance from the Company’s Chairwoman, and draws on the line of credit provided by the Company’s Chairwoman. As of December 31, 2023 and 2022, the Company had a total stockholders’ equity of $10,964,945 and $11,578,836, respectively.

 

The Company is in the initial stages of building facilities to grow, research, and distribute medical plants. It has incurred recurring losses from operations and, as of December 31, 2023 and 2022, had an accumulated deficit of $47,203,469 and $34,075,821, respectively, and negative working capital of $5,968,030 and $7,030,929, respectively. The Company does not have sufficient working capital to pay its operating expenses for a period of at least 12 months from the date the consolidated financial statements were authorized to be issued. Therefore, the Company’s continued existence depends on its ability to continue executing its operating plan and obtaining additional debt or equity financing. The Company has developed plans to raise funds and continues to pursue sources of funding that management believes, if successful, would be sufficient to support the Company’s operating plan. The Company’s operating plan is predicated on a variety of assumptions including, but not limited to, the level of product demand, cost estimates, its ability to continue to raise additional financing, and the state of the general economic environment in which the Company operates. There can be no assurance that these assumptions will prove accurate in all material respects or that the Company will be able to successfully execute its operating plan. In the event that the Company is not able to raise capital from investors or credit facilities in a timely manner, the Company will explore available options, including but not limited to an equity-backed loan against the property. In the absence of additional appropriate financing, the Company may have to modify its plan to slow down the pace of development and commercialization.

 

Sources of Liquidity

 

During the year ended December 31, 2023, the Company raised $3,104,750 through the issuance of the Company’s common stock and accompanying warrants to purchase shares of the Company’s common stock from the Company’s private placement offering in May 2023, $880,000 through issuances of the Company’s common stock from the Company’s EB-5 Program, and $210,000 through the exercise of warrants. The Company has drawn $400,000 from the Company’s $15 million related party line of credit.

 

Cash Flows

 

Operating Activities

 

   For the years ended 
   December 31, 2023   December 31, 2022 
           
Net cash used in operating activities   (2,455,612)   (2,265,770)

 

During the years ended December 31, 2023 and 2022, all cash used in operating activities was for general and administrative expenses.

 

Investing Activities

 

   For the years ended 
   December 31, 2023   December 31, 2022 
           
Net cash used in investing activities   (2,533,653)   (14,368,944)

 

During the year ended December 31, 2023, all cash used in investing activities was for the construction of the greenhouse.

 

During the year ended December 31, 2022, cash used in investing activities was $10,522,242 for the construction of the greenhouse, $2,689,115 to purchase an equity method investment, and $1,157,587 for deposits made towards an equipment purchase and a construction contract.

 

47
 

 

Financing Activities

 

   For the years ended 
   December 31, 2023   December 31, 2022 
           
Net cash provided by financing activities   4,584,750    15,766,723 

 

During the year ended December 31, 2023, cash provided by financing activities were proceeds of $3,974,750 from the issuance of common stock and warrants, net of issuance costs, $210,000 from warrants exercised, and $400,000 from the related party line of credit.

 

During the year ended December 31, 2022, cash provided by financing activities were proceeds of $12,186,733 from the issuance of common stock and warrants, net of issuance costs, and $3,579,990 from the related party line of credit.

 

Contractual Obligations and Commitments

 

The Company does not have any short or long-term contractual purchases with suppliers for future purchases, capital expenditure commitments that cannot be cancelled with minimal fees, noncancelable operating leases, or any commitment or contingency that would hinder management’s ability to scale down operations and management expenses until funding is raised.

 

Critical Accounting Policies and Estimates

 

The discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these consolidated financial statements requires us to make estimates and judgments that affect the amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, we evaluate our estimates based on historical experience and various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily available apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. For a detailed discussion about the Company’s significant accounting policies, refer to Note 3 “Summary of Significant Accounting Policies,” in the Company’s consolidated financial statements included in this Annual Report on Form 10-K. During the year ended December 31, 2023, no material changes were made to the Company’s significant accounting policies.

 

Recently Issued Accounting Pronouncements

 

A description of recently issued accounting pronouncements that may potentially impact our financial position and results of operations is disclosed in Note 3 to the Company’s consolidated financial statements.

 

JOBS Act Accounting Election

 

We qualify as an “emerging growth company” as defined in the JOBS Act. An emerging growth company may take advantage of reduced reporting requirements that are not otherwise applicable to public companies. These provisions include, but are not limited to:

 

  ● being permitted to present only two years of audited financial statements and only two years of related Management’s Discussion and Analysis of Financial Condition and Results of Operations in this Annual Report;
  ● not being required to comply with the auditor attestation requirements on the effectiveness of our internal controls over financial reporting;
  ● not being required to comply with any requirement that may be adopted by the PCAOB regarding mandatory audit firm rotation or a supplement to the auditor’s report providing additional information about the audit and the financial statements (auditor discussion and analysis);
  ● reduced disclosure obligations regarding executive compensation arrangements; and
  ● exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.

 

48
 

 

We may use these provisions until the last day of our fiscal year in which the fifth anniversary of the completion of our initial public offering occurred. However, if certain events occur prior to the end of such five-year period, including if we become a “large accelerated filer,” our annual gross revenue exceeds $1.235 billion, or we issue more than $1.0 billion of non-convertible debt in any three-year period, we will cease to be an emerging growth company prior to the end of such five-year period.

 

We have elected to take advantage of certain of the reduced disclosure obligations in this Annual Report and may elect to take advantage of other reduced reporting requirements in future filings. As a result, the information that we provide to our shareholders may be different than the information you receive from other public companies in which you hold stock.

 

The JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards, until those standards apply to private companies. We have elected to take advantage of the benefits of this extended transition period and, therefore, we will not be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies. Our consolidated financial statements may therefore not be comparable to those of companies that comply with such new or revised accounting standards. Until the date that we are no longer an emerging growth company or affirmatively and irrevocably opt out of the exemption provided by Section 7(a)(2)(B) of the Securities Act upon issuance of a new or revised accounting standard that applies to our financial statements and that has a different effective date for public and private companies, we will disclose the date on which we will adopt the recently issued accounting standard.

 

Item 7A. Quantitative and Qualitative Disclosures about Market Risk.

 

Not Applicable.

 

Item 8. Financial Statements and Supplementary Data.

 

Our consolidated financial statements, together with the report of our independent registered public accounting firm, appear beginning on page F-1 of this Annual Report for the years ended December 31, 2023 and 2022.

 

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.

 

None.

 

Item 9A. Controls and Procedures.

 

Evaluation of Disclosure Controls and Procedures

 

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer has evaluated the effectiveness of our disclosure controls and procedures. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the Company’s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure.

 

49
 

 

Under the supervision and with the participation of our management, including our former Interim Chief Executive Officer and Chief Financial Officer, we conducted an assessment of the effectiveness of our internal control over financial reporting as of June 30, 2022. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material error in our annual or interim financial statements will not be prevented or detected on a timely basis. In Management’s Report on Internal Control over Financial Reporting included in our quarterly report on Form 10-Q for the quarter ended June 30, 2022 filed August 12, 2022, our management previously concluded that we maintained effective internal control over financial reporting as of June 30, 2022. Our management subsequently concluded that a material weakness existed and our internal control over financial reporting was not effective as of June 30, 2022. This determination was made as a result of a recording error of the fair value of shares of common stock we issued for services in June 2022. Such shares have a fair value of $8.00 per share, the price of our common stock at the time of our Direct Listing, but were initially recorded at a fair value of $4.00 per share. With this error being corrected in amendment no. 1 to our quarterly report on Form 10-Q for the period ended June 30, 2022, net loss increased by $6,297,960. We have strengthened our review controls around the issuance of shares of common stock and the recording of the associated expense by adding an additional reviewer to the review process. The Company continues to evaluate and implement procedures as deemed appropriate to enhance our disclosure controls.

 

Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost benefit relationship of possible controls and procedures.

 

As of December 31, 2023, our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in the reports we file or submit under the Exchange Act is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of December 31, 2023.

 

Management’s Report on Internal Control over Financial Reporting

 

Our management is responsible for establishing and maintaining adequate internal control over financial reporting as such term is defined in Rule 13a-15(f) under the Exchange Act. Internal control over financial reporting is a process designed under the supervision and with the participation of our management including our Chief Executive Officer and Chief Financial Officer to provide reasonable assurance regarding the reliability of financial reporting and the preparation of consolidated financial statements for external purposes in accordance with generally accepted accounting principles. Our internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of our assets: (ii) provide reasonable assurance (a) transactions are recorded as necessary to permit preparation of consolidated financial statements in accordance with generally accepted accounting policies (b) our receipts and expenditures are being made only in accordance with authorizations of our management and directors: and (c) regarding the prevention or timely detection of the unauthorized acquisition use or disposition of assets that could have a material effect on our consolidated financial statements.

 

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions or that the degree of compliance with the policies or procedures may deteriorate.

 

50
 

 

As of December 31, 2023, our management assessed the effectiveness of our internal control over financial reporting using the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control-Integrated Framework (2013). In adopting the 2013 Framework , management assessed the applicability of the principles within each component of internal control and determined whether or not they have been adequately addressed within the current system of internal control and adequately documented. Based on this assessment, management, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, concluded that, as of December 31, 2023, our internal control over financial reporting was effective based on those criteria.

 

Changes in Internal Control Over Financial Reporting

 

As described above, we implemented certain remediation efforts as a result of the error identified in our financial statements for the quarter ended June 30, 2022, and the corresponding material weakness identified by management in such period. An evaluation was also performed under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer of any changes in our internal control over financial reporting that occurred during our last fiscal quarter and that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. Except as described above, there were no changes in our internal control over financial reporting identified in management’s evaluation pursuant to Rules 13a-15(d) or 15d-15(d) of the Exchange Act during the quarter ended December 31, 2023 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

Item 9B. Other Information.

 

None.

 

Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.

 

Not Applicable.

 

51
 

 

PART III

 

Item 10. Directors, Executive Officers and Corporate Governance.

 

Information required by this item will be contained in our Definitive Proxy Statement for our 2024 Annual Meeting of Stockholders, to be filed pursuant to Regulation 14A with the Securities and Exchange Commission within 120 days of December 31, 2023. Such information is incorporated herein by reference.

 

Item 11. Executive Compensation.

 

Information required by this item will be contained in our Definitive Proxy Statement for our 2024 Annual Meeting of Stockholders, to be filed pursuant to Regulation 14A with the Securities and Exchange Commission within 120 days of December 31, 2023. Such information is incorporated herein by reference.

 

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.

 

Information required by this item will be contained in our Definitive Proxy Statement for our 2024 Annual Meeting of Stockholders, to be filed pursuant to Regulation 14A with the Securities and Exchange Commission within 120 days of December 31, 2023. Such information is incorporated herein by reference.

 

Item 13. Certain Relationships and Related Transactions, and Director Independence.

 

Information required by this item will be contained in our Definitive Proxy Statement for our 2024 Annual Meeting of Stockholders, to be filed pursuant to Regulation 14A with the Securities and Exchange Commission within 120 days of December 31, 2023. Such information is incorporated herein by reference.

 

Item 14. Principal Accountant Fees and Services.

 

Information required by this item will be contained in our Definitive Proxy Statement for our 2024 Annual Meeting of Stockholders, to be filed pursuant to Regulation 14A with the Securities and Exchange Commission within 120 days of December 31, 2023. Such information is incorporated herein by reference.

 

52
 

 

PART IV

 

Item 15. Exhibits, Financial Statement Schedules.

 

(1) For a list of the financial statements included herein, see Index to the Financial Statements on page F-1 of this Annual Report, incorporated into this Item by reference.

 

(2) Financial statement schedules have been omitted because they are either not required or not applicable or the information is included in the financial statements or the notes thereto.

 

(3) Exhibits:

 

Exhibit   Description
2.1   Agreement and Plan of Merger between Bright Green Corporation and Bright Green Grown Innovation LLC dated May 28, 2019, filed as Exhibit 2.1 to the Company’s Registration Statement on Form S-1, filed with the SEC on May 4, 2022
2.2   Agreement and Plan of Merger between Bright Green Corporation and Grants Greenhouse Growers Inc. dated as of October 30, 2020, filed as Exhibit 2.2 to the Company’s Registration Statement on Form S-1, filed with the SEC on May 4, 2022
2.3   Agreement and Plan of Merger between Bright Green Corporation and Naseeb Inc. dated as of November 10, 2020, filed as Exhibit 2.3 to the Company’s Registration Statement on Form S-1, filed with the SEC on May 4, 2022
3.1   Certificate of Incorporation of the registrant, filed as Exhibit 3.1 to the Company’s Registration Statement on Form S-1, filed with the SEC on May 4, 2022
3.2   Amended and Restated Certificate of Incorporation of the registrant, filed as Exhibit 3.1 to the Company’s Quarterly Report on Form 10-Q, filed with the SEC on June 7, 2022.
3.3   Bylaws of the registrant, filed as Exhibit 3.3 to the Company’s Registration Statement on Form S-1, filed with the SEC on May 4, 2022
3.4   Amended and Restated Bylaws of the registrant, filed as Exhibit 3.2 to the Company’s Quarterly Report on Form 10-Q, filed with the SEC on June 7, 2022.
3.5   Certificate of Amendment to the Second Amended and Restated Certificate of Incorporation of Bright Green Corporation, filed as Exhibit 3.1 to the Company’s Current Report on Form 8-K, filed with the SEC on December 16, 2022.
4.1   Form of Warrant, filed as Exhibit 4.1 to the Company’s Current Report on Form 8-K, filed with the SEC on September 13, 2022.
4.2*   Description of Registrant’s Securities
4.3   Form of Warrant, filed as Exhibit 4.1 to the Company’s Current Report on Form 8-K filed with the SEC on May 24, 2023
4.4.   Form of Warrant, filed as Exhibit 4.1 to the Company’s Current Report on Form 8-K, filed with the SEC on September 6, 2023.
10.1   Memorandum of Agreement between Bright Green Corporation and the Department of Justice, Drug Enforcement 7 Administration, filed as Exhibit 10.1 to the Company’s Registration Statement on Form S-1, filed with the SEC on May 4, 2022
10.2   Line of Credit Note, dated June 4, 2022, filed as Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q, filed with the SEC on June 7, 2022
10.3   Executive Employment Agreement with Edward Robinson, filed as Exhibit 10.2 to the Company’s Registration Statement on Form S-1, filed with the SEC on May 4, 2022
10.4   Consulting Agreement with Saleem Elmasri, filed as Exhibit 10.3 to the Company’s Registration Statement on Form S-1, filed with the SEC on May 4, 2022

 

53
 

 

10.5#   Securities Purchase Agreement dated September 7, 2022, by and between the Company and the purchasers thereto, filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on September 13, 2022
10.6   Registration Rights Agreement dated September 12, 2022, by and between the Company and the purchasers thereto, filed as Exhibit 10.2 to the Company’s Current Report on Form 8-K filed with the SEC on September 13, 2022
10.7   Placement Agent Agreement dated September 12, 2022 by and between the Company and EF Hutton, division of Benchmark Investments, LLC, filed as Exhibit 10.3 to the Company’s Current Report on Form 8-K filed with the SEC on September 13, 2022
10.8¥   Executive Employment Agreement, dated September 22, 2022, by and between Bright Green Corporation. and Terry Rafih filed, filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on September 28, 2022.
10.9   Secondary Stock Purchase Agreement and Release dated October 3, 2022, by and among Bright Green Corporation, Alterola Biotech, Inc. and the Sellers (as defined therein), filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on October 7, 2022.
10.10   Amendment and Restated Line of Credit Note, dated November 14, 2022, filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on November 14, 2022.
10.11¥   Bright Green Corporation 2022 Omnibus Equity Compensation Plan, filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on December 16, 2022.
10.12¥   Executive Employment Agreement, dated as of February 9, 2023, by and between Bright Green Corporation. and Seamus McAuley, filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on February 15, 2023.
10.13   Memorandum of Agreement, dated April 27, 2023, filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on May 4, 2023
10.14   Addendum to Memorandum of Agreement, dated April 27, 2023, filed as Exhibit 10.2 to the Company’s Current Report on Form 8-K filed with the SEC on May 4, 2023
10.15#   Securities Purchase Agreement dated May 21, 2023, by and between the Company and the purchasers thereto, filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on May 24, 2023
10.16   Registration Rights Agreement dated May 24, 2023, by and between the Company and the purchasers thereto, filed as Exhibit 10.2 to the Company’s Current Report on Form 8-K filed with the SEC on May 24, 2023
10.17   Placement Agency Agreement dated May 21, 2023 by and between the Company and EF Hutton, division of Benchmark Investments, LLC, filed as Exhibit 10.3 to the Company’s Current Report on Form 8-K filed with the SEC on May 23, 2023
10.18 ¥   Executive Employment Agreement, dated as of September 20, 2023 and Effective October 2, 2023, by and between Bright Green Corporation and Gurvinder Singh, filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on October 6, 2023
10.19¥   Memorandum of Understanding between Bright Green Corporation and Terry Rafih, dated February 15, 2024, filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on February 20, 2024
10.20¥   Scope of Work between Bright Green Corporation and Titan Advisory Services LLC, dated March 7, 2024, filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on March 11, 2024.
10.21   Credit Agreement dated March 14, 2024, filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on March 19, 2024.
10.22   Settlement Agreement and Release dated March 13, 2024, filed as Exhibit 10.2 to the Company’s Current Report on Form 8-K filed with the SEC on March 19, 2024.

 

54
 

 

10.23¥   Executive Employment Agreement, dated as of March 29, 2024 and Effective March 31, 2024, by and between Bright Green Corporation and Gurvinder Singh, filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on April 2, 2024.
21.1*   List of subsidiaries of the registrant
23.1*   Consent of SRCO, C.P.A., Professional Corporation
24.1*   Power of Attorney (included on the signature page of this Annual Report).
31.1*   Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2*   Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1**   Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2**   Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
97.1   Bright Green Corporation Clawback Policy
101.INS   Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.
101.SCH   Inline XBRL Taxonomy Extension Schema Document
101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB   Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

* Filed herewith.

**Furnished herewith.

#Certain schedules and exhibits have been omitted pursuant to Item 601(A)(5) of Regulation S-K. The Company will furnish supplementally copies of omitted schedules and exhibits to the SEC or its staff upon its request.

¥ Indicates a management contract or compensatory plan, contract or arrangement.

 

Item 16. Form 10-K Summary.

 

None.

 

55
 

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Annual Report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  BRIGHT GREEN CORPORATION
     
Date: April 16, 2024    
     
  By: /s/ Gurvinder Singh
  Name: Gurvinder Singh
  Title: Chief Executive Officer

 

The undersigned officers and directors of Bright Green Corporation, hereby severally constitute and appoint Gurvinder Singh and Saleem Elmasri, and each of them individually, with full power of substitution and resubstitution, as their true and lawful attorneys and agents, to do any and all acts and things in their name and behalf in their capacities as directors and officers and to execute any and all instruments for them and in their names in the capacities indicated below, which said attorneys and agents, may deem necessary or advisable to enable said corporation to comply with the Securities Exchange Act of 1934, as amended, and any rules, regulations and requirements of the Securities and Exchange Commission, in connection with this Annual Report on Form 10-K, including specifically but without limitation, power and authority to sign for them or any of them in their names in the capacities indicated below, any and all amendments hereto, and they do hereby ratify and confirm all that said attorneys and agents, or either of them, may lawfully do or cause to be done by virtue hereof.

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Annual Report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.

 

Name   Title   Date
         
/s/ Gurvinder Singh   Chief Executive Officer and Director   April 16, 2024
Gurvinder Singh   (Principal Executive Officer)    
         
/s/ Saleem Elmasri   Chief Financial Officer   April 16, 2024
Saleem Elmasri   (Principal Financial Officer)    
         
/s/ Sean Deson   Director   April 16, 2024
Sean Deson        
         
/s/ Lynn Stockwell   Director   April 16, 2024
Lynn Stockwell, Director        
         
/s/ Dean Valore   Director   April 16, 2024
Dean Valore, Director        
         
/s/ Robert Arnone   Director   April 16, 2024
Robert Arnone, Director        

 

56
 

 

INDEX TO FINANCIAL STATEMENTS

 

Report of Independent Registered Public Accounting Firm F-2
Consolidated Balance Sheets as of December 31, 2023 and 2022 F-3
Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 2023 and 2022 F-4
Consolidated Statements of Changes in Stockholders’ Equity for the years ended December 31, 2023 and 2022 F-5
Consolidated Statements of Cash Flows for the years ended December 31, 2023 and 2022 F-6
Notes to Consolidated Financial Statements F-7

 

F-1

 

 

 

Report of Independent Registered Public Accounting Firm

 

To the Stockholders and Board of Directors of Bright Green Corporation

 

Opinion on the Consolidated Financial Statements

 

We have audited the accompanying consolidated balance sheets of Bright Green Corporation and its subsidiary (the “Company”) as of December 31, 2023 and 2022 and the related consolidated statements of operations and comprehensive loss, changes in stockholders’ equity, and cash flows for each of the years in the two-year period ended December 31, 2023, and related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as at December 31, 2023 and 2022 and the results of its operations and its cash flows for the years in the two-year period ended December 31, 2023, in conformity with accounting principles generally accepted in the United States of America.

 

Material Uncertainty Related to Going Concern

 

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the consolidated financial statements, the Company has incurred recurring losses from operations, has negative cash flows from operating activities, and has an accumulated deficit that raise substantial doubt about its ability to continue as a going concern. Management’s plans in regard to this matter are also described in Note 2. These consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

Basis for Opinion

 

These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the United States Securities and Exchange Commission and the PCAOB.

 

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

 

Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.

 

Critical Audit Matters

 

Critical audit matters are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. We determined that there are no critical audit matters.

 

 

We have served as the Company’s auditor since 2021

East Amherst, NY

April 16, 2024

/s/ SRCO, C.P.A., Professional Corporation

 

SRCO, C.P.A., Professional Corporation (6722)

CERTIFIED PUBLIC ACCOUNTANTS

 

F-2

 

 

BRIGHT GREEN CORPORATION

Consolidated Balance Sheets

As at December 31, 2023 and 2022

(Expressed in United States Dollars)

 

 

   December 31, 2023   December 31, 2022 
ASSETS          
Current assets          
Cash  $10,059   $414,574 
Prepaid expenses and other assets   258,230    77,847 
Total current assets   268,289    492,421 
           
Deposits (Notes 5, 9, and 16)   -    1,157,587 
Other investment held at fair value (Note 6)   726,343    - 
Equity method investment (Note 6)   -    3,990,960 
Property, plant, and equipment (Notes 7 and 16)   16,407,415    17,146,325 
Intangible assets (Note 8)   1,000    1,000 
           
Total assets  $17,403,047   $22,788,293 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY          
Current liabilities          
Accounts payable (Notes 14 and 16)  $4,175,220   $5,033,831 
Accrued liabilities (Note 14)   411,099    447,325 
Due to others (Note 6)   1,650,000    1,650,000 
Due to related party (Note 10)   -    392,194 
Total current liabilities   6,236,319    7,523,350 
           
Long-term liabilities          
Related party line of credit note (Notes 10, 11, 14 and 16)   201,783    3,686,107 
Total long-term liabilities   201,783    3,686,107 
           
Total liabilities   6,438,102    11,209,457 
           
STOCKHOLDERS’ EQUITY          
Preferred stock; $0.0001 par value; 10,000,000 shares authorized; no shares issued or outstanding as of December 31, 2023 and December 31, 2022, respectively (Note 11)   -    - 
Common stock; $.0001 par value; 500,000,000 stock authorized; 184,758,818 and 173,304,800 stock issued and outstanding at December 31, 2023 and December 31, 2022, respectively (Note 11)   18,476    17,329 
Additional paid-in capital (Notes 11)   58,149,938    45,637,328 
Accumulated deficit   (47,203,469)   (34,075,821)
Total stockholders’ equity   10,964,945    11,578,836 
           
Total liabilities and stockholders’ equity  $17,403,047   $22,788,293 
           
Going Concern (Note 2)          
Commitments (Note 9)          
Contingencies (Note 15)          
Subsequent Events (Note 16)          

 

The accompanying notes are an integral part of the consolidated financial statements.

 

F-3

 

 

BRIGHT GREEN CORPORATION

Consolidated Statements of Operations and Comprehensive Loss

For the Years Ended December 31, 2023 and 2022

(Expressed in United States Dollars)

 

 

   December 31, 2023   December 31, 2022 
   Years Ended 
   December 31, 2023   December 31, 2022 
         
Revenue  $-   $- 
           
Expenses          
           
General and administrative expenses   8,252,873    26,609,241 
Depreciation   638,507    704,681 
Total operating expenses   8,891,380    27,313,922 
           
Loss from operations  $(8,891,380)  $(27,313,922)
           
Other expense          
           
Foreign currency transaction loss   1,625    - 
Loss on forfeited deposit (Notes 5, 9, and 16)   970,026    - 
Change in fair value of assets, net (Note 6)   3,045,954    - 
Change in fair value of voting agreement derivative   -    213,000 
Total other expense   4,017,605    213,000 
           
Loss before income taxes and equity in net losses of affiliate  $(12,908,985)  $(27,526,922)
           
Income tax expense (Note 13)   -    - 
           
Loss before equity in net losses of affiliate  $(12,908,985)  $(27,526,922)
           
Equity in net losses of affiliate (Note 6)   (218,663)   (135,155)
           
Net loss and comprehensive loss  $(13,127,648)  $(27,662,077)
           
Weighted average common shares outstanding - basic and diluted   178,574,014    162,058,082 
           
Net loss per common share - basic and diluted  $(0.07)  $(0.17)

 

The accompanying notes are an integral part of the consolidated financial statements.

 

F-4

 

 

BRIGHT GREEN CORPORATION

Consolidated Statements of Changes in Stockholders’ Equity

For the Years Ended December 31, 2023 and 2022

(Expressed in United States Dollars)

 

 

                          
       Additional       Total 
   Common Stock   paid-in   Accumulated   stockholders’ 
   Shares   Amount   capital   deficit   equity 
                     
Balance, December 31, 2021   157,544,500   $15,754   $14,618,389   $(6,413,744)  $        8,220,399 
                          
Common stock issued for cash (Note 11)   312,500    31    3,049,969    -    3,050,000 
Common stock and warrants issued for cash in private placement, net of issuance costs of $863,267 (Note 11)   9,523,810    952    9,135,781    -    9,136,733 
Common stock issued for services (Note 11)   6,036,990    603    18,850,629    -    18,851,232 
Common stock cancelled that was issued for services (Note 11)   (113,000)   (11)   (17,440)   -    (17,451)
Net loss   -    -    -    (27,662,077)   (27,662,077)
                          
Balance, December 31, 2022   173,304,800   $17,329   $45,637,328   $(34,075,821)  $11,578,836 
                          
Common stock and warrants issued for cash in a private placement, net of issuance costs of $395,250 (Note 11)   3,684,210    368    3,104,382    -    3,104,750 
Warrants exercised for cash (Note 11)   200,000    20    209,980    -    210,000 
Common stock issued for a cashless conversion from related party LOC for EB-5 program (Notes 10 and 11)   22,005    2    879,998    -    880,000 
Common stock and warrants issued for a cashless conversion of related party LOC, net of issuance costs of $10,000 (Notes 10 and 11)   2,827,960    283    3,609,506    -    3,609,789 
Common stock issued for cash for EB-5 program (Note 11)   22,005    2    879,998    -    880,000 
Common stock issued for services (Note 11)   4,697,838    472    3,234,268    -    3,234,740 
Stock options issued for services (Notes 11 and 12)   -    -    594,478    -    594,478 
Net loss   -    -    -    (13,127,648)   (13,127,648)
                          
Balance, December 31, 2023   184,758,818   $18,476   $58,149,938   $(47,203,469)  $10,964,945 

 

The accompanying notes are an integral part of the consolidated financial statements.

 

F-5

 

 

BRIGHT GREEN CORPORATION

Consolidated Statements of Cash Flows

For the Years Ended December 31, 2023 and 2022

(Expressed in United States Dollars)

 

 

   December 31, 2023   December 31, 2022 
   Years Ended 
   December 31, 2023   December 31, 2022 
         
CASH FLOWS FROM OPERATING ACTIVITIES          
           
Net loss  $(13,127,648)  $(27,662,077)
           
Adjustments to reconcile net cash used in operating activities:          
Change in fair value of voting agreement derivative   -    213,000 
Loss on forfeited deposit   970,026    - 
Change in fair value of assets, net   3,045,954    - 
Equity in net losses of affiliate   218,663    135,155 
Depreciation   638,507    704,681 
Stock-based compensation   3,829,218    18,833,781 
Changes in operating assets and liabilities:          
Prepaid expenses and other assets   (40,766)   90,379 
Accounts payable   1,823,389    4,883,896 
Accrued liabilities   (36,226)   429,298 
Accrued interest   223,271    106,117 
Net cash used in operating activities   (2,455,612)   (2,265,770)
           
CASH FLOWS FROM INVESTING ACTIVITIES          
           
Deposits   -    (1,157,587)
Purchase of equity method investment   -    (2,689,115)
Purchase of property, plant, and equipment   (2,533,653)   (10,522,242)
Net cash used in investing activities   (2,533,653)   (14,368,944)
           
CASH FLOWS FROM FINANCING ACTIVITIES          
           
Proceeds from related party line of credit   400,000    5,191,057 
Payments to related party line of credit   -    (1,611,067)
Proceeds from issuance of common stock   880,000    3,050,000 
Proceeds from issuance of common stock and warrants, issued in private placement, net of issuance costs   3,104,750    9,136,733 
Payments to issuance costs for issuance of common stock and warrants issued in cashless conversion of related party line of credit   (10,000)   - 
Proceeds from warrants exercised   210,000    - 
Net cash provided by financing activities   4,584,750    15,766,723 
           
NET DECREASE IN CASH   (404,515)   (867,991)
CASH, BEGINNING OF YEAR   414,574    1,282,565 
CASH, END OF YEAR  $10,059   $414,574 
           
CASH PAID FOR          
Interest  $-   $- 
Taxes  $-   $- 
           
SUPPLEMENTAL NON-CASH INVESTING & FINANCING ACTIVITIES          
Transfer from due to related party to related party LOC  $392,194   $- 
Transfer from deposit on equipment to prepaid expenses and other assets  $139,617   $- 
Related party LOC in exchange for common stock for EB-5 program  $(880,000)  $- 
Related party LOC in exchange for common stock and warrants  $(3,619,789)  $- 
Adjustment to construction in progress for cancellation of agreement  $(2,682,000)  $- 
Due to others for purchase of common stock in Alterola Biotech, Inc.  $-   $1,650,000 

 

The accompanying notes are an integral part of the consolidated financial statements.

 

F-6

 

 

BRIGHT GREEN CORPORATION

Notes to the Consolidated Financial Statements

For the Years Ended December 31, 2023 and 2022

(Expressed in United States Dollars)

 

 

1. Description of Business and Organization

 

Bright Green Corporation was incorporated on April 16, 2019, under the Delaware General Corporation Law. The Company’s principal executive office is located in Grants, New Mexico. The Company holds the land, greenhouse, and patents required in the growth, production, and research of medicinal plants. When used herein, the terms the “Company,” “our,” “us,” “we,” or “Bright Green” refers to Bright Green Corporation and its consolidated subsidiary.

 

On March 29, 2022, the Company filed a registration statement pursuant to the Securities Act of 1933, as amended (the “Securities Act”) on Form S-1 with the Securities and Exchange Commission (“SEC”), which was declared effective May 13, 2022, (as amended, the “Registration Statement”), in connection with the direct listing of the Company’s common stock with the Capital Market of the Nasdaq Stock Market LLC (“Nasdaq”).

 

On May 17, 2022, the Company’s common stock commenced trading on Nasdaq under the symbol “BGXX.”

 

On February 1, 2023, the Company initiated a private placement offering of common stock, only to accredited or qualified institutional investors, in reliance upon Rule 506, Regulation D promulgated under the Securities Act, pursuant to the U.S. government’s EB-5 immigrant investor program. Under the EB-5 Program, the Company may issue up to an aggregate of 12,609,152 shares of common stock at $39.99 per share.

 

On May 21, 2023, the Company entered into a Securities Purchase Agreement with an accredited investor and existing stockholder of the Company for the sale by the Company of (i) 3,684,210 shares of the Company’s common stock, par value $0.0001 per share, and (ii) warrants to purchase up to an aggregate of 3,684,210 shares of the Company’s common stock, in a private placement offering. The combined purchase price of one share and accompanying warrant was $0.95. The shares and the warrants were sold and issued without registration under the Securities Act of 1933, in reliance on the exemptions provided by Section 4(a)(2) of the Securities Act as transactions not involving a public offering and Rule 506 of Regulation D promulgated under the Securities Act as sales to accredited investors, and in reliance on similar exemptions under applicable state laws.

 

On September 20, 2023, the Company formed Regional Center Bright Green, LLC (“RCBG”). RCBG is a wholly-owned subsidiary of the Company and is registered as a limited liability company in New Mexico. RCBG was created to assist foreign investors in obtaining permanent residency in the United States by investing in U.S. businesses, while adhering to the EB-5 Immigrant Investor Program guidelines. As of December 31, 2023, the subsidiary was not yet operational.

 

The Company is a start-up company at December 31, 2023 and has no revenue.

 

F-7

 

 

BRIGHT GREEN CORPORATION

Notes to the Consolidated Financial Statements

For the Years Ended December 31, 2023 and 2022

(Expressed in United States Dollars)

 

 

2. Going Concern and Basis of Presentation

 

The accompanying consolidated financial statements have been prepared by the Company in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”). U.S. GAAP contemplates the continuation of the Company as a going concern. For the fiscal years ended December 31, 2023 and 2022, the Company had no revenues from product sales and incurred a net loss of $13,127,648 and $27,662,077, respectively. Net cash used in operations for the years ended 2023 and 2022 was $2,455,612 and $2,265,770, respectively. The Company has incurred recurring losses from operations, and as of December 31, 2023, had an accumulated deficit of $47,203,469 (December 31, 2022 – $34,075,821) and had a negative working capital of $5,968,030 (December 31, 2022 – $7,030,929).

 

The Company is in its initial stages of building facilities to grow, research, and distribute medical plants. The Company has historically financed its operations through the sale of equity securities and debt financing. The Company does not have sufficient working capital to pay its operating expenses for a period of at least 12 months from the date the consolidated financial statements were authorized to be issued. Therefore, the Company’s continued existence depends on its ability to continue executing its operating plan and obtaining additional debt or equity financing. The Company has developed plans to raise funds and continues to pursue sources of funding that management believes, if successful, would be sufficient to support the Company’s operating plan.

 

In 2023, the Company raised $3,104,750 through the issuance of common stock and accompanying warrants to purchase shares of common stock from the Company’s private placement offering in May 2023, $880,000 through common stock issuances from the Company’s EB-5 Program, and $210,000 through the exercise of warrants. The Company has drawn $400,000 from the Company’s $15,000,000 related party line of credit. The related party line of credit was used to pay in full the related party loan balance of $392,194. The related party line of credit was paid down $880,000 in exchange for 22,005 shares of the Company’s common stock valued at $39.99 per share pursuant to the Company’s EB-5 Program, and the related party line of credit was paid down $3,619,789 in exchange for 2,827,960 shares of the Company’s common stock and accompanying warrants to purchase shares of common stock, leaving available $14,800,000 to draw from that credit facility (Note 10). However, there is substantial doubt about the Company’s ability to continue as a going concern due to the necessity to generate positive cash flows from operations and/or obtain additional financing. There is no assurance that the Company will be able to generate positive cash flows from operations or obtain additional financing on terms acceptable to the Company, if at all.

 

In addition, the Company’s current and future operations are subject to various risks and uncertainties, including but not limited to general economic conditions, competition, and regulatory matters. Accordingly, the Company’s operation plan is predicated on various assumptions including, but not limited to, the level of product demand, cost estimates, its ability to continue raising additional financing, and the state of the general economic environment in which the Company operates.

 

F-8

 

 

BRIGHT GREEN CORPORATION

Notes to the Consolidated Financial Statements

For the Years Ended December 31, 2023 and 2022

(Expressed in United States Dollars)

 

 

2. Going Concern and Basis of Presentation (continued)

 

These risks and uncertainties may have a material adverse effect on the Company’s financial condition and operating results. Management has taken actions to address the Company’s liquidity needs, including managing expenses, developing pathways to revenue, and pursuing additional financing, such as the EB-5 Program announced on February 1, 2023. However, there can be no assurance that such actions will be sufficient to enable the Company to continue as a going concern. There can be no assurance that these assumptions will prove accurate in all material respects or that the Company will be able to successfully execute its operating plan.

 

The consolidated financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. In addition, the Company does not have any short or long-term contractual purchases with suppliers for future purchases, capital expenditure commitments that cannot be canceled with minimal fees, noncancelable operating leases, or any commitment or contingency that would hinder management’s ability to scale down operations and management expenses until funding is raised.

 

The Company’s ability to continue as a going concern is dependent upon the outcome of the matters described above. The consolidated financial statements do not include any adjustments that might result from the outcome of these uncertainties.

 

This disclosure is intended to inform users of the consolidated financial statements about the Company’s current financial condition and its ability to continue as a going concern. The Company will continue to monitor its liquidity position and take appropriate actions as necessary to address any potential going concern issues.

 

3. Summary of Significant Accounting Policies

 

A. Basis of Measurement

 

The consolidated financial statements of the Company have been prepared on a historical cost basis except as indicated otherwise.

 

B. Principles of Consolidation

 

The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, Regional Center Bright Green, LLC. Intercompany transactions and balances have been eliminated upon consolidation.

 

F-9

 

 

BRIGHT GREEN CORPORATION

Notes to the Consolidated Financial Statements

For the Years Ended December 31, 2023 and 2022

(Expressed in United States Dollars)

 

 

3. Summary of Significant Accounting Policies (continued)

 

C. Property, Plant, and Equipment

 

Property, plant, and equipment are stated at cost less accumulated depreciation. Expenditures for maintenance and repairs are charged to earnings as incurred; additions, renewals, and betterments are capitalized. When property, plant, and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of property, plant, and equipment, except land, which is not depreciated, is provided using the declining balance method, or straight-line method, with estimated lives as follows:

 

Building and improvement - declining balance method 10 year life
Furniture and fixtures - straight-line method 3 year life

 

Construction in progress is not depreciated until the asset is placed in service.

 

D. Long-lived Assets

 

The Company applies the provisions of ASC Topic 360, Property, Plant, and Equipment, which addresses financial accounting and reporting for the impairment or disposal of long-lived assets. ASC Topic 360 requires that long-lived assets be reviewed annually for impairment whenever events or changes in circumstances indicate that the assets’ carrying amounts may not be recoverable; it further requires impairment losses to be recorded on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair value of the long-lived assets. Loss on long-lived assets to be disposed of is determined in a similar manner, except that fair values are reduced for the cost of disposal.

 

E. Intangible Assets

 

The Company’s intangible assets consist of certain licenses which will be amortized over the term of each license (Note 8). The intangible assets with finite useful lives are reviewed for impairment when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair value of the long-lived assets.

 

F-10

 

 

BRIGHT GREEN CORPORATION

Notes to the Consolidated Financial Statements

For the Years Ended December 31, 2023 and 2022

(Expressed in United States Dollars)

 

 

3. Summary of Significant Accounting Policies (continued)

 

F. Fair Value of Financial Instruments

 

In accordance with ASC 820 (Topic 820, Fair Value Measurements and Disclosures), the Company uses a three-level hierarchy for fair value measurements of certain assets and liabilities for financial reporting purposes that distinguishes between market participant assumptions developed from market data obtained from outside sources (observable inputs) and our own assumptions about market participant assumptions developed from the best information available to us in the circumstances (unobservable inputs). The fair value hierarchy is divided into three levels based on the source of inputs as follows:

 

  ●

Level 1 – inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets;

     
  ●

Level 2 – inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability other than quoted prices, either directly or indirectly including inputs in markets that are not considered to be active; and

     
  ● Level 3 – inputs to the valuation methodology are unobservable and significant to the fair value measurement.

 

Categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The carrying amounts of the Company’s cash, other assets, accounts payable, accrued liabilities, due to others, and due to related party approximated their fair values as of December 31, 2023 and 2022 due to their short-term nature. The Company’s Alterola investment is also accounted for at fair value and recorded in Other investment held at fair value on the consolidated balance sheets. In accordance with the levels defined above, Level 1, the fair value of the Company’s Alterola investment was $726,343 as of December 31, 2023.

 

G. Investment Under the Equity Method

 

When the Company does not have a controlling financial interest in an entity but can exert significant influence over the entity’s operating and financial policies, the investment is accounted for either (i) under the equity method of accounting or (ii) at fair value by electing the fair value option available under U.S. generally accepted accounting principles (“GAAP”). Significant influence generally exists when the Company owns 20% to 50% of the entity’s common stock or in-substance common stock. In addition, the Company may recognize its share of an investee’s earnings based on an estimated amount for the investee’s earnings when the investee’s financial information is not sufficiently timely for the Company’s reporting period.

 

F-11

 

 

BRIGHT GREEN CORPORATION

Notes to the Consolidated Financial Statements

For the Years Ended December 31, 2023 and 2022

(Expressed in United States Dollars)

 

 

3. Summary of Significant Accounting Policies (continued)

 

G. Investment Under the Equity Method (continued)

 

Under the equity method of accounting, the investment is initially recorded at cost, including transaction costs incurred to acquire the investment, and thereafter adjusted for additional investments, distributions, and the proportionate share of earnings or losses of the investee. The Company’s equity method investment is reviewed for impairment whenever events or changes in circumstances indicate that an other-than-temporary decline in value may have occurred. If it is determined that a loss in value of the equity method investment is other than temporary, an impairment loss is measured based on the excess of the carrying amount of an investment over its estimated fair value. Impairment analyses are based on current plans, intended holding periods, and available information at the time the analysis is prepared.

 

Derivative Financial Instruments

 

The Company evaluates all its financial instruments to determine if such instruments contain features that qualify as embedded derivatives. Embedded derivatives must be separately measured from the host contract if all the requirements for bifurcation are met. The assessment of the conditions surrounding the bifurcation of embedded derivatives depends on the nature of the host contract. Bifurcated embedded derivatives are recognized at fair value, with changes in fair value recognized in the consolidated statement of operations and comprehensive loss each period. Bifurcated embedded derivatives are classified with the related host contract in the Company’s consolidated balance sheets.

 

H. Other Investment Held at Fair Value

 

In accordance with ASC 825, the Company records its investment at fair value under the Other investment held at fair value in the Company’s consolidated balance sheets and changes in fair value are recognized as Change in fair value of assets, net, a component of Other expense in the consolidated statements of operations and comprehensive loss.

 

At the most recent remeasurement date, the Company evaluated its ability to continue to exercise significant influence over its investment and determined that it no longer had significant influence. The Company’s Alterola investment is accounted for at fair value under ASC 321 and recorded in Other investment held at fair value on the consolidated balance sheets and changes in fair value are recognized as Change in fair value of assets, a component of Other expense, net in the consolidated statements of operations and comprehensive loss (Note 6).

 

I. Advertising Costs

 

Advertising costs are charged to operations when incurred. Advertising costs totaled $43,867 and $78,193 for the year ended December 31, 2023 and 2022, respectively.

 

J. Income Taxes

 

The Company accounts for income taxes in accordance with ASC Topic 740, Income Taxes. ASC 740 requires a company to use the asset and liability method of accounting for income taxes, whereby deferred tax assets are recognized for deductible temporary differences, and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized.

 

F-12

 

 

BRIGHT GREEN CORPORATION

Notes to the Consolidated Financial Statements

For the Years Ended December 31, 2023 and 2022

(Expressed in United States Dollars)

 

 

3. Summary of Significant Accounting Policies (continued)

 

J. Income Taxes (continued)

 

Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment. The Company has not changed its methodology for estimating the valuation allowance. A change in valuation allowance affects earnings in the period the adjustments are made and could be significant due to the large valuation allowance currently established.

 

Under ASC 740, a tax position is recognized as a benefit only if it is “more likely than not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that is greater than 50% likely to be realized on examination. For tax positions not meeting the “more likely than not” test, no tax benefit is recorded. The Company has no material uncertain tax positions for any of the reporting periods presented (Note 13).

 

K. Basic and Diluted Earnings (Loss) Per Share

 

Basic earnings (loss) per share is calculated using the weighted average number of common shares outstanding during the period. The dilutive effect on earnings (loss) per share is calculated, presuming the exercise of outstanding stock options, warrants, and similar instruments. It assumes that the proceeds of such exercise would be used to repurchase common shares at the average market price during the period.

 

For the years ended December 31, 2023, and 2022, all outstanding stock options, warrants, and similar instruments were excluded from the computation of diluted net loss per share, because the exercise price of these instruments exceeded the average market price of the Company’s common stock, making them anti-dilutive.

 

L. Segment Reporting

 

ASC 280-10, “Disclosures about Segments of an Enterprise and Related Information”, establishes standards for how public business enterprises report information about operating segments in the Company’s consolidated financial statements. Operating segments are components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision-maker in deciding how to allocate resources and in assessing performance. Significantly all of the assets of the Company are located in the United States of America and the Company is a start-up company as at December 31, 2023 and 2022 and has no revenue. The Company’s reportable segments and operating segments will include its growth, production, and research of medicinal plants operations.

 

F-13

 

 

BRIGHT GREEN CORPORATION

Notes to the Consolidated Financial Statements

For the Years Ended December 31, 2023 and 2022

(Expressed in United States Dollars)

 

 

3. Summary of Significant Accounting Policies (continued)

 

M. Use of Estimates

 

The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions. The Company bases its estimates and assumptions on current facts, historical experience, various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities, and the accrual of costs and expenses that are not readily apparent from other sources. This applies in particular to valuation allowance for deferred tax assets, valuation of warrants, stock options, stock-based compensation, going concern assessment, impairment of non-current assets, and assignment of the useful lives of property, plant, and equipment. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.

 

N. Stock-Based Compensation

 

The Company accounts for stock-based payments in accordance with the provision of ASC 718, which requires that all stock-based payments issued to acquire goods or services, including grants of employee stock options, be recognized in the consolidated statements of operations and comprehensive loss based on their fair values, net of estimated forfeitures. ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Compensation expense related to stock-based awards is recognized over the requisite service period, which is generally the vesting period.

 

The Company accounts for stock-based compensation awards issued to non-employees for services, as prescribed by ASC 718-10, at either the fair value of the services rendered or the instruments issued in exchange for such services, whichever is more readily determinable, using the guidelines in ASC 505-50. The Company issues compensatory shares for services including, but not limited to, executive management, management, accounting, operations, corporate communication, and financial and administrative consulting services.

 

O. Warrants

 

The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in FASB, ASC 480 and ASC 815. The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own ordinary shares and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance, and each consolidated balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the consolidated statements of operations and comprehensive loss.

 

F-14

 

 

BRIGHT GREEN CORPORATION

Notes to the Consolidated Financial Statements

For the Years Ended December 31, 2023 and 2022

(Expressed in United States Dollars)

 

 

3. Summary of Significant Accounting Policies (continued)

 

P. Recently Adopted Accounting Standards

 

In February 2016, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2016-02, “Leases (Topic 842)”, which establishes a right-of-use (ROU) model that requires a lessee to record an ROU asset and a lease liability on the statement of financial position for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the statement of activities. The new standard became effective for public business entities on January 1, 2019, with early adoption permitted. The new standard became effective for the Company on May 17, 2022, the date the Company became a public entity. The Company adopted this accounting policy as of May 17, 2022. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. While the Company continues to evaluate certain aspects of the new standard, including those still being revised by the FASB, the new standard does not have a material effect on the Company’s consolidated financial statements. As of December 31, 2023, the Company has one month to month lease, whereas the new standard does not apply.

 

In October 2023, the FASB issued ASU No. 2023-06, Disclosure Improvements: Codification Amendments in Response to the SEC’s Disclosure Update and Simplification Initiative. The amendments in this update modify the disclosure or presentation requirements of a variety of topics in the codification. Certain amendments represent clarifications to or technical corrections of the current requirements. Each amendment in the ASU will only become effective if the SEC removes the related disclosure or presentation requirement from its existing regulations by June 30, 2027. The Company is currently assessing the impact this standard will have on the Company’s future consolidated financial statements.

 

F-15

 

 

BRIGHT GREEN CORPORATION

Notes to the Consolidated Financial Statements

For the Years Ended December 31, 2023 and 2022

(Expressed in United States Dollars)

 

 

3. Summary of Significant Accounting Policies (continued)

 

Q. Recently Issued but Not Adopted Accounting Standards

 

In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The amendments in ASU 2023-07 are intended to enhance disclosures for significant segment expenses for all public entities required to report segment information in accordance with ASC 280. ASC 280 requires a public entity to report for each reportable segment a measure of segment profit or loss that its chief operating decision maker (“CODM”) uses to assess segment performance and to make decisions about resource allocations. The amendments in ASU 2023-07 improve financial reporting by requiring disclosure of incremental segment information on an annual and interim basis for all public entities to enable investors to develop more useful financial analyses. Currently, Topic 280 requires that a public entity disclose certain information about its reportable segments. For example, a public entity is required to report a measure of segment profit or loss that the CODM uses to assess segment performance and make decisions about allocating resources. ASC 280 also requires other specified segment items and amounts, such as depreciation, amortization, and depletion expense, to be disclosed under certain circumstances. The amendments in ASU 2023-07 do not change or remove those disclosure requirements. The amendments in ASU 2023-07 also do not change how a public entity identifies its operating segments, aggregates those operating segments, or applies the quantitative thresholds to determine its reportable segments. The amendments in ASU 2023-07 are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. A public entity should apply the amendments in ASU 2023-07 retrospectively to all prior periods presented in the financial statements. The Company is currently assessing the impact this standard will have on the Company’s future consolidated financial statements.

 

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The amendments in ASU 2023-07 are intended to enhance the transparency and decision usefulness of income tax disclosures. The amendments in ASU 2023-09 require annual disclosures of specific categories in the rate reconciliation, additional information for reconciling items that meet a quantitative threshold, and a disaggregation of income taxes paid, net of refunds. The amendments in ASU 2023-09 also eliminate certain existing disclosure requirements related to uncertain tax positions and unrecognized deferred tax liabilities. The amendments in ASU 2023-09 are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The amendments in ASU 2023-09 should be applied prospectively. The Company is currently assessing the impact this standard will have on the Company’s future consolidated financial statements.

 

Management does not believe that other recently issued, but not yet effective, accounting standards could have a material effect on the Company’s consolidated financial statements. As new accounting pronouncements are issued, the Company will adopt those that are applicable under the circumstances.

 

F-16

 

 

BRIGHT GREEN CORPORATION

Notes to the Consolidated Financial Statements

For the Years Ended December 31, 2023 and 2022

(Expressed in United States Dollars)

 

 

4. Concentration of Credit Risk

 

Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash deposits. Accounts at each institution are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. The Company had $nil and $187,821in excess of the FDIC insured limit at December 31, 2023 and 2022, respectively.

 

5. Deposits

 

As of December 31, 2022, deposits were comprised of two down payments. One was for a construction of equipment contract for which the Company had not yet taken title. The other was for a construction contract for which the work had not started. As of December 31, 2023, the Company has still not taken title of the equipment and the construction contract was completed (Note 9).

 

On March 13, 2024, the Company entered into and signed a Settlement and Release Agreement, in which the deposit was forfeited, leased equipment was returned, and 118,535,168 shares of common stock of Alterola was transferred to the vendor in lieu of payment. Additionally, all parties involved mutually released, relieved, acquitted, remised, and discharged each other as per the Settlement and Release Agreement (Notes 9 and 16).

 

6. Equity Method Investment in Alterola

 

On October 3, 2022, the Company entered into a Secondary Stock Purchase Agreement and Release (the “Secondary SPA”) with Phytotherapeutix Holdings Ltd., a United Kingdom entity, Equipped4 Holdings Limited, a United Kingdom entity, TPR Global Limited, a United Kingdom entity (each, a “Seller” and collectively, the “Sellers”) and Alterola Biotech Inc., a Nevada corporation (“Alterola”) providing for the purchase by Bright Green of shares of Common Stock of Alterola from the Sellers (the “Transferred Shares”).

 

The Secondary SPA provided that, as of the date thereof, the authorized shares of Alterola consisted of 2,000,000,000 shares of common stock, $0.001 par value, of which 807,047,948 shares were issued and outstanding. The Sellers held 67% of Alterola’s total outstanding shares prior to the closing of the Secondary SPA. As a result of this transaction, the Company obtained ownership or voting power of approximately 25% of the total outstanding shares of Alterola. The Sellers Transferred Shares consisted of, in aggregate, 201,761,982 shares of Common Stock, which were sold to the Company for a purchase price of $3,999,999, pursuant to the payment schedule set forth in the Secondary SPA. Following the receipt of each installment payment, the Sellers agreed to loan to Alterola the proceeds such Seller received from the foregoing sale of its Transferred Shares, pursuant to a loan agreement. As of December 31, 2023 and 2022, the Company has a liability to the Sellers of $1,650,000, which is in default as of December 31, 2023. The liability is not interest-bearing and not secured.

 

On March 13, 2024, the Company entered into and signed a Settlement Agreement with the Sellers, in which the Company transferred 27,742,273 of the Transferred Shares to each of the Sellers. Additionally, all parties involved mutually released, relieved, acquitted, remised, and discharged each other from any further claims as outlined in the Release Agreement (Note 16).

 

Voting Agreement

 

Concurrently with the signing of the Secondary SPA, Bright Green and the Sellers entered into a voting agreement (the “Voting Agreement”) whereby the Sellers agreed to vote in favor of the adoption of an agreement to effect Bright Green’s acquisition of Alterola or the Alterola’s merger into Bright Green or a subsidiary of Bright Green, as the case may be, pursuant to additional terms set forth in the Voting Agreement.

 

F-17

 

 

BRIGHT GREEN CORPORATION

Notes to the Consolidated Financial Statements

For the Years Ended December 31, 2023 and 2022

(Expressed in United States Dollars)

 

 

6. Equity Method Investment in Alterola (continued)

 

The Voting Agreement was initially measured at fair value utilizing the Black-Scholes option pricing model based on the following assumptions: dividend rate of 0.0%, risk free rate of 4.0%, term of 0.5 years, volatility of 66.0%, the stock price of $26,400,000, inclusive of a Control Premium of 65% valued at $10,400,000, determined using the Recent Transaction Method as the transaction was determined to be arms-length, and a strike price of $61.3 million reflecting the option to purchase the remaining 75% of the outstanding shares of common stock for $46.0 million. The issuance date fair value of the Voting Agreement was determined to be $213,000 of the gross payment to the Sellers of $3,999,999.

 

As of December 31, 2022, the value of the option was impaired to $nil to reflect the likelihood that the option would be exercised according to the terms set forth. As of December 31, 2023, the option has expired.

 

Equity Method Accounting Treatment

 

The Company’s 25% ownership of Alterola allowed the Company to have significant influence over the operations and decision-making at Alterola. Accordingly, the Company accounted for the transaction under the equity method and recorded the carrying value of the Company’s investment in Alterola common shares at cost, including the transaction costs incurred to obtain the equity method investment, in the consolidated balance sheets.

 

The following table provides summarized balance sheet information for Alterola as of September 30, 2023 and December 31, 2022:

 

   September 30, 2023   December 31, 2022 
Current assets  $197,208   $192,011 
Non-current assets   300,000    12,018,147 
Current liabilities   2,519,231    1,822,696 
Non-current liabilities   -    151,255 
Equity (Deficit)  $(2,022,023)  $10,236,207 

 

The following table provides summarized income statement information for Alterola for the nine months ended September 30, 2023 and the year ended December 31, 2022:

 

         
   Nine Months Ended   Year Ended 
   September 30, 2023   December 31, 2022 
Total revenues  $-   $- 
Net loss  $874,653   $4,980,510 

 

F-18

 

 

BRIGHT GREEN CORPORATION

Notes to the Consolidated Financial Statements

For the Years Ended December 31, 2023 and 2022

(Expressed in United States Dollars)

 

 

6. Equity Method Investment in Alterola (continued)

 

For the year ended December 31, 2022 and the period through October 16, 2023, the Company maintained significant influence through its ownership interest and accounted for its Alterola investment under the equity method. For the year ended December 31, 2022, the Company recorded a loss of $135,155 to account for its 25% share of Alterola’s net loss from October 3, 2022, through the year ended December 31, 2022. As of December 31, 2022, the equity method investment balance was $3,990,960.

 

For the year ended December 31, 2023, the Company recorded a loss of $218,663 to account for its 25% share of Alterola’s net loss for the period ended October 16, 2023. On October 16, 2023, Alterola issued shares of its common stock in exchange for forgiveness of debt diluting the Company’s 25% share to approximately 15%. The Company evaluated its ability to continue to exercise significant influence over its investment and determined that it no longer had significant influence. Subsequent to this remeasurement date, the Company’s Alterola investment is accounted for at fair value under ASC 321 and recorded in Other investment held at fair value on the consolidated balance sheets. Any changes in fair value of the Company’s Alterola investment are recorded as a Change in fair value of assets in its consolidated statements of operations and comprehensive loss. Based on quoted market prices, the fair value of the Company’s Alterola investment was $726,343 as of December 31, 2023. For the year ended December 31, 2023, the Company recorded $3,045,954 of Change in fair value of assets.

 

The following table summarizes the activity of the Company’s equity method investment in Alterola:

 

 

   Equity Method 
   Investment in Alterola 
Balance at December 31, 2021  $- 
Company’s initial investment in Alterola   4,126,115 
Company’s 25% share in net loss recognized in 2022   (135,155)
Balance at December 31, 2022   3,990,960 
Company’s 25% share in net loss recognized through October 16, 2023   (218,663)
Change in fair value of assets   (3,045,954)
Balance at December 31, 2023  $726,343 

 

 

7. Property, Plant, and Equipment

 

The Company owns an expansive 22-acre modern Dutch “Venlo style” glass greenhouse situated on 70 acres in Grants, New Mexico. It is being retrofitted for growing, processing and distribution of medicinal plants, including Marijuana, for medical researchers licensed by the Drug Enforcement Administration.

 

Property, plant, and equipment at December 31, 2023 and 2022, consisted of the following:

 

   December 31, 2023   December 31, 2022 
Furniture and fixtures  $88,690   $88,690 
Land   260,000    260,000 
Construction in progress   10,635,866    10,736,269 
Building and improvements   8,883,851    8,883,851 
Property, plant and equipment gross   19,868,407    19,968,810 
Accumulated depreciation   (3,460,992)   (2,822,485)
Net property, plant, and equipment  $16,407,415   $17,146,325 

 

F-19

 

 

BRIGHT GREEN CORPORATION

Notes to the Consolidated Financial Statements

For the Years Ended December 31, 2023 and 2022

(Expressed in United States Dollars)

 

 

7. Property, Plant, and Equipment (continued)

 

The amount of interest expense capitalized and included in construction in progress was $223,271 and $106,117 for the years ended December 31, 2023 and 2022, respectively (Note 10).

 

On January 19, 2024, the Company reached an agreement with the vendor to cancel approximately $2,650,000 of construction in progress. As part of the agreement, the vendor also agreed to cancel the related accounts payable and completion of the project. The project was being constructed at the vendor’s location. The adjustment is reflected in the construction in progress balance as of December 31, 2023 (Note 16).

 

Real Estate Options

 

In 2020, the Company entered into a merger agreement with Grants Greenhouse Growers, Inc. and acquired the following two land options:

 

 -A Real Estate Option Agreement dated October 5, 2020, and expiring on December 31, 2021, for $1,500 monthly payments up until June 30, 2021, and $1,750 monthly payments from July 1, 2021 to December 31, 2021, with a one-year extension starting on January 1, 2022 for $2,000 monthly payments, with the option to purchase 330 acres for $5,000 per acre.
   
-A Real Estate Option Agreement dated October 21, 2020, and expiring on December 31, 2021, for $1,000 monthly payments, with a one-year extension starting on January 1, 2022 for $1,500 monthly payments, with the option to purchase 175 acres for $5,000 per acre.

 

As of December 31, 2022, the Company notified the two landowners of the Company’s intention to exercise the two Real Estate Option Agreements. The Company is in the process of negotiating final terms of the two acquisitions. As of December 31, 2023, the acquisitions have not been completed.

 

8. Intangible Assets

 

Intangible assets at December 31, 2023 and 2022, consisted of the following:

 

   December 31, 2023   December 31, 2022 
Licenses  $1,000   $1,000 
Accumulated amortization   -    - 
Net intangible assets  $1,000   $1,000 

 

9. Commitments

 

In 2022, the Company entered a contract to purchase equipment for $2,219,285. The Company made a deposit totaling $1,109,643 as of December 31, 2022. The remaining balance of $1,109,642 is due upon delivery of the equipment. In addition, the Company entered into and paid in full a construction contract for $47,944 as of December 31, 2022. The construction was completed in March 2023, and the contract was fulfilled (Note 5).

 

On March 13, 2024, the Company entered into and signed a Settlement and Release Agreement, in which the deposit was forfeited, leased equipment was returned, and 118,535,168 shares of common stock of Alterola was transferred to the vendor in lieu of payment. Additionally, all parties involved mutually released, relieved, acquitted, remised, and discharged each other as per the Settlement and Release Agreement  (Notes 5 and 16).

 

F-20

 

 

BRIGHT GREEN CORPORATION

Notes to the Consolidated Financial Statements

For the Years Ended December 31, 2023 and 2022

(Expressed in United States Dollars)

 

 

10. Related Party Line of Credit Note

 

On June 5, 2022, the Company and LDS Capital LLC (“Lender”), whose managing member is a member of the Company’s Board of Directors (the “Board”), entered into an unsecured line of credit in the form of a note (the “June Note”). The June Note provides that the Company may borrow up to $5,000,000, including an initial loan of $3,000,000, through June 4, 2025 (the “June Note Maturity Date”) from Lender. Prior to the June Note Maturity Date, the Company may borrow up to an additional $2,000,000 under the June Note, at Lender’s sole discretion, and subject to the Company’s request of such additional funds from Lender (each loan furnished under the June Note individually, a “Loan,” and collectively, the “Loans”). The Company has the right, but not the obligation, to prepay any Loan, in whole or in part, prior to the June Note Maturity Date. Interest on the unpaid principal amount of any Loan accrues through the earlier of the June Note Maturity Date or the date of prepayment on such Loan, at a rate of 2% per annum plus the Prime Rate (the rate of interest per annum announced from time to time by JP Morgan Chase Bank as its prime rate). If the principal and interest, if any, of any Loan is not paid in full on the June Note Maturity Date, additional penalty interest will accrue on such Loan in the amount of 2% per annum. The Company amended the line of credit on November 14, 2022, to increase the capacity by $10,000,000. On January 31, 2023, LDS Capital LLC assigned the note to its sole member, Lynn Stockwell, who is the Company’s Chairwoman and majority shareholder.

 

As of December 31, 2023, the Lender has funded the Company $5,983,250 (December 31, 2022 – $5,191,057), with the Company paying back $6,110,855 (December 31, 2022 – $1,611,067) of those funds, which includes $327,605 in interest. As of December 31, 2023, there was accrued interest of $1,783 (December 31, 2022 – $106,117). The funds have been used for the construction in progress, and during the year ended December 31, 2023, interest expense of $223,271 (December 31, 2022 – $106,117) has been capitalized (Note 7).

 

On February 1, 2023, through a cashless conversion, the related party line of credit note was used to pay the related party loan balance of $392,194 in full.

 

On February 6, 2023, through a cashless conversion, the related party line of credit note was paid down $880,000 in exchange for an $880,000 investment for 22,005 shares of the Company’s common stock valued at $39.99 per share pursuant to the Company’s EB-5 Program (Note 11).

 

On March 14, 2023, the Company drew an additional $200,000 on the related party line of credit note.

 

F-21

 

 

BRIGHT GREEN CORPORATION

Notes to the Consolidated Financial Statements

For the Years Ended December 31, 2023 and 2022

(Expressed in United States Dollars)

 

 

10. Related Party Line of Credit Note (continued)

 

At August 31, 2023, the amount of principal, interest, and other costs outstanding under the related party line of credit note was $3,619,789 (the “Repayment Obligation”). On September 1, 2023, the Company and the Lender entered into an agreement (the “Repayment Agreement”) pursuant to which, in consideration for the cancellation and full satisfaction of the Repayment Obligation, the Company issued to the Lender (i) 2,827,960 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), representing a conversion of outstanding principal at $1.15 per Share, and (ii) warrants representing a conversion of outstanding principal at $0.13 per warrant to purchase up to 2,827,960 shares of Common Stock at a price of $3.00 per share (Note 11).

 

The Company determined the Repayment Agreement should be accounted for as an extinguishment in accordance ASC 405, Liabilities, and ASC 470-50, Debt. The Company measured the difference between the fair value of the equity interests granted and the carrying value of the obligation, determining that the carrying value exceeded the fair value of the interests granted. The Company determined that a gain would be recorded; however, the Company recorded the $2,090,564 gain as a capital transaction due to the related party nature of the Lender.

 

On December 1, 2023, the Company drew an additional $200,000 on the related party line of credit note, leaving available $14,800,000 to draw from that credit facility.

 

11. Stockholders’ Equity

 

The Company has authorized 500,000,000 shares of $0.0001 par value common stock and 10,000,000 shares of $0.0001 par value preferred stock. As of December 31, 2023, and 2022, there were 184,758,818 and 173,304,800, respectively, of common shares issued and outstanding. The Company has not issued any preferred shares to date.

 

During the year ended December 31, 2023, the Company issued the following:

 

-200,000 warrants exercised in exchange for 200,000 shares of common stock issued for cash at $1.05 per share, to one accredited investor in February 2023;

 

-22,005 shares of common stock issued at $39.99 per share, to the Company’s Chairwoman in February 2023, through a cashless conversion; the related party line of credit note was paid down $880,000 in exchange for an $880,000 investment, pursuant to the Company’s EB-5 Program (Note 10);

 

-22,005 shares of common stock issued at $39.99 per share, to one accredited investor in March 2023, pursuant to the Company’s EB-5 Program;

 

F-22

 

 

BRIGHT GREEN CORPORATION

Notes to the Consolidated Financial Statements

For the Years Ended December 31, 2023 and 2022

(Expressed in United States Dollars)

 

 

11.Stockholders’ Equity (continued)

 

-875,000 shares of common stock for services rendered, at a fair value of $0.9416 per share, to the Company’s former Executive Chairman, in March 2023 (Note 14);

 

-500,000 shares of common stock for services rendered, at a fair value of $1.13 per share, to the Company’s former Chief Executive Officer, in May 2023 (Note 14);

 

-3,684,210 shares of common stock and warrants to purchase up to an aggregate of 3,684,210 shares of common stock, at a combined purchase price of $0.95 per share and accompanying warrant, in a private placement offering, in May 2023 (the “May 2023 Private Placement”);

 

-875,000 shares of common stock for services rendered, at a fair value of $1.01 per share, to the Company’s former Executive Chairman, in June 2023 (Note 14);

 

-137,838 shares of common stock for services rendered, at a fair value of $0.74 per share, to a consultant of the Company, in July 2023;

 

-2,827,960 shares of common stock and warrants to purchase up to an aggregate of 2,827,960 shares of common stock at an exercise price of $3.00 per share, issued at a combined price of $1.28 per share and accompanying warrant, to the Company’s Chairwoman, through a cashless conversion; the related party line of credit note was paid in full $3,619,789 in exchange for a $3,619,789 investment, in September 2023 (Note 10);

 

-60,000 shares of common stock for services rendered, at a fair value of $0.4015 per share, to a consultant of the Company, in September 2023;

 

-500,000 shares of common stock for services rendered, at a fair value of $0.4015 per share, to the Company’s Chief Financial Officer, in September 2023 (Note 14);

 

-875,000 shares of common stock for services rendered, at a fair value of $0.3959 per share, to the Company’s former Executive Chairman, in September 2023 (Note 14);

 

-1,800,000 shares of stock options for services rendered, at a fair value of $0.3303 per share, an exercise price of $0.3353 per share, which vest immediately, expire on November 16, 2033, with 600,000 each to three Directors of the Company, in November 2023 (Notes 12 and 14); and

 

F-23

 

 

BRIGHT GREEN CORPORATION

Notes to the Consolidated Financial Statements

For the Years Ended December 31, 2023 and 2022

(Expressed in United States Dollars)

 

 

11.Stockholders’ Equity (continued)

 

-875,000 shares of common stock for services rendered, at a fair value of $0.3301 per share, to the Company’s former Executive Chairman, in December 2023 (Note 14).

 

During the year December 31, 2022, the Company issued the following:

 

-12,500 shares of common stock at a purchase price of $4.00 per share, for gross cash proceeds of $50,000, to one accredited investor in January 2022;

 

-500,000 shares of common stock for services rendered, at a fair value of $4.00 per share determined using the per share purchase price of the latest $4.00 private placement Round, to the Chief Financial Officer of the Company, in April 2022;

 

-1,574,490 shares of common stock for services rendered, at a fair value of $8.00 per share determined using the per share purchase price of the latest $8.00 private placement Round, to six consultants in April 2022;

 

-5,000 shares of common stock that were issued in January 2021 to a director of the Company, for services valued at $2.00 per share determined using the per share purchase price of the $2.00 Round, were canceled in April 2022;

 

-300,000 shares of common stock at a purchase price of $10.00 per share, for gross cash proceeds of $3,000,000, to two accredited investors in May 2022;

 

-108,000 shares of common stock that were issued in June 2019 to a consultant of the Company, for services valued at $0.069 per share determined using an asset approach, were canceled in June 2022;

 

-9,523,810 shares of common stock and warrants to purchase up to an aggregate of 9,523,810 shares of common stock, at a combined purchase price of $1.05 per share and accompanying warrant, in a private placement offering, in September 2022 (the “September 2022 Private Placement”); and

 

-3,962,500 shares of common stock for services rendered, with (i) 3,000,000 shares issued at a fair value of $1.25 per share, (ii) 87,500 shares at a fair value of $1.08 per share, and (iii) 875,000 shares at a fair value of $0.4695 per share, to the former Chief Executive Officer of the Company, in December 2022.

 

Private Placement Offerings

 

September 2022 Private Placement

 

On September 7, 2022, the Company entered into a Securities Purchase Agreement with investors for the sale by the Company of 9,523,810 shares of common stock and warrants to purchase up to an aggregate of 9,523,810 shares of common stock. The combined purchase price of one share and the accompanying warrant (“September 2022 Warrants”) was $1.05.

 

F-24

 

 

BRIGHT GREEN CORPORATION

Notes to the Consolidated Financial Statements

For the Years Ended December 31, 2023 and 2022

(Expressed in United States Dollars)

 

 

11.Stockholders’ Equity (continued)

 

Subject to certain ownership limitations, the September 2022 Warrants are exercisable immediately after issuance at an exercise price equal to $1.05 per share of Common Stock, subject to adjustments as provided under the terms of the September 2022 Warrants. The September 2022 Warrants have a term of five years from the date of issuance. The September 2022 Private Placement closed on September 12, 2022. The Company received gross proceeds of approximately $10 million before deducting transaction-related fees and expenses payable by the Company. As of December 31, 2023, 200,000 of the September 2022 Warrants have been redeemed for $210,000.

 

In connection with the September 2022 Private Placement, the Company entered into a Registration Rights Agreement with the investors. The Company’s registration statement on Form S-1 to register the securities issued in the September 2022 Private Placement went effective on September 21, 2022.

 

Transaction costs incurred related to the September 2022 Private Placement include the following: (i) placement agent fees of $800,000, (ii) legal expenses of $55,617, and (iii) escrow agent expenses of $7,650.

 

May 2023 Private Placement

 

On May 21, 2023, the Company entered into a Securities Purchase Agreement with an accredited investor and existing stockholder of the Company. The combined purchase price of one share and the accompanying warrant (“May 2023 Warrants”) was $0.95. Subject to certain ownership limitations, the May 2023 Warrants are exercisable immediately after issuance at an exercise price equal to $0.95 per share of Common Stock, subject to adjustments as provided under the terms of the May 2023 Warrants. The May 2023 Warrants have a term of five years from the date of issuance. The May 2023 Private Placement closed on May 24, 2023. The Company received gross proceeds of approximately $3.5 million before deducting transaction related fees and expenses payable by the Company.

 

In connection with the May 2023 Private Placement, the Company entered into a Registration Rights Agreement with the investor. The Company’s registration statement on Form S-3 to register the securities issued in the May 2023 Private Placement went effective on June 5, 2023.

 

Transaction costs incurred related to the May 2023 Private Placement include the following: (i) placement agent fees of $316,850, and (ii) legal expenses of $78,400.

 

Warrants

 

September 2022 Warrants

 

In the Company’s September 2022 Private Placement, Warrants to purchase up to 9,523,810 shares of Common Stock were issued (“September 2022 Warrants”). The September 2022

 

F-25

 

 

BRIGHT GREEN CORPORATION

Notes to the Consolidated Financial Statements

For the Years Ended December 31, 2023 and 2022

(Expressed in United States Dollars)

 

 

11.Stockholders’ Equity (continued)

 

Warrants were initially exercisable at a price of $1.05 per share, subject to adjustment as set forth in the September 2022 Warrants, at any time after September 12, 2022 and will expire on September 13, 2027. In connection with the May 2023 Private Placement, the exercise price of the September 2022 Warrants issued in the September 2022 Private Placement was reduced to $0.95 per share.

 

The fair value of the September 2022 Warrants immediately prior to the modification was $7,399,000, and the fair value of the September 2022 Warrants immediately after the modification was $6,901,000, representing a decrease in fair value of $498,000. In accordance with ASU 2021- 04, as the modification was a result of issuing equity and there was no increase in fair value, the Company accounted for the adjustment as a reduction of additional paid-in capital with a corresponding offset recorded to additional paid-in capital.

 

May 2023 Warrants

 

In the Company’s May 2023 Private Placement, Warrants to purchase up to 3,684,210 shares of Common Stock were issued (“May 2023 Warrants”). The fair value of the May 2023 Warrants was determined utilizing a Black-Scholes model considering all relevant assumptions current at the date of issuance (i.e., share price of $0.78, exercise price of $0.95, term of five years, volatility of 165.0%, risk-free rate of 3.8%, and dividend rate of 0.0%). The grant date fair value of the May 2023 Warrants was estimated to be $1,600,000 on May 24, 2024 and is reflected within additional paid-in capital as of December 31, 2023.

 

September 2023 Warrants

 

In connection with the Repayment Obligation disclosed in Note 10, Warrants to purchase up to 2,827,960 shares of Common Stock were issued (“September 2023 Warrants”). The fair value of the September 2023 Warrants was determined utilizing a Monte Carlo simulation considering all relevant assumptions current at the date of issuance (i.e., share price of $0.46, exercise price of $3.00, expected life of one year, volatility of 149%, risk-free rate of 5.36%, and dividend rate of 0.0%). The grant date fair value of the September 2023 Warrants was estimated to be approximately $149,180 on September 1, 2023, and is reflected within additional paid-in capital as of December 31, 2023.

 

F-26

 

 

BRIGHT GREEN CORPORATION

Notes to the Consolidated Financial Statements

For the Years Ended December 31, 2023 and 2022

(Expressed in United States Dollars)

 

 

12. Stock-Based Compensation

 

In 2022, the Company adopted the Bright Green Corporation 2022 Omnibus Equity Compensation Plan, which allows for various types of stock-based awards. These awards can be in the form of stock options (including non-qualified and incentive stock options), SARs, restricted shares, performance shares, deferred stock, restricted stock units (“RSUs”), dividend equivalents, bonus shares, or other types of stock-based awards.

 

As of December 31, 2023 and 2022, there were 3,050,000 and nil, respectively, of awards granted under the Plan. The awards consisted of 2,425,000 shares of stock options and 625,000 shares of RSUs.

 

The Company’s stock-based compensation costs for the years ended December 31, 2023, and 2022 were $3,829,218 and $18,833,781, respectively, with the costs allocated to general and administrative expenses. Stock options accounted for $594,478 of the total stock-based compensation costs for the year ended December 31, 2023.

 

Stock Options

 

The Company uses the Black-Scholes option pricing model to value stock option grants to employees, non-employees, and directors. The fair value of the Company’s common stock is used to determine the fair value of stock options. The Black-Scholes option pricing model requires inputs based on certain subjective assumptions, including (i) the expected stock price volatility, (ii) the expected term of the award, (iii) the risk-free interest rate, and (iv) expected dividends. The historical volatility is calculated based on a period of time commensurate with the expected term assumption. The Company uses the simplified method to calculate the expected term for options granted to employees whereby the expected term equals the arithmetic average of the vesting term and the original contractual term of the options due to its lack of sufficient historical data. The risk-free interest rate is based on U.S. Treasury securities with a maturity date commensurate with the expected term of the associated award. The expected dividend yield is assumed to be zero as the Company has never paid dividends and has no current plans to pay any dividends on its common stock. The Company recognizes forfeitures as they occur.

 

The fair value of the stock options was estimated using the following assumptions:

Schedule of Fair Value of The Stock Options 

   2023   2022 
Weighted average fair value at grant date  $0.3303   $- 
Valuation assumptions:          
Expected life of options (years)   5.00    - 
Expected stock volatility   213.90%   - 
Risk-free interest rate   4.42%   - 
Expected dividend yield   0.00%   - 

 

F-27

 

 

BRIGHT GREEN CORPORATION

Notes to the Consolidated Financial Statements

For the Years Ended December 31, 2023 and 2022

(Expressed in United States Dollars)

 

 

12. Stock-Based Compensation (continued)

 

During the year ended December 31, 2023, the Company granted the following stock options:

 

-On September 20, 2023, the Company granted 625,000 shares of stock options with an exercise price of $0.385, which vest in thirty equal monthly installments beginning April 1, 2024, to the Chief Executive Officer of the Company (Note 14); and

 

-On November 16, 2023, the Company granted 1,800,000 shares of stock options with an exercise price of $0.3353, a fair value of $0.3303, vesting immediately, and expiring on November 16, 2033, with 600,000 each to three Directors of the Company (Notes 11 and 14).

 

During year ended December 31, 2022, the Company did not issue any stock options.

 

The following table summarizes stock option activity for the year ended December 31, 2023:

 

   Stock Options Outstanding & Exercisable 
           Weighted Average 
   Number of   Weighted Average   Remaining Life 
   Stock Options   Exercise Price   (Years) 
Balance, December 31, 2022   -   $-      
Granted   2,425,000    0.3353      
Exercised   -    -      
Expired   -    -      
Balance, December 31, 2023   2,425,000   $0.3353    9.90 

 

On March 31, 2024, the 625,000 shares of stock options granted to the Chief Executive Officer of the Company were canceled by mutual agreement between the Company and the Chief Executive Officer (Notes 14 and 16).

 

Restricted Stock Units

 

The Company accounts for the fair value of restricted stock units (“RSUs”) using the closing market price of the Company’s common stock on the date of the grant. Stock-based compensation cost for RSUs is measured at the grant date based on the estimated fair value of the award and is recognized as expense over the requisite service period (generally the vesting period), net of forfeitures.

 

During the year ended December 31, 2023, the Company granted the following RSUs:

 

-On September 20, 2023, the Company granted 625,000 shares of RSUs, which vest in thirty equal monthly installments beginning April 1, 2024, to the Chief Executive Officer of the Company (Note 14).

 

During the year ended December 31, 2022, the Company did not issue any RSUs.

 

On March 31, 2024, the 625,000 shares of RSUs granted to the Chief Executive Officer of the Company were canceled and replaced with 5,500,000 RSUs by mutual agreement between the Company and the Chief Executive Officer (Notes 14 and 16).

 

F-28

 

 

BRIGHT GREEN CORPORATION

Notes to the Consolidated Financial Statements

For the Years Ended December 31, 2023 and 2022

(Expressed in United States Dollars)

 

 

13. Income Taxes

 

Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. A full valuation allowance is established against all net deferred tax assets as of December 31, 2023 and 2022, based on estimates of recoverability. While the Company has optimistic plans for its business strategy, it determined that such a valuation allowance was necessary given the current and expected near term losses and the uncertainty with respect to its ability to generate sufficient profits from its business model.

 

The current and deferred income tax expenses for the year December 31, 2023 and 2022, was $nil. The provision for income taxes differs from that computed at combined corporate tax rate of approximately 25.8% (2022 – 25.8%) as follows:

 

 

   2023   2022 
           
Loss before income taxes  $(13,127,648)  $(27,662,077)

 

The (benefit) provision for income taxes for 2023 and 2022 consists of the following:

 

   2023   2022 
Current:          
Federal   -    - 
State   -    - 
Total current (benefit) provision   -    - 
           
Deferred:          
Federal   (2,520,309)   (5,727,839)
State   (576,071)   (1,309,220)
Total current (benefit) provision   (3,096,380)   (7,037,059)
Valuation allowance   3,096,380    7,037,059 
Total (benefit) expense  $-   $- 

 

The federal and state tax effects of the temporary differences and carry forwards that give rise to deferred tax assets consists of the following:

 

   2023   2022 
Other   1,401,963    728,201 
Net operating loss carry over   9,716,764    7,294,146 
Total deferred tax assets   11,118,727    8,022,347 
Less: valuation allowance   (11,118,727)   (8,022,347)
Deferred tax assets, net of valuation allowance  $-   $- 

 

F-29

 

 

BRIGHT GREEN CORPORATION

Notes to the Consolidated Financial Statements

For the Years Ended December 31, 2023 and 2022

(Expressed in United States Dollars)

 

 

13. Income Taxes (continued)

 

As of December 31, 2023 and 2022, the Company decided that a valuation allowance relating to the above deferred tax assets of the Company was necessary, largely based on the negative evidence represented by losses incurred and a determination that it is not more likely than not to realize these assets, such that, a corresponding valuation allowance, for each respective period, was recorded to offset deferred tax assets. Management has based its assessment on the Company’s lack of profitable operating history. As of December 31, 2023 and 2022, the Company has approximately $37,661,876 and $28,577,832 respectively, of Federal net of operating losses available to reduce taxable income of future years. The federal loss carryforward expires indefinitely. The benefit from the non-capital loss carry-forward balance has not been recorded in the consolidated financial statements.

 

The Company is subject to U.S. federal jurisdiction and the state of New Mexico income taxes. Management has not filed federal or state income tax returns due to incurring cumulative losses. Therefore, the Company’s actual tax position may differ from their book position. In the event that the Company is assessed interest or penalties at some point in the future, it will be classified in the consolidated financial statements as tax expense.

 

14. Related Party Transactions

 

Other than the transactions disclosed elsewhere in the consolidated financial statements, the following are the other significant related party transactions and balances:

 

Included in common stock issued for services during the year ended December 31, 2023, were 3,500,000 shares of common stock issued to the former Executive Chairman of the Company (Note 11).

 

Included in common stock issued for services during the year ended December 31, 2023, were 500,000 shares of common stock issued to the former Chief Executive Officer of the Company (Note 11).

 

Included in common stock issued for services during the year ended December 31, 2023, were 500,000 shares of common stock issued to the Chief Financial Officer of the Company (Note 11).

 

Included in stock options issued for services during the year ended December 31, 2023, were 1,800,000 shares of stock options issued to three Directors of the Company (Notes 11 and 12).

 

Included in stock-based awards granted during the year ended December 31, 2023, were 625,000 shares of stock options and 625,000 shares of RSUs issued to the Chief Executive Officer of the Company. On March 31, 2024, both the 625,000 shares of stock options and 625,000 shares of RSUs were canceled by mutual agreement between the Company and the Chief Executive Officer (Notes 12 and 16).

 

F-30

 

 

BRIGHT GREEN CORPORATION

Notes to the Consolidated Financial Statements

For the Years Ended December 31, 2023 and 2022

(Expressed in United States Dollars)

 

 

14. Related Party Transactions (continued)

 

At December 31, 2023 and 2022, $400,000 and $400,000, respectively, was due to the Company’s former interim Chief Executive Officer, who is also the Company’s former Executive Chairman. The amounts, which includes $200,000 and $300,000, respectively, in accrued bonus, is included in accrued liabilities in the consolidated balance sheet. On February 15, 2024, the Company issued 2,420,000 shares of common stock as a final settlement for the unpaid remuneration and bonus compensation (Notes 11 and 16).

 

At December 31, 2023 and 2022, $23,460 and $nil, respectively, was due to a company majority owned by the Company’s former Chief Executive Officer. The amount is included in accounts payable in the consolidated balance sheets.

 

At December 31, 2023 and 2022, $68,037 and $65,856, respectively, was due to a company wholly owned by the Company’s Chief Financial Officer, who also is a shareholder. The amount is included in accounts payable in the consolidated balance sheets.

 

At December 31, 2023 and 2022, $66,667 and $nil, respectively, was due to a company wholly owned by the Company’s Chief Executive Officer. The amount is included in accounts payable in the consolidated balance sheets.

 

At December 31, 2023 and 2022, $400,000 and $143,900, respectively, was due to a firm that has one of its partners serving on the Company’s Board of Directors. The amount is included in accounts payable in the consolidated balance sheets.

 

At December 31, 2023 and 2022, the outstanding balance on the line of credit of $201,783 and $3,686,107, respectively, was due to a Lender, who is the Company’s Chairwoman and majority shareholder (Note 10).

 

15. Contingencies

 

In the ordinary course of business, the Company is routinely defendants in, or parties to a number of pending and threatened legal actions including actions brought on behalf of various classes of claimants. In view of the inherent difficulty of predicting the outcome of such matters, the Company cannot state what the eventual outcome of such matters will be. Legal provisions are established when it becomes probable that the Company will incur an expense related to a legal action and the amount can be reliably estimated. Such provisions are recorded at the best estimate of the amount required to settle any obligation related to these legal actions as at the consolidated balance sheet date, taking into account the risks and uncertainties surrounding the obligation. Management and internal and external experts are involved in estimating any amounts that may be required. The actual costs of resolving these claims may vary significantly from the amount of the legal provisions. The Company’s estimate involves significant judgement, given the varying stages of the proceedings, the fact that the Company’s liability, if any, has yet to be determined and the fact that the underlying matters will change from time to time. Other than as set forth below, the Company is not presently a party to any litigation. The Company is not able to make a reliable assessment of the potential losses as these matters are at an early stage, accordingly, no amounts have been accrued in the consolidated financial statements.

 

F-31

 

 

BRIGHT GREEN CORPORATION

Notes to the Consolidated Financial Statements

For the Years Ended December 31, 2023 and 2022

(Expressed in United States Dollars)

 

 

15. Contingencies (continued)

 

Bright Green Corporation v. John Fikany, State of New Mexico, County of Cibola, Thirteenth Judicial District. In this matter, the Company filed a complaint for declaratory judgment against a consultant of the Bright Green Group of Companies, an entity unrelated to the Company, to determine if defendant is entitled to 5,000,000 shares of the Company’s common stock, based on a failure to fulfill agreed upon conditions precedent to earning such shares from the Company. Defendant counterclaimed and filed a third-party claim against a director of the Company, and her spouse, for claims including wrongful termination and breach of contract. The Company denies defendants allegations and have set forth arguments refuting defendant’s counterclaims and third-party claims. The trial date for the case has been scheduled for April 22, 2024.

 

Bright Green Corporation v. Jerry Capussi, State of New Mexico, County of Cibola, Thirteenth Judicial District. In this matter, the Company and defendant, a former consultant of Sunnyland Farms Inc., an entity unrelated to the Company, have each filed claims for declaratory judgment seeking to determine by court order whether defendant is entitled to (i) shares of common stock in the Company (amounting to no more than 108,000 shares) or (ii) fair market value of defendant’s equity ownership of BGGI. The lawsuit is in early discovery stages, and the Company is preparing arguments for a summary judgment motion. There are no claims for specific monetary liability against either party.

 

16. Subsequent Events

 

The Company’s management has evaluated the subsequent events up to April 16, 2024. The date the consolidated financial statements were issued, pursuant to the requirements of ASC 855, and has determined the following constitute material subsequent events:

 

On January 19, 2024, the Company reached an agreement with a vendor to cancel approximately $2,650,000 of construction in progress. As part of the agreement, the vendor also agreed to cancel the related accounts payable and completion of the project (Note 7).

 

On January 30, 2024, the Company issued 450,000 shares of common stock for services rendered, at a fair value of $0.2116 per share, to four consultants of the Company.

 

On February 7, 2024, the Company entered into a short-term note with 1401330 Ontario Ltd. (the “Bridge Lender”), a Company owned and controlled by a member of the Board of Directors, for $150,000. Additionally, the Company agreed to pay the Bridge Lender $15,000 as interest. The note is personally guaranteed by the Company’s Chairwoman.

 

On February 8, 2024, the Company drew an additional $100,000 on the related party line of credit note.

 

F-32

 

 

BRIGHT GREEN CORPORATION

Notes to the Consolidated Financial Statements

For the Years Ended December 31, 2023 and 2022

(Expressed in United States Dollars)

 

 

16.Subsequent Events (continued)

 

On February 15, 2024, Mr. Terry Rafih, the former Executive Chairman, resigned. Mr. Rafih and the Company entered into a Memorandum of Understanding (the “Separation Agreement”). The Separation Agreement provided that the Company (i) issue to Mr. Rafih 2,537,500 shares of the Company’s common stock, representing the acceleration of the vesting of the balance of shares of common stock issuable pursuant to a one-time award of 10 million shares of common stock approved by the stockholders of the Company at the 2022 Special Meeting of Stockholders, and (ii) further issue to Mr. Rafih 2,420,000 shares of common stock, in lieu of an aggregate of $450,000 of unpaid cash renumeration and bonus compensation during his tenure with the Company. The 4,957,000 shares of common stock were issued on February 15, 2024.

 

On March 7, 2024, the Company entered into a scope of work agreement with Titan Advisory Services, LLC, a limited liability company controlled by Saleem Elmasri, Chief Financial Officer of the Company, through which Mr. Elmasri provides services to the Company (the “CFO Agreement”). The CFO Agreement is effective as of March 1, 2024. Pursuant to the CFO Agreement, Mr. Elmasri shall continue to act as Chief Financial Officer of the Company through February 28, 2025, and provides Mr. Elmasri with a $25,000 monthly cash fee, and 600,000 restricted stock units, which were issued on March 7, 2024 and vest in equal monthly installments over a period of one year beginning one month from the date of grant.

 

On March 13, 2024, the Company entered into and signed a Settlement and Release Agreement  with United Science, LLC (“United”) and Alterola, in which a deposit made to United was forfeited, leased equipment was returned to United, 118,535,168 shares of common stock of Alterola was transferred to United in lieu of payment of outstanding invoices, and 83,226,820 shares of common stock of Alterola was returned to the three shareholders (Equipped4 Holdings Limited (“Equipped”), Phytotherapeutix Holdings Ltd. (“Phyto”), and TPR Global Limited (“TPR”)) who initially sold the shares to the Company for settlement of the $1,650,000 outstanding balance on the share purchase. Equipped, Phyto, and TPR each received 27,742,273 shares of common stock of Alterola

 

On March 14, 2024, the Company entered into a credit agreement with JVR Holdings, pursuant to which JVR Holdings agreed to provide the Company with a line of credit facility up to a maximum amount of $60 million, to be drawn in tranches. The line of credit is contingent on the Company formalizing a JVR Holdings approved plan for a construction project to expand the Company’s current research, production and extraction processing facility Grants, New Mexico.

 

On March 25, 2024, the Company drew an additional $10,000 on the related party line of credit note.

 

On March 31, 2024, the Company entered into an Amended Executive Employment Agreement with the Company’s Chief Executive Officer (the “CEO”), which replaced in its entirety the executive employment agreement entered into between the Company and the CEO on October 2, 2023. The Agreement provides the CEO a monthly base salary of $35,833.33 through October 2, 2024, a monthly base salary of $38,333.00 from October 2, 2024 to October 2, 2025, and a monthly base salary of $41,667.00 from October 2, 2025 to October 2, 2026. The agreement provides for customary reimbursement for certain expenses, and eligibility to participate in the Company’s benefit plans and executive compensation programs generally. Additionally, the 625,000 shares of stock options and 625,000 shares of RSUs that were issued in September 2023, under the original Executive Employment Agreement, were canceled and replaced with 5,500,000 RSUs. The Agreement provides for the award of up to an aggregate of 5,500,000 restricted stock units, which vest in accordance with the terms provided in the Agreement, with 500,000 RSUs vested on March 31, 2024, 3,000,000 RSUs vesting ratably over a period of twenty-four 24 months beginning April 2, 2024, and the remaining 2,000,000 RSUs, along with cash bonuses, vesting upon the achievement of certain milestones as outlined in the Amended Executive Employment Agreement.

 

On April 5, 2024, the Company drew an additional $20,000 on the related party line of credit note.

 

On April 9, 2024, the Company drew an additional $40,000 on the related party line of credit note, leaving available $14.6 million to draw from that credit facility.

 

F-33

 

 EX-4.2 2 ex4-2.htm

 

Exhibit 4.2

 

DESCRIPTION OF THE REGISTRANT’S SECURITIES

REGISTERED PURSUANT TO SECTION 12 OF THE

SECURITIES EXCHANGE ACT OF 1934, AS AMENDED (THE “EXCHANGE ACT”)

 

The following summary of the material terms of Bright Green Corporation’s (“we,” “our,” “us” or the “Company”) securities is not intended to be a complete summary of the rights and preferences of such securities. The descriptions below are qualified by reference to the actual text of our certificate of incorporation, as amended and restated (the “Certificate of Incorporation”), and our bylaws, as amended and restated (the “Bylaws”). We urge you to read our Certificate of Incorporation in its entirety for a complete description of the rights and preferences of our securities.

 

General

 

Our authorized capital stock consists of 500,000,000 shares of common stock, par value $0.0001 per share (the “Common Stock”), of which 190,166,318 are issued and outstanding as of April 11, 2024, and 10,000,000 shares of preferred stock, $0.0001 par value per share, of which none are issued or outstanding, as of the date hereof.

 

Common Stock

 

As of April 11, 2024, there were 190,166,318 shares of our Common Stock outstanding held by approximately 100 stockholders of record. Our Certificate of Incorporation provides that:

 

  ● holders of Common Stock will have voting rights for the election of our directors and all other matters requiring stockholder action, except with respect to amendments to our certificate of incorporation that alter or change the powers, preferences, rights or other terms of any outstanding preferred stock if the holders of such affected series of preferred stock are entitled to vote on such an amendment;
  ● holders of Common Stock will be entitled to one vote per share on matters to be voted on by stockholders and also will be entitled to receive such dividends, if any, as may be declared from time to time by our board of directors (the “Board”) in its discretion out of funds legally available therefor;
  ● the payment of dividends, if any, on the Common Stock will be subject to the prior payment of dividends on any outstanding preferred stock;
  ● upon our liquidation or dissolution, the holders of Common Stock will be entitled to receive pro rata all assets remaining available for distribution to stockholders after payment of all liabilities and provision for the liquidation of any shares of preferred stock outstanding at that time; and
  ● our stockholders have no conversion, preemptive or other subscription rights and there are no sinking fund or redemption provisions applicable to the Common Stock.

 

Certain Anti-takeover Provisions of Delaware Law, our Certificate of Incorporation and Bylaws

 

As a Delaware corporation, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which generally has an anti-takeover effect for transactions not approved in advance by our Board. This may discourage takeover attempts that might result in payment of a premium over the market price for the shares of Common Stock held by stockholders. In general, Section 203 prohibits a publicly held Delaware corporation from engaging in a “business combination” with an “interested stockholder” for a three-year period following the time that such stockholder becomes an interested stockholder, unless the business combination is approved in a prescribed manner. A “business combination” includes, among other things, a merger, asset or stock sale or other transaction resulting in a financial benefit to the interested stockholder. An “interested stockholder” is a person who, together with affiliates and associates, owns, or did own within three years prior to the determination of interested stockholder status, 15% or more of BGC’s voting stock.

 

Under Section 203, a business combination between a corporation and an interested stockholder is prohibited unless it satisfies one of the following conditions:

 

● before the stockholder became interested, the board of directors approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder; or
   
● upon consummation of the transaction which resulted in the stockholder becoming an interested outstanding, shares owned by:
   
● persons who are directors and also officers, and
   
● employee stock plans, in some instances; or
   
● at or after the time the stockholder became interested, the business combination was approved by the board of directors are authorized at an annual or special meeting of the stockholders by the affirmative vote of at least two-thirds of the outstanding voting stock which is not owned by the interested stockholder.

 

 

 

 

Exclusive Forum

 

Our amended and restated bylaws provides, and current amended and restated certificate of incorporation currently provides, that unless we consent in writing to the selection of an alternative forum, the sole and exclusive forum for (i) any derivative action or proceeding brought on behalf of us, (ii) any action asserting a claim of breach of a fiduciary duty owed by our directors, officers or other employees to us or our stockholders, (iii) any action asserting a claim arising pursuant to any provision of the DGCL, or (iv) any action asserting a claim governed by the internal affairs doctrine, shall be a state or federal court located within the state of Delaware, in all cases subject to the court’s having personal jurisdiction over the indispensable parties named as defendants. Any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock shall be deemed to have notice of and consented to the above forum exclusivity provisions. The enforceability of similar choice of forum provisions in other companies’ certificates of incorporation and bylaws has been challenged in legal proceedings, and it is possible that a court could find these types of provisions to be inapplicable or unenforceable.

 

The forum selection provision is intended to apply “to the fullest extent permitted by applicable law,” subject to certain exceptions. Section 27 of the Exchange Act creates exclusive federal jurisdiction over all suits brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder. As a result, the exclusive forum provision will not apply to suits brought to enforce any duty or liability created by the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction. In addition, the exclusive forum provision will not apply to actions brought under the Securities Act, or the rules and regulations thereunder.

 

Special meeting of stockholders

 

Our amended and restated certificate of incorporation further provide that special meetings of our stockholders may be called by the Board acting pursuant to a resolution approved by the affirmative vote of a majority of the directors then in office, the Chief Executive Officer (of if there is no Chief Executive Officer, the President) or the Chairperson of the Board.

 

Requirements for Advance Notification of Director Nominations and Stockholder Proposals

 

Our amended and restated bylaws provide that stockholders seeking to bring business before our annual meeting of stockholders, or to nominate candidates for election as directors at our annual meeting of stockholders, must provide timely notice of their intent in writing. To be timely to bring business before our annual meeting of stockholders (other than nominations), a stockholder’s notice needs to be delivered to the secretary at our principal executive offices not later than the close of business on the 90th day nor earlier than the close of business on the 120th day before the anniversary date of the immediately preceding annual meeting of stockholders; provided, however, that in the event that the annual meeting is called for a date that is more than 30 days before or more than 70 days after such anniversary date, notice by the stockholder to be timely must be so delivered not earlier than the close of business on the 120th day before the meeting and not later than the later of (x) the close of business on the 90th day before the meeting or (y) the close of business on the 10th day following the day on which public announcement of the date of the annual meeting is first made by the Company. To be timely to nominate candidates for election as directors at our annual meeting of stockholders, a record stockholder’s notice shall be received by the Company’s secretary at the principal executive offices of the Company not less than 45 or more than 75 days prior to the one-year anniversary of the date on which the Company first mailed its proxy materials for the preceding year’s annual meeting of stockholders; provided, however, that, subject to the other provisions of our amended and restated bylaws, if the meeting is convened more than 30 days prior to or delayed by more than 30 days after the anniversary of the preceding year’s annual meeting, or if no annual meeting was held in the preceding year, notice by a record stockholder to be timely must be so received not later than the close of business on the later of (i) 90th day before such annual meeting or (ii) the 10th day following the day on which public announcement of the date of such meeting is first made.

 

Our amended and restated bylaws specify certain requirements as to the form and content of a stockholders’ meeting. These provisions may preclude our stockholders from bringing matters before our annual meeting of stockholders or from making nominations for directors at our annual meeting of stockholders.

 

 

 

 

Authorized but unissued shares

 

Our amended and restated certificate of incorporation provides that authorized but unissued shares of Common Stock and preferred stock are available for future issuances without stockholder approval and could be utilized for a variety of corporate purposes, including future offerings to raise additional capital, acquisitions and employee benefit plans. The existence of authorized but unissued and unreserved common stock and preferred stock could render more difficult or discourage an attempt to obtain control of us by means of a proxy contest, tender offer, merger or otherwise.

 

Removal of directors

 

Our amended and restated bylaws provide that a member of our Board may be removed from service as a director, with or without cause, only by the affirmative vote of the holders of a majority of the shares of voting stock then outstanding and entitled to vote in an election of directors.

 

Limitation of Liability and Indemnification of Directors and Officers

 

Our amended and restated bylaws provide that our directors and officers will be indemnified by us to the fullest extent authorized by Delaware law.

 

These provisions may discourage stockholders from bringing a lawsuit against our directors for breach of their fiduciary duty. These provisions also may have the effect of reducing the likelihood of derivative litigation against directors and officers, even though such an action, if successful, might otherwise benefit us and our stockholders. Furthermore, a stockholder’s investment may be adversely affected to the extent we pay the costs of settlement and damage awards against directors and officers pursuant to these indemnification provisions. We believe that these provisions, insurance and the indemnity agreements are necessary to attract and retain talented and experienced directors and officers.

 

We are not aware of any threatened litigation or proceeding that might result in a claim for such indemnification, except as disclosed below. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers and controlling persons pursuant to the foregoing provisions, or otherwise, we have been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable.

 

Listing

 

Our common stock is listed on the Nasdaq Capital Market under the symbol “BGXX.”

 

Transfer Agent and Registrar

 

The transfer agent and registrar for our Common Stock is Vstock Transfer, LLC. The transfer agent and registrar’s address is 18 Lafayette Place, Woodmere, NY 11598. The transfer agent and registrar can be contacted by phone at: (212) 828-8436.

 

 

 

 EX-21.1 3 ex21-1.htm

 

Exhibit 21.1

 

LIST OF SUBSIDIARIES

 

Regional Center Bright Green, LLC – New Mexico limited liability company

 

 

 

 EX-23.1 4 ex23-1.htm

 

Exhibit 23.1

 

 

SRCO, C.P.A., Professional Corporation

Certified Public Accountants

18 Brownstone Court

East Amherst

NY 14051

U.S.A.

Tel: 416 428 1391 & 416 671 7292

Fax: 905 882 9580

Email: info@srco.ca

www.srco.ca

 

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

We hereby consent to the incorporation by reference in the Registration Statement of Bright Green Corporation on Form S-3 (File No. 333-272431), the post-effective amendments to Form S-1 on Form S-3 (File Nos. 333-263918 and 333-267546), and the Registration Statement on Form S-8 (File No. 333-272050) of our report dated April 16, 2024 relating to the consolidated financial statements of Bright Green Corporation and its subsidiary as of December 31, 2023 and 2022, and for the years then ended, which report is included in this Annual Report on Form 10-K. Our report relating to those consolidated financial statements includes an explanatory paragraph regarding substantial doubt as to the Company’s ability to continue as a going concern.

 

/s/ SRCO, C.P.A., Professional Corporation

 

Amherst, NY

April 16, 2024

 

 

 

 EX-31.1 5 ex31-1.htm

 

Exhibit 31.1

 

CERTIFICATION PURSUANT TO

RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Gurvinder Singh, certify that:

 

1. I have reviewed this Annual Report on Form 10-K of Bright Green Corporation;
   
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the small business issuer as of, and for, the periods presented in this report;
   
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

 

  (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the small business issuer, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  (c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
     
  (d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the small business issuer’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

  (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: April 16, 2024 By: /s/ Gurvinder Singh
    Gurvinder Singh
   

Chief Executive Officer

    (Principal Executive Officer)

 

 

 

 EX-31.2 6 ex31-2.htm

 

Exhibit 31.2

 

CERTIFICATION PURSUANT TO

RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Saleem Elmasri, certify that:

 

1. I have reviewed this Annual Report on Form 10-K of Bright Green Corporation;
   
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the small business issuer as of, and for, the periods presented in this report;
   
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

 

  (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the small business issuer, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  (c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
     
  (d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the small business issuer’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: April 16, 2024 By: /s/ Saleem Elmasri
   

Saleem Elmasri

    Chief Financial Officer
    (Principal Financial and Accounting Officer)

 

 

 

 EX-32.1 7 ex32-1.htm

 

Exhibit 32.1

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Annual Report of Bright Green Corporation (the “Company”) on Form 10-K for the period ending December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

 

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
   
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: April 16, 2024 By: /s/ Gurvinder Singh
    Gurvinder Singh
   

Chief Executive Officer

    (Principal Executive Officer)

 

 

 

 EX-32.2 8 ex32-2.htm

 

Exhibit 32.2

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Annual Report of Bright Green Corporation (the “Company”) on Form 10-K for the period ending December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

 

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
   
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: April 16, 2024 By: /s/ Saleem Elmasri
    Saleem Elmasri
   

Chief Financial Officer

    (Principal Financial and Accounting Officer)

 

 

 

 EX-97.1 9 ex97-1.htm

 

Exhibit 97.1

 

BRIGHT GREEN CORPORATION.

CLAWBACK POLICY

 

1. Introduction

 

Bright Green Corporation (the “Company”) believes that it is in the best interests of the Company and its stockholders to create and foster a culture of business ethics, integrity and accountability, and that, among other purposes, reinforces the Company’s incentive compensation philosophy.

 

The Board of Directors (the “Board”) therefore adopts this policy to provide for the Company’s recovery of certain compensation in the event of an accounting restatement of the Company’s financial statements resulting from material noncompliance with applicable financial reporting requirements under the federal securities laws (this “Policy”).

 

This Policy is designed to comply with Section 10D of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the rules and regulations promulgated thereunder, and Nasdaq listing rule 5608, “Recovery of Erroneously Awarded Compensation.”

 

2. General Administration

 

This Policy shall be administered by the Board or, if so designated by the Board, the Compensation Committee of the Board, in which case references herein to the Board shall be deemed to be references to the Compensation Committee of the Board. Any determinations made by the Board in respect of this Policy, or to matters as to this Policy’s amendment, enforcement, or otherwise, shall be final and binding on all individuals governed under this Policy as well as any related actions or procedures carried out by the Company’s Executive Officers (as defined herein) that are deemed necessary, appropriate, or advisable to effectuate the purposes of this Policy.

 

3. Applicability

 

This Policy applies to the Company’s current and former Executive Officers, as determined by the Board in accordance with Section 10D of the Exchange Act and the listing standards of the national securities exchange on which the Company’s securities are listed (such as Section 303A.14 of the New York Stock Exchange’s listing standards or Rule 5608 of Nasdaq’s listing rules, which are each approved by the U.S. Securities and Exchange Commission (the “SEC”) to implement Rule 10D-1 promulgated under the Exchange Act).

 

For purposes of this Policy, “Executive Officer” means the Company’s president, principal financial officer, principal accounting officer (or, if there is no such accounting officer, the controller); any vice president of the Company in charge of a principal business unit, division, or function (such as sales, administration, or finance); any other officer who performs a policy-making function; and any other person who performs a function similar to a policy-making function on behalf of the Company. Executive officers of the Company’s parent(s) or subsidiaries are deemed Executive Officers of the Company if they perform such policy-making or similar functions for or on behalf of the Company.

 

This Policy also applies to other senior executives, employees, or classes of employees of the Company as may be determined by the Board in its sole discretion from time to time (together with Executive Officers, “Covered Persons”).

 

 

 

 

4. Recoupment

 

If the Company is required to prepare an accounting restatement of its financial statements due to the Company’s material noncompliance with financial reporting requirements under the applicable federal securities laws (including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements, or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period) (an “Accounting Restatement”), without regard to any fault or misconduct of a Covered Person, then, the Board shall mandate the Company’s recovery, in the form of reimbursement, or forfeiture, as applicable (“Recoupment”), of any Excess Incentive Compensation (as defined herein) received by a Covered Person, provided that:

 

  (a) the receipt of any such Excess Incentive Compensation by a Covered Person occurred after the Covered Person became a Covered Person;
     
  (b) the Covered Person served as a Covered Person at any time during the performance period applicable to the Covered Person’s Incentive Compensation (as defined herein);
     
  (c) the Company had a class of securities listed on a national securities exchange or a national securities association during the Covered Person’s service as a Covered Person and during the performance period applicable to the Covered Person’s Incentive Compensation; and
     
  (d) the receipt of the Excess Incentive Compensation by the Covered Person occurred during the three completed fiscal years immediately preceding the date that the Company is required to prepare an Accounting Restatement, or during any transition period (that results from a change in the Company’s fiscal year) within or immediately following such three completed fiscal years.

 

For purposes of this Policy, a transition period between the last day of the Company’s previous fiscal year end and the first day of its new fiscal year that comprises a period of nine to 12 months is a completed fiscal year.

 

For purposes of this Policy, any Incentive Compensation is deemed to be “received” by a Covered Person at the point in time when a Financial Reporting Measure (as defined herein), as specified in a Covered Person’s incentive compensation agreement (or other equity or incentive compensation plan of the Company) providing for a Covered Person’s compensation that is contingent upon or tied to the attainment of a Financial Reporting Measure, is attained during the relevant fiscal period of the Company.

 

Therefore, under this Policy, a Covered Person is deemed to receive Incentive Compensation even if, for instance, the payment or grant of Incentive Compensation occurs after the end of the relevant fiscal period of the Company.

 

For purposes of this Policy, the date on which the Company is required to prepare an Accounting Restatement is deemed to have occurred on the earlier of (i) the date the Board concludes, or reasonably should have concluded, that the Company’s previously issued financial statements contain a material error and (ii) the date a court, regulator, or other legally authorized body directs the Company to restate its previously issued financial statements to correct a material error.

 

The Company’s obligation to seek Recoupment of a Covered Person’s Excess Incentive Compensation is not dependent on whether or when the restated financial statements are filed with the SEC.

 

2

 

 

5. Incentive Compensation; Financial Reporting Measures

 

For purposes of this Policy, “Incentive Compensation” means any compensation that is granted, earned, or vested based wholly or in part upon the attainment of a Financial Reporting Measure.1

 

Incentive Compensation includes (but is not limited to):

 

  ● Annual bonuses and other short- and long-term cash incentives;
     
  ● Stock options;
     
  ● Stock appreciation rights;
     
  ● Restricted stock;
     
  ● Restricted stock units;
     
  ● Performance shares; and
     
  ● Performance units.

 

For purposes of this Policy, “Financial Reporting Measure” means a measure that is determined and presented in accordance with the generally accepted accounting principles used in preparing the Company’s financial statements, or any measure that is derived wholly or in part therefrom. For avoidance of doubt, a Financial Reporting Measure need not be presented within the Company’s financial statements or included in a filing with the SEC.

 

Financial Reporting Measures include (but are not limited to):

 

  ● Company stock price;
     
  ● Total shareholder return;
     
  ● Revenues;
     
  ● Net income;
     
  ● Earnings before interest, taxes, depreciation and amortization, EBITDA, or adjusted EBITDA;
     
  ● Funds from operations;
     
  ● Liquidity measures, such as working capital or operating cash flow;
     
  ● Return measures, such as return on invested capital or return on assets; and
     
  ● Earnings measures, such as earnings per share.

 

 

1 Equity awards that vest exclusively upon completion of a specified employment period, without any performance condition, and bonus awards that are discretionary or exclusively based on subjective goals or goals unrelated to Financial Reporting Measures do not constitute Incentive Compensation under this Policy.

 

3

 

 

6. Excess Incentive Compensation

 

The amount subject to Recoupment is any Incentive Compensation received by a Covered Person that is determined by the Board, in good faith and upon the exercise of due care, to have been based on erroneous information that caused the Company’s material noncompliance with financial reporting requirements under the federal securities laws (without regard to any fault or misconduct of a Covered Person), which would not have been received by a Covered Person had the Incentive Compensation of a Covered Person been based on the restated financial statements’ results (“Excess Incentive Compensation”).

 

If the Board cannot calculate Excess Incentive Compensation received by a Covered Person from the information in an Accounting Restatement (i.e., the amount of Excess Incentive Compensation is not subject to mathematical recalculation directly from the information in an Accounting Restatement), then, the Board shall determine such Excess Incentive Compensation based on a reasonable estimate of the effect of such Accounting Restatement on the applicable Financial Reporting Measures upon which the Excess Incentive Compensation was received and in consideration of all facts relevant to the Company’s Recoupment of Excess Incentive Compensation received by a Covered Person in the circumstances.

 

The Company shall maintain documentation of any such reasonable estimates and provide such documentation, when and if reasonably requested, to the applicable national securities exchange on which the Company’s securities are listed in accordance with the applicable standards or rules of the national securities exchange.

 

With respect to Incentive Compensation based in part or whole on stock price or measures of shareholder return, the Board shall calculate Excess Incentive Compensation relating thereto in such manner as the Board deems appropriate or reasonable.

 

In no event shall the Company be required to award a Covered Person additional Incentive Compensation if the restated financial statements’ results would have resulted in the provision of Incentive Compensation that is higher in monetary value relative to the monetary value received by a Covered Person prior to the Accounting Restatement.

 

7. Recoupment Method

 

The Board shall determine in its sole discretion, to be exercised in good faith, and not inconsistent with applicable law, the method for Recoupment of a Covered Person’s Excess Incentive Compensation, which may include, without limitation, one or more of the following acts:

 

  (a) mandating reimbursement of cash-based Incentive Compensation previously paid to a Covered Person;
     
  (b) seeking recovery of any gain realized on the vesting, exercise, settlement, sale, transfer, or other disposition of any equity-based Incentive Compensation of a Covered Person;
     
  (c) offsetting the recouped amount from any compensation otherwise owed by the Company to a Covered Person;
     
  (d) cancelling outstanding vested or unvested equity-based Incentive Compensation of a Covered Person; and
     
  (e) taking any other remedial and recovery action not disallowed by applicable law, as determined by the Board, consistent with Sections 4, 6, 10, and 13 under this Policy.

 

4

 

 

The Board shall, in the exercise of its fiduciary duty to safeguard the assets of the Company (including the time value of any potentially recoverable Incentive Compensation), and, in the light of the particular facts and circumstances of a Covered Person who is determined by the Board to owe Excess Incentive Compensation to the Company, pursue the most appropriate balance of cost and speed in determining the means to seek Recoupment of a Covered Person’s Excess Incentive Compensation.

 

Consistent with this Section 7 and Rule 10D-1 of the Exchange Act, regardless of the means of Recoupment used, the Board intends that Recoupment of a Covered Person’s Excess Incentive Compensation shall be effected by the Company reasonably promptly. The Board further intends that the administration of this Policy shall abide by the Company’s recognition that what is reasonable may depend on the additional cost incident to Recoupment.

 

8. No Indemnification

 

In no event shall the Company indemnify any Covered Persons against the loss of any incorrectly awarded Incentive Compensation pursuant to Rule 10D-1 of the Exchange Act and applicable stock exchange listing rules.

 

9. Cooperation

 

Covered Persons shall facilitate the Company’s compliance with its disclosure obligations relating to this Policy in accordance with the requirements of the federal securities laws and applicable stock exchange listing rules.

 

10. Interpretation

 

Consistent with Section 2 of this Policy, the Board shall be authorized to construe and interpret this Policy and to make all determinations necessary, appropriate, or advisable for the administration of this Policy in accordance with the Company’s constitutional documents.

 

This Policy memorializes the Board’s intention that this Policy be interpreted in a manner that is consistent with Section 10D of the Exchange Act and any applicable rules, regulations, or standards adopted by the SEC (such as Rule 10D-1) and those adopted by the national securities exchange on which the Company’s securities are listed as well as any other relevant law, in each case as in effect from time to time (the “Applicable Rules”).

 

To the extent the Applicable Rules require recovery of Incentive Compensation in additional circumstances beyond those specified above, nothing in this Policy shall be deemed to limit or restrict the right or obligation of the Company to recover Incentive Compensation to the fullest extent required by the Applicable Rules.

 

11. Effective Date

 

This Policy is effective as of October 2, 2023 (the “Effective Date”) and shall be duly adopted by the Board in accordance with the Company’s constitutional documents. This Policy shall apply to all Incentive Compensation that is received by Covered Persons on or after the Effective Date.

 

5

 

 

12. Amendment; Termination

 

Consistent with Section 2 of this Policy, the Board may amend this Policy from time to time in its sole discretion and shall amend this Policy as the Board deems necessary or proper to (i) reflect any modification to the rules and regulations adopted by the SEC interpreting Section 954 of the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 and the rules and regulations adopted by the SEC under Section 10D of the Exchange Act and to (ii) comply with any rules or standards adopted by a national securities exchange on which the Company’s securities are listed.

 

The Board may, but is not required to, reassess the contents of this Policy on a yearly basis as part of the Company’s analysis of material risks.

 

The Board may terminate this Policy at any time, subject to compliance with any applicable rules or standards of a national securities exchange on which the Company’s securities are then listed.

 

13. Other Recoupment Rights

 

The Board intends that this Policy shall be applied to the fullest extent of the law.

 

In the Board’s good-faith determination, the Board may require that any employment agreement, equity award agreement, or similar enforceable agreement by and between the Company and a Covered Person entered into on or after the Effective Date shall, as a condition to the grant of any benefit thereunder, be amended and restated, or otherwise validly modified or supplemented, under the governing law of any such agreement, to require a Covered Person to agree to abide by the terms of this Policy.

 

All of the Company’s actions or powers associated with Recoupment contemplated by this Policy are in addition to, and not in lieu of, any contract or other rights of a compensation-recovery nature that may be available to the Company (including, without limitation, any right of repayment, forfeiture, or right of offset against any employees that is required pursuant to any statutory repayment requirement (regardless of whether implemented at any time prior to or following the adoption or amendment of this Policy), including Section 304 of the Sarbanes-Oxley Act of 2002 (“SOX”)).

 

Any amounts paid to the Company in accordance with Section 304 of SOX shall be considered by the Company in determining any amounts recovered under this Policy.

 

The application and enforcement of this Policy does not preclude the Company from taking any other action to enforce a Covered Person’s obligations to the Company, including termination of employment or institution of legal proceedings. Nothing in this Policy restricts the Company from seeking Recoupment under any other compensation recoupment-based policy or any applicable provisions in plans, agreements, awards, or other arrangements that contemplate the recovery of compensation from a Covered Person.

 

If a Covered Person fails to repay Excess Incentive Compensation that is owed to the Company under this Policy, then, the Company shall take all appropriate action to recover such Excess Incentive Compensation from the Covered Person, and the Covered Person shall be required to reimburse the Company for all expenses (including legal expenses) incurred by the Company in recovering such Excess Incentive Compensation.

 

6

 

 

14. Impracticability

 

The Board shall mandate Recoupment of any Excess Incentive Compensation of a Covered Person in accordance with this Policy unless effecting Recoupment would be impracticable, as the Compensation Committee of the Board may so determine (i) in consistence with its fiduciary duties owed to the Company’s shareholders and (ii) in accordance with Rule 10D-1 of the Exchange Act and the applicable listing standards of the national securities exchange on which the Company’s securities are traded.

 

Under Rule 10D-1 of the Exchange Act, a company’s obligation to recover any erroneously awarded compensation is subject only to the following limited instances in which recovery would be considered impracticable:

 

  (a) The direct expense paid to a third party to assist in enforcing the policy would exceed the amount to be recovered after a company has made and documented a reasonable attempt to recover;
     
  (b) Recovery would violate home country law where that law was adopted prior to November 28, 2022, and the issuer provides an opinion of home country counsel to the securities exchange on which the Company’s securities are traded; or
     
  (c) Recovery would likely cause an otherwise tax-qualified retirement plan to fail to meet the requirements of the Internal Revenue Code of 1986, as amended.

 

Therefore, the Board intends that this Policy shall be implemented in a manner that follows the aforementioned exceptions (as applicable to the Company), and that Recoupment of any Excess Incentive Compensation of a Covered Person under this Policy shall be mandatory unless one of the exceptions under Rule 10D-1 of the Exchange Act apply.

 

15. Severability

 

If any provision of this Policy or the application of such provision to any Covered Person shall be adjudicated to be invalid, illegal, or unenforceable in any respect, such invalidity, illegality, or unenforceability shall not affect any other provisions of this Policy, and the invalid, illegal, or unenforceable provisions shall be deemed amended to the minimum extent necessary to render any such provision (or the application of such provision) valid, legal or enforceable.

 

16. Successors

 

This Policy shall be binding and enforceable against all Covered Persons and their beneficiaries, heirs, executors, administrators, or other legal representatives.

 

7

 GRAPHIC 10 form10-k_001.jpg begin 644 form10-k_001.jpg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ex23-1_001.jpg begin 644 ex23-1_001.jpg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
  •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end EX-101.SCH 12 bgxx-20231231.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Consolidated Statements of Changes in Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Consolidated Statements of Changes in Stockholders' Equity (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000007 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Description of Business and Organization link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Going Concern and Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Concentration of Credit Risk link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Deposits link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Equity Method Investment in Alterola link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Property, Plant, and Equipment link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Intangible Assets link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Commitments link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Related Party Line of Credit Note link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Stockholders’ Equity link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Contingencies link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Equity Method Investment in Alterola (Tables) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Property, Plant, and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Description of Business and Organization (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Going Concern and Basis of Presentation (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Summary of Estimated Useful Life (Details) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Concentration of Credit Risk (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Deposits (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - Schedule of Financial Statement Information (Details) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - Schedule of Equity Method Investment in Alterola (Details) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - Equity Method Investment in Alterola (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - Schedule of Property Plant and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - Property, Plant, and Equipment (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - Schedule of Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - Commitments (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000044 - Disclosure - Related Party Line of Credit Note (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000045 - Disclosure - Stockholders’ Equity (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000046 - Disclosure - Schedule of Fair Value of The Stock Options (Details) link:presentationLink link:calculationLink link:definitionLink 00000047 - Disclosure - Schedule of Summarizes Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000048 - Disclosure - Stock-Based Compensation (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000049 - Disclosure - Schedule of Income Tax Provision (Details) link:presentationLink link:calculationLink link:definitionLink 00000050 - Disclosure - Schedule of Federal and State Tax Effects of Temporary Differences and Carryforwards (Details) link:presentationLink link:calculationLink link:definitionLink 00000051 - Disclosure - Income Taxes (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000052 - Disclosure - Related Party Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000053 - Disclosure - Contingencies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000054 - Disclosure - Subsequent Events (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 13 bgxx-20231231_cal.xml XBRL CALCULATION FILE EX-101.DEF 14 bgxx-20231231_def.xml XBRL DEFINITION FILE EX-101.LAB 15 bgxx-20231231_lab.xml XBRL LABEL FILE Related Party, Type [Axis] Related Party [Member] Equity Components [Axis] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Sale of Stock [Axis] Private Placement [Member] Statistical Measurement [Axis] Maximum [Member] Title of Individual [Axis] Accredited Investor and Existing Stockholder [Member] Long-Lived Tangible Asset [Axis] Building and Building Improvements [Member] Furniture and Fixtures [Member] Minimum [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Settlement And Release Agreement [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Investment, Name [Axis] Alterola Biotech, Inc. [Member] Sellers [Member] Voting Agreement [Member] Legal Entity [Axis] Venlo Style Green House [Member] Geographical [Axis] New Mexico [Member] Construction in Progress [Member] Grant Greenhouse GrowersInc [Member] Real Estate Option Agreement One [Member] Real Estate Option Agreement Two [Member] Equipment [Member] Credit Facility [Axis] Unsecured Line of Credit [Member] Lender Name [Axis] LDS Capital LLC [Member] Variable Rate [Axis] Prime Rate [Member] Amended Unsecured Line of Credit [Member] One Accredited Investor [Member] Board Member [Member] Executive Chairman [Member] Chief Executive Officer [Member] Consultant [Member] Warrant [Member] Chief Financial Officer [Member] Director [Member] Director One [Member] Director Two [Member] Director Three [Member] Six Consultants [Member] Directors [Member] Two Accredited Investor [Member] Consultants [Member] Common Stock One [Member] Common Stock Two [Member] Common Stock Three [Member] Securities Purchase Agreement [Member] Measurement Input Type [Axis] Measurement Input, Expected Term [Member] Measurement Input, Option Volatility [Member] Measurement Input, Risk Free Interest Rate [Member] Measurement Input, Expected Dividend Rate [Member] Scenario [Axis] Forecast [Member] Plan Name [Axis] Equity Compensation Plan [Member] Award Type [Axis] Restricted Stock [Member] Mutual Agreement [Member] Income Tax Authority [Axis] Domestic Tax Authority [Member] Former Executive Chairman [Member] Three Directors [Member] Balance Sheet Location [Axis] Accrued Liabilities [Member] Former Interim Chief Executive Officer [Member] Former Chief Executive Officer [Member] Accounts Payable [Member] Board of Directors [Member] Four Consultants [Member] Ontario Ltd [Member] Separation Agreement [Member] Mr.Terry Rafih [Member] CFO Agreement [Member] Mr.Elmasri [Member] Titan Advisory Services LLC [Member] Credit Agreement [Member] Executive Employment Agreement [Member] Restricted Stock Units (RSUs) [Member] Executive Employment Agreement Agreement [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] ICFR Auditor Attestation Flag Document Financial Statement Error Correction [Flag] Auditor Location Auditor Name Auditor Firm ID Schedule of Defined Benefit Plans Disclosures [Table] Defined Benefit Plan Disclosure [Line Items] ASSETS Current assets Cash Prepaid expenses and other assets Total current assets Deposits (Notes 5, 9, and 16) Other investment held at fair value (Note 6) Equity method investment (Note 6) Property, plant, and equipment (Notes 7 and 16) Intangible assets (Note 8) Total assets LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities Accounts payable (Notes 14 and 16) Accrued liabilities (Note 14) Due to others (Note 6) Due to related party (Note 10) Total current liabilities Long-term liabilities Related party line of credit note (Notes 10, 11, 14 and 16) Total long-term liabilities Total liabilities STOCKHOLDERS’ EQUITY Preferred stock; $0.0001 par value; 10,000,000 shares authorized; no shares issued or outstanding as of December 31, 2023 and December 31, 2022, respectively (Note 11) Common stock; $.0001 par value; 500,000,000 stock authorized; 184,758,818 and 173,304,800 stock issued and outstanding at December 31, 2023 and December 31, 2022, respectively (Note 11) Additional paid-in capital (Notes 11) Accumulated deficit Total stockholders’ equity Total liabilities and stockholders’ equity Statement of Financial Position [Abstract] Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Revenue Expenses General and administrative expenses Depreciation Total operating expenses Loss from operations Other expense Foreign currency transaction loss Loss on forfeited deposit (Notes 5, 9, and 16) Change in fair value of assets, net (Note 6) Change in fair value of voting agreement derivative Total other expense Loss before income taxes and equity in net losses of affiliate Income tax expense (Note 13) Loss before equity in net losses of affiliate Equity in net losses of affiliate (Note 6) Net loss and comprehensive loss Weighted average common shares outstanding - basic Weighted average common shares outstanding - diluted Net loss per common share - basic Net loss per common share - diluted Statement [Table] Statement [Line Items] Balance Balance, shares Common stock issued for cash for EB-5 program (Note 11) Common stock issued for cash for EB-5 program (Note 11), shares Common stock and warrants issued for cash in a private placement, net of issuance costs (Note 11) Common stock and warrants issued for cash in a private placement, net of issuance costs (Note 11), shares Common stock issued for services (Note 11) Common stock issued for services (Note 11), shares Common stock cancelled that was issued for services (Note 11) Common stock cancelled that was issued for services (Note 11), shares Net loss Warrants exercised for cash (Note 11) Warrants exercised for cash (Note 11), shares Common stock issued for a cashless conversion from related party LOC for EB-5 program (Notes 10 and 11) Common stock issued for a cashless conversion from related party LOC for EB-5 program (Notes 10 and 11), shares Common stock and warrants issued for a cashless conversion of related party LOC, net of issuance costs of $10,000 (Notes 10 and 11) Common stock and warrants issued for a cashless conversion of related party LOC, net of issuance costs of $10,000 (Notes 10 and 11), shares Stock options issued for services (Notes 11 and 12) Balance Balance, shares Statement of Stockholders' Equity [Abstract] Net of issuance cost Line of credit, net of issuance costs Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES Adjustments to reconcile net cash used in operating activities: Loss on forfeited deposit Change in fair value of assets, net Equity in net losses of affiliate Stock-based compensation Changes in operating assets and liabilities: Prepaid expenses and other assets Accounts payable Accrued liabilities Accrued interest Net cash used in operating activities CASH FLOWS FROM INVESTING ACTIVITIES Deposits Purchase of equity method investment Purchase of property, plant, and equipment Net cash used in investing activities CASH FLOWS FROM FINANCING ACTIVITIES Proceeds from related party line of credit Payments to related party line of credit Proceeds from issuance of common stock Proceeds from issuance of common stock and warrants, issued in private placement, net of issuance costs Payments to issuance costs for issuance of common stock and warrants issued in cashless conversion of related party line of credit Proceeds from warrants exercised Net cash provided by financing activities NET DECREASE IN CASH CASH, BEGINNING OF YEAR CASH, END OF YEAR CASH PAID FOR Interest Taxes SUPPLEMENTAL NON-CASH INVESTING & FINANCING ACTIVITIES Transfer from due to related party to related party LOC Transfer from deposit on equipment to prepaid expenses and other assets Related party LOC in exchange for common stock for EB-5 program Related party LOC in exchange for common stock and warrants Adjustment to construction in progress for cancellation of agreement Due to others for purchase of common stock in Alterola Biotech, Inc. Organization, Consolidation and Presentation of Financial Statements [Abstract] Description of Business and Organization Going Concern and Basis of Presentation Accounting Policies [Abstract] Summary of Significant Accounting Policies Risks and Uncertainties [Abstract] Concentration of Credit Risk Banking and Thrift Disclosure [Text Block] Deposits Investments, All Other Investments [Abstract] Equity Method Investment in Alterola Property, Plant and Equipment [Abstract] Property, Plant, and Equipment Goodwill and Intangible Assets Disclosure [Abstract] Intangible Assets Commitments and Contingencies Disclosure [Abstract] Commitments Related Party Line Of Credit Note Related Party Line of Credit Note Equity [Abstract] Stockholders’ Equity Retirement Benefits [Abstract] Stock-Based Compensation Income Tax Disclosure [Abstract] Income Taxes Related Party Transactions [Abstract] Related Party Transactions Contingencies Subsequent Events [Abstract] Subsequent Events Basis of Measurement Principles of Consolidation Property, Plant, and Equipment Long-lived Assets Intangible Assets Fair Value of Financial Instruments Investment Under the Equity Method Other Investment Held at Fair Value Advertising Costs Income Taxes Basic and Diluted Earnings (Loss) Per Share Segment Reporting Use of Estimates Stock-Based Compensation Warrants Recently Adopted Accounting Standards Recently Issued but Not Adopted Accounting Standards Summary of Estimated Useful Life Schedule of Financial Statement Information Schedule of Equity Method Investment in Alterola Schedule of Property Plant and Equipment Schedule of Intangible Assets Schedule of Fair Value of The Stock Options Schedule of Summarizes Stock Option Activity Schedule of Income Tax Provision Schedule of Federal and State Tax Effects of Temporary Differences and Carryforwards Date of incorporation Aggregate shares of common stock issued Shares issued price per share Number of shares sold Warrants to purchase shares Exercise price Revenue Net Income (Loss) Attributable to Parent Net Cash Provided by (Used in) Operating Activities Retained Earnings (Accumulated Deficit) Working capital deficit Warrants to purchase common stock Issuances of common stock Exercise of warrants Related party line of credit Related party line of credit paid down Related party loan balance Line of credit paid down Line of credit paid down in exchange of shares Common stock value per share Related party line of credit paid down in exchange of shares Credit facility Property, Plant and Equipment [Table] Property, Plant and Equipment [Line Items] Estimated useful life Investments Percentage of entity common stock Advertising cost Income tax examination, description Cash FDIC insured amount Excess of FDIC insured limit Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Number of shares forfeited Current assets Non-current assets Current liabilities Non-current liabilities Equity (Deficit) Total revenues Balance at December 31, 2022 Company’s initial investment in Alterola Company’s 25% share in net loss Change in fair value of assets Balance at December 31, 2023 Ownership percentage Sellers transferred shares Number of shares sold, value Liability to the sellers Number of shares transferred Dividend rate Rist free rate Expected term Volatility rate Stock price Control premium percentage Control premium Stock price Outstaanding common shares percentage Oustanding common shares value Fair value of agreement Noncontrolling interest equity in net losses of affiliate Equity method investments Change in fair value of assets and liabilities net Furniture and fixtures Land Construction in progress Building and improvements Property, plant and equipment gross Accumulated depreciation Net property, plant, and equipment Area of land for purchase Interest costs capitalized Agreement with vendor to cancel Expiration date Monthly payments Monthly payments for land Expense made Licenses Accumulated amortization Net intangible assets Purchase price Deposits Remaining payment Construction contract paid Shares Issued, Shares, Share-Based Payment Arrangement, Forfeited Line of Credit Facility [Table] Line of Credit Facility [Line Items] Increase in the line of credit capacity amount Additional borrowing capacity Interest rate stated percentage Lender committed funds Repayments of other debt Accrued interest Interest costs capitalized Payment of related party loan Related party line of credit paid Investment transfer for repayment of loan Debt conversion, shares issued Conversion of principal price per share Additional related party line of credit Line of credit Number of shares issued Warrants price per share Common stock price per share Capital transaction due to related party Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Line Items] Preferred stock par value Number of warrants exercised Common stock issued for services rendered Warrant exercise price Issuance of shares Issued price per share Warrants to purchase common stock Purchase price Exercise price per share Related party line of credit paid Stock options issued for services rendered, shares Exercise price per share Gross cash proceeds Shares of common stock cancelled Gross cash proceeds Number of shares issued Warrants and rights outstanding term Gross proceeds from private placement Warrants redeemed, shares Warrants redeemed, value Placement agent fees Legal fees Escrow deposit Warrants fair value Decrease in fair value of warrants Shares of warrants to purchase Share price Dividend rate Warrants estimate value Weighted average fair value at grant date Expected life of options (years) Expected stock volatility Risk-free interest rate Expected dividend yield Number of shares, outstanding beginning balance Weighted average exercise price beginning balance Number of stock options granted Weighted average exercise price granted Number of stock options exercised Weighted average exercise price exercised Number of stock options expired Weighted average exercise price expired Number of shares, outstanding ending balance Weighted average exercise price ending balance Weighted average remaining life (years) Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Stock options shares Restricted shares unit Share-Based Payment Arrangement, Noncash Expense Stock Issued During Period, Value, Issued for Services Stock options exercise price Stock options fair value Stock options expiring, shares Issuance of shares Restricted stock, shares Loss before income taxes Current: Federal State Total current (benefit) provision Deferred: Federal State Total current (benefit) provision Valuation allowance Total (benefit) expense Other Net operating loss carry over Total deferred tax assets Less: valuation allowance Deferred tax assets, net of valuation allowance Operating Loss Carryforwards [Table] Operating Loss Carryforwards [Line Items] Current and deferred income tax expenses Tax rate Operating loss carryforwards Schedule of Related Party Transactions, by Related Party [Table] Related Party Transaction [Line Items] Common stock issued for service, shares Due to related party Accrued bonus Long-term line of credit Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table] Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items] Contingency, taken by defendant description Subsequent Event [Table] Subsequent Event [Line Items] Owned interest expenses Interest expense short term borrowings Proceeds from related party debt Number of shares authorized Unpaid cash renumeration and bonus compensation Monthly cash fee Payment of lieu Outstanding shares of common stock Number of shares purchase assets Equipped purchase shares of common stock Salaries and wages Restricted stock vest, shares Due to others current. Stock cancelled during period value issued for services. Stock cancelled during shares value issued for services. Common stock and warrants issued for cashless conversion of related party line of credit. Common stock and warrants issued for cashless conversion of related party line of credit, shares. Stock issued during period value warrants exercised for cash. Stock issued during period shares warrants exercised for cash. Change in fair value of voting agreement derivative Income loss from continuing operations including portion attributable to noncontrolling interest equity in net losses of affiliate. Equity in net losses of affiliate. Payments for acquire property deposits. Transfer from dueto related party to related party loc. Related party loc in exchange for common stock and warrants Accredited Investor and Existing Stockholder [Member] Working capital deficit Property Plant And Equipment Estimated Useful Life [Table Text Block] Percentage of entity common stock. Warrants [Policy Text Block] Recently Issued But Not Adopted Accounting Standards Policy [Text Block] Alterola Biotech, Inc. [Member] Sellers [Member] Number of warrants exercised. One Accredited Investor [Member] Board Member [Member] Executive Chairman [Member] Warrant and share purchase price. Consultant [Member] Voting Agreement [Member] Exercise price of warrants. Share based compensation arrangement by share based payment award fair value assumptions stock price. Share based compensation arrangement by share based payment award fair value assumptions control premium percentage. Share based compensation arrangement by share based payment award fair value assumptions control premium. Share based compensation arrangement by share based payment award fair value assumptions strike price. Fair value of agreement. Venlo Style Green House [Member] New Mexico [Member] Director Two [Member] Director Three [Member] Director One [Member] Grant Greenhouse GrowersInc [Member] Real Estate Option Agreement One [Member] Lease payment made per acre. Real Estate Option Agreement Two [Member] Six Consultants [Member] Directors [Member] Two Accredited Investor [Member] Consultants [Member] Common Stock One [Member] Common Stock Two [Member] Common Stock Three [Member] Securities Purchase Agreement [Member] Related Party Line Of Credit [Text Block] Unsecured Line of Credit [Member] LDS Capital LLC [Member] Line of credit facility increase in borrowing capacity. Amended Unsecured Line Of Credit [Member] Equity Compensation Plan [Member] Gross proceeds from issuance of private placement. Warrant redeemed or called during period shares. Warrant redeemed or called during period value. Capital transaction due to related party Decrease in fair value of warrants. Common stock and warrants issued shares for cash in private placements. Four Consultants [Member] Former Interim Chief Executive Officer [Member] Valuation allowance of income tax provision. Schedule of federal and state tax effects of temporary difference and carryforwards [Table Text Block] Former Executive Chairman [Member] Three Directors [Member] Separation Agreement [Member] Mr.Terry Rafih [Member] CFO Agreement [Member] Mr.Elmasri [Member] Titan Advisory Services LLC [Member] Settlement Agreement [Member] United Science LLC [Member] Equipped4 Holdings Limited [Member] Phytotherapeutix Holdings Ltd [Member] TPR Global Limited [Member] Credit Agreement [Member] JVR Holdings [Member] Board of Directors [Member] Former Chief Executive Officer [Member] Related party LOC in exchange for common stock for EB-5 program. Adjustment to construction in progress for cancellation of agreement. Change in fair value of assets and liabilities, net Other Investments Held At Fair Value [Policy Text Block] Loss on forfeited deposit. Ontario Ltd [Member] Settlement And Release Agreement [Member] Payment of lieu outstanding shares of common stock. Equipped purchase shares of common stock. Assets, Current Assets Liabilities, Current Liabilities Liabilities and Equity Operating Expenses Operating Income (Loss) Gain (Loss), Foreign Currency Transaction, before Tax LossOnForfeitedDeposit Other Expenses Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest Shares, Outstanding Increase (Decrease) in Prepaid Expense and Other Assets Net Cash Provided by (Used in) Operating Activities PaymentsForAcquirePropertyDeposits Payments to Acquire Equity Method Investments Payments to Acquire Property, Plant, and Equipment Net Cash Provided by (Used in) Investing Activities Payments of Stock Issuance Costs Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Property, Plant and Equipment, Policy [Policy Text Block] Intangible Assets, Finite-Lived, Policy [Policy Text Block] Income Tax, Policy [Policy Text Block] Compensation Related Costs, Policy [Policy Text Block] Revenues Noncontrolling Interest, Increase from Subsidiary Equity Issuance ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStrikePrice Property, Plant and Equipment, Gross Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Deposits [Default Label] Interest Payable, Current Interest Costs Capitalized Warrants and Rights Outstanding, Measurement Input Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Current Income Tax Expense (Benefit) Deferred Federal Income Tax Expense (Benefit) Deferred State and Local Income Tax Expense (Benefit) Deferred Income Tax Expense (Benefit) ValuationAllowancesOfIncomeTaxExpenseBenefit Deferred Tax Assets, Gross Deferred Tax Assets, Valuation Allowance Deferred Tax Assets, Net of Valuation Allowance EX-101.PRE 16 bgxx-20231231_pre.xml XBRL PRESENTATION FILE XML 18 R1.htm IDEA: XBRL DOCUMENT v3.24.1.u1
    Cover - USD ($)
    		 12 Months Ended
    Dec. 31, 2023
    Apr. 11, 2024
    Jun. 30, 2023
    Cover [Abstract]      
    Document Type 10-K    
    Amendment Flag false    
    Document Annual Report true    
    Document Transition Report false    
    Document Period End Date Dec. 31, 2023    
    Document Fiscal Period Focus FY    
    Document Fiscal Year Focus 2023    
    Current Fiscal Year End Date --12-31    
    Entity File Number 001-41395    
    Entity Registrant Name BRIGHT GREEN CORPORATION    
    Entity Central Index Key 0001886799    
    Entity Tax Identification Number 83-4600841    
    Entity Incorporation, State or Country Code DE    
    Entity Address, Address Line One 1033 George Hanosh Boulevard    
    Entity Address, City or Town Grants    
    Entity Address, State or Province NM    
    Entity Address, Postal Zip Code 87020    
    City Area Code (833)    
    Local Phone Number 658-1799    
    Title of 12(b) Security Common stock, $0.0001 par value per share    
    Trading Symbol BGXX    
    Security Exchange Name NASDAQ    
    Entity Well-known Seasoned Issuer No    
    Entity Voluntary Filers No    
    Entity Current Reporting Status Yes    
    Entity Interactive Data Current Yes    
    Entity Filer Category Non-accelerated Filer    
    Entity Small Business true    
    Entity Emerging Growth Company true    
    Elected Not To Use the Extended Transition Period false    
    Entity Shell Company false    
    Entity Public Float     $ 75,060,837
    Entity Common Stock, Shares Outstanding   190,166,318  
    ICFR Auditor Attestation Flag false    
    Document Financial Statement Error Correction [Flag] false    
    Auditor Location East Amherst, NY    
    Auditor Name SRCO, C.P.A., Professional Corporation    
    Auditor Firm ID 6722    
    XML 19 R2.htm IDEA: XBRL DOCUMENT v3.24.1.u1
    Consolidated Balance Sheets - USD ($)
    Dec. 31, 2023
    Dec. 31, 2022
    Current assets    
    Cash $ 10,059 $ 414,574
    Prepaid expenses and other assets 258,230 77,847
    Total current assets 268,289 492,421
    Deposits (Notes 5, 9, and 16) 1,157,587
    Other investment held at fair value (Note 6) 726,343
    Equity method investment (Note 6) 3,990,960
    Property, plant, and equipment (Notes 7 and 16) 16,407,415 17,146,325
    Intangible assets (Note 8) 1,000 1,000
    Total assets 17,403,047 22,788,293
    Current liabilities    
    Accounts payable (Notes 14 and 16) 4,175,220 5,033,831
    Accrued liabilities (Note 14) 411,099 447,325
    Due to others (Note 6) 1,650,000 1,650,000
    Total current liabilities 6,236,319 7,523,350
    Long-term liabilities    
    Related party line of credit note (Notes 10, 11, 14 and 16) 201,783 3,686,107
    Total long-term liabilities 201,783 3,686,107
    Total liabilities 6,438,102 11,209,457
    STOCKHOLDERS’ EQUITY    
    Preferred stock; $0.0001 par value; 10,000,000 shares authorized; no shares issued or outstanding as of December 31, 2023 and December 31, 2022, respectively (Note 11)
    Common stock; $.0001 par value; 500,000,000 stock authorized; 184,758,818 and 173,304,800 stock issued and outstanding at December 31, 2023 and December 31, 2022, respectively (Note 11) 18,476 17,329
    Additional paid-in capital (Notes 11) 58,149,938 45,637,328
    Accumulated deficit (47,203,469) (34,075,821)
    Total stockholders’ equity 10,964,945 11,578,836
    Total liabilities and stockholders’ equity 17,403,047 22,788,293
    Related Party [Member]    
    Current liabilities    
    Due to related party (Note 10) $ 392,194
    XML 20 R3.htm IDEA: XBRL DOCUMENT v3.24.1.u1
    Consolidated Balance Sheets (Parenthetical) - $ / shares
    Dec. 31, 2023
    Dec. 31, 2022
    Statement of Financial Position [Abstract]    
    Preferred stock, par value $ 0.0001 $ 0.0001
    Preferred stock, shares authorized 10,000,000 10,000,000
    Preferred stock, shares issued 0 0
    Preferred stock, shares outstanding 0 0
    Common stock, par value $ 0.0001 $ 0.0001
    Common stock, shares authorized 500,000,000 500,000,000
    Common stock, shares issued 184,758,818 173,304,800
    Common stock, shares outstanding 184,758,818 173,304,800
    XML 21 R4.htm IDEA: XBRL DOCUMENT v3.24.1.u1
    Consolidated Statements of Operations and Comprehensive Loss - USD ($)
    		 12 Months Ended
    Dec. 31, 2023
    Dec. 31, 2022
    Income Statement [Abstract]    
    Revenue
    Expenses    
    General and administrative expenses 8,252,873 26,609,241
    Depreciation 638,507 704,681
    Total operating expenses 8,891,380 27,313,922
    Loss from operations (8,891,380) (27,313,922)
    Other expense    
    Foreign currency transaction loss 1,625
    Loss on forfeited deposit (Notes 5, 9, and 16) 970,026
    Change in fair value of assets, net (Note 6) 3,045,954
    Change in fair value of voting agreement derivative 213,000
    Total other expense 4,017,605 213,000
    Loss before income taxes and equity in net losses of affiliate (12,908,985) (27,526,922)
    Income tax expense (Note 13)
    Loss before equity in net losses of affiliate (12,908,985) (27,526,922)
    Equity in net losses of affiliate (Note 6) (218,663) (135,155)
    Net loss and comprehensive loss $ (13,127,648) $ (27,662,077)
    Weighted average common shares outstanding - basic 178,574,014 162,058,082
    Weighted average common shares outstanding - diluted 178,574,014 162,058,082
    Net loss per common share - basic $ (0.07) $ (0.17)
    Net loss per common share - diluted $ (0.07) $ (0.17)
    XML 22 R5.htm IDEA: XBRL DOCUMENT v3.24.1.u1
    Consolidated Statements of Changes in Stockholders' Equity - USD ($)
    Common Stock [Member]
    Additional Paid-in Capital [Member]
    Retained Earnings [Member]
    Total
    Balance at Dec. 31, 2021 $ 15,754 $ 14,618,389 $ (6,413,744) $ 8,220,399
    Balance, shares at Dec. 31, 2021 157,544,500      
    Common stock issued for cash for EB-5 program (Note 11) $ 31 3,049,969 3,050,000
    Common stock issued for cash for EB-5 program (Note 11), shares 312,500      
    Common stock and warrants issued for cash in a private placement, net of issuance costs (Note 11) $ 952 9,135,781 9,136,733
    Common stock and warrants issued for cash in a private placement, net of issuance costs (Note 11), shares 9,523,810      
    Common stock issued for services (Note 11) $ 603 18,850,629 18,851,232
    Common stock issued for services (Note 11), shares 6,036,990      
    Common stock cancelled that was issued for services (Note 11) $ (11) (17,440) (17,451)
    Common stock cancelled that was issued for services (Note 11), shares (113,000)      
    Net loss (27,662,077) (27,662,077)
    Balance at Dec. 31, 2022 $ 17,329 45,637,328 (34,075,821) 11,578,836
    Balance, shares at Dec. 31, 2022 173,304,800      
    Balance at Dec. 31, 2022 $ 17,329 45,637,328 (34,075,821) 11,578,836
    Balance, shares at Dec. 31, 2022 173,304,800      
    Common stock issued for cash for EB-5 program (Note 11) $ 2 879,998 880,000
    Common stock issued for cash for EB-5 program (Note 11), shares 22,005      
    Common stock and warrants issued for cash in a private placement, net of issuance costs (Note 11) $ 368 3,104,382 3,104,750
    Common stock and warrants issued for cash in a private placement, net of issuance costs (Note 11), shares 3,684,210      
    Common stock issued for services (Note 11) $ 472 3,234,268 3,234,740
    Common stock issued for services (Note 11), shares 4,697,838      
    Net loss (13,127,648) (13,127,648)
    Warrants exercised for cash (Note 11) $ 20 209,980 210,000
    Warrants exercised for cash (Note 11), shares 200,000      
    Common stock issued for a cashless conversion from related party LOC for EB-5 program (Notes 10 and 11) $ 2 879,998 880,000
    Common stock issued for a cashless conversion from related party LOC for EB-5 program (Notes 10 and 11), shares 22,005      
    Common stock and warrants issued for a cashless conversion of related party LOC, net of issuance costs of $10,000 (Notes 10 and 11) $ 283 3,609,506 3,609,789
    Common stock and warrants issued for a cashless conversion of related party LOC, net of issuance costs of $10,000 (Notes 10 and 11), shares 2,827,960      
    Stock options issued for services (Notes 11 and 12) 594,478 594,478
    Balance at Dec. 31, 2023 $ 18,476 $ 58,149,938 $ (47,203,469) $ 10,964,945
    Balance, shares at Dec. 31, 2023 184,758,818      
    XML 23 R6.htm IDEA: XBRL DOCUMENT v3.24.1.u1
    Consolidated Statements of Changes in Stockholders' Equity (Parenthetical) - USD ($)
    		 12 Months Ended
    Dec. 31, 2023
    Dec. 31, 2022
    Statement of Stockholders' Equity [Abstract]    
    Net of issuance cost $ 395,250 $ 863,267
    Line of credit, net of issuance costs $ 10,000  
    XML 24 R7.htm IDEA: XBRL DOCUMENT v3.24.1.u1
    Consolidated Statements of Cash Flows - USD ($)
    		 12 Months Ended
    Dec. 31, 2023
    Dec. 31, 2022
    CASH FLOWS FROM OPERATING ACTIVITIES    
    Net loss $ (13,127,648) $ (27,662,077)
    Adjustments to reconcile net cash used in operating activities:    
    Change in fair value of voting agreement derivative 213,000
    Loss on forfeited deposit 970,026
    Change in fair value of assets, net 3,045,954
    Equity in net losses of affiliate 218,663 135,155
    Depreciation 638,507 704,681
    Stock-based compensation 3,829,218 18,833,781
    Changes in operating assets and liabilities:    
    Prepaid expenses and other assets (40,766) 90,379
    Accounts payable 1,823,389 4,883,896
    Accrued liabilities (36,226) 429,298
    Accrued interest 223,271 106,117
    Net cash used in operating activities (2,455,612) (2,265,770)
    CASH FLOWS FROM INVESTING ACTIVITIES    
    Deposits (1,157,587)
    Purchase of equity method investment (2,689,115)
    Purchase of property, plant, and equipment (2,533,653) (10,522,242)
    Net cash used in investing activities (2,533,653) (14,368,944)
    CASH FLOWS FROM FINANCING ACTIVITIES    
    Proceeds from related party line of credit 400,000 5,191,057
    Payments to related party line of credit (1,611,067)
    Proceeds from issuance of common stock 880,000 3,050,000
    Proceeds from issuance of common stock and warrants, issued in private placement, net of issuance costs 3,104,750 9,136,733
    Payments to issuance costs for issuance of common stock and warrants issued in cashless conversion of related party line of credit (10,000)
    Proceeds from warrants exercised 210,000
    Net cash provided by financing activities 4,584,750 15,766,723
    NET DECREASE IN CASH (404,515) (867,991)
    CASH, BEGINNING OF YEAR 414,574 1,282,565
    CASH, END OF YEAR 10,059 414,574
    CASH PAID FOR    
    Interest
    Taxes
    SUPPLEMENTAL NON-CASH INVESTING & FINANCING ACTIVITIES    
    Transfer from due to related party to related party LOC 392,194
    Transfer from deposit on equipment to prepaid expenses and other assets 139,617
    Related party LOC in exchange for common stock for EB-5 program (880,000)
    Related party LOC in exchange for common stock and warrants (3,619,789)
    Adjustment to construction in progress for cancellation of agreement (2,682,000)
    Due to others for purchase of common stock in Alterola Biotech, Inc. $ 1,650,000
    XML 25 R8.htm IDEA: XBRL DOCUMENT v3.24.1.u1
    Description of Business and Organization
    		 12 Months Ended
    Dec. 31, 2023
    Organization, Consolidation and Presentation of Financial Statements [Abstract]  
    Description of Business and Organization

    1. Description of Business and Organization

     

    Bright Green Corporation was incorporated on April 16, 2019, under the Delaware General Corporation Law. The Company’s principal executive office is located in Grants, New Mexico. The Company holds the land, greenhouse, and patents required in the growth, production, and research of medicinal plants. When used herein, the terms the “Company,” “our,” “us,” “we,” or “Bright Green” refers to Bright Green Corporation and its consolidated subsidiary.

     

    On March 29, 2022, the Company filed a registration statement pursuant to the Securities Act of 1933, as amended (the “Securities Act”) on Form S-1 with the Securities and Exchange Commission (“SEC”), which was declared effective May 13, 2022, (as amended, the “Registration Statement”), in connection with the direct listing of the Company’s common stock with the Capital Market of the Nasdaq Stock Market LLC (“Nasdaq”).

     

    On May 17, 2022, the Company’s common stock commenced trading on Nasdaq under the symbol “BGXX.”

     

    On February 1, 2023, the Company initiated a private placement offering of common stock, only to accredited or qualified institutional investors, in reliance upon Rule 506, Regulation D promulgated under the Securities Act, pursuant to the U.S. government’s EB-5 immigrant investor program. Under the EB-5 Program, the Company may issue up to an aggregate of 12,609,152 shares of common stock at $39.99 per share.

     

    On May 21, 2023, the Company entered into a Securities Purchase Agreement with an accredited investor and existing stockholder of the Company for the sale by the Company of (i) 3,684,210 shares of the Company’s common stock, par value $0.0001 per share, and (ii) warrants to purchase up to an aggregate of 3,684,210 shares of the Company’s common stock, in a private placement offering. The combined purchase price of one share and accompanying warrant was $0.95. The shares and the warrants were sold and issued without registration under the Securities Act of 1933, in reliance on the exemptions provided by Section 4(a)(2) of the Securities Act as transactions not involving a public offering and Rule 506 of Regulation D promulgated under the Securities Act as sales to accredited investors, and in reliance on similar exemptions under applicable state laws.

     

    On September 20, 2023, the Company formed Regional Center Bright Green, LLC (“RCBG”). RCBG is a wholly-owned subsidiary of the Company and is registered as a limited liability company in New Mexico. RCBG was created to assist foreign investors in obtaining permanent residency in the United States by investing in U.S. businesses, while adhering to the EB-5 Immigrant Investor Program guidelines. As of December 31, 2023, the subsidiary was not yet operational.

     

    The Company is a start-up company at December 31, 2023 and has no revenue.

     

     

    BRIGHT GREEN CORPORATION

    Notes to the Consolidated Financial Statements

    For the Years Ended December 31, 2023 and 2022

    (Expressed in United States Dollars)

     

     
    XML 26 R9.htm IDEA: XBRL DOCUMENT v3.24.1.u1
    Going Concern and Basis of Presentation
    		 12 Months Ended
    Dec. 31, 2023
    Organization, Consolidation and Presentation of Financial Statements [Abstract]  
    Going Concern and Basis of Presentation

    2. Going Concern and Basis of Presentation

     

    The accompanying consolidated financial statements have been prepared by the Company in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”). U.S. GAAP contemplates the continuation of the Company as a going concern. For the fiscal years ended December 31, 2023 and 2022, the Company had no revenues from product sales and incurred a net loss of $13,127,648 and $27,662,077, respectively. Net cash used in operations for the years ended 2023 and 2022 was $2,455,612 and $2,265,770, respectively. The Company has incurred recurring losses from operations, and as of December 31, 2023, had an accumulated deficit of $47,203,469 (December 31, 2022 – $34,075,821) and had a negative working capital of $5,968,030 (December 31, 2022 – $7,030,929).

     

    The Company is in its initial stages of building facilities to grow, research, and distribute medical plants. The Company has historically financed its operations through the sale of equity securities and debt financing. The Company does not have sufficient working capital to pay its operating expenses for a period of at least 12 months from the date the consolidated financial statements were authorized to be issued. Therefore, the Company’s continued existence depends on its ability to continue executing its operating plan and obtaining additional debt or equity financing. The Company has developed plans to raise funds and continues to pursue sources of funding that management believes, if successful, would be sufficient to support the Company’s operating plan.

     

    In 2023, the Company raised $3,104,750 through the issuance of common stock and accompanying warrants to purchase shares of common stock from the Company’s private placement offering in May 2023, $880,000 through common stock issuances from the Company’s EB-5 Program, and $210,000 through the exercise of warrants. The Company has drawn $400,000 from the Company’s $15,000,000 related party line of credit. The related party line of credit was used to pay in full the related party loan balance of $392,194. The related party line of credit was paid down $880,000 in exchange for 22,005 shares of the Company’s common stock valued at $39.99 per share pursuant to the Company’s EB-5 Program, and the related party line of credit was paid down $3,619,789 in exchange for 2,827,960 shares of the Company’s common stock and accompanying warrants to purchase shares of common stock, leaving available $14,800,000 to draw from that credit facility (Note 10). However, there is substantial doubt about the Company’s ability to continue as a going concern due to the necessity to generate positive cash flows from operations and/or obtain additional financing. There is no assurance that the Company will be able to generate positive cash flows from operations or obtain additional financing on terms acceptable to the Company, if at all.

     

    In addition, the Company’s current and future operations are subject to various risks and uncertainties, including but not limited to general economic conditions, competition, and regulatory matters. Accordingly, the Company’s operation plan is predicated on various assumptions including, but not limited to, the level of product demand, cost estimates, its ability to continue raising additional financing, and the state of the general economic environment in which the Company operates.

     

     

    BRIGHT GREEN CORPORATION

    Notes to the Consolidated Financial Statements

    For the Years Ended December 31, 2023 and 2022

    (Expressed in United States Dollars)

     

     

    2. Going Concern and Basis of Presentation (continued)

     

    These risks and uncertainties may have a material adverse effect on the Company’s financial condition and operating results. Management has taken actions to address the Company’s liquidity needs, including managing expenses, developing pathways to revenue, and pursuing additional financing, such as the EB-5 Program announced on February 1, 2023. However, there can be no assurance that such actions will be sufficient to enable the Company to continue as a going concern. There can be no assurance that these assumptions will prove accurate in all material respects or that the Company will be able to successfully execute its operating plan.

     

    The consolidated financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. In addition, the Company does not have any short or long-term contractual purchases with suppliers for future purchases, capital expenditure commitments that cannot be canceled with minimal fees, noncancelable operating leases, or any commitment or contingency that would hinder management’s ability to scale down operations and management expenses until funding is raised.

     

    The Company’s ability to continue as a going concern is dependent upon the outcome of the matters described above. The consolidated financial statements do not include any adjustments that might result from the outcome of these uncertainties.

     

    This disclosure is intended to inform users of the consolidated financial statements about the Company’s current financial condition and its ability to continue as a going concern. The Company will continue to monitor its liquidity position and take appropriate actions as necessary to address any potential going concern issues.

     
    XML 27 R10.htm IDEA: XBRL DOCUMENT v3.24.1.u1
    Summary of Significant Accounting Policies
    		 12 Months Ended
    Dec. 31, 2023
    Accounting Policies [Abstract]  
    Summary of Significant Accounting Policies

    3. Summary of Significant Accounting Policies

     

    A. Basis of Measurement

     

    The consolidated financial statements of the Company have been prepared on a historical cost basis except as indicated otherwise.

     

    B. Principles of Consolidation

     

    The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, Regional Center Bright Green, LLC. Intercompany transactions and balances have been eliminated upon consolidation.

     

     

    BRIGHT GREEN CORPORATION

    Notes to the Consolidated Financial Statements

    For the Years Ended December 31, 2023 and 2022

    (Expressed in United States Dollars)

     

     

    3. Summary of Significant Accounting Policies (continued)

     

    C. Property, Plant, and Equipment

     

    Property, plant, and equipment are stated at cost less accumulated depreciation. Expenditures for maintenance and repairs are charged to earnings as incurred; additions, renewals, and betterments are capitalized. When property, plant, and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of property, plant, and equipment, except land, which is not depreciated, is provided using the declining balance method, or straight-line method, with estimated lives as follows:

     

    Building and improvement - declining balance method 10 year life
    Furniture and fixtures - straight-line method 3 year life

     

    Construction in progress is not depreciated until the asset is placed in service.

     

    D. Long-lived Assets

     

    The Company applies the provisions of ASC Topic 360, Property, Plant, and Equipment, which addresses financial accounting and reporting for the impairment or disposal of long-lived assets. ASC Topic 360 requires that long-lived assets be reviewed annually for impairment whenever events or changes in circumstances indicate that the assets’ carrying amounts may not be recoverable; it further requires impairment losses to be recorded on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair value of the long-lived assets. Loss on long-lived assets to be disposed of is determined in a similar manner, except that fair values are reduced for the cost of disposal.

     

    E. Intangible Assets

     

    The Company’s intangible assets consist of certain licenses which will be amortized over the term of each license (Note 8). The intangible assets with finite useful lives are reviewed for impairment when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair value of the long-lived assets.

     

     

    BRIGHT GREEN CORPORATION

    Notes to the Consolidated Financial Statements

    For the Years Ended December 31, 2023 and 2022

    (Expressed in United States Dollars)

     

     

    3. Summary of Significant Accounting Policies (continued)

     

    F. Fair Value of Financial Instruments

     

    In accordance with ASC 820 (Topic 820, Fair Value Measurements and Disclosures), the Company uses a three-level hierarchy for fair value measurements of certain assets and liabilities for financial reporting purposes that distinguishes between market participant assumptions developed from market data obtained from outside sources (observable inputs) and our own assumptions about market participant assumptions developed from the best information available to us in the circumstances (unobservable inputs). The fair value hierarchy is divided into three levels based on the source of inputs as follows:

     

      ●

    Level 1 – inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets;

         
      ●

    Level 2 – inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability other than quoted prices, either directly or indirectly including inputs in markets that are not considered to be active; and

         
      ● Level 3 – inputs to the valuation methodology are unobservable and significant to the fair value measurement.

     

    Categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The carrying amounts of the Company’s cash, other assets, accounts payable, accrued liabilities, due to others, and due to related party approximated their fair values as of December 31, 2023 and 2022 due to their short-term nature. The Company’s Alterola investment is also accounted for at fair value and recorded in Other investment held at fair value on the consolidated balance sheets. In accordance with the levels defined above, Level 1, the fair value of the Company’s Alterola investment was $726,343 as of December 31, 2023.

     

    G. Investment Under the Equity Method

     

    When the Company does not have a controlling financial interest in an entity but can exert significant influence over the entity’s operating and financial policies, the investment is accounted for either (i) under the equity method of accounting or (ii) at fair value by electing the fair value option available under U.S. generally accepted accounting principles (“GAAP”). Significant influence generally exists when the Company owns 20% to 50% of the entity’s common stock or in-substance common stock. In addition, the Company may recognize its share of an investee’s earnings based on an estimated amount for the investee’s earnings when the investee’s financial information is not sufficiently timely for the Company’s reporting period.

     

     

    BRIGHT GREEN CORPORATION

    Notes to the Consolidated Financial Statements

    For the Years Ended December 31, 2023 and 2022

    (Expressed in United States Dollars)

     

     

    3. Summary of Significant Accounting Policies (continued)

     

    G. Investment Under the Equity Method (continued)

     

    Under the equity method of accounting, the investment is initially recorded at cost, including transaction costs incurred to acquire the investment, and thereafter adjusted for additional investments, distributions, and the proportionate share of earnings or losses of the investee. The Company’s equity method investment is reviewed for impairment whenever events or changes in circumstances indicate that an other-than-temporary decline in value may have occurred. If it is determined that a loss in value of the equity method investment is other than temporary, an impairment loss is measured based on the excess of the carrying amount of an investment over its estimated fair value. Impairment analyses are based on current plans, intended holding periods, and available information at the time the analysis is prepared.

     

    Derivative Financial Instruments

     

    The Company evaluates all its financial instruments to determine if such instruments contain features that qualify as embedded derivatives. Embedded derivatives must be separately measured from the host contract if all the requirements for bifurcation are met. The assessment of the conditions surrounding the bifurcation of embedded derivatives depends on the nature of the host contract. Bifurcated embedded derivatives are recognized at fair value, with changes in fair value recognized in the consolidated statement of operations and comprehensive loss each period. Bifurcated embedded derivatives are classified with the related host contract in the Company’s consolidated balance sheets.

     

    H. Other Investment Held at Fair Value

     

    In accordance with ASC 825, the Company records its investment at fair value under the Other investment held at fair value in the Company’s consolidated balance sheets and changes in fair value are recognized as Change in fair value of assets, net, a component of Other expense in the consolidated statements of operations and comprehensive loss.

     

    At the most recent remeasurement date, the Company evaluated its ability to continue to exercise significant influence over its investment and determined that it no longer had significant influence. The Company’s Alterola investment is accounted for at fair value under ASC 321 and recorded in Other investment held at fair value on the consolidated balance sheets and changes in fair value are recognized as Change in fair value of assets, a component of Other expense, net in the consolidated statements of operations and comprehensive loss (Note 6).

     

    I. Advertising Costs

     

    Advertising costs are charged to operations when incurred. Advertising costs totaled $43,867 and $78,193 for the year ended December 31, 2023 and 2022, respectively.

     

    J. Income Taxes

     

    The Company accounts for income taxes in accordance with ASC Topic 740, Income Taxes. ASC 740 requires a company to use the asset and liability method of accounting for income taxes, whereby deferred tax assets are recognized for deductible temporary differences, and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized.

     

     

    BRIGHT GREEN CORPORATION

    Notes to the Consolidated Financial Statements

    For the Years Ended December 31, 2023 and 2022

    (Expressed in United States Dollars)

     

     

    3. Summary of Significant Accounting Policies (continued)

     

    J. Income Taxes (continued)

     

    Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment. The Company has not changed its methodology for estimating the valuation allowance. A change in valuation allowance affects earnings in the period the adjustments are made and could be significant due to the large valuation allowance currently established.

     

    Under ASC 740, a tax position is recognized as a benefit only if it is “more likely than not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that is greater than 50% likely to be realized on examination. For tax positions not meeting the “more likely than not” test, no tax benefit is recorded. The Company has no material uncertain tax positions for any of the reporting periods presented (Note 13).

     

    K. Basic and Diluted Earnings (Loss) Per Share

     

    Basic earnings (loss) per share is calculated using the weighted average number of common shares outstanding during the period. The dilutive effect on earnings (loss) per share is calculated, presuming the exercise of outstanding stock options, warrants, and similar instruments. It assumes that the proceeds of such exercise would be used to repurchase common shares at the average market price during the period.

     

    For the years ended December 31, 2023, and 2022, all outstanding stock options, warrants, and similar instruments were excluded from the computation of diluted net loss per share, because the exercise price of these instruments exceeded the average market price of the Company’s common stock, making them anti-dilutive.

     

    L. Segment Reporting

     

    ASC 280-10, “Disclosures about Segments of an Enterprise and Related Information”, establishes standards for how public business enterprises report information about operating segments in the Company’s consolidated financial statements. Operating segments are components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision-maker in deciding how to allocate resources and in assessing performance. Significantly all of the assets of the Company are located in the United States of America and the Company is a start-up company as at December 31, 2023 and 2022 and has no revenue. The Company’s reportable segments and operating segments will include its growth, production, and research of medicinal plants operations.

     

     

    BRIGHT GREEN CORPORATION

    Notes to the Consolidated Financial Statements

    For the Years Ended December 31, 2023 and 2022

    (Expressed in United States Dollars)

     

     

    3. Summary of Significant Accounting Policies (continued)

     

    M. Use of Estimates

     

    The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions. The Company bases its estimates and assumptions on current facts, historical experience, various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities, and the accrual of costs and expenses that are not readily apparent from other sources. This applies in particular to valuation allowance for deferred tax assets, valuation of warrants, stock options, stock-based compensation, going concern assessment, impairment of non-current assets, and assignment of the useful lives of property, plant, and equipment. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.

     

    N. Stock-Based Compensation

     

    The Company accounts for stock-based payments in accordance with the provision of ASC 718, which requires that all stock-based payments issued to acquire goods or services, including grants of employee stock options, be recognized in the consolidated statements of operations and comprehensive loss based on their fair values, net of estimated forfeitures. ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Compensation expense related to stock-based awards is recognized over the requisite service period, which is generally the vesting period.

     

    The Company accounts for stock-based compensation awards issued to non-employees for services, as prescribed by ASC 718-10, at either the fair value of the services rendered or the instruments issued in exchange for such services, whichever is more readily determinable, using the guidelines in ASC 505-50. The Company issues compensatory shares for services including, but not limited to, executive management, management, accounting, operations, corporate communication, and financial and administrative consulting services.

     

    O. Warrants

     

    The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in FASB, ASC 480 and ASC 815. The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own ordinary shares and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance, and each consolidated balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the consolidated statements of operations and comprehensive loss.

     

     

    BRIGHT GREEN CORPORATION

    Notes to the Consolidated Financial Statements

    For the Years Ended December 31, 2023 and 2022

    (Expressed in United States Dollars)

     

     

    3. Summary of Significant Accounting Policies (continued)

     

    P. Recently Adopted Accounting Standards

     

    In February 2016, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2016-02, “Leases (Topic 842)”, which establishes a right-of-use (ROU) model that requires a lessee to record an ROU asset and a lease liability on the statement of financial position for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the statement of activities. The new standard became effective for public business entities on January 1, 2019, with early adoption permitted. The new standard became effective for the Company on May 17, 2022, the date the Company became a public entity. The Company adopted this accounting policy as of May 17, 2022. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. While the Company continues to evaluate certain aspects of the new standard, including those still being revised by the FASB, the new standard does not have a material effect on the Company’s consolidated financial statements. As of December 31, 2023, the Company has one month to month lease, whereas the new standard does not apply.

     

    In October 2023, the FASB issued ASU No. 2023-06, Disclosure Improvements: Codification Amendments in Response to the SEC’s Disclosure Update and Simplification Initiative. The amendments in this update modify the disclosure or presentation requirements of a variety of topics in the codification. Certain amendments represent clarifications to or technical corrections of the current requirements. Each amendment in the ASU will only become effective if the SEC removes the related disclosure or presentation requirement from its existing regulations by June 30, 2027. The Company is currently assessing the impact this standard will have on the Company’s future consolidated financial statements.

     

     

    BRIGHT GREEN CORPORATION

    Notes to the Consolidated Financial Statements

    For the Years Ended December 31, 2023 and 2022

    (Expressed in United States Dollars)

     

     

    3. Summary of Significant Accounting Policies (continued)

     

    Q. Recently Issued but Not Adopted Accounting Standards

     

    In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The amendments in ASU 2023-07 are intended to enhance disclosures for significant segment expenses for all public entities required to report segment information in accordance with ASC 280. ASC 280 requires a public entity to report for each reportable segment a measure of segment profit or loss that its chief operating decision maker (“CODM”) uses to assess segment performance and to make decisions about resource allocations. The amendments in ASU 2023-07 improve financial reporting by requiring disclosure of incremental segment information on an annual and interim basis for all public entities to enable investors to develop more useful financial analyses. Currently, Topic 280 requires that a public entity disclose certain information about its reportable segments. For example, a public entity is required to report a measure of segment profit or loss that the CODM uses to assess segment performance and make decisions about allocating resources. ASC 280 also requires other specified segment items and amounts, such as depreciation, amortization, and depletion expense, to be disclosed under certain circumstances. The amendments in ASU 2023-07 do not change or remove those disclosure requirements. The amendments in ASU 2023-07 also do not change how a public entity identifies its operating segments, aggregates those operating segments, or applies the quantitative thresholds to determine its reportable segments. The amendments in ASU 2023-07 are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. A public entity should apply the amendments in ASU 2023-07 retrospectively to all prior periods presented in the financial statements. The Company is currently assessing the impact this standard will have on the Company’s future consolidated financial statements.

     

    In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The amendments in ASU 2023-07 are intended to enhance the transparency and decision usefulness of income tax disclosures. The amendments in ASU 2023-09 require annual disclosures of specific categories in the rate reconciliation, additional information for reconciling items that meet a quantitative threshold, and a disaggregation of income taxes paid, net of refunds. The amendments in ASU 2023-09 also eliminate certain existing disclosure requirements related to uncertain tax positions and unrecognized deferred tax liabilities. The amendments in ASU 2023-09 are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The amendments in ASU 2023-09 should be applied prospectively. The Company is currently assessing the impact this standard will have on the Company’s future consolidated financial statements.

     

    Management does not believe that other recently issued, but not yet effective, accounting standards could have a material effect on the Company’s consolidated financial statements. As new accounting pronouncements are issued, the Company will adopt those that are applicable under the circumstances.

     

     

    BRIGHT GREEN CORPORATION

    Notes to the Consolidated Financial Statements

    For the Years Ended December 31, 2023 and 2022

    (Expressed in United States Dollars)

     

     
    XML 28 R11.htm IDEA: XBRL DOCUMENT v3.24.1.u1
    Concentration of Credit Risk
    		 12 Months Ended
    Dec. 31, 2023
    Risks and Uncertainties [Abstract]  
    Concentration of Credit Risk

    4. Concentration of Credit Risk

     

    Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash deposits. Accounts at each institution are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. The Company had $nil and $187,821in excess of the FDIC insured limit at December 31, 2023 and 2022, respectively.

     
    XML 29 R12.htm IDEA: XBRL DOCUMENT v3.24.1.u1
    Deposits
    		 12 Months Ended
    Dec. 31, 2023
    Deposits

    5. Deposits

     

    As of December 31, 2022, deposits were comprised of two down payments. One was for a construction of equipment contract for which the Company had not yet taken title. The other was for a construction contract for which the work had not started. As of December 31, 2023, the Company has still not taken title of the equipment and the construction contract was completed (Note 9).

     

    On March 13, 2024, the Company entered into and signed a Settlement and Release Agreement, in which the deposit was forfeited, leased equipment was returned, and 118,535,168 shares of common stock of Alterola was transferred to the vendor in lieu of payment. Additionally, all parties involved mutually released, relieved, acquitted, remised, and discharged each other as per the Settlement and Release Agreement (Notes 9 and 16).

     
    XML 30 R13.htm IDEA: XBRL DOCUMENT v3.24.1.u1
    Equity Method Investment in Alterola
    		 12 Months Ended
    Dec. 31, 2023
    Investments, All Other Investments [Abstract]  
    Equity Method Investment in Alterola

    6. Equity Method Investment in Alterola

     

    On October 3, 2022, the Company entered into a Secondary Stock Purchase Agreement and Release (the “Secondary SPA”) with Phytotherapeutix Holdings Ltd., a United Kingdom entity, Equipped4 Holdings Limited, a United Kingdom entity, TPR Global Limited, a United Kingdom entity (each, a “Seller” and collectively, the “Sellers”) and Alterola Biotech Inc., a Nevada corporation (“Alterola”) providing for the purchase by Bright Green of shares of Common Stock of Alterola from the Sellers (the “Transferred Shares”).

     

    The Secondary SPA provided that, as of the date thereof, the authorized shares of Alterola consisted of 2,000,000,000 shares of common stock, $0.001 par value, of which 807,047,948 shares were issued and outstanding. The Sellers held 67% of Alterola’s total outstanding shares prior to the closing of the Secondary SPA. As a result of this transaction, the Company obtained ownership or voting power of approximately 25% of the total outstanding shares of Alterola. The Sellers Transferred Shares consisted of, in aggregate, 201,761,982 shares of Common Stock, which were sold to the Company for a purchase price of $3,999,999, pursuant to the payment schedule set forth in the Secondary SPA. Following the receipt of each installment payment, the Sellers agreed to loan to Alterola the proceeds such Seller received from the foregoing sale of its Transferred Shares, pursuant to a loan agreement. As of December 31, 2023 and 2022, the Company has a liability to the Sellers of $1,650,000, which is in default as of December 31, 2023. The liability is not interest-bearing and not secured.

     

    On March 13, 2024, the Company entered into and signed a Settlement Agreement with the Sellers, in which the Company transferred 27,742,273 of the Transferred Shares to each of the Sellers. Additionally, all parties involved mutually released, relieved, acquitted, remised, and discharged each other from any further claims as outlined in the Release Agreement (Note 16).

     

    Voting Agreement

     

    Concurrently with the signing of the Secondary SPA, Bright Green and the Sellers entered into a voting agreement (the “Voting Agreement”) whereby the Sellers agreed to vote in favor of the adoption of an agreement to effect Bright Green’s acquisition of Alterola or the Alterola’s merger into Bright Green or a subsidiary of Bright Green, as the case may be, pursuant to additional terms set forth in the Voting Agreement.

     

     

    BRIGHT GREEN CORPORATION

    Notes to the Consolidated Financial Statements

    For the Years Ended December 31, 2023 and 2022

    (Expressed in United States Dollars)

     

     

    6. Equity Method Investment in Alterola (continued)

     

    The Voting Agreement was initially measured at fair value utilizing the Black-Scholes option pricing model based on the following assumptions: dividend rate of 0.0%, risk free rate of 4.0%, term of 0.5 years, volatility of 66.0%, the stock price of $26,400,000, inclusive of a Control Premium of 65% valued at $10,400,000, determined using the Recent Transaction Method as the transaction was determined to be arms-length, and a strike price of $61.3 million reflecting the option to purchase the remaining 75% of the outstanding shares of common stock for $46.0 million. The issuance date fair value of the Voting Agreement was determined to be $213,000 of the gross payment to the Sellers of $3,999,999.

     

    As of December 31, 2022, the value of the option was impaired to $nil to reflect the likelihood that the option would be exercised according to the terms set forth. As of December 31, 2023, the option has expired.

     

    Equity Method Accounting Treatment

     

    The Company’s 25% ownership of Alterola allowed the Company to have significant influence over the operations and decision-making at Alterola. Accordingly, the Company accounted for the transaction under the equity method and recorded the carrying value of the Company’s investment in Alterola common shares at cost, including the transaction costs incurred to obtain the equity method investment, in the consolidated balance sheets.

     

    The following table provides summarized balance sheet information for Alterola as of September 30, 2023 and December 31, 2022:

     

       September 30, 2023   December 31, 2022 
    Current assets  $197,208   $192,011 
    Non-current assets   300,000    12,018,147 
    Current liabilities   2,519,231    1,822,696 
    Non-current liabilities   -    151,255 
    Equity (Deficit)  $(2,022,023)  $10,236,207 

     

    The following table provides summarized income statement information for Alterola for the nine months ended September 30, 2023 and the year ended December 31, 2022:

     

             
       Nine Months Ended   Year Ended 
       September 30, 2023   December 31, 2022 
    Total revenues  $-   $- 
    Net loss  $874,653   $4,980,510 

     

     

    BRIGHT GREEN CORPORATION

    Notes to the Consolidated Financial Statements

    For the Years Ended December 31, 2023 and 2022

    (Expressed in United States Dollars)

     

     

    6. Equity Method Investment in Alterola (continued)

     

    For the year ended December 31, 2022 and the period through October 16, 2023, the Company maintained significant influence through its ownership interest and accounted for its Alterola investment under the equity method. For the year ended December 31, 2022, the Company recorded a loss of $135,155 to account for its 25% share of Alterola’s net loss from October 3, 2022, through the year ended December 31, 2022. As of December 31, 2022, the equity method investment balance was $3,990,960.

     

    For the year ended December 31, 2023, the Company recorded a loss of $218,663 to account for its 25% share of Alterola’s net loss for the period ended October 16, 2023. On October 16, 2023, Alterola issued shares of its common stock in exchange for forgiveness of debt diluting the Company’s 25% share to approximately 15%. The Company evaluated its ability to continue to exercise significant influence over its investment and determined that it no longer had significant influence. Subsequent to this remeasurement date, the Company’s Alterola investment is accounted for at fair value under ASC 321 and recorded in Other investment held at fair value on the consolidated balance sheets. Any changes in fair value of the Company’s Alterola investment are recorded as a Change in fair value of assets in its consolidated statements of operations and comprehensive loss. Based on quoted market prices, the fair value of the Company’s Alterola investment was $726,343 as of December 31, 2023. For the year ended December 31, 2023, the Company recorded $3,045,954 of Change in fair value of assets.

     

    The following table summarizes the activity of the Company’s equity method investment in Alterola:

     

     

       Equity Method 
       Investment in Alterola 
    Balance at December 31, 2021  $- 
    Company’s initial investment in Alterola   4,126,115 
    Company’s 25% share in net loss recognized in 2022   (135,155)
    Balance at December 31, 2022   3,990,960 
    Company’s 25% share in net loss recognized through October 16, 2023   (218,663)
    Change in fair value of assets   (3,045,954)
    Balance at December 31, 2023  $726,343 

     

     
    XML 31 R14.htm IDEA: XBRL DOCUMENT v3.24.1.u1
    Property, Plant, and Equipment
    		 12 Months Ended
    Dec. 31, 2023
    Property, Plant and Equipment [Abstract]  
    Property, Plant, and Equipment

    7. Property, Plant, and Equipment

     

    The Company owns an expansive 22-acre modern Dutch “Venlo style” glass greenhouse situated on 70 acres in Grants, New Mexico. It is being retrofitted for growing, processing and distribution of medicinal plants, including Marijuana, for medical researchers licensed by the Drug Enforcement Administration.

     

    Property, plant, and equipment at December 31, 2023 and 2022, consisted of the following:

     

       December 31, 2023   December 31, 2022 
    Furniture and fixtures  $88,690   $88,690 
    Land   260,000    260,000 
    Construction in progress   10,635,866    10,736,269 
    Building and improvements   8,883,851    8,883,851 
    Property, plant and equipment gross   19,868,407    19,968,810 
    Accumulated depreciation   (3,460,992)   (2,822,485)
    Net property, plant, and equipment  $16,407,415   $17,146,325 

     

     

    BRIGHT GREEN CORPORATION

    Notes to the Consolidated Financial Statements

    For the Years Ended December 31, 2023 and 2022

    (Expressed in United States Dollars)

     

     

    7. Property, Plant, and Equipment (continued)

     

    The amount of interest expense capitalized and included in construction in progress was $223,271 and $106,117 for the years ended December 31, 2023 and 2022, respectively (Note 10).

     

    On January 19, 2024, the Company reached an agreement with the vendor to cancel approximately $2,650,000 of construction in progress. As part of the agreement, the vendor also agreed to cancel the related accounts payable and completion of the project. The project was being constructed at the vendor’s location. The adjustment is reflected in the construction in progress balance as of December 31, 2023 (Note 16).

     

    Real Estate Options

     

    In 2020, the Company entered into a merger agreement with Grants Greenhouse Growers, Inc. and acquired the following two land options:

     

     -A Real Estate Option Agreement dated October 5, 2020, and expiring on December 31, 2021, for $1,500 monthly payments up until June 30, 2021, and $1,750 monthly payments from July 1, 2021 to December 31, 2021, with a one-year extension starting on January 1, 2022 for $2,000 monthly payments, with the option to purchase 330 acres for $5,000 per acre.
       
    -A Real Estate Option Agreement dated October 21, 2020, and expiring on December 31, 2021, for $1,000 monthly payments, with a one-year extension starting on January 1, 2022 for $1,500 monthly payments, with the option to purchase 175 acres for $5,000 per acre.

     

    As of December 31, 2022, the Company notified the two landowners of the Company’s intention to exercise the two Real Estate Option Agreements. The Company is in the process of negotiating final terms of the two acquisitions. As of December 31, 2023, the acquisitions have not been completed.

     
    XML 32 R15.htm IDEA: XBRL DOCUMENT v3.24.1.u1
    Intangible Assets
    		 12 Months Ended
    Dec. 31, 2023
    Goodwill and Intangible Assets Disclosure [Abstract]  
    Intangible Assets

    8. Intangible Assets

     

    Intangible assets at December 31, 2023 and 2022, consisted of the following:

     

       December 31, 2023   December 31, 2022 
    Licenses  $1,000   $1,000 
    Accumulated amortization   -    - 
    Net intangible assets  $1,000   $1,000 

     
    XML 33 R16.htm IDEA: XBRL DOCUMENT v3.24.1.u1
    Commitments
    		 12 Months Ended
    Dec. 31, 2023
    Commitments and Contingencies Disclosure [Abstract]  
    Commitments

    9. Commitments

     

    In 2022, the Company entered a contract to purchase equipment for $2,219,285. The Company made a deposit totaling $1,109,643 as of December 31, 2022. The remaining balance of $1,109,642 is due upon delivery of the equipment. In addition, the Company entered into and paid in full a construction contract for $47,944 as of December 31, 2022. The construction was completed in March 2023, and the contract was fulfilled (Note 5).

     

    On March 13, 2024, the Company entered into and signed a Settlement and Release Agreement, in which the deposit was forfeited, leased equipment was returned, and 118,535,168 shares of common stock of Alterola was transferred to the vendor in lieu of payment. Additionally, all parties involved mutually released, relieved, acquitted, remised, and discharged each other as per the Settlement and Release Agreement  (Notes 5 and 16).

     

     

    BRIGHT GREEN CORPORATION

    Notes to the Consolidated Financial Statements

    For the Years Ended December 31, 2023 and 2022

    (Expressed in United States Dollars)

     

     
    XML 34 R17.htm IDEA: XBRL DOCUMENT v3.24.1.u1
    Related Party Line of Credit Note
    		 12 Months Ended
    Dec. 31, 2023
    Related Party Line Of Credit Note  
    Related Party Line of Credit Note

    10. Related Party Line of Credit Note

     

    On June 5, 2022, the Company and LDS Capital LLC (“Lender”), whose managing member is a member of the Company’s Board of Directors (the “Board”), entered into an unsecured line of credit in the form of a note (the “June Note”). The June Note provides that the Company may borrow up to $5,000,000, including an initial loan of $3,000,000, through June 4, 2025 (the “June Note Maturity Date”) from Lender. Prior to the June Note Maturity Date, the Company may borrow up to an additional $2,000,000 under the June Note, at Lender’s sole discretion, and subject to the Company’s request of such additional funds from Lender (each loan furnished under the June Note individually, a “Loan,” and collectively, the “Loans”). The Company has the right, but not the obligation, to prepay any Loan, in whole or in part, prior to the June Note Maturity Date. Interest on the unpaid principal amount of any Loan accrues through the earlier of the June Note Maturity Date or the date of prepayment on such Loan, at a rate of 2% per annum plus the Prime Rate (the rate of interest per annum announced from time to time by JP Morgan Chase Bank as its prime rate). If the principal and interest, if any, of any Loan is not paid in full on the June Note Maturity Date, additional penalty interest will accrue on such Loan in the amount of 2% per annum. The Company amended the line of credit on November 14, 2022, to increase the capacity by $10,000,000. On January 31, 2023, LDS Capital LLC assigned the note to its sole member, Lynn Stockwell, who is the Company’s Chairwoman and majority shareholder.

     

    As of December 31, 2023, the Lender has funded the Company $5,983,250 (December 31, 2022 – $5,191,057), with the Company paying back $6,110,855 (December 31, 2022 – $1,611,067) of those funds, which includes $327,605 in interest. As of December 31, 2023, there was accrued interest of $1,783 (December 31, 2022 – $106,117). The funds have been used for the construction in progress, and during the year ended December 31, 2023, interest expense of $223,271 (December 31, 2022 – $106,117) has been capitalized (Note 7).

     

    On February 1, 2023, through a cashless conversion, the related party line of credit note was used to pay the related party loan balance of $392,194 in full.

     

    On February 6, 2023, through a cashless conversion, the related party line of credit note was paid down $880,000 in exchange for an $880,000 investment for 22,005 shares of the Company’s common stock valued at $39.99 per share pursuant to the Company’s EB-5 Program (Note 11).

     

    On March 14, 2023, the Company drew an additional $200,000 on the related party line of credit note.

     

     

    BRIGHT GREEN CORPORATION

    Notes to the Consolidated Financial Statements

    For the Years Ended December 31, 2023 and 2022

    (Expressed in United States Dollars)

     

     

    10. Related Party Line of Credit Note (continued)

     

    At August 31, 2023, the amount of principal, interest, and other costs outstanding under the related party line of credit note was $3,619,789 (the “Repayment Obligation”). On September 1, 2023, the Company and the Lender entered into an agreement (the “Repayment Agreement”) pursuant to which, in consideration for the cancellation and full satisfaction of the Repayment Obligation, the Company issued to the Lender (i) 2,827,960 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), representing a conversion of outstanding principal at $1.15 per Share, and (ii) warrants representing a conversion of outstanding principal at $0.13 per warrant to purchase up to 2,827,960 shares of Common Stock at a price of $3.00 per share (Note 11).

     

    The Company determined the Repayment Agreement should be accounted for as an extinguishment in accordance ASC 405, Liabilities, and ASC 470-50, Debt. The Company measured the difference between the fair value of the equity interests granted and the carrying value of the obligation, determining that the carrying value exceeded the fair value of the interests granted. The Company determined that a gain would be recorded; however, the Company recorded the $2,090,564 gain as a capital transaction due to the related party nature of the Lender.

     

    On December 1, 2023, the Company drew an additional $200,000 on the related party line of credit note, leaving available $14,800,000 to draw from that credit facility.

     
    XML 35 R18.htm IDEA: XBRL DOCUMENT v3.24.1.u1
    Stockholders’ Equity
    		 12 Months Ended
    Dec. 31, 2023
    Equity [Abstract]  
    Stockholders’ Equity

    11. Stockholders’ Equity

     

    The Company has authorized 500,000,000 shares of $0.0001 par value common stock and 10,000,000 shares of $0.0001 par value preferred stock. As of December 31, 2023, and 2022, there were 184,758,818 and 173,304,800, respectively, of common shares issued and outstanding. The Company has not issued any preferred shares to date.

     

    During the year ended December 31, 2023, the Company issued the following:

     

    -200,000 warrants exercised in exchange for 200,000 shares of common stock issued for cash at $1.05 per share, to one accredited investor in February 2023;

     

    -22,005 shares of common stock issued at $39.99 per share, to the Company’s Chairwoman in February 2023, through a cashless conversion; the related party line of credit note was paid down $880,000 in exchange for an $880,000 investment, pursuant to the Company’s EB-5 Program (Note 10);

     

    -22,005 shares of common stock issued at $39.99 per share, to one accredited investor in March 2023, pursuant to the Company’s EB-5 Program;

     

     

    BRIGHT GREEN CORPORATION

    Notes to the Consolidated Financial Statements

    For the Years Ended December 31, 2023 and 2022

    (Expressed in United States Dollars)

     

     

    11.Stockholders’ Equity (continued)

     

    -875,000 shares of common stock for services rendered, at a fair value of $0.9416 per share, to the Company’s former Executive Chairman, in March 2023 (Note 14);

     

    -500,000 shares of common stock for services rendered, at a fair value of $1.13 per share, to the Company’s former Chief Executive Officer, in May 2023 (Note 14);

     

    -3,684,210 shares of common stock and warrants to purchase up to an aggregate of 3,684,210 shares of common stock, at a combined purchase price of $0.95 per share and accompanying warrant, in a private placement offering, in May 2023 (the “May 2023 Private Placement”);

     

    -875,000 shares of common stock for services rendered, at a fair value of $1.01 per share, to the Company’s former Executive Chairman, in June 2023 (Note 14);

     

    -137,838 shares of common stock for services rendered, at a fair value of $0.74 per share, to a consultant of the Company, in July 2023;

     

    -2,827,960 shares of common stock and warrants to purchase up to an aggregate of 2,827,960 shares of common stock at an exercise price of $3.00 per share, issued at a combined price of $1.28 per share and accompanying warrant, to the Company’s Chairwoman, through a cashless conversion; the related party line of credit note was paid in full $3,619,789 in exchange for a $3,619,789 investment, in September 2023 (Note 10);

     

    -60,000 shares of common stock for services rendered, at a fair value of $0.4015 per share, to a consultant of the Company, in September 2023;

     

    -500,000 shares of common stock for services rendered, at a fair value of $0.4015 per share, to the Company’s Chief Financial Officer, in September 2023 (Note 14);

     

    -875,000 shares of common stock for services rendered, at a fair value of $0.3959 per share, to the Company’s former Executive Chairman, in September 2023 (Note 14);

     

    -1,800,000 shares of stock options for services rendered, at a fair value of $0.3303 per share, an exercise price of $0.3353 per share, which vest immediately, expire on November 16, 2033, with 600,000 each to three Directors of the Company, in November 2023 (Notes 12 and 14); and

     

     

    BRIGHT GREEN CORPORATION

    Notes to the Consolidated Financial Statements

    For the Years Ended December 31, 2023 and 2022

    (Expressed in United States Dollars)

     

     

    11.Stockholders’ Equity (continued)

     

    -875,000 shares of common stock for services rendered, at a fair value of $0.3301 per share, to the Company’s former Executive Chairman, in December 2023 (Note 14).

     

    During the year December 31, 2022, the Company issued the following:

     

    -12,500 shares of common stock at a purchase price of $4.00 per share, for gross cash proceeds of $50,000, to one accredited investor in January 2022;

     

    -500,000 shares of common stock for services rendered, at a fair value of $4.00 per share determined using the per share purchase price of the latest $4.00 private placement Round, to the Chief Financial Officer of the Company, in April 2022;

     

    -1,574,490 shares of common stock for services rendered, at a fair value of $8.00 per share determined using the per share purchase price of the latest $8.00 private placement Round, to six consultants in April 2022;

     

    -5,000 shares of common stock that were issued in January 2021 to a director of the Company, for services valued at $2.00 per share determined using the per share purchase price of the $2.00 Round, were canceled in April 2022;

     

    -300,000 shares of common stock at a purchase price of $10.00 per share, for gross cash proceeds of $3,000,000, to two accredited investors in May 2022;

     

    -108,000 shares of common stock that were issued in June 2019 to a consultant of the Company, for services valued at $0.069 per share determined using an asset approach, were canceled in June 2022;

     

    -9,523,810 shares of common stock and warrants to purchase up to an aggregate of 9,523,810 shares of common stock, at a combined purchase price of $1.05 per share and accompanying warrant, in a private placement offering, in September 2022 (the “September 2022 Private Placement”); and

     

    -3,962,500 shares of common stock for services rendered, with (i) 3,000,000 shares issued at a fair value of $1.25 per share, (ii) 87,500 shares at a fair value of $1.08 per share, and (iii) 875,000 shares at a fair value of $0.4695 per share, to the former Chief Executive Officer of the Company, in December 2022.

     

    Private Placement Offerings

     

    September 2022 Private Placement

     

    On September 7, 2022, the Company entered into a Securities Purchase Agreement with investors for the sale by the Company of 9,523,810 shares of common stock and warrants to purchase up to an aggregate of 9,523,810 shares of common stock. The combined purchase price of one share and the accompanying warrant (“September 2022 Warrants”) was $1.05.

     

     

    BRIGHT GREEN CORPORATION

    Notes to the Consolidated Financial Statements

    For the Years Ended December 31, 2023 and 2022

    (Expressed in United States Dollars)

     

     

    11.Stockholders’ Equity (continued)

     

    Subject to certain ownership limitations, the September 2022 Warrants are exercisable immediately after issuance at an exercise price equal to $1.05 per share of Common Stock, subject to adjustments as provided under the terms of the September 2022 Warrants. The September 2022 Warrants have a term of five years from the date of issuance. The September 2022 Private Placement closed on September 12, 2022. The Company received gross proceeds of approximately $10 million before deducting transaction-related fees and expenses payable by the Company. As of December 31, 2023, 200,000 of the September 2022 Warrants have been redeemed for $210,000.

     

    In connection with the September 2022 Private Placement, the Company entered into a Registration Rights Agreement with the investors. The Company’s registration statement on Form S-1 to register the securities issued in the September 2022 Private Placement went effective on September 21, 2022.

     

    Transaction costs incurred related to the September 2022 Private Placement include the following: (i) placement agent fees of $800,000, (ii) legal expenses of $55,617, and (iii) escrow agent expenses of $7,650.

     

    May 2023 Private Placement

     

    On May 21, 2023, the Company entered into a Securities Purchase Agreement with an accredited investor and existing stockholder of the Company. The combined purchase price of one share and the accompanying warrant (“May 2023 Warrants”) was $0.95. Subject to certain ownership limitations, the May 2023 Warrants are exercisable immediately after issuance at an exercise price equal to $0.95 per share of Common Stock, subject to adjustments as provided under the terms of the May 2023 Warrants. The May 2023 Warrants have a term of five years from the date of issuance. The May 2023 Private Placement closed on May 24, 2023. The Company received gross proceeds of approximately $3.5 million before deducting transaction related fees and expenses payable by the Company.

     

    In connection with the May 2023 Private Placement, the Company entered into a Registration Rights Agreement with the investor. The Company’s registration statement on Form S-3 to register the securities issued in the May 2023 Private Placement went effective on June 5, 2023.

     

    Transaction costs incurred related to the May 2023 Private Placement include the following: (i) placement agent fees of $316,850, and (ii) legal expenses of $78,400.

     

    Warrants

     

    September 2022 Warrants

     

    In the Company’s September 2022 Private Placement, Warrants to purchase up to 9,523,810 shares of Common Stock were issued (“September 2022 Warrants”). The September 2022

     

     

    BRIGHT GREEN CORPORATION

    Notes to the Consolidated Financial Statements

    For the Years Ended December 31, 2023 and 2022

    (Expressed in United States Dollars)

     

     

    11.Stockholders’ Equity (continued)

     

    Warrants were initially exercisable at a price of $1.05 per share, subject to adjustment as set forth in the September 2022 Warrants, at any time after September 12, 2022 and will expire on September 13, 2027. In connection with the May 2023 Private Placement, the exercise price of the September 2022 Warrants issued in the September 2022 Private Placement was reduced to $0.95 per share.

     

    The fair value of the September 2022 Warrants immediately prior to the modification was $7,399,000, and the fair value of the September 2022 Warrants immediately after the modification was $6,901,000, representing a decrease in fair value of $498,000. In accordance with ASU 2021- 04, as the modification was a result of issuing equity and there was no increase in fair value, the Company accounted for the adjustment as a reduction of additional paid-in capital with a corresponding offset recorded to additional paid-in capital.

     

    May 2023 Warrants

     

    In the Company’s May 2023 Private Placement, Warrants to purchase up to 3,684,210 shares of Common Stock were issued (“May 2023 Warrants”). The fair value of the May 2023 Warrants was determined utilizing a Black-Scholes model considering all relevant assumptions current at the date of issuance (i.e., share price of $0.78, exercise price of $0.95, term of five years, volatility of 165.0%, risk-free rate of 3.8%, and dividend rate of 0.0%). The grant date fair value of the May 2023 Warrants was estimated to be $1,600,000 on May 24, 2024 and is reflected within additional paid-in capital as of December 31, 2023.

     

    September 2023 Warrants

     

    In connection with the Repayment Obligation disclosed in Note 10, Warrants to purchase up to 2,827,960 shares of Common Stock were issued (“September 2023 Warrants”). The fair value of the September 2023 Warrants was determined utilizing a Monte Carlo simulation considering all relevant assumptions current at the date of issuance (i.e., share price of $0.46, exercise price of $3.00, expected life of one year, volatility of 149%, risk-free rate of 5.36%, and dividend rate of 0.0%). The grant date fair value of the September 2023 Warrants was estimated to be approximately $149,180 on September 1, 2023, and is reflected within additional paid-in capital as of December 31, 2023.

     

     

    BRIGHT GREEN CORPORATION

    Notes to the Consolidated Financial Statements

    For the Years Ended December 31, 2023 and 2022

    (Expressed in United States Dollars)

     

     
    XML 36 R19.htm IDEA: XBRL DOCUMENT v3.24.1.u1
    Stock-Based Compensation
    		 12 Months Ended
    Dec. 31, 2023
    Retirement Benefits [Abstract]  
    Stock-Based Compensation

    12. Stock-Based Compensation

     

    In 2022, the Company adopted the Bright Green Corporation 2022 Omnibus Equity Compensation Plan, which allows for various types of stock-based awards. These awards can be in the form of stock options (including non-qualified and incentive stock options), SARs, restricted shares, performance shares, deferred stock, restricted stock units (“RSUs”), dividend equivalents, bonus shares, or other types of stock-based awards.

     

    As of December 31, 2023 and 2022, there were 3,050,000 and nil, respectively, of awards granted under the Plan. The awards consisted of 2,425,000 shares of stock options and 625,000 shares of RSUs.

     

    The Company’s stock-based compensation costs for the years ended December 31, 2023, and 2022 were $3,829,218 and $18,833,781, respectively, with the costs allocated to general and administrative expenses. Stock options accounted for $594,478 of the total stock-based compensation costs for the year ended December 31, 2023.

     

    Stock Options

     

    The Company uses the Black-Scholes option pricing model to value stock option grants to employees, non-employees, and directors. The fair value of the Company’s common stock is used to determine the fair value of stock options. The Black-Scholes option pricing model requires inputs based on certain subjective assumptions, including (i) the expected stock price volatility, (ii) the expected term of the award, (iii) the risk-free interest rate, and (iv) expected dividends. The historical volatility is calculated based on a period of time commensurate with the expected term assumption. The Company uses the simplified method to calculate the expected term for options granted to employees whereby the expected term equals the arithmetic average of the vesting term and the original contractual term of the options due to its lack of sufficient historical data. The risk-free interest rate is based on U.S. Treasury securities with a maturity date commensurate with the expected term of the associated award. The expected dividend yield is assumed to be zero as the Company has never paid dividends and has no current plans to pay any dividends on its common stock. The Company recognizes forfeitures as they occur.

     

    The fair value of the stock options was estimated using the following assumptions:

    Schedule of Fair Value of The Stock Options 

       2023   2022 
    Weighted average fair value at grant date  $0.3303   $- 
    Valuation assumptions:          
    Expected life of options (years)   5.00    - 
    Expected stock volatility   213.90%   - 
    Risk-free interest rate   4.42%   - 
    Expected dividend yield   0.00%   - 

     

     

    BRIGHT GREEN CORPORATION

    Notes to the Consolidated Financial Statements

    For the Years Ended December 31, 2023 and 2022

    (Expressed in United States Dollars)

     

     

    12. Stock-Based Compensation (continued)

     

    During the year ended December 31, 2023, the Company granted the following stock options:

     

    -On September 20, 2023, the Company granted 625,000 shares of stock options with an exercise price of $0.385, which vest in thirty equal monthly installments beginning April 1, 2024, to the Chief Executive Officer of the Company (Note 14); and

     

    -On November 16, 2023, the Company granted 1,800,000 shares of stock options with an exercise price of $0.3353, a fair value of $0.3303, vesting immediately, and expiring on November 16, 2033, with 600,000 each to three Directors of the Company (Notes 11 and 14).

     

    During year ended December 31, 2022, the Company did not issue any stock options.

     

    The following table summarizes stock option activity for the year ended December 31, 2023:

     

       Stock Options Outstanding & Exercisable 
               Weighted Average 
       Number of   Weighted Average   Remaining Life 
       Stock Options   Exercise Price   (Years) 
    Balance, December 31, 2022   -   $-      
    Granted   2,425,000    0.3353      
    Exercised   -    -      
    Expired   -    -      
    Balance, December 31, 2023   2,425,000   $0.3353    9.90 

     

    On March 31, 2024, the 625,000 shares of stock options granted to the Chief Executive Officer of the Company were canceled by mutual agreement between the Company and the Chief Executive Officer (Notes 14 and 16).

     

    Restricted Stock Units

     

    The Company accounts for the fair value of restricted stock units (“RSUs”) using the closing market price of the Company’s common stock on the date of the grant. Stock-based compensation cost for RSUs is measured at the grant date based on the estimated fair value of the award and is recognized as expense over the requisite service period (generally the vesting period), net of forfeitures.

     

    During the year ended December 31, 2023, the Company granted the following RSUs:

     

    -On September 20, 2023, the Company granted 625,000 shares of RSUs, which vest in thirty equal monthly installments beginning April 1, 2024, to the Chief Executive Officer of the Company (Note 14).

     

    During the year ended December 31, 2022, the Company did not issue any RSUs.

     

    On March 31, 2024, the 625,000 shares of RSUs granted to the Chief Executive Officer of the Company were canceled and replaced with 5,500,000 RSUs by mutual agreement between the Company and the Chief Executive Officer (Notes 14 and 16).

     

     

    BRIGHT GREEN CORPORATION

    Notes to the Consolidated Financial Statements

    For the Years Ended December 31, 2023 and 2022

    (Expressed in United States Dollars)

     

     
    XML 37 R20.htm IDEA: XBRL DOCUMENT v3.24.1.u1
    Income Taxes
    		 12 Months Ended
    Dec. 31, 2023
    Income Tax Disclosure [Abstract]  
    Income Taxes

    13. Income Taxes

     

    Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. A full valuation allowance is established against all net deferred tax assets as of December 31, 2023 and 2022, based on estimates of recoverability. While the Company has optimistic plans for its business strategy, it determined that such a valuation allowance was necessary given the current and expected near term losses and the uncertainty with respect to its ability to generate sufficient profits from its business model.

     

    The current and deferred income tax expenses for the year December 31, 2023 and 2022, was $nil. The provision for income taxes differs from that computed at combined corporate tax rate of approximately 25.8% (2022 – 25.8%) as follows:

     

     

       2023   2022 
               
    Loss before income taxes  $(13,127,648)  $(27,662,077)

     

    The (benefit) provision for income taxes for 2023 and 2022 consists of the following:

     

       2023   2022 
    Current:          
    Federal   -    - 
    State   -    - 
    Total current (benefit) provision   -    - 
               
    Deferred:          
    Federal   (2,520,309)   (5,727,839)
    State   (576,071)   (1,309,220)
    Total current (benefit) provision   (3,096,380)   (7,037,059)
    Valuation allowance   3,096,380    7,037,059 
    Total (benefit) expense  $-   $- 

     

    The federal and state tax effects of the temporary differences and carry forwards that give rise to deferred tax assets consists of the following:

     

       2023   2022 
    Other   1,401,963    728,201 
    Net operating loss carry over   9,716,764    7,294,146 
    Total deferred tax assets   11,118,727    8,022,347 
    Less: valuation allowance   (11,118,727)   (8,022,347)
    Deferred tax assets, net of valuation allowance  $-   $- 

     

     

    BRIGHT GREEN CORPORATION

    Notes to the Consolidated Financial Statements

    For the Years Ended December 31, 2023 and 2022

    (Expressed in United States Dollars)

     

     

    13. Income Taxes (continued)

     

    As of December 31, 2023 and 2022, the Company decided that a valuation allowance relating to the above deferred tax assets of the Company was necessary, largely based on the negative evidence represented by losses incurred and a determination that it is not more likely than not to realize these assets, such that, a corresponding valuation allowance, for each respective period, was recorded to offset deferred tax assets. Management has based its assessment on the Company’s lack of profitable operating history. As of December 31, 2023 and 2022, the Company has approximately $37,661,876 and $28,577,832 respectively, of Federal net of operating losses available to reduce taxable income of future years. The federal loss carryforward expires indefinitely. The benefit from the non-capital loss carry-forward balance has not been recorded in the consolidated financial statements.

     

    The Company is subject to U.S. federal jurisdiction and the state of New Mexico income taxes. Management has not filed federal or state income tax returns due to incurring cumulative losses. Therefore, the Company’s actual tax position may differ from their book position. In the event that the Company is assessed interest or penalties at some point in the future, it will be classified in the consolidated financial statements as tax expense.

     
    XML 38 R21.htm IDEA: XBRL DOCUMENT v3.24.1.u1
    Related Party Transactions
    		 12 Months Ended
    Dec. 31, 2023
    Related Party Transactions [Abstract]  
    Related Party Transactions

    14. Related Party Transactions

     

    Other than the transactions disclosed elsewhere in the consolidated financial statements, the following are the other significant related party transactions and balances:

     

    Included in common stock issued for services during the year ended December 31, 2023, were 3,500,000 shares of common stock issued to the former Executive Chairman of the Company (Note 11).

     

    Included in common stock issued for services during the year ended December 31, 2023, were 500,000 shares of common stock issued to the former Chief Executive Officer of the Company (Note 11).

     

    Included in common stock issued for services during the year ended December 31, 2023, were 500,000 shares of common stock issued to the Chief Financial Officer of the Company (Note 11).

     

    Included in stock options issued for services during the year ended December 31, 2023, were 1,800,000 shares of stock options issued to three Directors of the Company (Notes 11 and 12).

     

    Included in stock-based awards granted during the year ended December 31, 2023, were 625,000 shares of stock options and 625,000 shares of RSUs issued to the Chief Executive Officer of the Company. On March 31, 2024, both the 625,000 shares of stock options and 625,000 shares of RSUs were canceled by mutual agreement between the Company and the Chief Executive Officer (Notes 12 and 16).

     

     

    BRIGHT GREEN CORPORATION

    Notes to the Consolidated Financial Statements

    For the Years Ended December 31, 2023 and 2022

    (Expressed in United States Dollars)

     

     

    14. Related Party Transactions (continued)

     

    At December 31, 2023 and 2022, $400,000 and $400,000, respectively, was due to the Company’s former interim Chief Executive Officer, who is also the Company’s former Executive Chairman. The amounts, which includes $200,000 and $300,000, respectively, in accrued bonus, is included in accrued liabilities in the consolidated balance sheet. On February 15, 2024, the Company issued 2,420,000 shares of common stock as a final settlement for the unpaid remuneration and bonus compensation (Notes 11 and 16).

     

    At December 31, 2023 and 2022, $23,460 and $nil, respectively, was due to a company majority owned by the Company’s former Chief Executive Officer. The amount is included in accounts payable in the consolidated balance sheets.

     

    At December 31, 2023 and 2022, $68,037 and $65,856, respectively, was due to a company wholly owned by the Company’s Chief Financial Officer, who also is a shareholder. The amount is included in accounts payable in the consolidated balance sheets.

     

    At December 31, 2023 and 2022, $66,667 and $nil, respectively, was due to a company wholly owned by the Company’s Chief Executive Officer. The amount is included in accounts payable in the consolidated balance sheets.

     

    At December 31, 2023 and 2022, $400,000 and $143,900, respectively, was due to a firm that has one of its partners serving on the Company’s Board of Directors. The amount is included in accounts payable in the consolidated balance sheets.

     

    At December 31, 2023 and 2022, the outstanding balance on the line of credit of $201,783 and $3,686,107, respectively, was due to a Lender, who is the Company’s Chairwoman and majority shareholder (Note 10).

     
    XML 39 R22.htm IDEA: XBRL DOCUMENT v3.24.1.u1
    Contingencies
    		 12 Months Ended
    Dec. 31, 2023
    Commitments and Contingencies Disclosure [Abstract]  
    Contingencies

    15. Contingencies

     

    In the ordinary course of business, the Company is routinely defendants in, or parties to a number of pending and threatened legal actions including actions brought on behalf of various classes of claimants. In view of the inherent difficulty of predicting the outcome of such matters, the Company cannot state what the eventual outcome of such matters will be. Legal provisions are established when it becomes probable that the Company will incur an expense related to a legal action and the amount can be reliably estimated. Such provisions are recorded at the best estimate of the amount required to settle any obligation related to these legal actions as at the consolidated balance sheet date, taking into account the risks and uncertainties surrounding the obligation. Management and internal and external experts are involved in estimating any amounts that may be required. The actual costs of resolving these claims may vary significantly from the amount of the legal provisions. The Company’s estimate involves significant judgement, given the varying stages of the proceedings, the fact that the Company’s liability, if any, has yet to be determined and the fact that the underlying matters will change from time to time. Other than as set forth below, the Company is not presently a party to any litigation. The Company is not able to make a reliable assessment of the potential losses as these matters are at an early stage, accordingly, no amounts have been accrued in the consolidated financial statements.

     

     

    BRIGHT GREEN CORPORATION

    Notes to the Consolidated Financial Statements

    For the Years Ended December 31, 2023 and 2022

    (Expressed in United States Dollars)

     

     

    15. Contingencies (continued)

     

    Bright Green Corporation v. John Fikany, State of New Mexico, County of Cibola, Thirteenth Judicial District. In this matter, the Company filed a complaint for declaratory judgment against a consultant of the Bright Green Group of Companies, an entity unrelated to the Company, to determine if defendant is entitled to 5,000,000 shares of the Company’s common stock, based on a failure to fulfill agreed upon conditions precedent to earning such shares from the Company. Defendant counterclaimed and filed a third-party claim against a director of the Company, and her spouse, for claims including wrongful termination and breach of contract. The Company denies defendants allegations and have set forth arguments refuting defendant’s counterclaims and third-party claims. The trial date for the case has been scheduled for April 22, 2024.

     

    Bright Green Corporation v. Jerry Capussi, State of New Mexico, County of Cibola, Thirteenth Judicial District. In this matter, the Company and defendant, a former consultant of Sunnyland Farms Inc., an entity unrelated to the Company, have each filed claims for declaratory judgment seeking to determine by court order whether defendant is entitled to (i) shares of common stock in the Company (amounting to no more than 108,000 shares) or (ii) fair market value of defendant’s equity ownership of BGGI. The lawsuit is in early discovery stages, and the Company is preparing arguments for a summary judgment motion. There are no claims for specific monetary liability against either party.

     
    XML 40 R23.htm IDEA: XBRL DOCUMENT v3.24.1.u1
    Subsequent Events
    		 12 Months Ended
    Dec. 31, 2023
    Subsequent Events [Abstract]  
    Subsequent Events

    16. Subsequent Events

     

    The Company’s management has evaluated the subsequent events up to April 16, 2024. The date the consolidated financial statements were issued, pursuant to the requirements of ASC 855, and has determined the following constitute material subsequent events:

     

    On January 19, 2024, the Company reached an agreement with a vendor to cancel approximately $2,650,000 of construction in progress. As part of the agreement, the vendor also agreed to cancel the related accounts payable and completion of the project (Note 7).

     

    On January 30, 2024, the Company issued 450,000 shares of common stock for services rendered, at a fair value of $0.2116 per share, to four consultants of the Company.

     

    On February 7, 2024, the Company entered into a short-term note with 1401330 Ontario Ltd. (the “Bridge Lender”), a Company owned and controlled by a member of the Board of Directors, for $150,000. Additionally, the Company agreed to pay the Bridge Lender $15,000 as interest. The note is personally guaranteed by the Company’s Chairwoman.

     

    On February 8, 2024, the Company drew an additional $100,000 on the related party line of credit note.

     

     

    BRIGHT GREEN CORPORATION

    Notes to the Consolidated Financial Statements

    For the Years Ended December 31, 2023 and 2022

    (Expressed in United States Dollars)

     

     

    16.Subsequent Events (continued)

     

    On February 15, 2024, Mr. Terry Rafih, the former Executive Chairman, resigned. Mr. Rafih and the Company entered into a Memorandum of Understanding (the “Separation Agreement”). The Separation Agreement provided that the Company (i) issue to Mr. Rafih 2,537,500 shares of the Company’s common stock, representing the acceleration of the vesting of the balance of shares of common stock issuable pursuant to a one-time award of 10 million shares of common stock approved by the stockholders of the Company at the 2022 Special Meeting of Stockholders, and (ii) further issue to Mr. Rafih 2,420,000 shares of common stock, in lieu of an aggregate of $450,000 of unpaid cash renumeration and bonus compensation during his tenure with the Company. The 4,957,000 shares of common stock were issued on February 15, 2024.

     

    On March 7, 2024, the Company entered into a scope of work agreement with Titan Advisory Services, LLC, a limited liability company controlled by Saleem Elmasri, Chief Financial Officer of the Company, through which Mr. Elmasri provides services to the Company (the “CFO Agreement”). The CFO Agreement is effective as of March 1, 2024. Pursuant to the CFO Agreement, Mr. Elmasri shall continue to act as Chief Financial Officer of the Company through February 28, 2025, and provides Mr. Elmasri with a $25,000 monthly cash fee, and 600,000 restricted stock units, which were issued on March 7, 2024 and vest in equal monthly installments over a period of one year beginning one month from the date of grant.

     

    On March 13, 2024, the Company entered into and signed a Settlement and Release Agreement  with United Science, LLC (“United”) and Alterola, in which a deposit made to United was forfeited, leased equipment was returned to United, 118,535,168 shares of common stock of Alterola was transferred to United in lieu of payment of outstanding invoices, and 83,226,820 shares of common stock of Alterola was returned to the three shareholders (Equipped4 Holdings Limited (“Equipped”), Phytotherapeutix Holdings Ltd. (“Phyto”), and TPR Global Limited (“TPR”)) who initially sold the shares to the Company for settlement of the $1,650,000 outstanding balance on the share purchase. Equipped, Phyto, and TPR each received 27,742,273 shares of common stock of Alterola

     

    On March 14, 2024, the Company entered into a credit agreement with JVR Holdings, pursuant to which JVR Holdings agreed to provide the Company with a line of credit facility up to a maximum amount of $60 million, to be drawn in tranches. The line of credit is contingent on the Company formalizing a JVR Holdings approved plan for a construction project to expand the Company’s current research, production and extraction processing facility Grants, New Mexico.

     

    On March 25, 2024, the Company drew an additional $10,000 on the related party line of credit note.

     

    On March 31, 2024, the Company entered into an Amended Executive Employment Agreement with the Company’s Chief Executive Officer (the “CEO”), which replaced in its entirety the executive employment agreement entered into between the Company and the CEO on October 2, 2023. The Agreement provides the CEO a monthly base salary of $35,833.33 through October 2, 2024, a monthly base salary of $38,333.00 from October 2, 2024 to October 2, 2025, and a monthly base salary of $41,667.00 from October 2, 2025 to October 2, 2026. The agreement provides for customary reimbursement for certain expenses, and eligibility to participate in the Company’s benefit plans and executive compensation programs generally. Additionally, the 625,000 shares of stock options and 625,000 shares of RSUs that were issued in September 2023, under the original Executive Employment Agreement, were canceled and replaced with 5,500,000 RSUs. The Agreement provides for the award of up to an aggregate of 5,500,000 restricted stock units, which vest in accordance with the terms provided in the Agreement, with 500,000 RSUs vested on March 31, 2024, 3,000,000 RSUs vesting ratably over a period of twenty-four 24 months beginning April 2, 2024, and the remaining 2,000,000 RSUs, along with cash bonuses, vesting upon the achievement of certain milestones as outlined in the Amended Executive Employment Agreement.

     

    On April 5, 2024, the Company drew an additional $20,000 on the related party line of credit note.

     

    On April 9, 2024, the Company drew an additional $40,000 on the related party line of credit note, leaving available $14.6 million to draw from that credit facility.
    XML 41 R24.htm IDEA: XBRL DOCUMENT v3.24.1.u1
    Summary of Significant Accounting Policies (Policies)
    		 12 Months Ended
    Dec. 31, 2023
    Accounting Policies [Abstract]  
    Basis of Measurement

    A. Basis of Measurement

     

    The consolidated financial statements of the Company have been prepared on a historical cost basis except as indicated otherwise.

     
    Principles of Consolidation

    B. Principles of Consolidation

     

    The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, Regional Center Bright Green, LLC. Intercompany transactions and balances have been eliminated upon consolidation.

     

     

    BRIGHT GREEN CORPORATION

    Notes to the Consolidated Financial Statements

    For the Years Ended December 31, 2023 and 2022

    (Expressed in United States Dollars)

     

     

    3. Summary of Significant Accounting Policies (continued)

     
    Property, Plant, and Equipment

    C. Property, Plant, and Equipment

     

    Property, plant, and equipment are stated at cost less accumulated depreciation. Expenditures for maintenance and repairs are charged to earnings as incurred; additions, renewals, and betterments are capitalized. When property, plant, and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of property, plant, and equipment, except land, which is not depreciated, is provided using the declining balance method, or straight-line method, with estimated lives as follows:

     

    Building and improvement - declining balance method 10 year life
    Furniture and fixtures - straight-line method 3 year life

     

    Construction in progress is not depreciated until the asset is placed in service.

     
    Long-lived Assets

    D. Long-lived Assets

     

    The Company applies the provisions of ASC Topic 360, Property, Plant, and Equipment, which addresses financial accounting and reporting for the impairment or disposal of long-lived assets. ASC Topic 360 requires that long-lived assets be reviewed annually for impairment whenever events or changes in circumstances indicate that the assets’ carrying amounts may not be recoverable; it further requires impairment losses to be recorded on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair value of the long-lived assets. Loss on long-lived assets to be disposed of is determined in a similar manner, except that fair values are reduced for the cost of disposal.

     
    Intangible Assets

    E. Intangible Assets

     

    The Company’s intangible assets consist of certain licenses which will be amortized over the term of each license (Note 8). The intangible assets with finite useful lives are reviewed for impairment when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair value of the long-lived assets.

     

     

    BRIGHT GREEN CORPORATION

    Notes to the Consolidated Financial Statements

    For the Years Ended December 31, 2023 and 2022

    (Expressed in United States Dollars)

     

     

    3. Summary of Significant Accounting Policies (continued)

     
    Fair Value of Financial Instruments

    F. Fair Value of Financial Instruments

     

    In accordance with ASC 820 (Topic 820, Fair Value Measurements and Disclosures), the Company uses a three-level hierarchy for fair value measurements of certain assets and liabilities for financial reporting purposes that distinguishes between market participant assumptions developed from market data obtained from outside sources (observable inputs) and our own assumptions about market participant assumptions developed from the best information available to us in the circumstances (unobservable inputs). The fair value hierarchy is divided into three levels based on the source of inputs as follows:

     

      ●

    Level 1 – inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets;

         
      ●

    Level 2 – inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability other than quoted prices, either directly or indirectly including inputs in markets that are not considered to be active; and

         
      ● Level 3 – inputs to the valuation methodology are unobservable and significant to the fair value measurement.

     

    Categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The carrying amounts of the Company’s cash, other assets, accounts payable, accrued liabilities, due to others, and due to related party approximated their fair values as of December 31, 2023 and 2022 due to their short-term nature. The Company’s Alterola investment is also accounted for at fair value and recorded in Other investment held at fair value on the consolidated balance sheets. In accordance with the levels defined above, Level 1, the fair value of the Company’s Alterola investment was $726,343 as of December 31, 2023.

     
    Investment Under the Equity Method

    G. Investment Under the Equity Method

     

    When the Company does not have a controlling financial interest in an entity but can exert significant influence over the entity’s operating and financial policies, the investment is accounted for either (i) under the equity method of accounting or (ii) at fair value by electing the fair value option available under U.S. generally accepted accounting principles (“GAAP”). Significant influence generally exists when the Company owns 20% to 50% of the entity’s common stock or in-substance common stock. In addition, the Company may recognize its share of an investee’s earnings based on an estimated amount for the investee’s earnings when the investee’s financial information is not sufficiently timely for the Company’s reporting period.

     

     

    BRIGHT GREEN CORPORATION

    Notes to the Consolidated Financial Statements

    For the Years Ended December 31, 2023 and 2022

    (Expressed in United States Dollars)

     

     

    3. Summary of Significant Accounting Policies (continued)

     

    G. Investment Under the Equity Method (continued)

     

    Under the equity method of accounting, the investment is initially recorded at cost, including transaction costs incurred to acquire the investment, and thereafter adjusted for additional investments, distributions, and the proportionate share of earnings or losses of the investee. The Company’s equity method investment is reviewed for impairment whenever events or changes in circumstances indicate that an other-than-temporary decline in value may have occurred. If it is determined that a loss in value of the equity method investment is other than temporary, an impairment loss is measured based on the excess of the carrying amount of an investment over its estimated fair value. Impairment analyses are based on current plans, intended holding periods, and available information at the time the analysis is prepared.

     

    Derivative Financial Instruments

     

    The Company evaluates all its financial instruments to determine if such instruments contain features that qualify as embedded derivatives. Embedded derivatives must be separately measured from the host contract if all the requirements for bifurcation are met. The assessment of the conditions surrounding the bifurcation of embedded derivatives depends on the nature of the host contract. Bifurcated embedded derivatives are recognized at fair value, with changes in fair value recognized in the consolidated statement of operations and comprehensive loss each period. Bifurcated embedded derivatives are classified with the related host contract in the Company’s consolidated balance sheets.

     
    Other Investment Held at Fair Value

    H. Other Investment Held at Fair Value

     

    In accordance with ASC 825, the Company records its investment at fair value under the Other investment held at fair value in the Company’s consolidated balance sheets and changes in fair value are recognized as Change in fair value of assets, net, a component of Other expense in the consolidated statements of operations and comprehensive loss.

     

    At the most recent remeasurement date, the Company evaluated its ability to continue to exercise significant influence over its investment and determined that it no longer had significant influence. The Company’s Alterola investment is accounted for at fair value under ASC 321 and recorded in Other investment held at fair value on the consolidated balance sheets and changes in fair value are recognized as Change in fair value of assets, a component of Other expense, net in the consolidated statements of operations and comprehensive loss (Note 6).

     
    Advertising Costs

    I. Advertising Costs

     

    Advertising costs are charged to operations when incurred. Advertising costs totaled $43,867 and $78,193 for the year ended December 31, 2023 and 2022, respectively.

     
    Income Taxes

    J. Income Taxes

     

    The Company accounts for income taxes in accordance with ASC Topic 740, Income Taxes. ASC 740 requires a company to use the asset and liability method of accounting for income taxes, whereby deferred tax assets are recognized for deductible temporary differences, and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized.

     

     

    BRIGHT GREEN CORPORATION

    Notes to the Consolidated Financial Statements

    For the Years Ended December 31, 2023 and 2022

    (Expressed in United States Dollars)

     

     

    3. Summary of Significant Accounting Policies (continued)

     

    J. Income Taxes (continued)

     

    Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment. The Company has not changed its methodology for estimating the valuation allowance. A change in valuation allowance affects earnings in the period the adjustments are made and could be significant due to the large valuation allowance currently established.

     

    Under ASC 740, a tax position is recognized as a benefit only if it is “more likely than not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that is greater than 50% likely to be realized on examination. For tax positions not meeting the “more likely than not” test, no tax benefit is recorded. The Company has no material uncertain tax positions for any of the reporting periods presented (Note 13).

     
    Basic and Diluted Earnings (Loss) Per Share

    K. Basic and Diluted Earnings (Loss) Per Share

     

    Basic earnings (loss) per share is calculated using the weighted average number of common shares outstanding during the period. The dilutive effect on earnings (loss) per share is calculated, presuming the exercise of outstanding stock options, warrants, and similar instruments. It assumes that the proceeds of such exercise would be used to repurchase common shares at the average market price during the period.

     

    For the years ended December 31, 2023, and 2022, all outstanding stock options, warrants, and similar instruments were excluded from the computation of diluted net loss per share, because the exercise price of these instruments exceeded the average market price of the Company’s common stock, making them anti-dilutive.

     
    Segment Reporting

    L. Segment Reporting

     

    ASC 280-10, “Disclosures about Segments of an Enterprise and Related Information”, establishes standards for how public business enterprises report information about operating segments in the Company’s consolidated financial statements. Operating segments are components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision-maker in deciding how to allocate resources and in assessing performance. Significantly all of the assets of the Company are located in the United States of America and the Company is a start-up company as at December 31, 2023 and 2022 and has no revenue. The Company’s reportable segments and operating segments will include its growth, production, and research of medicinal plants operations.

     

     

    BRIGHT GREEN CORPORATION

    Notes to the Consolidated Financial Statements

    For the Years Ended December 31, 2023 and 2022

    (Expressed in United States Dollars)

     

     

    3. Summary of Significant Accounting Policies (continued)

     
    Use of Estimates

    M. Use of Estimates

     

    The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions. The Company bases its estimates and assumptions on current facts, historical experience, various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities, and the accrual of costs and expenses that are not readily apparent from other sources. This applies in particular to valuation allowance for deferred tax assets, valuation of warrants, stock options, stock-based compensation, going concern assessment, impairment of non-current assets, and assignment of the useful lives of property, plant, and equipment. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.

     
    Stock-Based Compensation

    N. Stock-Based Compensation

     

    The Company accounts for stock-based payments in accordance with the provision of ASC 718, which requires that all stock-based payments issued to acquire goods or services, including grants of employee stock options, be recognized in the consolidated statements of operations and comprehensive loss based on their fair values, net of estimated forfeitures. ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Compensation expense related to stock-based awards is recognized over the requisite service period, which is generally the vesting period.

     

    The Company accounts for stock-based compensation awards issued to non-employees for services, as prescribed by ASC 718-10, at either the fair value of the services rendered or the instruments issued in exchange for such services, whichever is more readily determinable, using the guidelines in ASC 505-50. The Company issues compensatory shares for services including, but not limited to, executive management, management, accounting, operations, corporate communication, and financial and administrative consulting services.

     
    Warrants

    O. Warrants

     

    The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in FASB, ASC 480 and ASC 815. The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own ordinary shares and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance, and each consolidated balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the consolidated statements of operations and comprehensive loss.

     

     

    BRIGHT GREEN CORPORATION

    Notes to the Consolidated Financial Statements

    For the Years Ended December 31, 2023 and 2022

    (Expressed in United States Dollars)

     

     

    3. Summary of Significant Accounting Policies (continued)

     
    Recently Adopted Accounting Standards

    P. Recently Adopted Accounting Standards

     

    In February 2016, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2016-02, “Leases (Topic 842)”, which establishes a right-of-use (ROU) model that requires a lessee to record an ROU asset and a lease liability on the statement of financial position for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the statement of activities. The new standard became effective for public business entities on January 1, 2019, with early adoption permitted. The new standard became effective for the Company on May 17, 2022, the date the Company became a public entity. The Company adopted this accounting policy as of May 17, 2022. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. While the Company continues to evaluate certain aspects of the new standard, including those still being revised by the FASB, the new standard does not have a material effect on the Company’s consolidated financial statements. As of December 31, 2023, the Company has one month to month lease, whereas the new standard does not apply.

     

    In October 2023, the FASB issued ASU No. 2023-06, Disclosure Improvements: Codification Amendments in Response to the SEC’s Disclosure Update and Simplification Initiative. The amendments in this update modify the disclosure or presentation requirements of a variety of topics in the codification. Certain amendments represent clarifications to or technical corrections of the current requirements. Each amendment in the ASU will only become effective if the SEC removes the related disclosure or presentation requirement from its existing regulations by June 30, 2027. The Company is currently assessing the impact this standard will have on the Company’s future consolidated financial statements.

     

     

    BRIGHT GREEN CORPORATION

    Notes to the Consolidated Financial Statements

    For the Years Ended December 31, 2023 and 2022

    (Expressed in United States Dollars)

     

     

    3. Summary of Significant Accounting Policies (continued)

     
    Recently Issued but Not Adopted Accounting Standards

    Q. Recently Issued but Not Adopted Accounting Standards

     

    In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The amendments in ASU 2023-07 are intended to enhance disclosures for significant segment expenses for all public entities required to report segment information in accordance with ASC 280. ASC 280 requires a public entity to report for each reportable segment a measure of segment profit or loss that its chief operating decision maker (“CODM”) uses to assess segment performance and to make decisions about resource allocations. The amendments in ASU 2023-07 improve financial reporting by requiring disclosure of incremental segment information on an annual and interim basis for all public entities to enable investors to develop more useful financial analyses. Currently, Topic 280 requires that a public entity disclose certain information about its reportable segments. For example, a public entity is required to report a measure of segment profit or loss that the CODM uses to assess segment performance and make decisions about allocating resources. ASC 280 also requires other specified segment items and amounts, such as depreciation, amortization, and depletion expense, to be disclosed under certain circumstances. The amendments in ASU 2023-07 do not change or remove those disclosure requirements. The amendments in ASU 2023-07 also do not change how a public entity identifies its operating segments, aggregates those operating segments, or applies the quantitative thresholds to determine its reportable segments. The amendments in ASU 2023-07 are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. A public entity should apply the amendments in ASU 2023-07 retrospectively to all prior periods presented in the financial statements. The Company is currently assessing the impact this standard will have on the Company’s future consolidated financial statements.

     

    In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The amendments in ASU 2023-07 are intended to enhance the transparency and decision usefulness of income tax disclosures. The amendments in ASU 2023-09 require annual disclosures of specific categories in the rate reconciliation, additional information for reconciling items that meet a quantitative threshold, and a disaggregation of income taxes paid, net of refunds. The amendments in ASU 2023-09 also eliminate certain existing disclosure requirements related to uncertain tax positions and unrecognized deferred tax liabilities. The amendments in ASU 2023-09 are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The amendments in ASU 2023-09 should be applied prospectively. The Company is currently assessing the impact this standard will have on the Company’s future consolidated financial statements.

     

    Management does not believe that other recently issued, but not yet effective, accounting standards could have a material effect on the Company’s consolidated financial statements. As new accounting pronouncements are issued, the Company will adopt those that are applicable under the circumstances.
    XML 42 R25.htm IDEA: XBRL DOCUMENT v3.24.1.u1
    Summary of Significant Accounting Policies (Tables)
    		 12 Months Ended
    Dec. 31, 2023
    Accounting Policies [Abstract]  
    Summary of Estimated Useful Life

    Building and improvement - declining balance method 10 year life
    Furniture and fixtures - straight-line method 3 year life
    XML 43 R26.htm IDEA: XBRL DOCUMENT v3.24.1.u1
    Equity Method Investment in Alterola (Tables)
    		 12 Months Ended
    Dec. 31, 2023
    Investments, All Other Investments [Abstract]  
    Schedule of Financial Statement Information

    The following table provides summarized balance sheet information for Alterola as of September 30, 2023 and December 31, 2022:

     

       September 30, 2023   December 31, 2022 
    Current assets  $197,208   $192,011 
    Non-current assets   300,000    12,018,147 
    Current liabilities   2,519,231    1,822,696 
    Non-current liabilities   -    151,255 
    Equity (Deficit)  $(2,022,023)  $10,236,207 

     

    The following table provides summarized income statement information for Alterola for the nine months ended September 30, 2023 and the year ended December 31, 2022:

     

             
       Nine Months Ended   Year Ended 
       September 30, 2023   December 31, 2022 
    Total revenues  $-   $- 
    Net loss  $874,653   $4,980,510 
    Schedule of Equity Method Investment in Alterola

    The following table summarizes the activity of the Company’s equity method investment in Alterola:

     

     

       Equity Method 
       Investment in Alterola 
    Balance at December 31, 2021  $- 
    Company’s initial investment in Alterola   4,126,115 
    Company’s 25% share in net loss recognized in 2022   (135,155)
    Balance at December 31, 2022   3,990,960 
    Company’s 25% share in net loss recognized through October 16, 2023   (218,663)
    Change in fair value of assets   (3,045,954)
    Balance at December 31, 2023  $726,343 

     
    XML 44 R27.htm IDEA: XBRL DOCUMENT v3.24.1.u1
    Property, Plant, and Equipment (Tables)
    		 12 Months Ended
    Dec. 31, 2023
    Property, Plant and Equipment [Abstract]  
    Schedule of Property Plant and Equipment

    Property, plant, and equipment at December 31, 2023 and 2022, consisted of the following:

     

       December 31, 2023   December 31, 2022 
    Furniture and fixtures  $88,690   $88,690 
    Land   260,000    260,000 
    Construction in progress   10,635,866    10,736,269 
    Building and improvements   8,883,851    8,883,851 
    Property, plant and equipment gross   19,868,407    19,968,810 
    Accumulated depreciation   (3,460,992)   (2,822,485)
    Net property, plant, and equipment  $16,407,415   $17,146,325 
    XML 45 R28.htm IDEA: XBRL DOCUMENT v3.24.1.u1
    Intangible Assets (Tables)
    		 12 Months Ended
    Dec. 31, 2023
    Goodwill and Intangible Assets Disclosure [Abstract]  
    Schedule of Intangible Assets

    Intangible assets at December 31, 2023 and 2022, consisted of the following:

     

       December 31, 2023   December 31, 2022 
    Licenses  $1,000   $1,000 
    Accumulated amortization   -    - 
    Net intangible assets  $1,000   $1,000 
    XML 46 R29.htm IDEA: XBRL DOCUMENT v3.24.1.u1
    Stock-Based Compensation (Tables)
    		 12 Months Ended
    Dec. 31, 2023
    Retirement Benefits [Abstract]  
    Schedule of Fair Value of The Stock Options

    The fair value of the stock options was estimated using the following assumptions:

    Schedule of Fair Value of The Stock Options 

       2023   2022 
    Weighted average fair value at grant date  $0.3303   $- 
    Valuation assumptions:          
    Expected life of options (years)   5.00    - 
    Expected stock volatility   213.90%   - 
    Risk-free interest rate   4.42%   - 
    Expected dividend yield   0.00%   - 
    Schedule of Summarizes Stock Option Activity

    The following table summarizes stock option activity for the year ended December 31, 2023:

     

       Stock Options Outstanding & Exercisable 
               Weighted Average 
       Number of   Weighted Average   Remaining Life 
       Stock Options   Exercise Price   (Years) 
    Balance, December 31, 2022   -   $-      
    Granted   2,425,000    0.3353      
    Exercised   -    -      
    Expired   -    -      
    Balance, December 31, 2023   2,425,000   $0.3353    9.90 
    XML 47 R30.htm IDEA: XBRL DOCUMENT v3.24.1.u1
    Income Taxes (Tables)
    		 12 Months Ended
    Dec. 31, 2023
    Income Tax Disclosure [Abstract]  
    Schedule of Income Tax Provision

     

     

       2023   2022 
               
    Loss before income taxes  $(13,127,648)  $(27,662,077)

     

    The (benefit) provision for income taxes for 2023 and 2022 consists of the following:

     

       2023   2022 
    Current:          
    Federal   -    - 
    State   -    - 
    Total current (benefit) provision   -    - 
               
    Deferred:          
    Federal   (2,520,309)   (5,727,839)
    State   (576,071)   (1,309,220)
    Total current (benefit) provision   (3,096,380)   (7,037,059)
    Valuation allowance   3,096,380    7,037,059 
    Total (benefit) expense  $-   $- 
    Schedule of Federal and State Tax Effects of Temporary Differences and Carryforwards

    The federal and state tax effects of the temporary differences and carry forwards that give rise to deferred tax assets consists of the following:

     

       2023   2022 
    Other   1,401,963    728,201 
    Net operating loss carry over   9,716,764    7,294,146 
    Total deferred tax assets   11,118,727    8,022,347 
    Less: valuation allowance   (11,118,727)   (8,022,347)
    Deferred tax assets, net of valuation allowance  $-   $- 
    XML 48 R31.htm IDEA: XBRL DOCUMENT v3.24.1.u1
    Description of Business and Organization (Details Narrative) - USD ($)
    		 1 Months Ended 12 Months Ended
    May 21, 2023
    Feb. 01, 2023
    May 31, 2023
    Dec. 31, 2023
    Dec. 31, 2022
    Sep. 30, 2023
    Aug. 31, 2023
    Sep. 07, 2022
    Apr. 30, 2022
    Date of incorporation       Apr. 16, 2019          
    Shares issued price per share             $ 3.00    
    Common stock, par value       $ 0.0001 $ 0.0001   0.0001    
    Exercise price             $ 0.13    
    Revenue       $ 0          
    Common Stock [Member]                  
    Aggregate shares of common stock issued       22,005 312,500        
    Exercise price           $ 3.00      
    Common Stock [Member] | Accredited Investor and Existing Stockholder [Member]                  
    Number of shares sold 3,684,210                
    Common stock, par value $ 0.0001                
    Private Placement [Member]                  
    Aggregate shares of common stock issued     3,684,210            
    Shares issued price per share   $ 39.99              
    Warrants to purchase shares     3,684,210         9,523,810  
    Exercise price               $ 1.05  
    Private Placement [Member] | Accredited Investor and Existing Stockholder [Member]                  
    Warrants to purchase shares 3,684,210                
    Exercise price $ 0.95                
    Private Placement [Member] | Common Stock [Member]                  
    Shares issued price per share                 $ 4.00
    Private Placement [Member] | Maximum [Member]                  
    Aggregate shares of common stock issued   12,609,152              
    XML 49 R32.htm IDEA: XBRL DOCUMENT v3.24.1.u1
    Going Concern and Basis of Presentation (Details Narrative) - USD ($)
    		 1 Months Ended 12 Months Ended
    Aug. 31, 2023
    Feb. 06, 2023
    Sep. 30, 2023
    Feb. 28, 2023
    Dec. 31, 2023
    Dec. 31, 2022
    Dec. 01, 2023
    Defined Benefit Plan Disclosure [Line Items]              
    Net Income (Loss) Attributable to Parent         $ 13,127,648 $ 27,662,077  
    Net Cash Provided by (Used in) Operating Activities         2,455,612 2,265,770  
    Retained Earnings (Accumulated Deficit)         47,203,469 34,075,821  
    Working capital deficit         5,968,030 7,030,929  
    Warrants to purchase common stock         3,104,750 9,136,733  
    Issuances of common stock $ 2,827,960       880,000 3,050,000  
    Exercise of warrants         210,000  
    Related party line of credit         400,000    
    Related party line of credit paid down $ 3,619,789       15,000,000    
    Related party loan balance         392,194    
    Line of credit paid down   $ 880,000   $ 880,000 $ 880,000    
    Line of credit paid down in exchange of shares 2,827,960 22,005 2,827,960   22,005    
    Common stock value per share $ 1.15 $ 39.99     $ 39.99    
    Related party line of credit paid down in exchange of shares         2,827,960    
    Credit facility         $ 14,800,000   $ 14,800,000
    Related Party [Member]              
    Defined Benefit Plan Disclosure [Line Items]              
    Related party line of credit paid down         $ 3,619,789    
    XML 50 R33.htm IDEA: XBRL DOCUMENT v3.24.1.u1
    Summary of Estimated Useful Life (Details)
    Dec. 31, 2023
    Building and Building Improvements [Member]  
    Property, Plant and Equipment [Line Items]  
    Estimated useful life 10 years
    Furniture and Fixtures [Member]  
    Property, Plant and Equipment [Line Items]  
    Estimated useful life 3 years
    XML 51 R34.htm IDEA: XBRL DOCUMENT v3.24.1.u1
    Summary of Significant Accounting Policies (Details Narrative) - USD ($)
    		 12 Months Ended
    Dec. 31, 2023
    Dec. 31, 2022
    Property, Plant and Equipment [Line Items]    
    Investments $ 726,343  
    Advertising cost $ 43,867 $ 78,193
    Income tax examination, description The amount recognized is the largest amount of tax benefit that is greater than 50% likely to be realized on examination.  
    Minimum [Member]    
    Property, Plant and Equipment [Line Items]    
    Percentage of entity common stock 20.00%  
    Maximum [Member]    
    Property, Plant and Equipment [Line Items]    
    Percentage of entity common stock 50.00%  
    XML 52 R35.htm IDEA: XBRL DOCUMENT v3.24.1.u1
    Concentration of Credit Risk (Details Narrative) - USD ($)
    Dec. 31, 2023
    Dec. 31, 2022
    Risks and Uncertainties [Abstract]    
    Cash FDIC insured amount $ 250,000  
    Excess of FDIC insured limit $ 0 $ 187,821
    XML 53 R36.htm IDEA: XBRL DOCUMENT v3.24.1.u1
    Deposits (Details Narrative)
    Mar. 13, 2024
    shares
    Settlement And Release Agreement [Member] | Subsequent Event [Member]  
    Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]  
    Number of shares forfeited 118,535,168
    XML 54 R37.htm IDEA: XBRL DOCUMENT v3.24.1.u1
    Schedule of Financial Statement Information (Details) - USD ($)
    		 9 Months Ended 12 Months Ended
    Sep. 30, 2023
    Dec. 31, 2023
    Dec. 31, 2022
    Dec. 31, 2021
    Current assets   $ 268,289 $ 492,421  
    Current liabilities   6,236,319 7,523,350  
    Non-current liabilities   201,783 3,686,107  
    Equity (Deficit)   10,964,945 11,578,836 $ 8,220,399
    Total revenues    
    Net loss   $ (13,127,648) (27,662,077)  
    Alterola Biotech, Inc. [Member]        
    Current assets $ 197,208   192,011  
    Non-current assets 300,000   12,018,147  
    Current liabilities 2,519,231   1,822,696  
    Non-current liabilities   151,255  
    Equity (Deficit) (2,022,023)   10,236,207  
    Total revenues    
    Net loss $ 874,653   $ 4,980,510  
    XML 55 R38.htm IDEA: XBRL DOCUMENT v3.24.1.u1
    Schedule of Equity Method Investment in Alterola (Details) - USD ($)
    		 12 Months Ended
    Dec. 31, 2023
    Dec. 31, 2022
    Balance at December 31, 2022 $ 3,990,960  
    Change in fair value of assets (3,045,954)
    Balance at December 31, 2023 3,990,960
    Alterola Biotech, Inc. [Member]    
    Balance at December 31, 2022 3,990,960
    Company’s initial investment in Alterola   4,126,115
    Company’s 25% share in net loss (218,663) (135,155)
    Change in fair value of assets (3,045,954)  
    Balance at December 31, 2023 $ 726,343 $ 3,990,960
    XML 56 R39.htm IDEA: XBRL DOCUMENT v3.24.1.u1
    Equity Method Investment in Alterola (Details Narrative) - USD ($)
    		 12 Months Ended
    Mar. 13, 2024
    Oct. 03, 2022
    Dec. 31, 2023
    Dec. 31, 2022
    Aug. 31, 2023
    Dec. 31, 2021
    Common stock, shares authorized     500,000,000 500,000,000    
    Common stock, par value     $ 0.0001 $ 0.0001 $ 0.0001  
    Common stock, shares outstanding     184,758,818 173,304,800    
    Dividend rate     0.00%    
    Rist free rate     4.42%    
    Expected term     5 years    
    Volatility rate     213.90%    
    Noncontrolling interest equity in net losses of affiliate     $ 218,663 $ 135,155    
    Equity method investments     3,990,960    
    Investments     726,343      
    Change in fair value of assets and liabilities net     3,045,954    
    Voting Agreement [Member]            
    Number of shares sold, value     $ 3,999,999      
    Dividend rate     0.00%      
    Rist free rate     4.00%      
    Expected term     6 months      
    Volatility rate     66.00%      
    Stock price     $ 26,400,000      
    Control premium percentage     65.00%      
    Control premium     $ 10,400,000      
    Stock price     $ 61,300,000      
    Outstaanding common shares percentage     75.00%      
    Oustanding common shares value     $ 46,000,000.0      
    Fair value of agreement     213,000      
    Sellers [Member]            
    Liability to the sellers     $ 1,650,000 1,650,000    
    Alterola Biotech, Inc. [Member]            
    Common stock, shares authorized   2,000,000,000        
    Common stock, par value   $ 0.001        
    Common stock, shares outstanding   807,047,948        
    Ownership percentage   25.00% 25.00%      
    Equity method investments     $ 726,343 $ 3,990,960  
    Change in fair value of assets and liabilities net     $ 3,045,954      
    Alterola Biotech, Inc. [Member] | Sellers [Member]            
    Ownership percentage   67.00%        
    Sellers transferred shares   201,761,982        
    Number of shares sold, value   $ 3,999,999        
    Alterola Biotech, Inc. [Member] | Sellers [Member] | Subsequent Event [Member]            
    Number of shares transferred 27,742,273          
    XML 57 R40.htm IDEA: XBRL DOCUMENT v3.24.1.u1
    Schedule of Property Plant and Equipment (Details) - USD ($)
    Dec. 31, 2023
    Dec. 31, 2022
    Property, Plant and Equipment [Abstract]    
    Furniture and fixtures $ 88,690 $ 88,690
    Land 260,000 260,000
    Construction in progress 10,635,866 10,736,269
    Building and improvements 8,883,851 8,883,851
    Property, plant and equipment gross 19,868,407 19,968,810
    Accumulated depreciation (3,460,992) (2,822,485)
    Net property, plant, and equipment $ 16,407,415 $ 17,146,325
    XML 58 R41.htm IDEA: XBRL DOCUMENT v3.24.1.u1
    Property, Plant, and Equipment (Details Narrative)
    		 6 Months Ended 9 Months Ended 12 Months Ended
    Jan. 19, 2024
    USD ($)
    Jan. 01, 2022
    USD ($)
    a
    Oct. 21, 2020
    Oct. 05, 2020
    Dec. 31, 2021
    USD ($)
    Jun. 30, 2021
    USD ($)
    Dec. 31, 2021
    USD ($)
    Dec. 31, 2023
    USD ($)
    a
    Dec. 31, 2022
    USD ($)
    a
    Grant Greenhouse GrowersInc [Member] | Real Estate Option Agreement One [Member]                  
    Property, Plant and Equipment [Line Items]                  
    Area of land for purchase | a   330              
    Expiration date       Dec. 31, 2021          
    Monthly payments   $ 2,000       $ 1,500      
    Monthly payments for land         $ 1,750        
    Expense made   $ 5,000              
    Grant Greenhouse GrowersInc [Member] | Real Estate Option Agreement Two [Member]                  
    Property, Plant and Equipment [Line Items]                  
    Area of land for purchase | a   175              
    Expiration date     Dec. 31, 2021            
    Monthly payments   $ 1,500              
    Monthly payments for land             $ 1,000    
    Expense made   $ 5,000              
    Subsequent Event [Member]                  
    Property, Plant and Equipment [Line Items]                  
    Agreement with vendor to cancel $ 2,650,000                
    New Mexico [Member]                  
    Property, Plant and Equipment [Line Items]                  
    Area of land for purchase | a                 70
    Venlo Style Green House [Member] | New Mexico [Member]                  
    Property, Plant and Equipment [Line Items]                  
    Area of land for purchase | a               22  
    Construction in Progress [Member]                  
    Property, Plant and Equipment [Line Items]                  
    Interest costs capitalized               $ 223,271 $ 106,117
    XML 59 R42.htm IDEA: XBRL DOCUMENT v3.24.1.u1
    Schedule of Intangible Assets (Details) - USD ($)
    Dec. 31, 2023
    Dec. 31, 2022
    Goodwill and Intangible Assets Disclosure [Abstract]    
    Licenses $ 1,000 $ 1,000
    Accumulated amortization
    Net intangible assets $ 1,000 $ 1,000
    XML 60 R43.htm IDEA: XBRL DOCUMENT v3.24.1.u1
    Commitments (Details Narrative) - USD ($)
    		 12 Months Ended
    Mar. 13, 2024
    Dec. 31, 2022
    Dec. 31, 2023
    Property, Plant and Equipment [Line Items]      
    Purchase price   $ 17,146,325 $ 16,407,415
    Construction contract paid   47,944  
    Settlement And Release Agreement [Member] | Subsequent Event [Member]      
    Property, Plant and Equipment [Line Items]      
    Shares Issued, Shares, Share-Based Payment Arrangement, Forfeited 118,535,168    
    Equipment [Member]      
    Property, Plant and Equipment [Line Items]      
    Purchase price   2,219,285  
    Deposits   1,109,643  
    Remaining payment   $ 1,109,642  
    XML 61 R44.htm IDEA: XBRL DOCUMENT v3.24.1.u1
    Related Party Line of Credit Note (Details Narrative) - USD ($)
    		 1 Months Ended 12 Months Ended
    Dec. 01, 2023
    Aug. 31, 2023
    Mar. 14, 2023
    Feb. 06, 2023
    Feb. 01, 2023
    Sep. 30, 2023
    Feb. 28, 2023
    Dec. 31, 2023
    Dec. 31, 2022
    Nov. 14, 2022
    Jun. 05, 2022
    Line of Credit Facility [Line Items]                      
    Payment of related party loan         $ 392,194     $ 1,611,067    
    Related party line of credit paid       $ 880,000     $ 880,000 $ 880,000      
    Investment transfer for repayment of loan       $ 880,000   $ 3,619,789 $ 880,000        
    Debt conversion, shares issued   2,827,960   22,005   2,827,960   22,005      
    Conversion of principal price per share   $ 1.15   $ 39.99       $ 39.99      
    Additional related party line of credit $ 200,000   $ 200,000         $ 400,000 5,191,057    
    Line of credit   $ 3,619,789           15,000,000      
    Number of shares issued   $ 2,827,960           $ 880,000 $ 3,050,000    
    Common stock, par value   $ 0.0001           $ 0.0001 $ 0.0001    
    Warrants price per share   0.13                  
    Common stock price per share   $ 3.00                  
    Capital transaction due to related party               $ 2,090,564      
    Credit facility $ 14,800,000             14,800,000      
    Unsecured Line of Credit [Member] | LDS Capital LLC [Member]                      
    Line of Credit Facility [Line Items]                      
    Increase in the line of credit capacity amount                     $ 3,000,000
    Additional borrowing capacity                     $ 2,000,000
    Interest rate stated percentage                     2.00%
    Lender committed funds               5,983,250 $ 5,191,057    
    Repayments of other debt               6,110,855 1,611,067    
    Accrued interest               1,783 106,117    
    Interest costs capitalized               223,271 $ 106,117    
    Unsecured Line of Credit [Member] | LDS Capital LLC [Member] | Construction in Progress [Member]                      
    Line of Credit Facility [Line Items]                      
    Accrued interest               $ 327,605      
    Unsecured Line of Credit [Member] | LDS Capital LLC [Member] | Prime Rate [Member]                      
    Line of Credit Facility [Line Items]                      
    Interest rate stated percentage                     2.00%
    Unsecured Line of Credit [Member] | LDS Capital LLC [Member] | Maximum [Member]                      
    Line of Credit Facility [Line Items]                      
    Increase in the line of credit capacity amount                     $ 5,000,000
    Amended Unsecured Line of Credit [Member]                      
    Line of Credit Facility [Line Items]                      
    Increase in the line of credit capacity amount                   $ 10,000,000  
    XML 62 R45.htm IDEA: XBRL DOCUMENT v3.24.1.u1
    Stockholders’ Equity (Details Narrative)
    		 1 Months Ended 9 Months Ended 12 Months Ended
    May 24, 2024
    USD ($)
    Nov. 16, 2023
    shares
    Sep. 20, 2023
    shares
    Sep. 01, 2023
    USD ($)
    Aug. 31, 2023
    $ / shares
    shares
    May 24, 2023
    USD ($)
    Feb. 06, 2023
    USD ($)
    shares
    Sep. 21, 2022
    USD ($)
    Sep. 12, 2022
    USD ($)
    Sep. 07, 2022
    USD ($)
    $ / shares
    shares
    Dec. 31, 2023
    $ / shares
    shares
    Nov. 30, 2023
    $ / shares
    shares
    Sep. 30, 2023
    USD ($)
    $ / shares
    shares
    Jul. 31, 2023
    $ / shares
    shares
    Jun. 30, 2023
    $ / shares
    shares
    May 31, 2023
    USD ($)
    $ / shares
    shares
    Mar. 31, 2023
    $ / shares
    shares
    Feb. 28, 2023
    USD ($)
    $ / shares
    shares
    Dec. 31, 2022
    $ / shares
    shares
    Jun. 30, 2022
    $ / shares
    shares
    May 31, 2022
    USD ($)
    $ / shares
    shares
    Apr. 30, 2022
    $ / shares
    shares
    Jan. 31, 2022
    USD ($)
    $ / shares
    shares
    Sep. 30, 2023
    $ / shares
    shares
    Dec. 31, 2023
    USD ($)
    $ / shares
    shares
    Dec. 31, 2022
    USD ($)
    $ / shares
    shares
    May 21, 2023
    $ / shares
    Feb. 01, 2023
    $ / shares
    Sep. 06, 2022
    USD ($)
    Accumulated Other Comprehensive Income (Loss) [Line Items]                                                          
    Common stock, shares authorized | shares                     500,000,000               500,000,000           500,000,000 500,000,000      
    Common stock, par value         $ 0.0001           $ 0.0001               $ 0.0001           $ 0.0001 $ 0.0001      
    Preferred stock, shares authorized | shares                     10,000,000               10,000,000           10,000,000 10,000,000      
    Preferred stock par value                     $ 0.0001               $ 0.0001           $ 0.0001 $ 0.0001      
    Common stock, shares issued | shares                     184,758,818               173,304,800           184,758,818 173,304,800      
    Common stock, shares outstanding | shares                     184,758,818               173,304,800           184,758,818 173,304,800      
    Warrant exercise price         0.13                                                
    Issued price per share         $ 3.00                                                
    Related party line of credit paid | $             $ 880,000                     $ 880,000             $ 880,000        
    Investment transfer for repayment of loan | $             $ 880,000           $ 3,619,789         $ 880,000                      
    Debt conversion, shares issued | shares         2,827,960   22,005           2,827,960                       22,005        
    Related party line of credit paid | $                         $ 3,619,789                                
    Stock options issued for services rendered, shares | shares   1,800,000 625,000                                           0      
    Exercise price per share                                                        
    Gross cash proceeds | $                                                 $ 3,234,740 $ 18,851,232      
    Warrants redeemed, shares | shares                                                 200,000        
    Warrants redeemed, value | $                   $ 210,000                                      
    Placement agent fees | $               $ 800,000               $ 316,850                          
    Legal fees | $               55,617               $ 78,400                          
    Escrow deposit | $               $ 7,650                                          
    Warrants fair value | $                 $ 6,901,000                                       $ 7,399,000
    Decrease in fair value of warrants | $                 498,000                                        
    Securities Purchase Agreement [Member]                                                          
    Accumulated Other Comprehensive Income (Loss) [Line Items]                                                          
    Warrant exercise price                                                     $ 0.95    
    Purchase price                                                     $ 0.95    
    Warrants and rights outstanding term                                                     5 years    
    Private Placement [Member]                                                          
    Accumulated Other Comprehensive Income (Loss) [Line Items]                                                          
    Warrant exercise price                   $ 1.05                                      
    Issuance of shares | shares                               3,684,210                          
    Issued price per share                                                       $ 39.99  
    Warrants to purchase common stock | shares                   9,523,810           3,684,210                          
    Purchase price                               $ 0.95                          
    Gross proceeds from private placement | $           $ 3,500,000     $ 10,000,000                                        
    Private Placement [Member] | Securities Purchase Agreement [Member]                                                          
    Accumulated Other Comprehensive Income (Loss) [Line Items]                                                          
    Warrant exercise price                   $ 1.05                                      
    Issuance of shares | shares                   9,523,810                                      
    Warrants to purchase common stock | shares                   9,523,810                                      
    Purchase price                   $ 1.05                                      
    Warrants and rights outstanding term                   5 years                                      
    Common Stock [Member]                                                          
    Accumulated Other Comprehensive Income (Loss) [Line Items]                                                          
    Common stock issued for services rendered | shares                                                 4,697,838 6,036,990      
    Warrant exercise price                         $ 3.00                     $ 3.00          
    Issuance of shares | shares                                                 22,005 312,500      
    Gross cash proceeds | $                                                 $ 472 $ 603      
    Common Stock [Member] | Private Placement [Member]                                                          
    Accumulated Other Comprehensive Income (Loss) [Line Items]                                                          
    Issued price per share                                           $ 4.00              
    Common Stock [Member] | Board Member [Member]                                                          
    Accumulated Other Comprehensive Income (Loss) [Line Items]                                                          
    Issuance of shares | shares                                   22,005                      
    Issued price per share                                   $ 39.99                      
    Common Stock [Member] | One Accredited Investor [Member]                                                          
    Accumulated Other Comprehensive Income (Loss) [Line Items]                                                          
    Issuance of shares | shares                                 22,005           12,500            
    Issued price per share                                 $ 39.99           $ 4.00            
    Gross cash proceeds | $                                             $ 50,000            
    Common Stock [Member] | Executive Chairman [Member]                                                          
    Accumulated Other Comprehensive Income (Loss) [Line Items]                                                          
    Common stock issued for services rendered | shares                     875,000   875,000   875,000   875,000                        
    Issued price per share                     $ 0.3301   $ 0.3959   $ 1.01   $ 0.9416             0.3959 $ 0.3301        
    Common Stock [Member] | Chief Executive Officer [Member]                                                          
    Accumulated Other Comprehensive Income (Loss) [Line Items]                                                          
    Common stock issued for services rendered | shares                               500,000     3,962,500           500,000        
    Issued price per share                               $ 1.13                          
    Common Stock [Member] | Consultant [Member]                                                          
    Accumulated Other Comprehensive Income (Loss) [Line Items]                                                          
    Common stock issued for services rendered | shares                         60,000 137,838                              
    Issued price per share                         $ 0.4015 $ 0.74                   0.4015          
    Common Stock [Member] | Chief Financial Officer [Member]                                                          
    Accumulated Other Comprehensive Income (Loss) [Line Items]                                                          
    Common stock issued for services rendered | shares                         500,000                 500,000     500,000        
    Issued price per share                         $ 0.4015                 $ 4.00   0.4015          
    Common Stock [Member] | Director [Member]                                                          
    Accumulated Other Comprehensive Income (Loss) [Line Items]                                                          
    Issued price per share                       $ 0.3303                                  
    Stock options issued for services rendered, shares | shares                       1,800,000                                  
    Exercise price per share                       $ 0.3353                                  
    Common Stock [Member] | Director One [Member]                                                          
    Accumulated Other Comprehensive Income (Loss) [Line Items]                                                          
    Stock options issued for services rendered, shares | shares                       600,000                                  
    Common Stock [Member] | Director Two [Member]                                                          
    Accumulated Other Comprehensive Income (Loss) [Line Items]                                                          
    Stock options issued for services rendered, shares | shares                       600,000                                  
    Common Stock [Member] | Director Three [Member]                                                          
    Accumulated Other Comprehensive Income (Loss) [Line Items]                                                          
    Stock options issued for services rendered, shares | shares                       600,000                                  
    Common Stock [Member] | Six Consultants [Member]                                                          
    Accumulated Other Comprehensive Income (Loss) [Line Items]                                                          
    Common stock issued for services rendered | shares                                           1,574,490              
    Issued price per share                                           $ 8.00              
    Common Stock [Member] | Six Consultants [Member] | Private Placement [Member]                                                          
    Accumulated Other Comprehensive Income (Loss) [Line Items]                                                          
    Issued price per share                                           8.00              
    Common Stock [Member] | Directors [Member]                                                          
    Accumulated Other Comprehensive Income (Loss) [Line Items]                                                          
    Issued price per share                                           $ 2.00              
    Shares of common stock cancelled | shares                                           5,000              
    Common Stock [Member] | Two Accredited Investor [Member]                                                          
    Accumulated Other Comprehensive Income (Loss) [Line Items]                                                          
    Issuance of shares | shares                                         300,000                
    Issued price per share                                         $ 10.00                
    Gross cash proceeds | $                                         $ 3,000,000                
    Common Stock [Member] | Consultants [Member]                                                          
    Accumulated Other Comprehensive Income (Loss) [Line Items]                                                          
    Issued price per share                                       $ 0.069                  
    Shares of common stock cancelled | shares                                       108,000                  
    Warrant [Member]                                                          
    Accumulated Other Comprehensive Income (Loss) [Line Items]                                                          
    Warrant exercise price                         3.00                     $ 3.00          
    Issuance of shares | shares                                               9,523,810          
    Issued price per share                         $ 1.05                     $ 1.05          
    Warrants to purchase common stock | shares                         2,827,960                     2,827,960          
    Exercise price per share                         $ 1.28                     $ 1.28          
    Shares of warrants to purchase | shares                         2,827,960                                
    Share price                         $ 0.46                     $ 0.46          
    Warrants estimate value | $       $ 149,180                                                  
    Warrant [Member] | Measurement Input, Expected Term [Member]                                                          
    Accumulated Other Comprehensive Income (Loss) [Line Items]                                                          
    Warrants and rights outstanding term                         1 year                     1 year          
    Warrant [Member] | Measurement Input, Option Volatility [Member]                                                          
    Accumulated Other Comprehensive Income (Loss) [Line Items]                                                          
    Dividend rate                         149                     149          
    Warrant [Member] | Measurement Input, Risk Free Interest Rate [Member]                                                          
    Accumulated Other Comprehensive Income (Loss) [Line Items]                                                          
    Dividend rate                         5.36                     5.36          
    Warrant [Member] | Measurement Input, Expected Dividend Rate [Member]                                                          
    Accumulated Other Comprehensive Income (Loss) [Line Items]                                                          
    Dividend rate                         0.000                     0.000          
    Warrant [Member] | Private Placement [Member]                                                          
    Accumulated Other Comprehensive Income (Loss) [Line Items]                                                          
    Warrant exercise price                               $ 0.95                          
    Shares of warrants to purchase | shares                               3,684,210                          
    Share price                               $ 0.78                          
    Warrant [Member] | Private Placement [Member] | Forecast [Member]                                                          
    Accumulated Other Comprehensive Income (Loss) [Line Items]                                                          
    Warrants estimate value | $ $ 1,600,000                                                        
    Warrant [Member] | Private Placement [Member] | Measurement Input, Expected Term [Member]                                                          
    Accumulated Other Comprehensive Income (Loss) [Line Items]                                                          
    Warrants and rights outstanding term                               5 years                          
    Warrant [Member] | Private Placement [Member] | Measurement Input, Option Volatility [Member]                                                          
    Accumulated Other Comprehensive Income (Loss) [Line Items]                                                          
    Dividend rate                               165.00                          
    Warrant [Member] | Private Placement [Member] | Measurement Input, Risk Free Interest Rate [Member]                                                          
    Accumulated Other Comprehensive Income (Loss) [Line Items]                                                          
    Dividend rate                               3.08                          
    Warrant [Member] | Private Placement [Member] | Measurement Input, Expected Dividend Rate [Member]                                                          
    Accumulated Other Comprehensive Income (Loss) [Line Items]                                                          
    Dividend rate                               0.000                          
    Common Stock One [Member] | Chief Executive Officer [Member]                                                          
    Accumulated Other Comprehensive Income (Loss) [Line Items]                                                          
    Issued price per share                                     $ 1.25             $ 1.25      
    Number of shares issued | shares                                     3,000,000                    
    Common Stock Two [Member] | Chief Executive Officer [Member]                                                          
    Accumulated Other Comprehensive Income (Loss) [Line Items]                                                          
    Issued price per share                                     $ 1.08             1.08      
    Number of shares issued | shares                                     87,500                    
    Common Stock Three [Member] | Chief Executive Officer [Member]                                                          
    Accumulated Other Comprehensive Income (Loss) [Line Items]                                                          
    Issued price per share                                     $ 0.4695             $ 0.4695      
    Number of shares issued | shares                                     875,000                    
    One Accredited Investor [Member]                                                          
    Accumulated Other Comprehensive Income (Loss) [Line Items]                                                          
    Number of warrants exercised | shares                                   200,000                      
    Common stock issued for services rendered | shares                                   200,000                      
    Warrant exercise price                                   $ 1.05                      
    XML 63 R46.htm IDEA: XBRL DOCUMENT v3.24.1.u1
    Schedule of Fair Value of The Stock Options (Details) - $ / shares
    		 12 Months Ended
    Dec. 31, 2023
    Dec. 31, 2022
    Retirement Benefits [Abstract]    
    Weighted average fair value at grant date $ 0.3303
    Expected life of options (years) 5 years
    Expected stock volatility 213.90%
    Risk-free interest rate 4.42%
    Expected dividend yield 0.00%
    XML 64 R47.htm IDEA: XBRL DOCUMENT v3.24.1.u1
    Schedule of Summarizes Stock Option Activity (Details) - $ / shares
    		 12 Months Ended
    Nov. 16, 2023
    Sep. 20, 2023
    Dec. 31, 2023
    Dec. 31, 2022
    Retirement Benefits [Abstract]        
    Number of shares, outstanding beginning balance      
    Weighted average exercise price beginning balance      
    Number of stock options granted     2,425,000  
    Weighted average exercise price granted $ 0.3353 $ 0.385 $ 0.3353  
    Number of stock options exercised 1,800,000 625,000 0
    Weighted average exercise price exercised      
    Number of stock options expired      
    Weighted average exercise price expired      
    Number of shares, outstanding ending balance     2,425,000
    Weighted average exercise price ending balance     $ 0.3353
    Weighted average remaining life (years)     9 years 10 months 24 days  
    XML 65 R48.htm IDEA: XBRL DOCUMENT v3.24.1.u1
    Stock-Based Compensation (Details Narrative) - USD ($)
    		 12 Months Ended
    Mar. 31, 2024
    Nov. 16, 2023
    Sep. 20, 2023
    Dec. 31, 2023
    Dec. 31, 2022
    Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]          
    Stock options shares   1,800,000 625,000 0
    Share-Based Payment Arrangement, Noncash Expense       $ 3,829,218 $ 18,833,781
    Stock Issued During Period, Value, Issued for Services       $ 3,234,740 $ 18,851,232
    Stock options exercise price   $ 0.3353 $ 0.385 $ 0.3353  
    Stock options fair value   $ 0.3303      
    Stock options expiring, shares   600,000      
    Issuance of shares       2,425,000  
    Restricted stock, shares     625,000   0
    Chief Executive Officer [Member] | Subsequent Event [Member]          
    Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]          
    Restricted stock, shares 625,000        
    Chief Executive Officer [Member] | Subsequent Event [Member] | Mutual Agreement [Member]          
    Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]          
    Restricted stock, shares 5,500,000        
    Common Stock [Member]          
    Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]          
    Common stock issued for cash for EB-5 program (Note 11), shares       22,005 312,500
    Stock Issued During Period, Value, Issued for Services       $ 472 $ 603
    Common Stock [Member] | Chief Executive Officer [Member]          
    Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]          
    Issuance of shares       625,000  
    Common Stock [Member] | Chief Executive Officer [Member] | Subsequent Event [Member]          
    Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]          
    Issuance of shares 625,000        
    Restricted Stock [Member] | Subsequent Event [Member]          
    Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]          
    Restricted shares unit 625,000        
    Restricted Stock [Member] | Chief Executive Officer [Member]          
    Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]          
    Issuance of shares       625,000  
    Equity Compensation Plan [Member]          
    Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]          
    Common stock issued for cash for EB-5 program (Note 11), shares       3,050,000
    Stock options shares       2,425,000  
    Share-Based Payment Arrangement, Noncash Expense       $ 3,829,218 $ 18,833,781
    Stock Issued During Period, Value, Issued for Services       $ 594,478  
    Equity Compensation Plan [Member] | Restricted Stock [Member]          
    Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]          
    Restricted shares unit       625,000  
    XML 66 R49.htm IDEA: XBRL DOCUMENT v3.24.1.u1
    Schedule of Income Tax Provision (Details) - USD ($)
    		 12 Months Ended
    Dec. 31, 2023
    Dec. 31, 2022
    Income Tax Disclosure [Abstract]    
    Loss before income taxes $ (13,127,648) $ (27,662,077)
    Current:    
    Federal
    State
    Total current (benefit) provision
    Deferred:    
    Federal (2,520,309) (5,727,839)
    State (576,071) (1,309,220)
    Total current (benefit) provision (3,096,380) (7,037,059)
    Valuation allowance 3,096,380 7,037,059
    Total (benefit) expense
    XML 67 R50.htm IDEA: XBRL DOCUMENT v3.24.1.u1
    Schedule of Federal and State Tax Effects of Temporary Differences and Carryforwards (Details) - USD ($)
    Dec. 31, 2023
    Dec. 31, 2022
    Income Tax Disclosure [Abstract]    
    Other $ 1,401,963 $ 728,201
    Net operating loss carry over 9,716,764 7,294,146
    Total deferred tax assets 11,118,727 8,022,347
    Less: valuation allowance (11,118,727) (8,022,347)
    Deferred tax assets, net of valuation allowance
    XML 68 R51.htm IDEA: XBRL DOCUMENT v3.24.1.u1
    Income Taxes (Details Narrative) - USD ($)
    		 12 Months Ended
    Dec. 31, 2023
    Dec. 31, 2022
    Operating Loss Carryforwards [Line Items]    
    Current and deferred income tax expenses
    Tax rate 25.80% 25.80%
    Domestic Tax Authority [Member]    
    Operating Loss Carryforwards [Line Items]    
    Operating loss carryforwards $ 37,661,876 $ 28,577,832
    XML 69 R52.htm IDEA: XBRL DOCUMENT v3.24.1.u1
    Related Party Transactions (Details Narrative) - USD ($)
    		 1 Months Ended 12 Months Ended
    Mar. 31, 2024
    Feb. 15, 2024
    Sep. 20, 2023
    Sep. 30, 2023
    May 31, 2023
    Dec. 31, 2022
    Apr. 30, 2022
    Dec. 31, 2023
    Dec. 31, 2022
    Related Party Transaction [Line Items]                  
    Issuance of shares               2,425,000  
    Restricted stock, shares     625,000           0
    Long-term line of credit           $ 3,686,107   $ 201,783 $ 3,686,107
    Executive Chairman [Member] | Accrued Liabilities [Member]                  
    Related Party Transaction [Line Items]                  
    Due to related party           400,000   400,000 400,000
    Accrued bonus           300,000   200,000 300,000
    Former Chief Executive Officer [Member] | Accounts Payable [Member]                  
    Related Party Transaction [Line Items]                  
    Due to related party               23,460  
    Chief Financial Officer [Member] | Accounts Payable [Member]                  
    Related Party Transaction [Line Items]                  
    Due to related party           65,856   68,037 65,856
    Chief Executive Officer [Member] | Accounts Payable [Member]                  
    Related Party Transaction [Line Items]                  
    Due to related party           66,667   66,667 66,667
    Board of Directors [Member] | Accounts Payable [Member]                  
    Related Party Transaction [Line Items]                  
    Due to related party           $ 143,900   $ 400,000 $ 143,900
    Chief Executive Officer [Member] | Subsequent Event [Member]                  
    Related Party Transaction [Line Items]                  
    Restricted stock, shares 625,000                
    Chief Executive Officer [Member] | Restricted Stock [Member]                  
    Related Party Transaction [Line Items]                  
    Issuance of shares               625,000  
    Three Directors [Member]                  
    Related Party Transaction [Line Items]                  
    Common stock issued for service, shares               1,800,000  
    Common Stock [Member]                  
    Related Party Transaction [Line Items]                  
    Common stock issued for service, shares               4,697,838 6,036,990
    Common Stock [Member] | Former Executive Chairman [Member]                  
    Related Party Transaction [Line Items]                  
    Common stock issued for service, shares               3,500,000  
    Common Stock [Member] | Chief Executive Officer [Member]                  
    Related Party Transaction [Line Items]                  
    Common stock issued for service, shares         500,000 3,962,500   500,000  
    Issuance of shares               625,000  
    Common Stock [Member] | Chief Executive Officer [Member] | Subsequent Event [Member]                  
    Related Party Transaction [Line Items]                  
    Issuance of shares 625,000                
    Common Stock [Member] | Chief Financial Officer [Member]                  
    Related Party Transaction [Line Items]                  
    Common stock issued for service, shares       500,000     500,000 500,000  
    Common Stock [Member] | Former Interim Chief Executive Officer [Member] | Subsequent Event [Member]                  
    Related Party Transaction [Line Items]                  
    Common stock issued for service, shares   2,420,000              
    XML 70 R53.htm IDEA: XBRL DOCUMENT v3.24.1.u1
    Contingencies (Details Narrative)
    		 12 Months Ended
    Dec. 31, 2023
    Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]  
    Contingency, taken by defendant description (i) shares of common stock in the Company (amounting to no more than 108,000 shares) or (ii) fair market value of defendant’s equity ownership of BGGI.
    Chief Executive Officer [Member]  
    Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]  
    Contingency, taken by defendant description Bright Green Group of Companies, an entity unrelated to the Company, to determine if defendant is entitled to 5,000,000 shares of the Company’s common stock, based on a failure to fulfill agreed upon conditions precedent to earning such shares from the Company.
    XML 71 R54.htm IDEA: XBRL DOCUMENT v3.24.1.u1
    Subsequent Events (Details Narrative) - USD ($)
    		 1 Months Ended 12 Months Ended
    Oct. 02, 2024
    Apr. 09, 2024
    Apr. 05, 2024
    Apr. 02, 2024
    Mar. 31, 2024
    Mar. 25, 2024
    Mar. 13, 2024
    Mar. 07, 2024
    Feb. 15, 2024
    Feb. 08, 2024
    Feb. 07, 2024
    Jan. 30, 2024
    Jan. 19, 2024
    Dec. 01, 2023
    Sep. 20, 2023
    Mar. 14, 2023
    May 31, 2023
    Dec. 31, 2022
    Oct. 02, 2026
    Oct. 02, 2025
    Dec. 31, 2023
    Dec. 31, 2022
    Mar. 14, 2024
    Aug. 31, 2023
    Subsequent Event [Line Items]                                                
    Shares issued price per share                                               $ 3.00
    Proceeds from related party debt                           $ 200,000   $ 200,000         $ 400,000 $ 5,191,057    
    Restricted stock, shares                             625,000             0    
    Line of credit                                         15,000,000     $ 3,619,789
    Credit facility                           $ 14,800,000             $ 14,800,000      
    Equity Compensation Plan [Member]                                                
    Subsequent Event [Line Items]                                                
    Common stock issued for cash for EB-5 program (Note 11), shares                                         3,050,000    
    Restricted Stock [Member] | Equity Compensation Plan [Member]                                                
    Subsequent Event [Line Items]                                                
    Restricted shares unit                                         625,000      
    Common Stock [Member]                                                
    Subsequent Event [Line Items]                                                
    Common stock issued for services (Note 11), shares                                         4,697,838 6,036,990    
    Common stock issued for cash for EB-5 program (Note 11), shares                                         22,005 312,500    
    Common Stock [Member] | Chief Executive Officer [Member]                                                
    Subsequent Event [Line Items]                                                
    Common stock issued for services (Note 11), shares                                 500,000 3,962,500     500,000      
    Shares issued price per share                                 $ 1.13              
    Subsequent Event [Member]                                                
    Subsequent Event [Line Items]                                                
    Agreement with vendor to cancel                         $ 2,650,000                      
    Proceeds from related party debt   $ 40,000 $ 20,000     $ 10,000       $ 100,000                            
    Credit facility   $ 14,600,000                                            
    Subsequent Event [Member] | Restricted Stock [Member]                                                
    Subsequent Event [Line Items]                                                
    Restricted shares unit         625,000                                      
    Subsequent Event [Member] | Settlement And Release Agreement [Member]                                                
    Subsequent Event [Line Items]                                                
    Number of shares forfeited             118,535,168                                  
    Payment of lieu Outstanding shares of common stock             83,226,820                                  
    Number of shares purchase assets             $ 1,650,000                                  
    Equipped purchase shares of common stock             27,742,273                                  
    Subsequent Event [Member] | Credit Agreement [Member]                                                
    Subsequent Event [Line Items]                                                
    Line of credit                                             $ 60,000,000  
    Subsequent Event [Member] | Executive Employment Agreement [Member]                                                
    Subsequent Event [Line Items]                                                
    Salaries and wages $ 35,833.33                                   $ 41,667.00 $ 38,333.00        
    Restricted stock vest, shares         5,500,000                                      
    Subsequent Event [Member] | Executive Employment Agreement [Member] | Restricted Stock Units (RSUs) [Member]                                                
    Subsequent Event [Line Items]                                                
    Restricted stock vest, shares         500,000                                      
    Subsequent Event [Member] | Executive Employment Agreement Agreement [Member]                                                
    Subsequent Event [Line Items]                                                
    Restricted stock vest, shares       3,000,000 2,000,000                                      
    Subsequent Event [Member] | Ontario Ltd [Member]                                                
    Subsequent Event [Line Items]                                                
    Owned interest expenses                     $ 150,000                          
    Interest expense short term borrowings                     $ 15,000                          
    Subsequent Event [Member] | Mr.Elmasri [Member] | Titan Advisory Services LLC [Member] | CFO Agreement [Member]                                                
    Subsequent Event [Line Items]                                                
    Monthly cash fee               $ 25,000                                
    Restricted stock, shares               600,000                                
    Subsequent Event [Member] | Chief Executive Officer [Member]                                                
    Subsequent Event [Line Items]                                                
    Restricted stock, shares         625,000                                      
    Subsequent Event [Member] | Chief Executive Officer [Member] | Mutual Agreement [Member]                                                
    Subsequent Event [Line Items]                                                
    Restricted stock, shares         5,500,000                                      
    Subsequent Event [Member] | Common Stock [Member] | Separation Agreement [Member]                                                
    Subsequent Event [Line Items]                                                
    Common stock issued for cash for EB-5 program (Note 11), shares                 4,957,000                              
    Subsequent Event [Member] | Common Stock [Member] | Four Consultants [Member]                                                
    Subsequent Event [Line Items]                                                
    Common stock issued for services (Note 11), shares                       450,000                        
    Shares issued price per share                       $ 0.2116                        
    Subsequent Event [Member] | Common Stock [Member] | Mr.Terry Rafih [Member] | Separation Agreement [Member]                                                
    Subsequent Event [Line Items]                                                
    Common stock issued for services (Note 11), shares                 2,420,000                              
    Common stock issued for cash for EB-5 program (Note 11), shares                 2,537,500                              
    Number of shares authorized                 10,000,000                              
    Unpaid cash renumeration and bonus compensation                 $ 450,000                              
    EXCEL 72 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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�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�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end XML 73 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 74 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 76 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 211 304 1 false 77 0 false 5 false false R1.htm 00000001 - Document - Cover Sheet http://brightgreen.us/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - Consolidated Balance Sheets Sheet http://brightgreen.us/role/BalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://brightgreen.us/role/BalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss Sheet http://brightgreen.us/role/StatementsOfOperationsAndComprehensiveLoss Consolidated Statements of Operations and Comprehensive Loss Statements 4 false false R5.htm 00000005 - Statement - Consolidated Statements of Changes in Stockholders' Equity Sheet http://brightgreen.us/role/StatementsOfChangesInStockholdersEquity Consolidated Statements of Changes in Stockholders' Equity Statements 5 false false R6.htm 00000006 - Statement - Consolidated Statements of Changes in Stockholders' Equity (Parenthetical) Sheet http://brightgreen.us/role/StatementsOfChangesInStockholdersEquityParenthetical Consolidated Statements of Changes in Stockholders' Equity (Parenthetical) Statements 6 false false R7.htm 00000007 - Statement - Consolidated Statements of Cash Flows Sheet http://brightgreen.us/role/StatementsOfCashFlows Consolidated Statements of Cash Flows Statements 7 false false R8.htm 00000008 - Disclosure - Description of Business and Organization Sheet http://brightgreen.us/role/DescriptionOfBusinessAndOrganization Description of Business and Organization Notes 8 false false R9.htm 00000009 - Disclosure - Going Concern and Basis of Presentation Sheet http://brightgreen.us/role/GoingConcernAndBasisOfPresentation Going Concern and Basis of Presentation Notes 9 false false R10.htm 00000010 - Disclosure - Summary of Significant Accounting Policies Sheet http://brightgreen.us/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 10 false false R11.htm 00000011 - Disclosure - Concentration of Credit Risk Sheet http://brightgreen.us/role/ConcentrationOfCreditRisk Concentration of Credit Risk Notes 11 false false R12.htm 00000012 - Disclosure - Deposits Sheet http://brightgreen.us/role/Deposits Deposits Notes 12 false false R13.htm 00000013 - Disclosure - Equity Method Investment in Alterola Sheet http://brightgreen.us/role/EquityMethodInvestmentInAlterola Equity Method Investment in Alterola Notes 13 false false R14.htm 00000014 - Disclosure - Property, Plant, and Equipment Sheet http://brightgreen.us/role/PropertyPlantAndEquipment Property, Plant, and Equipment Notes 14 false false R15.htm 00000015 - Disclosure - Intangible Assets Sheet http://brightgreen.us/role/IntangibleAssets Intangible Assets Notes 15 false false R16.htm 00000016 - Disclosure - Commitments Sheet http://brightgreen.us/role/Commitments Commitments Notes 16 false false R17.htm 00000017 - Disclosure - Related Party Line of Credit Note Sheet http://brightgreen.us/role/RelatedPartyLineOfCreditNote Related Party Line of Credit Note Notes 17 false false R18.htm 00000018 - Disclosure - Stockholders??? Equity Sheet http://brightgreen.us/role/StockholdersEquity Stockholders??? Equity Notes 18 false false R19.htm 00000019 - Disclosure - Stock-Based Compensation Sheet http://brightgreen.us/role/Stock-basedCompensation Stock-Based Compensation Notes 19 false false R20.htm 00000020 - Disclosure - Income Taxes Sheet http://brightgreen.us/role/IncomeTaxes Income Taxes Notes 20 false false R21.htm 00000021 - Disclosure - Related Party Transactions Sheet http://brightgreen.us/role/RelatedPartyTransactions Related Party Transactions Notes 21 false false R22.htm 00000022 - Disclosure - Contingencies Sheet http://brightgreen.us/role/Contingencies Contingencies Notes 22 false false R23.htm 00000023 - Disclosure - Subsequent Events Sheet http://brightgreen.us/role/SubsequentEvents Subsequent Events Notes 23 false false R24.htm 00000024 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://brightgreen.us/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://brightgreen.us/role/SummaryOfSignificantAccountingPolicies 24 false false R25.htm 00000025 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://brightgreen.us/role/SummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://brightgreen.us/role/SummaryOfSignificantAccountingPolicies 25 false false R26.htm 00000026 - Disclosure - Equity Method Investment in Alterola (Tables) Sheet http://brightgreen.us/role/EquityMethodInvestmentInAlterolaTables Equity Method Investment in Alterola (Tables) Tables http://brightgreen.us/role/EquityMethodInvestmentInAlterola 26 false false R27.htm 00000027 - Disclosure - Property, Plant, and Equipment (Tables) Sheet http://brightgreen.us/role/PropertyPlantAndEquipmentTables Property, Plant, and Equipment (Tables) Tables http://brightgreen.us/role/PropertyPlantAndEquipment 27 false false R28.htm 00000028 - Disclosure - Intangible Assets (Tables) Sheet http://brightgreen.us/role/IntangibleAssetsTables Intangible Assets (Tables) Tables http://brightgreen.us/role/IntangibleAssets 28 false false R29.htm 00000029 - Disclosure - Stock-Based Compensation (Tables) Sheet http://brightgreen.us/role/Stock-basedCompensationTables Stock-Based Compensation (Tables) Tables http://brightgreen.us/role/Stock-basedCompensation 29 false false R30.htm 00000030 - Disclosure - Income Taxes (Tables) Sheet http://brightgreen.us/role/IncomeTaxesTables Income Taxes (Tables) Tables http://brightgreen.us/role/IncomeTaxes 30 false false R31.htm 00000031 - Disclosure - Description of Business and Organization (Details Narrative) Sheet http://brightgreen.us/role/DescriptionOfBusinessAndOrganizationDetailsNarrative Description of Business and Organization (Details Narrative) Details http://brightgreen.us/role/DescriptionOfBusinessAndOrganization 31 false false R32.htm 00000032 - Disclosure - Going Concern and Basis of Presentation (Details Narrative) Sheet http://brightgreen.us/role/GoingConcernAndBasisOfPresentationDetailsNarrative Going Concern and Basis of Presentation (Details Narrative) Details http://brightgreen.us/role/GoingConcernAndBasisOfPresentation 32 false false R33.htm 00000033 - Disclosure - Summary of Estimated Useful Life (Details) Sheet http://brightgreen.us/role/SummaryOfEstimatedUsefulLifeDetails Summary of Estimated Useful Life (Details) Details 33 false false R34.htm 00000034 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) Sheet http://brightgreen.us/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative Summary of Significant Accounting Policies (Details Narrative) Details http://brightgreen.us/role/SummaryOfSignificantAccountingPoliciesTables 34 false false R35.htm 00000035 - Disclosure - Concentration of Credit Risk (Details Narrative) Sheet http://brightgreen.us/role/ConcentrationOfCreditRiskDetailsNarrative Concentration of Credit Risk (Details Narrative) Details http://brightgreen.us/role/ConcentrationOfCreditRisk 35 false false R36.htm 00000036 - Disclosure - Deposits (Details Narrative) Sheet http://brightgreen.us/role/DepositsDetailsNarrative Deposits (Details Narrative) Details http://brightgreen.us/role/Deposits 36 false false R37.htm 00000037 - Disclosure - Schedule of Financial Statement Information (Details) Sheet http://brightgreen.us/role/ScheduleOfFinancialStatementInformationDetails Schedule of Financial Statement Information (Details) Details 37 false false R38.htm 00000038 - Disclosure - Schedule of Equity Method Investment in Alterola (Details) Sheet http://brightgreen.us/role/ScheduleOfEquityMethodInvestmentInAlterolaDetails Schedule of Equity Method Investment in Alterola (Details) Details 38 false false R39.htm 00000039 - Disclosure - Equity Method Investment in Alterola (Details Narrative) Sheet http://brightgreen.us/role/EquityMethodInvestmentInAlterolaDetailsNarrative Equity Method Investment in Alterola (Details Narrative) Details http://brightgreen.us/role/EquityMethodInvestmentInAlterolaTables 39 false false R40.htm 00000040 - Disclosure - Schedule of Property Plant and Equipment (Details) Sheet http://brightgreen.us/role/ScheduleOfPropertyPlantAndEquipmentDetails Schedule of Property Plant and Equipment (Details) Details 40 false false R41.htm 00000041 - Disclosure - Property, Plant, and Equipment (Details Narrative) Sheet http://brightgreen.us/role/PropertyPlantAndEquipmentDetailsNarrative Property, Plant, and Equipment (Details Narrative) Details http://brightgreen.us/role/PropertyPlantAndEquipmentTables 41 false false R42.htm 00000042 - Disclosure - Schedule of Intangible Assets (Details) Sheet http://brightgreen.us/role/ScheduleOfIntangibleAssetsDetails Schedule of Intangible Assets (Details) Details 42 false false R43.htm 00000043 - Disclosure - Commitments (Details Narrative) Sheet http://brightgreen.us/role/CommitmentsDetailsNarrative Commitments (Details Narrative) Details http://brightgreen.us/role/Commitments 43 false false R44.htm 00000044 - Disclosure - Related Party Line of Credit Note (Details Narrative) Sheet http://brightgreen.us/role/RelatedPartyLineOfCreditNoteDetailsNarrative Related Party Line of Credit Note (Details Narrative) Details http://brightgreen.us/role/RelatedPartyLineOfCreditNote 44 false false R45.htm 00000045 - Disclosure - Stockholders??? Equity (Details Narrative) Sheet http://brightgreen.us/role/StockholdersEquityDetailsNarrative Stockholders??? Equity (Details Narrative) Details http://brightgreen.us/role/StockholdersEquity 45 false false R46.htm 00000046 - Disclosure - Schedule of Fair Value of The Stock Options (Details) Sheet http://brightgreen.us/role/ScheduleOfFairValueOfStockOptionsDetails Schedule of Fair Value of The Stock Options (Details) Details 46 false false R47.htm 00000047 - Disclosure - Schedule of Summarizes Stock Option Activity (Details) Sheet http://brightgreen.us/role/ScheduleOfSummarizesStockOptionActivityDetails Schedule of Summarizes Stock Option Activity (Details) Details 47 false false R48.htm 00000048 - Disclosure - Stock-Based Compensation (Details Narrative) Sheet http://brightgreen.us/role/Stock-basedCompensationDetailsNarrative Stock-Based Compensation (Details Narrative) Details http://brightgreen.us/role/Stock-basedCompensationTables 48 false false R49.htm 00000049 - Disclosure - Schedule of Income Tax Provision (Details) Sheet http://brightgreen.us/role/ScheduleOfIncomeTaxProvisionDetails Schedule of Income Tax Provision (Details) Details 49 false false R50.htm 00000050 - Disclosure - Schedule of Federal and State Tax Effects of Temporary Differences and Carryforwards (Details) Sheet http://brightgreen.us/role/ScheduleOfFederalAndStateTaxEffectsOfTemporaryDifferencesAndCarryforwardsDetails Schedule of Federal and State Tax Effects of Temporary Differences and Carryforwards (Details) Details 50 false false R51.htm 00000051 - Disclosure - Income Taxes (Details Narrative) Sheet http://brightgreen.us/role/IncomeTaxesDetailsNarrative Income Taxes (Details Narrative) Details http://brightgreen.us/role/IncomeTaxesTables 51 false false R52.htm 00000052 - Disclosure - Related Party Transactions (Details Narrative) Sheet http://brightgreen.us/role/RelatedPartyTransactionsDetailsNarrative Related Party Transactions (Details Narrative) Details http://brightgreen.us/role/RelatedPartyTransactions 52 false false R53.htm 00000053 - Disclosure - Contingencies (Details Narrative) Sheet http://brightgreen.us/role/ContingenciesDetailsNarrative Contingencies (Details Narrative) Details http://brightgreen.us/role/Contingencies 53 false false R54.htm 00000054 - Disclosure - Subsequent Events (Details Narrative) Sheet http://brightgreen.us/role/SubsequentEventsDetailsNarrative Subsequent Events (Details Narrative) Details http://brightgreen.us/role/SubsequentEvents 54 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 2 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:TimeDepositLiabilityAboveUsInsuranceLimit, us-gaap:WarrantsAndRightsOutstandingMeasurementInput - form10-k.htm 75, 82 bgxx-20231231.xsd bgxx-20231231_cal.xml bgxx-20231231_def.xml bgxx-20231231_lab.xml bgxx-20231231_pre.xml form10-k.htm form10-k_001.jpg http://fasb.org/srt/2023 http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 true true JSON 79 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "form10-k.htm": { "nsprefix": "BGXX", "nsuri": "http://brightgreen.us/20231231", "dts": { "schema": { "local": [ "bgxx-20231231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "calculationLink": { "local": [ "bgxx-20231231_cal.xml" ] }, "definitionLink": { "local": [ "bgxx-20231231_def.xml" ] }, "labelLink": { "local": [ "bgxx-20231231_lab.xml" ] }, "presentationLink": { "local": [ "bgxx-20231231_pre.xml" ] }, "inline": { "local": [ "form10-k.htm" ] } }, "keyStandard": 259, "keyCustom": 45, "axisStandard": 20, "axisCustom": 0, "memberStandard": 27, "memberCustom": 45, "hidden": { "total": 84, "http://fasb.org/us-gaap/2023": 66, "http://brightgreen.us/20231231": 15, "http://xbrl.sec.gov/dei/2023": 3 }, "contextCount": 211, "entityCount": 1, "segmentCount": 77, "elementCount": 499, "unitCount": 5, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 625, "http://xbrl.sec.gov/dei/2023": 39, "http://fasb.org/srt/2023": 1 }, "report": { "R1": { "role": "http://brightgreen.us/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R2": { "role": "http://brightgreen.us/role/BalanceSheets", "longName": "00000002 - Statement - Consolidated Balance Sheets", "shortName": "Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:Cash", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:Cash", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R3": { "role": "http://brightgreen.us/role/BalanceSheetsParenthetical", "longName": "00000003 - Statement - Consolidated Balance Sheets (Parenthetical)", "shortName": "Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:PreferredStockSharesIssued", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "span", "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R4": { "role": "http://brightgreen.us/role/StatementsOfOperationsAndComprehensiveLoss", "longName": "00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss", "shortName": "Consolidated Statements of Operations and Comprehensive Loss", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:GeneralAndAdministrativeExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:GeneralAndAdministrativeExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R5": { "role": "http://brightgreen.us/role/StatementsOfChangesInStockholdersEquity", "longName": "00000005 - Statement - Consolidated Statements of Changes in Stockholders' Equity", "shortName": "Consolidated Statements of Changes in Stockholders' Equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "AsOf2021-12-31_us-gaap_CommonStockMember", "name": "us-gaap:StockholdersEquity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2021-12-31_us-gaap_CommonStockMember", "name": "us-gaap:StockholdersEquity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R6": { "role": "http://brightgreen.us/role/StatementsOfChangesInStockholdersEquityParenthetical", "longName": "00000006 - Statement - Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)", "shortName": "Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:PaymentOfFinancingAndStockIssuanceCosts", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:PaymentOfFinancingAndStockIssuanceCosts", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R7": { "role": "http://brightgreen.us/role/StatementsOfCashFlows", "longName": "00000007 - Statement - Consolidated Statements of Cash Flows", "shortName": "Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "BGXX:EquityInNetLossesOfAffiliate", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R8": { "role": "http://brightgreen.us/role/DescriptionOfBusinessAndOrganization", "longName": "00000008 - Disclosure - Description of Business and Organization", "shortName": "Description of Business and Organization", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R9": { "role": "http://brightgreen.us/role/GoingConcernAndBasisOfPresentation", "longName": "00000009 - Disclosure - Going Concern and Basis of Presentation", "shortName": "Going Concern and Basis of Presentation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:LiquidationBasisOfAccountingTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:LiquidationBasisOfAccountingTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R10": { "role": "http://brightgreen.us/role/SummaryOfSignificantAccountingPolicies", "longName": "00000010 - Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R11": { "role": "http://brightgreen.us/role/ConcentrationOfCreditRisk", "longName": "00000011 - Disclosure - Concentration of Credit Risk", "shortName": "Concentration of Credit Risk", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R12": { "role": "http://brightgreen.us/role/Deposits", "longName": "00000012 - Disclosure - Deposits", "shortName": "Deposits", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:DepositLiabilitiesDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:DepositLiabilitiesDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R13": { "role": "http://brightgreen.us/role/EquityMethodInvestmentInAlterola", "longName": "00000013 - Disclosure - Equity Method Investment in Alterola", "shortName": "Equity Method Investment in Alterola", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:InvestmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:InvestmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R14": { "role": "http://brightgreen.us/role/PropertyPlantAndEquipment", "longName": "00000014 - Disclosure - Property, Plant, and Equipment", "shortName": "Property, Plant, and Equipment", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R15": { "role": "http://brightgreen.us/role/IntangibleAssets", "longName": "00000015 - Disclosure - Intangible Assets", "shortName": "Intangible Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R16": { "role": "http://brightgreen.us/role/Commitments", "longName": "00000016 - Disclosure - Commitments", "shortName": "Commitments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:CommitmentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:CommitmentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R17": { "role": "http://brightgreen.us/role/RelatedPartyLineOfCreditNote", "longName": "00000017 - Disclosure - Related Party Line of Credit Note", "shortName": "Related Party Line of Credit Note", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "BGXX:RelatedPartyLineOfCreditTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "BGXX:RelatedPartyLineOfCreditTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R18": { "role": "http://brightgreen.us/role/StockholdersEquity", "longName": "00000018 - Disclosure - Stockholders\u2019 Equity", "shortName": "Stockholders\u2019 Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R19": { "role": "http://brightgreen.us/role/Stock-basedCompensation", "longName": "00000019 - Disclosure - Stock-Based Compensation", "shortName": "Stock-Based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R20": { "role": "http://brightgreen.us/role/IncomeTaxes", "longName": "00000020 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R21": { "role": "http://brightgreen.us/role/RelatedPartyTransactions", "longName": "00000021 - Disclosure - Related Party Transactions", "shortName": "Related Party Transactions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R22": { "role": "http://brightgreen.us/role/Contingencies", "longName": "00000022 - Disclosure - Contingencies", "shortName": "Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:LossContingencyDisclosures", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:LossContingencyDisclosures", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R23": { "role": "http://brightgreen.us/role/SubsequentEvents", "longName": "00000023 - Disclosure - Subsequent Events", "shortName": "Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R24": { "role": "http://brightgreen.us/role/SummaryOfSignificantAccountingPoliciesPolicies", "longName": "00000024 - Disclosure - Summary of Significant Accounting Policies (Policies)", "shortName": "Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "24", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R25": { "role": "http://brightgreen.us/role/SummaryOfSignificantAccountingPoliciesTables", "longName": "00000025 - Disclosure - Summary of Significant Accounting Policies (Tables)", "shortName": "Summary of Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "BGXX:PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "BGXX:PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R26": { "role": "http://brightgreen.us/role/EquityMethodInvestmentInAlterolaTables", "longName": "00000026 - Disclosure - Equity Method Investment in Alterola (Tables)", "shortName": "Equity Method Investment in Alterola (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "srt:ScheduleOfCondensedFinancialStatementsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:InvestmentTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "srt:ScheduleOfCondensedFinancialStatementsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:InvestmentTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R27": { "role": "http://brightgreen.us/role/PropertyPlantAndEquipmentTables", "longName": "00000027 - Disclosure - Property, Plant, and Equipment (Tables)", "shortName": "Property, Plant, and Equipment (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R28": { "role": "http://brightgreen.us/role/IntangibleAssetsTables", "longName": "00000028 - Disclosure - Intangible Assets (Tables)", "shortName": "Intangible Assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R29": { "role": "http://brightgreen.us/role/Stock-basedCompensationTables", "longName": "00000029 - Disclosure - Stock-Based Compensation (Tables)", "shortName": "Stock-Based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R30": { "role": "http://brightgreen.us/role/IncomeTaxesTables", "longName": "00000030 - Disclosure - Income Taxes (Tables)", "shortName": "Income Taxes (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R31": { "role": "http://brightgreen.us/role/DescriptionOfBusinessAndOrganizationDetailsNarrative", "longName": "00000031 - Disclosure - Description of Business and Organization (Details Narrative)", "shortName": "Description of Business and Organization (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "dei:EntityIncorporationDateOfIncorporation", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "dei:EntityIncorporationDateOfIncorporation", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R32": { "role": "http://brightgreen.us/role/GoingConcernAndBasisOfPresentationDetailsNarrative", "longName": "00000032 - Disclosure - Going Concern and Basis of Presentation (Details Narrative)", "shortName": "Going Concern and Basis of Presentation (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "BGXX:WorkingCapitalDeficit", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:LiquidationBasisOfAccountingTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R33": { "role": "http://brightgreen.us/role/SummaryOfEstimatedUsefulLifeDetails", "longName": "00000033 - Disclosure - Summary of Estimated Useful Life (Details)", "shortName": "Summary of Estimated Useful Life (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "AsOf2023-12-31_us-gaap_BuildingAndBuildingImprovementsMember", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "td", "tr", "table", "BGXX:PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31_us-gaap_BuildingAndBuildingImprovementsMember", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "td", "tr", "table", "BGXX:PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R34": { "role": "http://brightgreen.us/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "longName": "00000034 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)", "shortName": "Summary of Significant Accounting Policies (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:Investments", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:FairValueOfFinancialInstrumentsPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:AdvertisingExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:AdvertisingCostsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R35": { "role": "http://brightgreen.us/role/ConcentrationOfCreditRiskDetailsNarrative", "longName": "00000035 - Disclosure - Concentration of Credit Risk (Details Narrative)", "shortName": "Concentration of Credit Risk (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:CashFDICInsuredAmount", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:ConcentrationRiskDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:CashFDICInsuredAmount", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:ConcentrationRiskDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R36": { "role": "http://brightgreen.us/role/DepositsDetailsNarrative", "longName": "00000036 - Disclosure - Deposits (Details Narrative)", "shortName": "Deposits (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "From2024-03-132024-03-13_custom_SettlementAndReleaseAgreementMember_us-gaap_SubsequentEventMember", "name": "us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:DepositLiabilitiesDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": null }, "R37": { "role": "http://brightgreen.us/role/ScheduleOfFinancialStatementInformationDetails", "longName": "00000037 - Disclosure - Schedule of Financial Statement Information (Details)", "shortName": "Schedule of Financial Statement Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:AssetsCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2023-09-30_custom_AlterolaBiotechIncMember", "name": "us-gaap:AssetsCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "srt:ScheduleOfCondensedFinancialStatementsTableTextBlock", "us-gaap:InvestmentTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R38": { "role": "http://brightgreen.us/role/ScheduleOfEquityMethodInvestmentInAlterolaDetails", "longName": "00000038 - Disclosure - Schedule of Equity Method Investment in Alterola (Details)", "shortName": "Schedule of Equity Method Investment in Alterola (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "AsOf2022-12-31", "name": "us-gaap:EquityMethodInvestments", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2022-01-012022-12-31_custom_AlterolaBiotechIncMember407091921", "name": "us-gaap:MinorityInterestPeriodIncreaseDecrease", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:EquityMethodInvestmentsTextBlock", "us-gaap:InvestmentTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R39": { "role": "http://brightgreen.us/role/EquityMethodInvestmentInAlterolaDetailsNarrative", "longName": "00000039 - Disclosure - Equity Method Investment in Alterola (Details Narrative)", "shortName": "Equity Method Investment in Alterola (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:CommonStockSharesAuthorized", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-01-012023-12-31_custom_VotingAgreementMember", "name": "us-gaap:SaleOfStockConsiderationReceivedOnTransaction", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:InvestmentTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R40": { "role": "http://brightgreen.us/role/ScheduleOfPropertyPlantAndEquipmentDetails", "longName": "00000040 - Disclosure - Schedule of Property Plant and Equipment (Details)", "shortName": "Schedule of Property Plant and Equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:FurnitureAndFixturesGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:FurnitureAndFixturesGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R41": { "role": "http://brightgreen.us/role/PropertyPlantAndEquipmentDetailsNarrative", "longName": "00000041 - Disclosure - Property, Plant, and Equipment (Details Narrative)", "shortName": "Property, Plant, and Equipment (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "AsOf2022-01-01_custom_GrantGreenhouseGrowersIncMember_custom_RealEstateOptionAgreementOneMember", "name": "us-gaap:AreaOfLand", "unitRef": "Acre", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2022-01-01_custom_GrantGreenhouseGrowersIncMember_custom_RealEstateOptionAgreementOneMember", "name": "us-gaap:AreaOfLand", "unitRef": "Acre", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R42": { "role": "http://brightgreen.us/role/ScheduleOfIntangibleAssetsDetails", "longName": "00000042 - Disclosure - Schedule of Intangible Assets (Details)", "shortName": "Schedule of Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:FiniteLivedLicenseAgreementsGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:FiniteLivedLicenseAgreementsGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R43": { "role": "http://brightgreen.us/role/CommitmentsDetailsNarrative", "longName": "00000043 - Disclosure - Commitments (Details Narrative)", "shortName": "Commitments (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "AsOf2022-12-31", "name": "us-gaap:PropertyPlantAndEquipmentNet", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2022-12-31", "name": "us-gaap:ConstructionContractCostProgressPaymentOffset", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:CommitmentsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R44": { "role": "http://brightgreen.us/role/RelatedPartyLineOfCreditNoteDetailsNarrative", "longName": "00000044 - Disclosure - Related Party Line of Credit Note (Details Narrative)", "shortName": "Related Party Line of Credit Note (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "From2023-02-012023-02-01", "name": "us-gaap:RepaymentsOfRelatedPartyDebt", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "BGXX:RelatedPartyLineOfCreditTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-02-012023-02-01", "name": "us-gaap:RepaymentsOfRelatedPartyDebt", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "BGXX:RelatedPartyLineOfCreditTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R45": { "role": "http://brightgreen.us/role/StockholdersEquityDetailsNarrative", "longName": "00000045 - Disclosure - Stockholders\u2019 Equity (Details Narrative)", "shortName": "Stockholders\u2019 Equity (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:CommonStockSharesAuthorized", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-09-012023-09-30", "name": "us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R46": { "role": "http://brightgreen.us/role/ScheduleOfFairValueOfStockOptionsDetails", "longName": "00000046 - Disclosure - Schedule of Fair Value of The Stock Options (Details)", "shortName": "Schedule of Fair Value of The Stock Options (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R47": { "role": "http://brightgreen.us/role/ScheduleOfSummarizesStockOptionActivityDetails", "longName": "00000047 - Disclosure - Schedule of Summarizes Stock Option Activity (Details)", "shortName": "Schedule of Summarizes Stock Option Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R48": { "role": "http://brightgreen.us/role/Stock-basedCompensationDetailsNarrative", "longName": "00000048 - Disclosure - Stock-Based Compensation (Details Narrative)", "shortName": "Stock-Based Compensation (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "From2023-11-162023-11-16", "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-11-162023-11-16", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R49": { "role": "http://brightgreen.us/role/ScheduleOfIncomeTaxProvisionDetails", "longName": "00000049 - Disclosure - Schedule of Income Tax Provision (Details)", "shortName": "Schedule of Income Tax Provision (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:DeferredFederalIncomeTaxExpenseBenefit", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R50": { "role": "http://brightgreen.us/role/ScheduleOfFederalAndStateTaxEffectsOfTemporaryDifferencesAndCarryforwardsDetails", "longName": "00000050 - Disclosure - Schedule of Federal and State Tax Effects of Temporary Differences and Carryforwards (Details)", "shortName": "Schedule of Federal and State Tax Effects of Temporary Differences and Carryforwards (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:DeferredTaxAssetsOther", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "BGXX:ScheduleOfFederalAndStateTaxEffectsOfTemporaryDifferenceAndCarryforwardsTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:DeferredTaxAssetsOther", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "BGXX:ScheduleOfFederalAndStateTaxEffectsOfTemporaryDifferenceAndCarryforwardsTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R51": { "role": "http://brightgreen.us/role/IncomeTaxesDetailsNarrative", "longName": "00000051 - Disclosure - Income Taxes (Details Narrative)", "shortName": "Income Taxes (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R52": { "role": "http://brightgreen.us/role/RelatedPartyTransactionsDetailsNarrative", "longName": "00000052 - Disclosure - Related Party Transactions (Details Narrative)", "shortName": "Related Party Transactions (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31_custom_ExecutiveChairmanMember_us-gaap_AccruedLiabilitiesMember", "name": "us-gaap:OtherLiabilities", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R53": { "role": "http://brightgreen.us/role/ContingenciesDetailsNarrative", "longName": "00000053 - Disclosure - Contingencies (Details Narrative)", "shortName": "Contingencies (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:LossContingencyActionsTakenByDefendant", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "p", "us-gaap:LossContingencyDisclosures", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:LossContingencyActionsTakenByDefendant", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "p", "us-gaap:LossContingencyDisclosures", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R54": { "role": "http://brightgreen.us/role/SubsequentEventsDetailsNarrative", "longName": "00000054 - Disclosure - Subsequent Events (Details Narrative)", "shortName": "Subsequent Events (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "AsOf2023-08-31", "name": "us-gaap:SharesIssuedPricePerShare", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "BGXX:RelatedPartyLineOfCreditTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-04-092024-04-09_us-gaap_SubsequentEventMember", "name": "us-gaap:ProceedsFromRelatedPartyDebt", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://brightgreen.us/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://brightgreen.us/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accounts payable (Notes 14 and 16)", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r20", "r539" ] }, "us-gaap_AccountsPayableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableMember", "presentation": [ "http://brightgreen.us/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Accounts Payable [Member]", "documentation": "Obligations incurred and payable to vendors for goods and services received." } } }, "auth_ref": [ "r18" ] }, "BGXX_AccreditedInvestorAndExistingStockholderMember": { "xbrltype": "domainItemType", "nsuri": "http://brightgreen.us/20231231", "localname": "AccreditedInvestorAndExistingStockholderMember", "presentation": [ "http://brightgreen.us/role/DescriptionOfBusinessAndOrganizationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Accredited Investor and Existing Stockholder [Member]", "documentation": "Accredited Investor and Existing Stockholder [Member]" } } }, "auth_ref": [] }, "us-gaap_AccruedBonusesCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedBonusesCurrentAndNoncurrent", "crdr": "credit", "presentation": [ "http://brightgreen.us/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Accrued bonus", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements." } } }, "auth_ref": [ "r76" ] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://brightgreen.us/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://brightgreen.us/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accrued liabilities (Note 14)", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r23" ] }, "us-gaap_AccruedLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedLiabilitiesMember", "presentation": [ "http://brightgreen.us/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Accrued Liabilities [Member]", "documentation": "This item represents obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered." } } }, "auth_ref": [ "r23" ] }, "us-gaap_AccumulatedCapitalizedInterestCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedCapitalizedInterestCosts", "crdr": "debit", "presentation": [ "http://brightgreen.us/role/PropertyPlantAndEquipmentDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Interest costs capitalized", "documentation": "Amount of accumulated interest costs capitalized as part of property, plant and equipment cost basis." } } }, "auth_ref": [] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://brightgreen.us/role/ScheduleOfPropertyPlantAndEquipmentDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://brightgreen.us/role/ScheduleOfPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Accumulated depreciation", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r48", "r165", "r414" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "presentation": [ "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r172", "r173", "r364", "r365", "r366", "r367", "r368", "r369" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "presentation": [ "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r172", "r173", "r364", "r365", "r366", "r367", "r368", "r369" ] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "calculation": { "http://brightgreen.us/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://brightgreen.us/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Additional paid-in capital (Notes 11)", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": [ "r88" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://brightgreen.us/role/StatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r315", "r316", "r317", "r436", "r592", "r593", "r594", "r636", "r656" ] }, "BGXX_AdjustmentToConstructionInProgressForCancellationOfAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://brightgreen.us/20231231", "localname": "AdjustmentToConstructionInProgressForCancellationOfAgreement", "crdr": "credit", "presentation": [ "http://brightgreen.us/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustment to construction in progress for cancellation of agreement", "documentation": "Adjustment to construction in progress for cancellation of agreement." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://brightgreen.us/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net cash used in operating activities:" } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition", "crdr": "credit", "presentation": [ "http://brightgreen.us/role/StatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stock options issued for services (Notes 11 and 12)", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_AdvertisingCostsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdvertisingCostsPolicyTextBlock", "presentation": [ "http://brightgreen.us/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Advertising Costs", "documentation": "Disclosure of accounting policy for advertising cost." } } }, "auth_ref": [ "r134" ] }, "us-gaap_AdvertisingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdvertisingExpense", "crdr": "debit", "presentation": [ "http://brightgreen.us/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Advertising cost", "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line." } } }, "auth_ref": [ "r318" ] }, "BGXX_AlterolaBiotechIncMember": { "xbrltype": "domainItemType", "nsuri": "http://brightgreen.us/20231231", "localname": "AlterolaBiotechIncMember", "presentation": [ "http://brightgreen.us/role/EquityMethodInvestmentInAlterolaDetailsNarrative", "http://brightgreen.us/role/ScheduleOfEquityMethodInvestmentInAlterolaDetails", "http://brightgreen.us/role/ScheduleOfFinancialStatementInformationDetails" ], "lang": { "en-us": { "role": { "label": "Alterola Biotech, Inc. [Member]", "documentation": "Alterola Biotech, Inc. [Member]" } } }, "auth_ref": [] }, "BGXX_AmendedUnsecuredLineOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://brightgreen.us/20231231", "localname": "AmendedUnsecuredLineOfCreditMember", "presentation": [ "http://brightgreen.us/role/RelatedPartyLineOfCreditNoteDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Amended Unsecured Line of Credit [Member]", "documentation": "Amended Unsecured Line Of Credit [Member]" } } }, "auth_ref": [] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://brightgreen.us/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://brightgreen.us/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://brightgreen.us/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r566" ] }, "us-gaap_AreaOfLand": { "xbrltype": "areaItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AreaOfLand", "presentation": [ "http://brightgreen.us/role/PropertyPlantAndEquipmentDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Area of land for purchase", "documentation": "Area of land held." } } }, "auth_ref": [] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": [ "http://brightgreen.us/role/CommitmentsDetailsNarrative", "http://brightgreen.us/role/DepositsDetailsNarrative", "http://brightgreen.us/role/EquityMethodInvestmentInAlterolaDetailsNarrative", "http://brightgreen.us/role/PropertyPlantAndEquipmentDetailsNarrative", "http://brightgreen.us/role/Stock-basedCompensationDetailsNarrative", "http://brightgreen.us/role/StockholdersEquityDetailsNarrative", "http://brightgreen.us/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r342" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://brightgreen.us/role/BalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://brightgreen.us/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r126", "r167", "r184", "r211", "r224", "r228", "r239", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r343", "r345", "r359", "r407", "r464", "r539", "r551", "r601", "r602", "r642" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://brightgreen.us/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://brightgreen.us/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://brightgreen.us/role/BalanceSheets", "http://brightgreen.us/role/ScheduleOfFinancialStatementInformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "verboseLabel": "Current assets", "label": "Assets, Current", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r162", "r168", "r184", "r239", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r343", "r345", "r359", "r539", "r601", "r602", "r642" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://brightgreen.us/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current assets" } } }, "auth_ref": [] }, "us-gaap_AssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsNoncurrent", "crdr": "debit", "presentation": [ "http://brightgreen.us/role/ScheduleOfFinancialStatementInformationDetails" ], "lang": { "en-us": { "role": { "label": "Non-current assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r184", "r239", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r343", "r345", "r359", "r601", "r602", "r642" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://brightgreen.us/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r566" ] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorFirmId", "presentation": [ "http://brightgreen.us/role/Cover" ], "lang": { "en-us": { "role": { "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": [ "r563", "r565", "r566" ] }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorLocation", "presentation": [ "http://brightgreen.us/role/Cover" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "auth_ref": [ "r563", "r565", "r566" ] }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorName", "presentation": [ "http://brightgreen.us/role/Cover" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "auth_ref": [ "r563", "r565", "r566" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://brightgreen.us/role/RelatedPartyTransactionsDetailsNarrative", "http://brightgreen.us/role/Stock-basedCompensationDetailsNarrative", "http://brightgreen.us/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314" ] }, "us-gaap_BalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BalanceSheetLocationAxis", "presentation": [ "http://brightgreen.us/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Balance Sheet Location [Axis]", "documentation": "Information by location on balance sheet (statement of financial position)." } } }, "auth_ref": [] }, "us-gaap_BalanceSheetLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BalanceSheetLocationDomain", "presentation": [ "http://brightgreen.us/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position)." } } }, "auth_ref": [ "r67", "r68" ] }, "us-gaap_BankingAndThriftDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BankingAndThriftDisclosureTextBlock", "lang": { "en-us": { "role": { "label": "Banking and Thrift Disclosure [Text Block]", "documentation": "The entire disclosure for financial services specifically banking and thrift entities at the end of the reporting period." } } }, "auth_ref": [ "r125" ] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://brightgreen.us/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Basis of Measurement", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "BGXX_BoardMemberMember": { "xbrltype": "domainItemType", "nsuri": "http://brightgreen.us/20231231", "localname": "BoardMemberMember", "presentation": [ "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Board Member [Member]", "documentation": "Board Member [Member]" } } }, "auth_ref": [] }, "BGXX_BoardOfDirectorsMember": { "xbrltype": "domainItemType", "nsuri": "http://brightgreen.us/20231231", "localname": "BoardOfDirectorsMember", "presentation": [ "http://brightgreen.us/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Board of Directors [Member]", "documentation": "Board of Directors [Member]" } } }, "auth_ref": [] }, "us-gaap_BuildingAndBuildingImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BuildingAndBuildingImprovementsMember", "presentation": [ "http://brightgreen.us/role/SummaryOfEstimatedUsefulLifeDetails" ], "lang": { "en-us": { "role": { "label": "Building and Building Improvements [Member]", "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing." } } }, "auth_ref": [] }, "us-gaap_BuildingsAndImprovementsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BuildingsAndImprovementsGross", "crdr": "debit", "calculation": { "http://brightgreen.us/role/ScheduleOfPropertyPlantAndEquipmentDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://brightgreen.us/role/ScheduleOfPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Building and improvements", "documentation": "Amount before accumulated depreciation of building structures held for productive use including addition, improvement, or renovation to the structure, including, but not limited to, interior masonry, interior flooring, electrical, and plumbing." } } }, "auth_ref": [ "r107" ] }, "BGXX_CFOAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://brightgreen.us/20231231", "localname": "CFOAgreementMember", "presentation": [ "http://brightgreen.us/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "CFO Agreement [Member]", "documentation": "CFO Agreement [Member]" } } }, "auth_ref": [] }, "BGXX_CapitalTransactionDueToRelatedParty": { "xbrltype": "monetaryItemType", "nsuri": "http://brightgreen.us/20231231", "localname": "CapitalTransactionDueToRelatedParty", "crdr": "credit", "presentation": [ "http://brightgreen.us/role/RelatedPartyLineOfCreditNoteDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Capital transaction due to related party", "documentation": "Capital transaction due to related party" } } }, "auth_ref": [] }, "us-gaap_Cash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Cash", "crdr": "debit", "calculation": { "http://brightgreen.us/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://brightgreen.us/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Cash", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r133", "r408", "r437", "r459", "r539", "r551", "r580" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "presentation": [ "http://brightgreen.us/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "periodStartLabel": "CASH, BEGINNING OF YEAR", "periodEndLabel": "CASH, END OF YEAR", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r33", "r99", "r181" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://brightgreen.us/role/StatementsOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://brightgreen.us/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "NET DECREASE IN CASH", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r2", "r99" ] }, "us-gaap_CashFDICInsuredAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashFDICInsuredAmount", "crdr": "debit", "presentation": [ "http://brightgreen.us/role/ConcentrationOfCreditRiskDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Cash FDIC insured amount", "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation." } } }, "auth_ref": [] }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "presentation": [ "http://brightgreen.us/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "SUPPLEMENTAL NON-CASH INVESTING & FINANCING ACTIVITIES" } } }, "auth_ref": [] }, "BGXX_ChangeInFairValueOfAssetsAndLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://brightgreen.us/20231231", "localname": "ChangeInFairValueOfAssetsAndLiabilitiesNet", "crdr": "debit", "calculation": { "http://brightgreen.us/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_OtherExpenses", "weight": 1.0, "order": 3.0 }, "http://brightgreen.us/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://brightgreen.us/role/EquityMethodInvestmentInAlterolaDetailsNarrative", "http://brightgreen.us/role/ScheduleOfEquityMethodInvestmentInAlterolaDetails", "http://brightgreen.us/role/StatementsOfCashFlows", "http://brightgreen.us/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Change in fair value of assets, net (Note 6)", "verboseLabel": "Change in fair value of assets, net", "negatedLabel": "Change in fair value of assets", "terseLabel": "Change in fair value of assets and liabilities net", "documentation": "Change in fair value of assets and liabilities, net" } } }, "auth_ref": [] }, "BGXX_ChangeInFairValueOfVotingAgreementDerivative": { "xbrltype": "monetaryItemType", "nsuri": "http://brightgreen.us/20231231", "localname": "ChangeInFairValueOfVotingAgreementDerivative", "crdr": "debit", "calculation": { "http://brightgreen.us/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 }, "http://brightgreen.us/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_OtherExpenses", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://brightgreen.us/role/StatementsOfCashFlows", "http://brightgreen.us/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Change in fair value of voting agreement derivative", "documentation": "Change in fair value of voting agreement derivative" } } }, "auth_ref": [] }, "srt_ChiefExecutiveOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ChiefExecutiveOfficerMember", "presentation": [ "http://brightgreen.us/role/ContingenciesDetailsNarrative", "http://brightgreen.us/role/RelatedPartyTransactionsDetailsNarrative", "http://brightgreen.us/role/Stock-basedCompensationDetailsNarrative", "http://brightgreen.us/role/StockholdersEquityDetailsNarrative", "http://brightgreen.us/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Chief Executive Officer [Member]", "documentation": "Person with designation of chief executive officer." } } }, "auth_ref": [ "r596" ] }, "srt_ChiefFinancialOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ChiefFinancialOfficerMember", "presentation": [ "http://brightgreen.us/role/RelatedPartyTransactionsDetailsNarrative", "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Chief Financial Officer [Member]", "documentation": "Person with designation of chief financial officer." } } }, "auth_ref": [ "r596" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://brightgreen.us/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": [ "http://brightgreen.us/role/DescriptionOfBusinessAndOrganizationDetailsNarrative", "http://brightgreen.us/role/RelatedPartyLineOfCreditNoteDetailsNarrative", "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Exercise price", "verboseLabel": "Warrants price per share", "terseLabel": "Warrant exercise price", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": [ "r279" ] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": [ "http://brightgreen.us/role/DescriptionOfBusinessAndOrganizationDetailsNarrative", "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrants to purchase shares", "verboseLabel": "Warrants to purchase common stock", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": [ "r279" ] }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": [ "http://brightgreen.us/role/GoingConcernAndBasisOfPresentationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Related party line of credit paid down in exchange of shares", "documentation": "Number of warrants or rights outstanding." } } }, "auth_ref": [] }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "presentation": [ "http://brightgreen.us/role/DepositsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r342" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsDisclosureTextBlock", "presentation": [ "http://brightgreen.us/role/Commitments" ], "lang": { "en-us": { "role": { "label": "Commitments", "documentation": "The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights." } } }, "auth_ref": [ "r109" ] }, "BGXX_CommonStockAndWarrantsIssuedForCashlessConversionOfRelatedPartyLineOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://brightgreen.us/20231231", "localname": "CommonStockAndWarrantsIssuedForCashlessConversionOfRelatedPartyLineOfCredit", "crdr": "credit", "presentation": [ "http://brightgreen.us/role/StatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Common stock and warrants issued for a cashless conversion of related party LOC, net of issuance costs of $10,000 (Notes 10 and 11)", "documentation": "Common stock and warrants issued for cashless conversion of related party line of credit." } } }, "auth_ref": [] }, "BGXX_CommonStockAndWarrantsIssuedForCashlessConversionOfRelatedPartyLineOfCreditShares": { "xbrltype": "sharesItemType", "nsuri": "http://brightgreen.us/20231231", "localname": "CommonStockAndWarrantsIssuedForCashlessConversionOfRelatedPartyLineOfCreditShares", "presentation": [ "http://brightgreen.us/role/StatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Common stock and warrants issued for a cashless conversion of related party LOC, net of issuance costs of $10,000 (Notes 10 and 11), shares", "documentation": "Common stock and warrants issued for cashless conversion of related party line of credit, shares." } } }, "auth_ref": [] }, "BGXX_CommonStockAndWarrantsIssuedSharesForCashInPrivatePlacements": { "xbrltype": "sharesItemType", "nsuri": "http://brightgreen.us/20231231", "localname": "CommonStockAndWarrantsIssuedSharesForCashInPrivatePlacements", "presentation": [ "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Shares of warrants to purchase", "documentation": "Common stock and warrants issued shares for cash in private placements." } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://brightgreen.us/role/DescriptionOfBusinessAndOrganizationDetailsNarrative", "http://brightgreen.us/role/RelatedPartyTransactionsDetailsNarrative", "http://brightgreen.us/role/StatementsOfChangesInStockholdersEquity", "http://brightgreen.us/role/Stock-basedCompensationDetailsNarrative", "http://brightgreen.us/role/StockholdersEquityDetailsNarrative", "http://brightgreen.us/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r541", "r542", "r543", "r545", "r546", "r547", "r548", "r592", "r593", "r636", "r652", "r656" ] }, "BGXX_CommonStockOneMember": { "xbrltype": "domainItemType", "nsuri": "http://brightgreen.us/20231231", "localname": "CommonStockOneMember", "presentation": [ "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common Stock One [Member]", "documentation": "Common Stock One [Member]" } } }, "auth_ref": [] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://brightgreen.us/role/BalanceSheetsParenthetical", "http://brightgreen.us/role/DescriptionOfBusinessAndOrganizationDetailsNarrative", "http://brightgreen.us/role/EquityMethodInvestmentInAlterolaDetailsNarrative", "http://brightgreen.us/role/RelatedPartyLineOfCreditNoteDetailsNarrative", "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common stock, par value", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r87" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://brightgreen.us/role/BalanceSheetsParenthetical", "http://brightgreen.us/role/EquityMethodInvestmentInAlterolaDetailsNarrative", "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common stock, shares authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r87", "r451" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://brightgreen.us/role/BalanceSheetsParenthetical", "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common stock, shares issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r87" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://brightgreen.us/role/BalanceSheetsParenthetical", "http://brightgreen.us/role/EquityMethodInvestmentInAlterolaDetailsNarrative", "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common stock, shares outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r16", "r87", "r451", "r470", "r656", "r657" ] }, "BGXX_CommonStockThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://brightgreen.us/20231231", "localname": "CommonStockThreeMember", "presentation": [ "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common Stock Three [Member]", "documentation": "Common Stock Three [Member]" } } }, "auth_ref": [] }, "BGXX_CommonStockTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://brightgreen.us/20231231", "localname": "CommonStockTwoMember", "presentation": [ "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common Stock Two [Member]", "documentation": "Common Stock Two [Member]" } } }, "auth_ref": [] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://brightgreen.us/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://brightgreen.us/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Common stock; $.0001 par value; 500,000,000 stock authorized; 184,758,818 and 173,304,800 stock issued and outstanding at December 31, 2023 and December 31, 2022, respectively (Note 11)", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r87", "r410", "r539" ] }, "us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock", "presentation": [ "http://brightgreen.us/role/Stock-basedCompensation" ], "lang": { "en-us": { "role": { "label": "Stock-Based Compensation", "documentation": "The entire disclosure of an entity's employee compensation and benefit plans, excluding share-based compensation and including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, life insurance, severance, health care, unemployment and other benefit plans." } } }, "auth_ref": [ "r114", "r116", "r117" ] }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CompensationAndRetirementDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Retirement Benefits [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CompensationExpenseExcludingCostOfGoodAndServiceSold", "crdr": "debit", "presentation": [ "http://brightgreen.us/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Unpaid cash renumeration and bonus compensation", "documentation": "Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit. Other employee benefit expense includes, but is not limited to, service component of net periodic benefit cost for defined benefit plan. Excludes compensation cost in cost of good and service sold." } } }, "auth_ref": [ "r586" ] }, "us-gaap_CompensationRelatedCostsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CompensationRelatedCostsPolicyTextBlock", "presentation": [ "http://brightgreen.us/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "verboseLabel": "Stock-Based Compensation", "label": "Compensation Related Costs, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense." } } }, "auth_ref": [ "r60" ] }, "us-gaap_ConcentrationRiskDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskDisclosureTextBlock", "presentation": [ "http://brightgreen.us/role/ConcentrationOfCreditRisk" ], "lang": { "en-us": { "role": { "label": "Concentration of Credit Risk", "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date." } } }, "auth_ref": [ "r103" ] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConsolidationPolicyTextBlock", "presentation": [ "http://brightgreen.us/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Principles of Consolidation", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": [ "r66", "r528" ] }, "us-gaap_ConstructionContractCostProgressPaymentOffset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConstructionContractCostProgressPaymentOffset", "crdr": "credit", "presentation": [ "http://brightgreen.us/role/CommitmentsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Construction contract paid", "documentation": "Amount of progress payment netted against construction contract cost." } } }, "auth_ref": [ "r136" ] }, "us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConstructionInProgressExpendituresIncurredButNotYetPaid", "crdr": "credit", "presentation": [ "http://brightgreen.us/role/PropertyPlantAndEquipmentDetailsNarrative", "http://brightgreen.us/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Agreement with vendor to cancel", "documentation": "Future cash outflow to pay for construction in progress expenditures that have occurred." } } }, "auth_ref": [ "r35", "r36", "r37" ] }, "us-gaap_ConstructionInProgressGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConstructionInProgressGross", "crdr": "debit", "calculation": { "http://brightgreen.us/role/ScheduleOfPropertyPlantAndEquipmentDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://brightgreen.us/role/ScheduleOfPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Construction in progress", "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service." } } }, "auth_ref": [ "r107" ] }, "us-gaap_ConstructionInProgressMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConstructionInProgressMember", "presentation": [ "http://brightgreen.us/role/PropertyPlantAndEquipmentDetailsNarrative", "http://brightgreen.us/role/RelatedPartyLineOfCreditNoteDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Construction in Progress [Member]", "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service." } } }, "auth_ref": [] }, "BGXX_ConsultantMember": { "xbrltype": "domainItemType", "nsuri": "http://brightgreen.us/20231231", "localname": "ConsultantMember", "presentation": [ "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Consultant [Member]", "documentation": "Consultant [Member]" } } }, "auth_ref": [] }, "BGXX_ConsultantsMember": { "xbrltype": "domainItemType", "nsuri": "http://brightgreen.us/20231231", "localname": "ConsultantsMember", "presentation": [ "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Consultants [Member]", "documentation": "Consultants [Member]" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://brightgreen.us/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "BGXX_CreditAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://brightgreen.us/20231231", "localname": "CreditAgreementMember", "presentation": [ "http://brightgreen.us/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Credit Agreement [Member]", "documentation": "Credit Agreement [Member]" } } }, "auth_ref": [] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityAxis", "presentation": [ "http://brightgreen.us/role/RelatedPartyLineOfCreditNoteDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityDomain", "presentation": [ "http://brightgreen.us/role/RelatedPartyLineOfCreditNoteDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [] }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrentFederalTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://brightgreen.us/role/ScheduleOfIncomeTaxProvisionDetails": { "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://brightgreen.us/role/ScheduleOfIncomeTaxProvisionDetails" ], "lang": { "en-us": { "role": { "label": "Federal", "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r575", "r590", "r635" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://brightgreen.us/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrentIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://brightgreen.us/role/ScheduleOfIncomeTaxProvisionDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://brightgreen.us/role/ScheduleOfIncomeTaxProvisionDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total current (benefit) provision", "label": "Current Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations." } } }, "auth_ref": [ "r121", "r331", "r337", "r590" ] }, "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract", "presentation": [ "http://brightgreen.us/role/ScheduleOfIncomeTaxProvisionDetails" ], "lang": { "en-us": { "role": { "label": "Current:" } } }, "auth_ref": [] }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrentStateAndLocalTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://brightgreen.us/role/ScheduleOfIncomeTaxProvisionDetails": { "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://brightgreen.us/role/ScheduleOfIncomeTaxProvisionDetails" ], "lang": { "en-us": { "role": { "label": "State", "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r575", "r590", "r635" ] }, "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtConversionConvertedInstrumentSharesIssued1", "presentation": [ "http://brightgreen.us/role/GoingConcernAndBasisOfPresentationDetailsNarrative", "http://brightgreen.us/role/RelatedPartyLineOfCreditNoteDetailsNarrative", "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Line of credit paid down in exchange of shares", "verboseLabel": "Debt conversion, shares issued", "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period." } } }, "auth_ref": [ "r35", "r37" ] }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentConvertibleConversionPrice1", "presentation": [ "http://brightgreen.us/role/GoingConcernAndBasisOfPresentationDetailsNarrative", "http://brightgreen.us/role/RelatedPartyLineOfCreditNoteDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common stock value per share", "verboseLabel": "Conversion of principal price per share", "documentation": "The price per share of the conversion feature embedded in the debt instrument." } } }, "auth_ref": [ "r111", "r264" ] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://brightgreen.us/role/RelatedPartyLineOfCreditNoteDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Interest rate stated percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r25", "r263" ] }, "us-gaap_DebtInstrumentPeriodicPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentPeriodicPayment", "crdr": "debit", "presentation": [ "http://brightgreen.us/role/PropertyPlantAndEquipmentDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Monthly payments", "documentation": "Amount of the required periodic payments including both interest and principal payments." } } }, "auth_ref": [ "r26", "r78" ] }, "BGXX_DecreaseInFairValueOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://brightgreen.us/20231231", "localname": "DecreaseInFairValueOfWarrants", "crdr": "debit", "presentation": [ "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Decrease in fair value of warrants", "documentation": "Decrease in fair value of warrants." } } }, "auth_ref": [] }, "us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems", "presentation": [ "http://brightgreen.us/role/ContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredFederalIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://brightgreen.us/role/ScheduleOfIncomeTaxProvisionDetails": { "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://brightgreen.us/role/ScheduleOfIncomeTaxProvisionDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Federal", "label": "Deferred Federal Income Tax Expense (Benefit)", "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r590", "r634", "r635" ] }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://brightgreen.us/role/ScheduleOfIncomeTaxProvisionDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://brightgreen.us/role/ScheduleOfIncomeTaxProvisionDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total current (benefit) provision", "label": "Deferred Income Tax Expense (Benefit)", "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r8", "r121", "r143", "r336", "r337", "r590" ] }, "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract", "presentation": [ "http://brightgreen.us/role/ScheduleOfIncomeTaxProvisionDetails" ], "lang": { "en-us": { "role": { "label": "Deferred:" } } }, "auth_ref": [] }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://brightgreen.us/role/ScheduleOfIncomeTaxProvisionDetails": { "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://brightgreen.us/role/ScheduleOfIncomeTaxProvisionDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "State", "label": "Deferred State and Local Income Tax Expense (Benefit)", "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r590", "r634", "r635" ] }, "us-gaap_DeferredTaxAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsGross", "crdr": "debit", "calculation": { "http://brightgreen.us/role/ScheduleOfFederalAndStateTaxEffectsOfTemporaryDifferencesAndCarryforwardsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://brightgreen.us/role/ScheduleOfFederalAndStateTaxEffectsOfTemporaryDifferencesAndCarryforwardsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total deferred tax assets", "label": "Deferred Tax Assets, Gross", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r326" ] }, "us-gaap_DeferredTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsNet", "crdr": "debit", "presentation": [ "http://brightgreen.us/role/ScheduleOfFederalAndStateTaxEffectsOfTemporaryDifferencesAndCarryforwardsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Deferred tax assets, net of valuation allowance", "label": "Deferred Tax Assets, Net of Valuation Allowance", "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r632" ] }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "crdr": "debit", "calculation": { "http://brightgreen.us/role/ScheduleOfFederalAndStateTaxEffectsOfTemporaryDifferencesAndCarryforwardsDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://brightgreen.us/role/ScheduleOfFederalAndStateTaxEffectsOfTemporaryDifferencesAndCarryforwardsDetails" ], "lang": { "en-us": { "role": { "label": "Net operating loss carry over", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards." } } }, "auth_ref": [ "r64", "r633" ] }, "us-gaap_DeferredTaxAssetsOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsOther", "crdr": "debit", "calculation": { "http://brightgreen.us/role/ScheduleOfFederalAndStateTaxEffectsOfTemporaryDifferencesAndCarryforwardsDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://brightgreen.us/role/ScheduleOfFederalAndStateTaxEffectsOfTemporaryDifferencesAndCarryforwardsDetails" ], "lang": { "en-us": { "role": { "label": "Other", "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other." } } }, "auth_ref": [ "r64", "r633" ] }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsValuationAllowance", "crdr": "credit", "presentation": [ "http://brightgreen.us/role/ScheduleOfFederalAndStateTaxEffectsOfTemporaryDifferencesAndCarryforwardsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Less: valuation allowance", "label": "Deferred Tax Assets, Valuation Allowance", "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized." } } }, "auth_ref": [ "r327" ] }, "us-gaap_DefinedBenefitPlanDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanDisclosureLineItems", "presentation": [ "http://brightgreen.us/role/BalanceSheets", "http://brightgreen.us/role/GoingConcernAndBasisOfPresentationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan Disclosure [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_DepositLiabilitiesDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepositLiabilitiesDisclosuresTextBlock", "presentation": [ "http://brightgreen.us/role/Deposits" ], "lang": { "en-us": { "role": { "label": "Deposits", "documentation": "The entire disclosure for deposit liabilities including data and tables. It may include a description of the entity's deposit liabilities, the aggregate amount of time deposits (including certificates of deposit) in denominations of $100,000 or more at the balance sheet date; the aggregate amount of any demand deposits that have been reclassified as loan balances, such as overdrafts, at the balance sheet date; deposits that are received on terms other than those in the normal course of business, the amount of accrued interest on deposit liabilities; securities, mortgage loans or other financial instruments that serve as collateral for deposits; for time deposits having a remaining term of more than one year, the aggregate amount of maturities for each of the five years following the balance sheet date; and the weighted average interest rate for all deposit liabilities held by the entity." } } }, "auth_ref": [ "r13", "r75", "r147", "r149" ] }, "us-gaap_Deposits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Deposits", "crdr": "credit", "presentation": [ "http://brightgreen.us/role/CommitmentsDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Deposits", "label": "Deposits [Default Label]", "documentation": "The aggregate of all deposit liabilities held by the entity, including foreign and domestic, interest and noninterest bearing; may include demand deposits, saving deposits, Negotiable Order of Withdrawal (NOW) and time deposits among others." } } }, "auth_ref": [ "r75" ] }, "us-gaap_DepositsAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepositsAssetsNoncurrent", "crdr": "debit", "calculation": { "http://brightgreen.us/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://brightgreen.us/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Deposits (Notes 5, 9, and 16)", "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer." } } }, "auth_ref": [ "r583" ] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Depreciation", "crdr": "debit", "calculation": { "http://brightgreen.us/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 }, "http://brightgreen.us/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://brightgreen.us/role/StatementsOfCashFlows", "http://brightgreen.us/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r8", "r47" ] }, "srt_DirectorMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "DirectorMember", "presentation": [ "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Director [Member]", "documentation": "Person serving on board of directors." } } }, "auth_ref": [ "r596", "r653" ] }, "BGXX_DirectorOneMember": { "xbrltype": "domainItemType", "nsuri": "http://brightgreen.us/20231231", "localname": "DirectorOneMember", "presentation": [ "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Director One [Member]", "documentation": "Director One [Member]" } } }, "auth_ref": [] }, "BGXX_DirectorThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://brightgreen.us/20231231", "localname": "DirectorThreeMember", "presentation": [ "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Director Three [Member]", "documentation": "Director Three [Member]" } } }, "auth_ref": [] }, "BGXX_DirectorTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://brightgreen.us/20231231", "localname": "DirectorTwoMember", "presentation": [ "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Director Two [Member]", "documentation": "Director Two [Member]" } } }, "auth_ref": [] }, "BGXX_DirectorsMember": { "xbrltype": "domainItemType", "nsuri": "http://brightgreen.us/20231231", "localname": "DirectorsMember", "presentation": [ "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Directors [Member]", "documentation": "Directors [Member]" } } }, "auth_ref": [] }, "BGXX_DisclosureRelatedPartyLineOfCreditNoteAbstract": { "xbrltype": "stringItemType", "nsuri": "http://brightgreen.us/20231231", "localname": "DisclosureRelatedPartyLineOfCreditNoteAbstract", "lang": { "en-us": { "role": { "label": "Related Party Line Of Credit Note" } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://brightgreen.us/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r565" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://brightgreen.us/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r563", "r565", "r566" ] }, "dei_DocumentFinStmtErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFinStmtErrorCorrectionFlag", "presentation": [ "http://brightgreen.us/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Financial Statement Error Correction [Flag]", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": [ "r563", "r565", "r566", "r568" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://brightgreen.us/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://brightgreen.us/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://brightgreen.us/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://brightgreen.us/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://brightgreen.us/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r564" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://brightgreen.us/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r552" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://brightgreen.us/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r565" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://brightgreen.us/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r565" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://brightgreen.us/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r567" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://brightgreen.us/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://brightgreen.us/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r555" ] }, "us-gaap_DomesticCountryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DomesticCountryMember", "presentation": [ "http://brightgreen.us/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Domestic Tax Authority [Member]", "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile." } } }, "auth_ref": [] }, "BGXX_DueToOthersCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://brightgreen.us/20231231", "localname": "DueToOthersCurrent", "crdr": "credit", "calculation": { "http://brightgreen.us/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://brightgreen.us/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Due to others (Note 6)", "documentation": "Due to others current." } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://brightgreen.us/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Net loss per common share - basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r176", "r193", "r194", "r195", "r196", "r197", "r202", "r204", "r206", "r207", "r208", "r209", "r355", "r356", "r402", "r418", "r530" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://brightgreen.us/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Net loss per common share - diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r176", "r193", "r194", "r195", "r196", "r197", "r204", "r206", "r207", "r208", "r209", "r355", "r356", "r402", "r418", "r530" ] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerSharePolicyTextBlock", "presentation": [ "http://brightgreen.us/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Basic and Diluted Earnings (Loss) Per Share", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": [ "r38", "r39" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate", "presentation": [ "http://brightgreen.us/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Tax rate", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates." } } }, "auth_ref": [ "r338", "r631" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://brightgreen.us/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://brightgreen.us/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://brightgreen.us/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://brightgreen.us/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://brightgreen.us/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://brightgreen.us/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://brightgreen.us/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://brightgreen.us/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r558" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://brightgreen.us/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r554" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://brightgreen.us/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://brightgreen.us/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityDomain", "presentation": [ "http://brightgreen.us/role/PropertyPlantAndEquipmentDetailsNarrative", "http://brightgreen.us/role/ScheduleOfFinancialStatementInformationDetails", "http://brightgreen.us/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://brightgreen.us/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r554" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://brightgreen.us/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r572" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://brightgreen.us/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://brightgreen.us/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r554" ] }, "dei_EntityIncorporationDateOfIncorporation": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationDateOfIncorporation", "presentation": [ "http://brightgreen.us/role/DescriptionOfBusinessAndOrganizationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Date of incorporation", "documentation": "Date when an entity was incorporated" } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://brightgreen.us/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://brightgreen.us/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r569" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://brightgreen.us/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r566" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://brightgreen.us/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://brightgreen.us/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r554" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://brightgreen.us/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r554" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://brightgreen.us/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r554" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://brightgreen.us/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r554" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://brightgreen.us/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://brightgreen.us/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r570" ] }, "us-gaap_EquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquipmentMember", "presentation": [ "http://brightgreen.us/role/CommitmentsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Equipment [Member]", "documentation": "Tangible personal property used to produce goods and services." } } }, "auth_ref": [] }, "BGXX_EquippedPurchaseSharesOfCommonStock": { "xbrltype": "sharesItemType", "nsuri": "http://brightgreen.us/20231231", "localname": "EquippedPurchaseSharesOfCommonStock", "presentation": [ "http://brightgreen.us/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Equipped purchase shares of common stock", "documentation": "Equipped purchase shares of common stock." } } }, "auth_ref": [] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "BGXX_EquityCompensationPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://brightgreen.us/20231231", "localname": "EquityCompensationPlanMember", "presentation": [ "http://brightgreen.us/role/Stock-basedCompensationDetailsNarrative", "http://brightgreen.us/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Equity Compensation Plan [Member]", "documentation": "Equity Compensation Plan [Member]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://brightgreen.us/role/DescriptionOfBusinessAndOrganizationDetailsNarrative", "http://brightgreen.us/role/RelatedPartyTransactionsDetailsNarrative", "http://brightgreen.us/role/StatementsOfChangesInStockholdersEquity", "http://brightgreen.us/role/Stock-basedCompensationDetailsNarrative", "http://brightgreen.us/role/StockholdersEquityDetailsNarrative", "http://brightgreen.us/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r16", "r160", "r172", "r173", "r174", "r188", "r189", "r190", "r192", "r198", "r200", "r210", "r240", "r241", "r280", "r315", "r316", "r317", "r332", "r333", "r347", "r348", "r349", "r350", "r351", "r352", "r354", "r364", "r365", "r366", "r367", "r368", "r369", "r371", "r421", "r422", "r423", "r436", "r495" ] }, "BGXX_EquityInNetLossesOfAffiliate": { "xbrltype": "monetaryItemType", "nsuri": "http://brightgreen.us/20231231", "localname": "EquityInNetLossesOfAffiliate", "crdr": "debit", "calculation": { "http://brightgreen.us/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://brightgreen.us/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Equity in net losses of affiliate", "documentation": "Equity in net losses of affiliate." } } }, "auth_ref": [] }, "srt_EquityMethodInvesteeNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "EquityMethodInvesteeNameDomain", "presentation": [ "http://brightgreen.us/role/EquityMethodInvestmentInAlterolaDetailsNarrative", "http://brightgreen.us/role/ScheduleOfEquityMethodInvestmentInAlterolaDetails" ], "lang": { "en-us": { "role": { "documentation": "Name of investment including named security. Excludes entity that is consolidated." } } }, "auth_ref": [ "r236", "r237", "r238" ] }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestmentOwnershipPercentage", "presentation": [ "http://brightgreen.us/role/EquityMethodInvestmentInAlterolaDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Ownership percentage", "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting." } } }, "auth_ref": [ "r236" ] }, "us-gaap_EquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestments", "crdr": "debit", "calculation": { "http://brightgreen.us/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://brightgreen.us/role/BalanceSheets", "http://brightgreen.us/role/EquityMethodInvestmentInAlterolaDetailsNarrative", "http://brightgreen.us/role/ScheduleOfEquityMethodInvestmentInAlterolaDetails" ], "lang": { "en-us": { "role": { "label": "Equity method investment (Note 6)", "periodStartLabel": "Balance at December 31, 2022", "periodEndLabel": "Balance at December 31, 2023", "verboseLabel": "Equity method investments", "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized." } } }, "auth_ref": [ "r215", "r234", "r581", "r598" ] }, "us-gaap_EquityMethodInvestmentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestmentsPolicy", "presentation": [ "http://brightgreen.us/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Investment Under the Equity Method", "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received." } } }, "auth_ref": [ "r5", "r69", "r237" ] }, "us-gaap_EquityMethodInvestmentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestmentsTextBlock", "presentation": [ "http://brightgreen.us/role/EquityMethodInvestmentInAlterolaTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Equity Method Investment in Alterola", "documentation": "Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information." } } }, "auth_ref": [ "r235" ] }, "us-gaap_EscrowDeposit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EscrowDeposit", "crdr": "debit", "presentation": [ "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Escrow deposit", "documentation": "The designation of funds furnished by a borrower to a lender to assure future payments of the borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy." } } }, "auth_ref": [ "r74", "r515" ] }, "BGXX_ExecutiveChairmanMember": { "xbrltype": "domainItemType", "nsuri": "http://brightgreen.us/20231231", "localname": "ExecutiveChairmanMember", "presentation": [ "http://brightgreen.us/role/RelatedPartyTransactionsDetailsNarrative", "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Executive Chairman [Member]", "documentation": "Executive Chairman [Member]" } } }, "auth_ref": [] }, "BGXX_ExecutiveEmploymentAgreementAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://brightgreen.us/20231231", "localname": "ExecutiveEmploymentAgreementAgreementMember", "presentation": [ "http://brightgreen.us/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Executive Employment Agreement Agreement [Member]" } } }, "auth_ref": [] }, "BGXX_ExecutiveEmploymentAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://brightgreen.us/20231231", "localname": "ExecutiveEmploymentAgreementMember", "presentation": [ "http://brightgreen.us/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Executive Employment Agreement [Member]" } } }, "auth_ref": [] }, "BGXX_ExercisePriceOfWarrants": { "xbrltype": "perShareItemType", "nsuri": "http://brightgreen.us/20231231", "localname": "ExercisePriceOfWarrants", "presentation": [ "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Exercise price per share", "documentation": "Exercise price of warrants." } } }, "auth_ref": [] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://brightgreen.us/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "BGXX_FairValueOfAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://brightgreen.us/20231231", "localname": "FairValueOfAgreement", "crdr": "debit", "presentation": [ "http://brightgreen.us/role/EquityMethodInvestmentInAlterolaDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Fair value of agreement", "documentation": "Fair value of agreement." } } }, "auth_ref": [] }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueOfFinancialInstrumentsPolicy", "presentation": [ "http://brightgreen.us/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Fair Value of Financial Instruments", "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments." } } }, "auth_ref": [ "r10", "r17" ] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "calculation": { "http://brightgreen.us/role/ScheduleOfIntangibleAssetsDetails": { "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://brightgreen.us/role/ScheduleOfIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Accumulated amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r166", "r243" ] }, "us-gaap_FiniteLivedLicenseAgreementsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedLicenseAgreementsGross", "crdr": "debit", "calculation": { "http://brightgreen.us/role/ScheduleOfIntangibleAssetsDetails": { "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://brightgreen.us/role/ScheduleOfIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Licenses", "documentation": "Gross carrying amount as of the balance sheet date of certain rights acquired to exercise a certain privilege or pursue a particular business or occupation and which is deemed to have a finite economic life." } } }, "auth_ref": [ "r105" ] }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "crdr": "credit", "calculation": { "http://brightgreen.us/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_OtherExpenses", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://brightgreen.us/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "negatedLabel": "Foreign currency transaction loss", "label": "Gain (Loss), Foreign Currency Transaction, before Tax", "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction." } } }, "auth_ref": [ "r360", "r361", "r362", "r363", "r492" ] }, "BGXX_FormerChiefExecutiveOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://brightgreen.us/20231231", "localname": "FormerChiefExecutiveOfficerMember", "presentation": [ "http://brightgreen.us/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Former Chief Executive Officer [Member]", "documentation": "Former Chief Executive Officer [Member]" } } }, "auth_ref": [] }, "BGXX_FormerExecutiveChairmanMember": { "xbrltype": "domainItemType", "nsuri": "http://brightgreen.us/20231231", "localname": "FormerExecutiveChairmanMember", "presentation": [ "http://brightgreen.us/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Former Executive Chairman [Member]", "documentation": "Former Executive Chairman [Member]" } } }, "auth_ref": [] }, "BGXX_FormerInterimChiefExecutiveOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://brightgreen.us/20231231", "localname": "FormerInterimChiefExecutiveOfficerMember", "presentation": [ "http://brightgreen.us/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Former Interim Chief Executive Officer [Member]", "documentation": "Former Interim Chief Executive Officer [Member]" } } }, "auth_ref": [] }, "BGXX_FourConsultantsMember": { "xbrltype": "domainItemType", "nsuri": "http://brightgreen.us/20231231", "localname": "FourConsultantsMember", "presentation": [ "http://brightgreen.us/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Four Consultants [Member]", "documentation": "Four Consultants [Member]" } } }, "auth_ref": [] }, "us-gaap_FurnitureAndFixturesGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FurnitureAndFixturesGross", "crdr": "debit", "calculation": { "http://brightgreen.us/role/ScheduleOfPropertyPlantAndEquipmentDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://brightgreen.us/role/ScheduleOfPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Furniture and fixtures", "documentation": "Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases." } } }, "auth_ref": [ "r107" ] }, "us-gaap_FurnitureAndFixturesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FurnitureAndFixturesMember", "presentation": [ "http://brightgreen.us/role/SummaryOfEstimatedUsefulLifeDetails" ], "lang": { "en-us": { "role": { "label": "Furniture and Fixtures [Member]", "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases." } } }, "auth_ref": [] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://brightgreen.us/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://brightgreen.us/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "General and administrative expenses", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r96", "r474" ] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "auth_ref": [] }, "BGXX_GrantGreenhouseGrowersIncMember": { "xbrltype": "domainItemType", "nsuri": "http://brightgreen.us/20231231", "localname": "GrantGreenhouseGrowersIncMember", "presentation": [ "http://brightgreen.us/role/PropertyPlantAndEquipmentDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Grant Greenhouse GrowersInc [Member]", "documentation": "Grant Greenhouse GrowersInc [Member]" } } }, "auth_ref": [] }, "BGXX_GrossProceedsFromIssuanceOfPrivatePlacement": { "xbrltype": "monetaryItemType", "nsuri": "http://brightgreen.us/20231231", "localname": "GrossProceedsFromIssuanceOfPrivatePlacement", "crdr": "debit", "presentation": [ "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Gross proceeds from private placement", "documentation": "Gross proceeds from issuance of private placement." } } }, "auth_ref": [] }, "dei_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "IcfrAuditorAttestationFlag", "presentation": [ "http://brightgreen.us/role/Cover" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "auth_ref": [ "r563", "r565", "r566" ] }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "presentation": [ "http://brightgreen.us/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Long-lived Assets", "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets." } } }, "auth_ref": [ "r0", "r108" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://brightgreen.us/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://brightgreen.us/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Loss before income taxes and equity in net losses of affiliate", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r1", "r93", "r129", "r211", "r223", "r227", "r229", "r403", "r416", "r532" ] }, "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://brightgreen.us/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://brightgreen.us/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Loss before equity in net losses of affiliate", "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r123", "r184", "r191", "r211", "r223", "r227", "r229", "r239", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r356", "r359", "r416", "r532", "r601" ] }, "BGXX_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterestEquityInNetLossesOfAffiliate": { "xbrltype": "monetaryItemType", "nsuri": "http://brightgreen.us/20231231", "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterestEquityInNetLossesOfAffiliate", "crdr": "credit", "calculation": { "http://brightgreen.us/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://brightgreen.us/role/EquityMethodInvestmentInAlterolaDetailsNarrative", "http://brightgreen.us/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Equity in net losses of affiliate (Note 6)", "negatedLabel": "Noncontrolling interest equity in net losses of affiliate", "documentation": "Income loss from continuing operations including portion attributable to noncontrolling interest equity in net losses of affiliate." } } }, "auth_ref": [] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxAuthorityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxAuthorityAxis", "presentation": [ "http://brightgreen.us/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Income Tax Authority [Axis]", "documentation": "Information by tax jurisdiction." } } }, "auth_ref": [ "r14" ] }, "us-gaap_IncomeTaxAuthorityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxAuthorityDomain", "presentation": [ "http://brightgreen.us/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes." } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://brightgreen.us/role/IncomeTaxes" ], "lang": { "en-us": { "role": { "label": "Income Taxes", "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information." } } }, "auth_ref": [ "r185", "r319", "r323", "r324", "r329", "r334", "r339", "r340", "r341", "r432" ] }, "us-gaap_IncomeTaxExaminationDescription": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExaminationDescription", "presentation": [ "http://brightgreen.us/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Income tax examination, description", "documentation": "A brief description of status of the tax examination, significant findings to date, and the entity's position with respect to the findings." } } }, "auth_ref": [ "r61" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://brightgreen.us/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "weight": -1.0, "order": 2.0 }, "http://brightgreen.us/role/ScheduleOfIncomeTaxProvisionDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://brightgreen.us/role/IncomeTaxesDetailsNarrative", "http://brightgreen.us/role/ScheduleOfIncomeTaxProvisionDetails", "http://brightgreen.us/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Income tax expense (Note 13)", "totalLabel": "Total (benefit) expense", "verboseLabel": "Current and deferred income tax expenses", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r132", "r144", "r199", "r200", "r214", "r322", "r335", "r419" ] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxPolicyTextBlock", "presentation": [ "http://brightgreen.us/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "verboseLabel": "Income Taxes", "label": "Income Tax, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": [ "r171", "r320", "r321", "r324", "r325", "r328", "r330", "r429" ] }, "us-gaap_IncomeTaxesPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxesPaidNet", "crdr": "credit", "presentation": [ "http://brightgreen.us/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Taxes", "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes." } } }, "auth_ref": [ "r34" ] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": { "http://brightgreen.us/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://brightgreen.us/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Accounts payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": [ "r7" ] }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccruedLiabilities", "crdr": "debit", "calculation": { "http://brightgreen.us/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://brightgreen.us/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Accrued liabilities", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid." } } }, "auth_ref": [ "r7" ] }, "us-gaap_IncreaseDecreaseInInterestPayableNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInInterestPayableNet", "crdr": "debit", "calculation": { "http://brightgreen.us/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://brightgreen.us/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Accrued interest", "documentation": "The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity." } } }, "auth_ref": [ "r7" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://brightgreen.us/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://brightgreen.us/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://brightgreen.us/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Prepaid expenses and other assets", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r7" ] }, "us-gaap_IncreaseDecreaseInSecuritiesLendingPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInSecuritiesLendingPayable", "crdr": "debit", "presentation": [ "http://brightgreen.us/role/RelatedPartyLineOfCreditNoteDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Lender committed funds", "documentation": "The increase (decrease) during the period in the carrying amount of the liability pertaining to obligations to return collateral that the entity received when it loaned securities to the counterparty to the transaction." } } }, "auth_ref": [] }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsDisclosureTextBlock", "presentation": [ "http://brightgreen.us/role/IntangibleAssets" ], "lang": { "en-us": { "role": { "label": "Intangible Assets", "documentation": "The entire disclosure for all or part of the information related to intangible assets." } } }, "auth_ref": [ "r242" ] }, "us-gaap_IntangibleAssetsFiniteLivedPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsFiniteLivedPolicy", "presentation": [ "http://brightgreen.us/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "verboseLabel": "Intangible Assets", "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets." } } }, "auth_ref": [ "r46", "r385", "r386", "r387", "r389", "r529" ] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://brightgreen.us/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 }, "http://brightgreen.us/role/ScheduleOfIntangibleAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://brightgreen.us/role/BalanceSheets", "http://brightgreen.us/role/ScheduleOfIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Intangible assets (Note 8)", "totalLabel": "Net intangible assets", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": [ "r43", "r45" ] }, "us-gaap_InterestAndDebtExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestAndDebtExpense", "crdr": "debit", "presentation": [ "http://brightgreen.us/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Owned interest expenses", "documentation": "Interest and debt related expenses associated with nonoperating financing activities of the entity." } } }, "auth_ref": [ "r12" ] }, "us-gaap_InterestCostsCapitalized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestCostsCapitalized", "crdr": "debit", "presentation": [ "http://brightgreen.us/role/RelatedPartyLineOfCreditNoteDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Interest costs capitalized", "label": "Interest Costs Capitalized", "documentation": "Amount of interest capitalized during the period." } } }, "auth_ref": [ "r70" ] }, "us-gaap_InterestExpenseShortTermBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpenseShortTermBorrowings", "crdr": "debit", "presentation": [ "http://brightgreen.us/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Interest expense short term borrowings", "documentation": "The aggregate interest expense incurred on short-term borrowings including commercial paper and Federal funds purchased and securities sold under agreements to repurchase." } } }, "auth_ref": [ "r131", "r145", "r146" ] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://brightgreen.us/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Interest", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r177", "r179", "r180" ] }, "us-gaap_InterestPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPayableCurrent", "crdr": "credit", "presentation": [ "http://brightgreen.us/role/RelatedPartyLineOfCreditNoteDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Accrued interest", "label": "Interest Payable, Current", "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r23" ] }, "us-gaap_InvestmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentTextBlock", "presentation": [ "http://brightgreen.us/role/EquityMethodInvestmentInAlterola" ], "lang": { "en-us": { "role": { "label": "Equity Method Investment in Alterola", "documentation": "The entire disclosure for investment." } } }, "auth_ref": [ "r576", "r577", "r597" ] }, "us-gaap_Investments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Investments", "crdr": "debit", "presentation": [ "http://brightgreen.us/role/EquityMethodInvestmentInAlterolaDetailsNarrative", "http://brightgreen.us/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Investments", "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments." } } }, "auth_ref": [ "r406" ] }, "us-gaap_InvestmentsAllOtherInvestmentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentsAllOtherInvestmentsAbstract", "lang": { "en-us": { "role": { "label": "Investments, All Other Investments [Abstract]" } } }, "auth_ref": [] }, "BGXX_LDSCapitalLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://brightgreen.us/20231231", "localname": "LDSCapitalLLCMember", "presentation": [ "http://brightgreen.us/role/RelatedPartyLineOfCreditNoteDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "LDS Capital LLC [Member]", "documentation": "LDS Capital LLC [Member]" } } }, "auth_ref": [] }, "us-gaap_Land": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Land", "crdr": "debit", "calculation": { "http://brightgreen.us/role/ScheduleOfPropertyPlantAndEquipmentDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://brightgreen.us/role/ScheduleOfPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Land", "documentation": "Amount before accumulated depletion of real estate held for productive use, excluding land held for sale." } } }, "auth_ref": [ "r582" ] }, "us-gaap_LeaseExpirationDate1": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseExpirationDate1", "presentation": [ "http://brightgreen.us/role/PropertyPlantAndEquipmentDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Expiration date", "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "BGXX_LeasePaymentMadePerAcre": { "xbrltype": "monetaryItemType", "nsuri": "http://brightgreen.us/20231231", "localname": "LeasePaymentMadePerAcre", "crdr": "debit", "presentation": [ "http://brightgreen.us/role/PropertyPlantAndEquipmentDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Expense made", "documentation": "Lease payment made per acre." } } }, "auth_ref": [] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LegalEntityAxis", "presentation": [ "http://brightgreen.us/role/PropertyPlantAndEquipmentDetailsNarrative", "http://brightgreen.us/role/ScheduleOfFinancialStatementInformationDetails", "http://brightgreen.us/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "us-gaap_LegalFees": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LegalFees", "crdr": "debit", "presentation": [ "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Legal fees", "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings." } } }, "auth_ref": [ "r95" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://brightgreen.us/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://brightgreen.us/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r22", "r184", "r239", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r344", "r345", "r346", "r359", "r450", "r531", "r551", "r601", "r642", "r643" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://brightgreen.us/role/BalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://brightgreen.us/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and stockholders\u2019 equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r92", "r128", "r412", "r539", "r589", "r599", "r639" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://brightgreen.us/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://brightgreen.us/role/BalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://brightgreen.us/role/BalanceSheets", "http://brightgreen.us/role/ScheduleOfFinancialStatementInformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "verboseLabel": "Current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r24", "r163", "r184", "r239", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r344", "r345", "r346", "r359", "r539", "r601", "r642", "r643" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://brightgreen.us/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current liabilities" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://brightgreen.us/role/BalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://brightgreen.us/role/BalanceSheets", "http://brightgreen.us/role/ScheduleOfFinancialStatementInformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total long-term liabilities", "label": "Non-current liabilities", "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r19", "r82", "r83", "r84", "r85", "r184", "r239", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r344", "r345", "r346", "r359", "r601", "r642", "r643" ] }, "us-gaap_LiabilitiesNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesNoncurrentAbstract", "presentation": [ "http://brightgreen.us/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Long-term liabilities" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesRelatedToInvestmentContractsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesRelatedToInvestmentContractsFairValueDisclosure", "crdr": "credit", "presentation": [ "http://brightgreen.us/role/EquityMethodInvestmentInAlterolaDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Liability to the sellers", "documentation": "Fair value portion of liability related to investment contracts for example, but not limited to, guaranteed investment contract or annuities." } } }, "auth_ref": [ "r79" ] }, "us-gaap_LineOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCredit", "crdr": "credit", "presentation": [ "http://brightgreen.us/role/GoingConcernAndBasisOfPresentationDetailsNarrative", "http://brightgreen.us/role/RelatedPartyLineOfCreditNoteDetailsNarrative", "http://brightgreen.us/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Related party line of credit paid down", "verboseLabel": "Line of credit", "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement." } } }, "auth_ref": [ "r19", "r127", "r650" ] }, "us-gaap_LineOfCreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityAxis", "presentation": [ "http://brightgreen.us/role/RelatedPartyLineOfCreditNoteDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Lender Name [Axis]", "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit." } } }, "auth_ref": [ "r21", "r588" ] }, "us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityCurrentBorrowingCapacity", "crdr": "credit", "presentation": [ "http://brightgreen.us/role/RelatedPartyLineOfCreditNoteDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Increase in the line of credit capacity amount", "documentation": "Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility." } } }, "auth_ref": [ "r21" ] }, "BGXX_LineOfCreditFacilityIncreaseInBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://brightgreen.us/20231231", "localname": "LineOfCreditFacilityIncreaseInBorrowingCapacity", "crdr": "credit", "presentation": [ "http://brightgreen.us/role/RelatedPartyLineOfCreditNoteDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Additional borrowing capacity", "documentation": "Line of credit facility increase in borrowing capacity." } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityLenderDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityLenderDomain", "presentation": [ "http://brightgreen.us/role/RelatedPartyLineOfCreditNoteDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility." } } }, "auth_ref": [ "r21", "r588" ] }, "us-gaap_LineOfCreditFacilityLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityLineItems", "presentation": [ "http://brightgreen.us/role/RelatedPartyLineOfCreditNoteDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Line of Credit Facility [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r588" ] }, "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityRemainingBorrowingCapacity", "crdr": "credit", "presentation": [ "http://brightgreen.us/role/GoingConcernAndBasisOfPresentationDetailsNarrative", "http://brightgreen.us/role/RelatedPartyLineOfCreditNoteDetailsNarrative", "http://brightgreen.us/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Credit facility", "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding)." } } }, "auth_ref": [ "r21" ] }, "us-gaap_LineOfCreditFacilityTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityTable", "presentation": [ "http://brightgreen.us/role/RelatedPartyLineOfCreditNoteDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Line of Credit Facility [Table]", "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line." } } }, "auth_ref": [ "r21", "r588" ] }, "us-gaap_LiquidationBasisOfAccountingTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiquidationBasisOfAccountingTextBlock", "presentation": [ "http://brightgreen.us/role/GoingConcernAndBasisOfPresentation" ], "lang": { "en-us": { "role": { "label": "Going Concern and Basis of Presentation", "documentation": "The entire disclosure for the liquidation basis of accounting." } } }, "auth_ref": [ "r81" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://brightgreen.us/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermLineOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermLineOfCredit", "crdr": "credit", "calculation": { "http://brightgreen.us/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://brightgreen.us/role/BalanceSheets", "http://brightgreen.us/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Related party line of credit note (Notes 10, 11, 14 and 16)", "verboseLabel": "Long-term line of credit", "documentation": "The carrying value as of the balance sheet date of the noncurrent portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement." } } }, "auth_ref": [ "r26", "r51", "r52" ] }, "us-gaap_LossContingencyActionsTakenByDefendant": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingencyActionsTakenByDefendant", "presentation": [ "http://brightgreen.us/role/ContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Contingency, taken by defendant description", "documentation": "Describe actions taken by the defendant in the legal matter." } } }, "auth_ref": [ "r49", "r50", "r110" ] }, "us-gaap_LossContingencyDisclosures": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingencyDisclosures", "presentation": [ "http://brightgreen.us/role/Contingencies" ], "lang": { "en-us": { "role": { "label": "Contingencies", "documentation": "The entire disclosure for loss and gain contingencies. Describes any existing condition, situation, or set of circumstances involving uncertainty as of the balance sheet date (or prior to issuance of the financial statements) as to a probable or reasonably possible loss incurred by an entity that will ultimately be resolved when one or more future events occur or fail to occur, and typically discloses the amount of loss recorded or a range of possible loss, or an assertion that no reasonable estimate can be made." } } }, "auth_ref": [ "r244", "r245", "r246", "r248", "r250", "r251", "r252", "r253" ] }, "BGXX_LossOnForfeitedDeposit": { "xbrltype": "monetaryItemType", "nsuri": "http://brightgreen.us/20231231", "localname": "LossOnForfeitedDeposit", "crdr": "credit", "calculation": { "http://brightgreen.us/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_OtherExpenses", "weight": -1.0, "order": 2.0 }, "http://brightgreen.us/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://brightgreen.us/role/StatementsOfCashFlows", "http://brightgreen.us/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "negatedLabel": "Loss on forfeited deposit (Notes 5, 9, and 16)", "negatedTerseLabel": "Loss on forfeited deposit", "documentation": "Loss on forfeited deposit.", "label": "LossOnForfeitedDeposit" } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://brightgreen.us/role/DescriptionOfBusinessAndOrganizationDetailsNarrative", "http://brightgreen.us/role/RelatedPartyLineOfCreditNoteDetailsNarrative", "http://brightgreen.us/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "documentation": "Upper limit of the provided range." } } }, "auth_ref": [ "r247", "r249", "r250", "r251", "r285", "r384", "r420", "r442", "r443", "r503", "r505", "r507", "r508", "r510", "r525", "r526", "r534", "r535", "r537", "r540", "r603", "r644", "r645", "r646", "r647", "r648", "r649" ] }, "us-gaap_MeasurementInputExpectedDividendRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputExpectedDividendRateMember", "presentation": [ "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Expected Dividend Rate [Member]", "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year." } } }, "auth_ref": [ "r637" ] }, "us-gaap_MeasurementInputExpectedTermMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputExpectedTermMember", "presentation": [ "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Expected Term [Member]", "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date." } } }, "auth_ref": [ "r637" ] }, "us-gaap_MeasurementInputOptionVolatilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputOptionVolatilityMember", "presentation": [ "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Option Volatility [Member]", "documentation": "Measurement input using rate at which price of option increases (decreases) for given set of returns." } } }, "auth_ref": [ "r637" ] }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputRiskFreeInterestRateMember", "presentation": [ "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Risk Free Interest Rate [Member]", "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss." } } }, "auth_ref": [ "r637" ] }, "us-gaap_MeasurementInputTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputTypeAxis", "presentation": [ "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Measurement Input Type [Axis]", "documentation": "Information by type of measurement input used to determine value of asset and liability." } } }, "auth_ref": [ "r357" ] }, "us-gaap_MeasurementInputTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputTypeDomain", "presentation": [ "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability." } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://brightgreen.us/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "documentation": "Lower limit of the provided range." } } }, "auth_ref": [ "r247", "r249", "r250", "r251", "r285", "r384", "r420", "r442", "r443", "r503", "r505", "r507", "r508", "r510", "r525", "r526", "r534", "r535", "r537", "r540", "r603", "r644", "r645", "r646", "r647", "r648", "r649" ] }, "us-gaap_MinorityInterestPeriodIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterestPeriodIncreaseDecrease", "presentation": [ "http://brightgreen.us/role/ScheduleOfEquityMethodInvestmentInAlterolaDetails" ], "lang": { "en-us": { "role": { "label": "Company\u2019s initial investment in Alterola", "documentation": "Net Increase or Decrease in balance of noncontrolling interest in the subsidiary during the reporting period." } } }, "auth_ref": [ "r65" ] }, "BGXX_Mr.ElmasriMember": { "xbrltype": "domainItemType", "nsuri": "http://brightgreen.us/20231231", "localname": "Mr.ElmasriMember", "presentation": [ "http://brightgreen.us/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Mr.Elmasri [Member]", "documentation": "Mr.Elmasri [Member]" } } }, "auth_ref": [] }, "BGXX_Mr.TerryRafihMember": { "xbrltype": "domainItemType", "nsuri": "http://brightgreen.us/20231231", "localname": "Mr.TerryRafihMember", "presentation": [ "http://brightgreen.us/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Mr.Terry Rafih [Member]", "documentation": "Mr.Terry Rafih [Member]" } } }, "auth_ref": [] }, "BGXX_MutualAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://brightgreen.us/20231231", "localname": "MutualAgreementMember", "presentation": [ "http://brightgreen.us/role/Stock-basedCompensationDetailsNarrative", "http://brightgreen.us/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Mutual Agreement [Member]" } } }, "auth_ref": [] }, "BGXX_NMMember": { "xbrltype": "domainItemType", "nsuri": "http://brightgreen.us/20231231", "localname": "NMMember", "presentation": [ "http://brightgreen.us/role/PropertyPlantAndEquipmentDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "New Mexico [Member]", "documentation": "New Mexico [Member]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://brightgreen.us/role/StatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://brightgreen.us/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r178" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://brightgreen.us/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM FINANCING ACTIVITIES" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://brightgreen.us/role/StatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://brightgreen.us/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r178" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://brightgreen.us/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM INVESTING ACTIVITIES" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://brightgreen.us/role/StatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://brightgreen.us/role/GoingConcernAndBasisOfPresentationDetailsNarrative", "http://brightgreen.us/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating activities", "negatedLabel": "Net Cash Provided by (Used in) Operating Activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r99", "r100", "r101" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://brightgreen.us/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM OPERATING ACTIVITIES" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://brightgreen.us/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 }, "http://brightgreen.us/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://brightgreen.us/role/GoingConcernAndBasisOfPresentationDetailsNarrative", "http://brightgreen.us/role/ScheduleOfFinancialStatementInformationDetails", "http://brightgreen.us/role/ScheduleOfIncomeTaxProvisionDetails", "http://brightgreen.us/role/StatementsOfCashFlows", "http://brightgreen.us/role/StatementsOfChangesInStockholdersEquity", "http://brightgreen.us/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss and comprehensive loss", "label": "Net loss", "negatedLabel": "Net Income (Loss) Attributable to Parent", "verboseLabel": "Loss before income taxes", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r94", "r101", "r130", "r161", "r169", "r170", "r174", "r184", "r191", "r193", "r194", "r195", "r196", "r199", "r200", "r205", "r211", "r223", "r227", "r229", "r239", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r356", "r359", "r417", "r472", "r493", "r494", "r532", "r549", "r601" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://brightgreen.us/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Recently Adopted Accounting Standards", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://brightgreen.us/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance", "crdr": "credit", "presentation": [ "http://brightgreen.us/role/ScheduleOfEquityMethodInvestmentInAlterolaDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Company\u2019s 25% share in net loss", "label": "Noncontrolling Interest, Increase from Subsidiary Equity Issuance", "documentation": "Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders." } } }, "auth_ref": [ "r15", "r54", "r124" ] }, "BGXX_NumberOfWarrantsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://brightgreen.us/20231231", "localname": "NumberOfWarrantsExercised", "presentation": [ "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Number of warrants exercised", "documentation": "Number of warrants exercised." } } }, "auth_ref": [] }, "us-gaap_OfficersCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OfficersCompensation", "crdr": "debit", "presentation": [ "http://brightgreen.us/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Monthly cash fee", "documentation": "Amount of expense for salary and wage arising from service rendered by officer. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold." } } }, "auth_ref": [ "r585" ] }, "BGXX_OneAccreditedInvestorMember": { "xbrltype": "domainItemType", "nsuri": "http://brightgreen.us/20231231", "localname": "OneAccreditedInvestorMember", "presentation": [ "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "One Accredited Investor [Member]", "documentation": "One Accredited Investor [Member]" } } }, "auth_ref": [] }, "BGXX_OntarioLtdMember": { "xbrltype": "domainItemType", "nsuri": "http://brightgreen.us/20231231", "localname": "OntarioLtdMember", "presentation": [ "http://brightgreen.us/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Ontario Ltd [Member]", "documentation": "Ontario Ltd [Member]" } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://brightgreen.us/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://brightgreen.us/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpensesAbstract", "presentation": [ "http://brightgreen.us/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Expenses" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://brightgreen.us/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://brightgreen.us/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Loss from operations", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r211", "r223", "r227", "r229", "r532" ] }, "us-gaap_OperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLossCarryforwards", "crdr": "debit", "presentation": [ "http://brightgreen.us/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Operating loss carryforwards", "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws." } } }, "auth_ref": [ "r63" ] }, "us-gaap_OperatingLossCarryforwardsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLossCarryforwardsLineItems", "presentation": [ "http://brightgreen.us/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Operating Loss Carryforwards [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_OperatingLossCarryforwardsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLossCarryforwardsTable", "presentation": [ "http://brightgreen.us/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Operating Loss Carryforwards [Table]", "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization." } } }, "auth_ref": [ "r62" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": [ "http://brightgreen.us/role/DescriptionOfBusinessAndOrganization" ], "lang": { "en-us": { "role": { "label": "Description of Business and Organization", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": [ "r80", "r122", "r426", "r427" ] }, "us-gaap_OtherExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherExpenses", "crdr": "debit", "calculation": { "http://brightgreen.us/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://brightgreen.us/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Total other expense", "label": "Other Expenses", "documentation": "Amount of expense classified as other." } } }, "auth_ref": [ "r97" ] }, "us-gaap_OtherExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherExpensesAbstract", "presentation": [ "http://brightgreen.us/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Other expense" } } }, "auth_ref": [] }, "us-gaap_OtherInvestmentNotReadilyMarketableFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherInvestmentNotReadilyMarketableFairValue", "crdr": "debit", "calculation": { "http://brightgreen.us/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://brightgreen.us/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Other investment held at fair value (Note 6)", "documentation": "Value of the other investment not readily marketable determined by management based upon fair value methods, including pricing of similar securities and valuation techniques, that was used to record the investment for financial reporting purposes." } } }, "auth_ref": [ "r73" ] }, "BGXX_OtherInvestmentsHeldAtFairValuePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://brightgreen.us/20231231", "localname": "OtherInvestmentsHeldAtFairValuePolicyTextBlock", "presentation": [ "http://brightgreen.us/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Other Investment Held at Fair Value", "documentation": "Other Investments Held At Fair Value [Policy Text Block]" } } }, "auth_ref": [] }, "us-gaap_OtherLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilities", "crdr": "credit", "presentation": [ "http://brightgreen.us/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Due to related party", "documentation": "Amount of liabilities classified as other." } } }, "auth_ref": [ "r77", "r405", "r446", "r447", "r551", "r653" ] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://brightgreen.us/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://brightgreen.us/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Due to related party (Note 10)", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r23", "r539" ] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://brightgreen.us/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r565" ] }, "us-gaap_PaymentOfFinancingAndStockIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentOfFinancingAndStockIssuanceCosts", "crdr": "credit", "presentation": [ "http://brightgreen.us/role/StatementsOfChangesInStockholdersEquityParenthetical" ], "lang": { "en-us": { "role": { "label": "Net of issuance cost", "documentation": "The total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities." } } }, "auth_ref": [ "r31" ] }, "BGXX_PaymentOfLieuOutstandingSharesOfCommonStock": { "xbrltype": "sharesItemType", "nsuri": "http://brightgreen.us/20231231", "localname": "PaymentOfLieuOutstandingSharesOfCommonStock", "presentation": [ "http://brightgreen.us/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Payment of lieu Outstanding shares of common stock", "documentation": "Payment of lieu outstanding shares of common stock." } } }, "auth_ref": [] }, "BGXX_PaymentsForAcquirePropertyDeposits": { "xbrltype": "monetaryItemType", "nsuri": "http://brightgreen.us/20231231", "localname": "PaymentsForAcquirePropertyDeposits", "crdr": "credit", "calculation": { "http://brightgreen.us/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://brightgreen.us/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Deposits", "documentation": "Payments for acquire property deposits.", "label": "PaymentsForAcquirePropertyDeposits" } } }, "auth_ref": [] }, "us-gaap_PaymentsForPurchaseOfOtherAssets1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForPurchaseOfOtherAssets1", "crdr": "credit", "presentation": [ "http://brightgreen.us/role/CommitmentsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Remaining payment", "documentation": "Amount of cash paid to purchase other assets as part of operating activities." } } }, "auth_ref": [ "r4", "r6" ] }, "us-gaap_PaymentsOfFinancingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfFinancingCosts", "crdr": "credit", "presentation": [ "http://brightgreen.us/role/StatementsOfChangesInStockholdersEquityParenthetical" ], "lang": { "en-us": { "role": { "label": "Line of credit, net of issuance costs", "documentation": "The cash outflow for loan and debt issuance costs." } } }, "auth_ref": [ "r31" ] }, "us-gaap_PaymentsOfStockIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfStockIssuanceCosts", "crdr": "credit", "calculation": { "http://brightgreen.us/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://brightgreen.us/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Payments to issuance costs for issuance of common stock and warrants issued in cashless conversion of related party line of credit", "label": "Payments of Stock Issuance Costs", "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security." } } }, "auth_ref": [ "r31" ] }, "us-gaap_PaymentsToAcquireBusinessesAndInterestInAffiliates": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireBusinessesAndInterestInAffiliates", "crdr": "credit", "presentation": [ "http://brightgreen.us/role/EquityMethodInvestmentInAlterolaDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Oustanding common shares value", "documentation": "The cash outflow associated with the acquisition of a controlling interest in another entity or an entity that is related to it but not strictly controlled (for example, an unconsolidated subsidiary, affiliate, joint venture or equity method investment)." } } }, "auth_ref": [ "r29" ] }, "us-gaap_PaymentsToAcquireEquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireEquityMethodInvestments", "crdr": "credit", "calculation": { "http://brightgreen.us/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://brightgreen.us/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchase of equity method investment", "label": "Payments to Acquire Equity Method Investments", "documentation": "The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence." } } }, "auth_ref": [ "r29" ] }, "us-gaap_PaymentsToAcquireLand": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireLand", "crdr": "credit", "presentation": [ "http://brightgreen.us/role/PropertyPlantAndEquipmentDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Monthly payments for land", "documentation": "The cash outflow from the acquisition of real estate intended to generate income for the owner; excludes land acquired for use by the owner." } } }, "auth_ref": [ "r98" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://brightgreen.us/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://brightgreen.us/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchase of property, plant, and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r98" ] }, "BGXX_PercentageOfEntityCommonStock": { "xbrltype": "percentItemType", "nsuri": "http://brightgreen.us/20231231", "localname": "PercentageOfEntityCommonStock", "presentation": [ "http://brightgreen.us/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Percentage of entity common stock", "documentation": "Percentage of entity common stock." } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameAxis", "presentation": [ "http://brightgreen.us/role/Stock-basedCompensationDetailsNarrative", "http://brightgreen.us/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameDomain", "presentation": [ "http://brightgreen.us/role/Stock-basedCompensationDetailsNarrative", "http://brightgreen.us/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://brightgreen.us/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r559" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://brightgreen.us/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r560" ] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://brightgreen.us/role/BalanceSheetsParenthetical", "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Preferred stock, par value", "verboseLabel": "Preferred stock par value", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r86", "r267" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://brightgreen.us/role/BalanceSheetsParenthetical", "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Preferred stock, shares authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r86", "r451" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesIssued", "presentation": [ "http://brightgreen.us/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred stock, shares issued", "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt." } } }, "auth_ref": [ "r86", "r267" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://brightgreen.us/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred stock, shares outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r86", "r451", "r470", "r656", "r657" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://brightgreen.us/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://brightgreen.us/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Preferred stock; $0.0001 par value; 10,000,000 shares authorized; no shares issued or outstanding as of December 31, 2023 and December 31, 2022, respectively (Note 11)", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r86", "r409", "r539" ] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://brightgreen.us/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://brightgreen.us/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Prepaid expenses and other assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r584" ] }, "us-gaap_PrimeRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrimeRateMember", "presentation": [ "http://brightgreen.us/role/RelatedPartyLineOfCreditNoteDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Prime Rate [Member]", "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers." } } }, "auth_ref": [] }, "us-gaap_PrivatePlacementMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrivatePlacementMember", "presentation": [ "http://brightgreen.us/role/DescriptionOfBusinessAndOrganizationDetailsNarrative", "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Private Placement [Member]", "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "calculation": { "http://brightgreen.us/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://brightgreen.us/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from issuance of common stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": [ "r3" ] }, "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfPrivatePlacement", "crdr": "debit", "calculation": { "http://brightgreen.us/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://brightgreen.us/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from issuance of common stock and warrants, issued in private placement, net of issuance costs", "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement." } } }, "auth_ref": [ "r3" ] }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOrSaleOfEquity", "crdr": "debit", "presentation": [ "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Gross cash proceeds", "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity." } } }, "auth_ref": [ "r3", "r430" ] }, "us-gaap_ProceedsFromLongTermLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromLongTermLinesOfCredit", "crdr": "debit", "presentation": [ "http://brightgreen.us/role/GoingConcernAndBasisOfPresentationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Related party line of credit", "documentation": "The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer." } } }, "auth_ref": [ "r30" ] }, "us-gaap_ProceedsFromPaymentsForLongTermLoansForRelatedParties": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromPaymentsForLongTermLoansForRelatedParties", "crdr": "debit", "presentation": [ "http://brightgreen.us/role/GoingConcernAndBasisOfPresentationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Related party loan balance", "documentation": "The cash inflow or outflow associated with long-term loans for related parties where one party can exercise control or significant influence over another party, including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from (Payments for) Advances to Affiliates." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromRelatedPartyDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromRelatedPartyDebt", "crdr": "debit", "calculation": { "http://brightgreen.us/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://brightgreen.us/role/RelatedPartyLineOfCreditNoteDetailsNarrative", "http://brightgreen.us/role/StatementsOfCashFlows", "http://brightgreen.us/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Proceeds from related party line of credit", "verboseLabel": "Additional related party line of credit", "terseLabel": "Proceeds from related party debt", "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates." } } }, "auth_ref": [ "r30" ] }, "us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromRepaymentsOfRelatedPartyDebt", "crdr": "debit", "presentation": [ "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Related party line of credit paid", "documentation": "Amount of cash inflow (outflow) from long-term debt by a related party. Related parties, include, but are not limited to, affiliates, owners or officers and their immediate families, and pension trusts." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromWarrantExercises": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromWarrantExercises", "crdr": "debit", "calculation": { "http://brightgreen.us/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://brightgreen.us/role/GoingConcernAndBasisOfPresentationDetailsNarrative", "http://brightgreen.us/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from warrants exercised", "verboseLabel": "Exercise of warrants", "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants." } } }, "auth_ref": [ "r587" ] }, "us-gaap_ProfessionalFees": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProfessionalFees", "crdr": "debit", "presentation": [ "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Placement agent fees", "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer." } } }, "auth_ref": [ "r549", "r654", "r655" ] }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://brightgreen.us/role/CommitmentsDetailsNarrative", "http://brightgreen.us/role/PropertyPlantAndEquipmentDetailsNarrative", "http://brightgreen.us/role/RelatedPartyLineOfCreditNoteDetailsNarrative", "http://brightgreen.us/role/SummaryOfEstimatedUsefulLifeDetails" ], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r9" ] }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": [ "http://brightgreen.us/role/PropertyPlantAndEquipment" ], "lang": { "en-us": { "role": { "label": "Property, Plant, and Equipment", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r106", "r138", "r141", "r142" ] }, "BGXX_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://brightgreen.us/20231231", "localname": "PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock", "presentation": [ "http://brightgreen.us/role/SummaryOfSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "Summary of Estimated Useful Life", "documentation": "Property Plant And Equipment Estimated Useful Life [Table Text Block]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://brightgreen.us/role/ScheduleOfPropertyPlantAndEquipmentDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://brightgreen.us/role/ScheduleOfPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Property, plant and equipment gross", "label": "Property, Plant and Equipment, Gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r107", "r164", "r415" ] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": [ "http://brightgreen.us/role/CommitmentsDetailsNarrative", "http://brightgreen.us/role/PropertyPlantAndEquipmentDetailsNarrative", "http://brightgreen.us/role/SummaryOfEstimatedUsefulLifeDetails", "http://brightgreen.us/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://brightgreen.us/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 }, "http://brightgreen.us/role/ScheduleOfPropertyPlantAndEquipmentDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://brightgreen.us/role/BalanceSheets", "http://brightgreen.us/role/CommitmentsDetailsNarrative", "http://brightgreen.us/role/ScheduleOfPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Property, plant, and equipment (Notes 7 and 16)", "totalLabel": "Net property, plant, and equipment", "verboseLabel": "Purchase price", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r9", "r404", "r415", "r539" ] }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "presentation": [ "http://brightgreen.us/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "verboseLabel": "Property, Plant, and Equipment", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r9", "r138", "r141", "r413" ] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://brightgreen.us/role/PropertyPlantAndEquipmentTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Property Plant and Equipment", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r9" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://brightgreen.us/role/CommitmentsDetailsNarrative", "http://brightgreen.us/role/PropertyPlantAndEquipmentDetailsNarrative", "http://brightgreen.us/role/RelatedPartyLineOfCreditNoteDetailsNarrative", "http://brightgreen.us/role/SummaryOfEstimatedUsefulLifeDetails" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r107" ] }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": [ "http://brightgreen.us/role/SummaryOfEstimatedUsefulLifeDetails" ], "lang": { "en-us": { "role": { "label": "Estimated useful life", "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": [] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://brightgreen.us/role/DescriptionOfBusinessAndOrganizationDetailsNarrative", "http://brightgreen.us/role/RelatedPartyLineOfCreditNoteDetailsNarrative", "http://brightgreen.us/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": [ "r247", "r249", "r250", "r251", "r283", "r285", "r311", "r312", "r313", "r383", "r384", "r420", "r442", "r443", "r503", "r505", "r507", "r508", "r510", "r525", "r526", "r534", "r535", "r537", "r540", "r543", "r600", "r603", "r645", "r646", "r647", "r648", "r649" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://brightgreen.us/role/DescriptionOfBusinessAndOrganizationDetailsNarrative", "http://brightgreen.us/role/RelatedPartyLineOfCreditNoteDetailsNarrative", "http://brightgreen.us/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": [ "r247", "r249", "r250", "r251", "r283", "r285", "r311", "r312", "r313", "r383", "r384", "r420", "r442", "r443", "r503", "r505", "r507", "r508", "r510", "r525", "r526", "r534", "r535", "r537", "r540", "r543", "r600", "r603", "r645", "r646", "r647", "r648", "r649" ] }, "BGXX_RealEstateOptionAgreementOneMember": { "xbrltype": "domainItemType", "nsuri": "http://brightgreen.us/20231231", "localname": "RealEstateOptionAgreementOneMember", "presentation": [ "http://brightgreen.us/role/PropertyPlantAndEquipmentDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Real Estate Option Agreement One [Member]", "documentation": "Real Estate Option Agreement One [Member]" } } }, "auth_ref": [] }, "BGXX_RealEstateOptionAgreementTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://brightgreen.us/20231231", "localname": "RealEstateOptionAgreementTwoMember", "presentation": [ "http://brightgreen.us/role/PropertyPlantAndEquipmentDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Real Estate Option Agreement Two [Member]", "documentation": "Real Estate Option Agreement Two [Member]" } } }, "auth_ref": [] }, "BGXX_RecentlyIssuedButNotAdoptedAccountingStandardsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://brightgreen.us/20231231", "localname": "RecentlyIssuedButNotAdoptedAccountingStandardsPolicyTextBlock", "presentation": [ "http://brightgreen.us/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Recently Issued but Not Adopted Accounting Standards", "documentation": "Recently Issued But Not Adopted Accounting Standards Policy [Text Block]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyDomain", "presentation": [ "http://brightgreen.us/role/BalanceSheets", "http://brightgreen.us/role/EquityMethodInvestmentInAlterolaDetailsNarrative", "http://brightgreen.us/role/GoingConcernAndBasisOfPresentationDetailsNarrative", "http://brightgreen.us/role/RelatedPartyTransactionsDetailsNarrative", "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r284", "r375", "r376", "r445", "r446", "r447", "r448", "r449", "r469", "r471", "r502" ] }, "BGXX_RelatedPartyLineOfCreditTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://brightgreen.us/20231231", "localname": "RelatedPartyLineOfCreditTextBlock", "presentation": [ "http://brightgreen.us/role/RelatedPartyLineOfCreditNote" ], "lang": { "en-us": { "role": { "label": "Related Party Line of Credit Note", "documentation": "Related Party Line Of Credit [Text Block]" } } }, "auth_ref": [] }, "BGXX_RelatedPartyLocInExchangeForCommonStockAndWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://brightgreen.us/20231231", "localname": "RelatedPartyLocInExchangeForCommonStockAndWarrants", "crdr": "credit", "presentation": [ "http://brightgreen.us/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Related party LOC in exchange for common stock and warrants", "documentation": "Related party loc in exchange for common stock and warrants" } } }, "auth_ref": [] }, "BGXX_RelatedPartyLocInExchangeForCommonStockForEb5Program": { "xbrltype": "monetaryItemType", "nsuri": "http://brightgreen.us/20231231", "localname": "RelatedPartyLocInExchangeForCommonStockForEb5Program", "crdr": "credit", "presentation": [ "http://brightgreen.us/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Related party LOC in exchange for common stock for EB-5 program", "documentation": "Related party LOC in exchange for common stock for EB-5 program." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyMember", "presentation": [ "http://brightgreen.us/role/BalanceSheets", "http://brightgreen.us/role/GoingConcernAndBasisOfPresentationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Related Party [Member]", "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family." } } }, "auth_ref": [ "r186", "r187", "r375", "r376", "r377", "r378", "r445", "r446", "r447", "r448", "r449", "r469", "r471", "r502" ] }, "us-gaap_RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionLineItems", "presentation": [ "http://brightgreen.us/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r475", "r476", "r479" ] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [ "http://brightgreen.us/role/BalanceSheets", "http://brightgreen.us/role/EquityMethodInvestmentInAlterolaDetailsNarrative", "http://brightgreen.us/role/GoingConcernAndBasisOfPresentationDetailsNarrative", "http://brightgreen.us/role/RelatedPartyTransactionsDetailsNarrative", "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Related Party, Type [Axis]", "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r284", "r375", "r376", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r445", "r446", "r447", "r448", "r449", "r469", "r471", "r502", "r641" ] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [ "http://brightgreen.us/role/RelatedPartyTransactions" ], "lang": { "en-us": { "role": { "label": "Related Party Transactions", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r372", "r373", "r374", "r376", "r379", "r433", "r434", "r435", "r477", "r478", "r479", "r499", "r501" ] }, "us-gaap_RepaymentsOfLongTermLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfLongTermLinesOfCredit", "crdr": "credit", "presentation": [ "http://brightgreen.us/role/GoingConcernAndBasisOfPresentationDetailsNarrative", "http://brightgreen.us/role/RelatedPartyLineOfCreditNoteDetailsNarrative", "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Line of credit paid down", "verboseLabel": "Related party line of credit paid", "documentation": "The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer." } } }, "auth_ref": [ "r32" ] }, "us-gaap_RepaymentsOfOtherDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfOtherDebt", "crdr": "credit", "presentation": [ "http://brightgreen.us/role/RelatedPartyLineOfCreditNoteDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Repayments of other debt", "documentation": "Amount of cash outflow for the payment of debt classified as other." } } }, "auth_ref": [ "r32" ] }, "us-gaap_RepaymentsOfRelatedPartyDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfRelatedPartyDebt", "crdr": "credit", "calculation": { "http://brightgreen.us/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://brightgreen.us/role/RelatedPartyLineOfCreditNoteDetailsNarrative", "http://brightgreen.us/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Payments to related party line of credit", "label": "Payment of related party loan", "documentation": "The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates." } } }, "auth_ref": [ "r32" ] }, "us-gaap_RestrictedStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockMember", "presentation": [ "http://brightgreen.us/role/RelatedPartyTransactionsDetailsNarrative", "http://brightgreen.us/role/Stock-basedCompensationDetailsNarrative", "http://brightgreen.us/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Restricted Stock [Member]", "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met." } } }, "auth_ref": [ "r38" ] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockUnitsRSUMember", "presentation": [ "http://brightgreen.us/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://brightgreen.us/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://brightgreen.us/role/BalanceSheets", "http://brightgreen.us/role/GoingConcernAndBasisOfPresentationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Accumulated deficit", "negatedLabel": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r89", "r113", "r411", "r424", "r425", "r431", "r452", "r539" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://brightgreen.us/role/StatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r160", "r188", "r189", "r190", "r192", "r198", "r200", "r240", "r241", "r315", "r316", "r317", "r332", "r333", "r347", "r349", "r350", "r352", "r354", "r421", "r423", "r436", "r656" ] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://brightgreen.us/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://brightgreen.us/role/ScheduleOfFinancialStatementInformationDetails", "http://brightgreen.us/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Revenue", "verboseLabel": "Total revenues", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r212", "r213", "r222", "r225", "r226", "r230", "r231", "r233", "r281", "r282", "r388" ] }, "us-gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Revenues", "crdr": "credit", "presentation": [ "http://brightgreen.us/role/DescriptionOfBusinessAndOrganizationDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Revenue", "label": "Revenues", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": [ "r175", "r184", "r212", "r213", "r222", "r225", "r226", "r230", "r231", "r233", "r239", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r359", "r403", "r601" ] }, "us-gaap_RisksAndUncertaintiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RisksAndUncertaintiesAbstract", "lang": { "en-us": { "role": { "label": "Risks and Uncertainties [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SalariesAndWages": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SalariesAndWages", "crdr": "debit", "presentation": [ "http://brightgreen.us/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Salaries and wages", "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold." } } }, "auth_ref": [ "r585" ] }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockConsiderationReceivedOnTransaction", "crdr": "debit", "presentation": [ "http://brightgreen.us/role/EquityMethodInvestmentInAlterolaDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Number of shares sold, value", "documentation": "Cash received on stock transaction after deduction of issuance costs." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": [ "http://brightgreen.us/role/DescriptionOfBusinessAndOrganizationDetailsNarrative", "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "presentation": [ "http://brightgreen.us/role/DescriptionOfBusinessAndOrganizationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Number of shares sold", "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction." } } }, "auth_ref": [] }, "srt_ScenarioForecastMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScenarioForecastMember", "presentation": [ "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Forecast [Member]", "documentation": "Information reported for future period. Excludes information expected to be reported in future period for effect on historical fact." } } }, "auth_ref": [ "r286", "r578", "r595" ] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScenarioUnspecifiedDomain", "presentation": [ "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts." } } }, "auth_ref": [ "r201", "r286", "r573", "r595" ] }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "presentation": [ "http://brightgreen.us/role/DepositsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r342" ] }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "presentation": [ "http://brightgreen.us/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Income Tax Provision", "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years." } } }, "auth_ref": [ "r120" ] }, "srt_ScheduleOfCondensedFinancialStatementsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScheduleOfCondensedFinancialStatementsTableTextBlock", "presentation": [ "http://brightgreen.us/role/EquityMethodInvestmentInAlterolaTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Financial Statement Information", "documentation": "Tabular disclosure of condensed financial statements, including, but not limited to, the balance sheet, income statement, and statement of cash flows." } } }, "auth_ref": [ "r579", "r591" ] }, "us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable", "presentation": [ "http://brightgreen.us/role/ContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table]", "documentation": "Schedule, table or text reflecting arrangements that are not equity-based payments, or pension and other postretirement benefits, with individual employees. The arrangements (for example, profit sharing, deferred bonuses or certain split-dollar life insurance arrangements) are generally based on employment contracts between the entity and one or more selected officers or key employees, and which contain a promise by the employer to pay certain amounts at designated future dates, sometimes including a period after retirement, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Disclosure also typically includes the amount of related compensation expense recognized during the reporting period and the carrying amount as of the balance sheet date of the related liability." } } }, "auth_ref": [ "r55", "r115" ] }, "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable", "presentation": [ "http://brightgreen.us/role/BalanceSheets", "http://brightgreen.us/role/GoingConcernAndBasisOfPresentationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Schedule of Defined Benefit Plans Disclosures [Table]", "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r11", "r56", "r57", "r58", "r59" ] }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "presentation": [ "http://brightgreen.us/role/EquityMethodInvestmentInAlterolaDetailsNarrative", "http://brightgreen.us/role/ScheduleOfEquityMethodInvestmentInAlterolaDetails" ], "lang": { "en-us": { "role": { "label": "Investment, Name [Axis]", "documentation": "Information by name of investment including named security. Excludes entity that is consolidated." } } }, "auth_ref": [ "r236", "r237", "r238" ] }, "BGXX_ScheduleOfFederalAndStateTaxEffectsOfTemporaryDifferenceAndCarryforwardsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://brightgreen.us/20231231", "localname": "ScheduleOfFederalAndStateTaxEffectsOfTemporaryDifferenceAndCarryforwardsTableTextBlock", "presentation": [ "http://brightgreen.us/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Federal and State Tax Effects of Temporary Differences and Carryforwards", "documentation": "Schedule of federal and state tax effects of temporary difference and carryforwards [Table Text Block]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "presentation": [ "http://brightgreen.us/role/IntangibleAssetsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Intangible Assets", "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment." } } }, "auth_ref": [ "r44", "r46" ] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": [ "http://brightgreen.us/role/CommitmentsDetailsNarrative", "http://brightgreen.us/role/PropertyPlantAndEquipmentDetailsNarrative", "http://brightgreen.us/role/SummaryOfEstimatedUsefulLifeDetails", "http://brightgreen.us/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r9" ] }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "presentation": [ "http://brightgreen.us/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Schedule of Related Party Transactions, by Related Party [Table]", "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r71", "r72", "r475", "r476", "r479" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://brightgreen.us/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314" ] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": [ "http://brightgreen.us/role/Stock-basedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Fair Value of The Stock Options", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": [ "r119" ] }, "BGXX_SecuritiesPurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://brightgreen.us/20231231", "localname": "SecuritiesPurchaseAgreementMember", "presentation": [ "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Securities Purchase Agreement [Member]", "documentation": "Securities Purchase Agreement [Member]" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://brightgreen.us/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r553" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://brightgreen.us/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r557" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://brightgreen.us/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r556" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://brightgreen.us/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r561" ] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "SegmentGeographicalDomain", "presentation": [ "http://brightgreen.us/role/PropertyPlantAndEquipmentDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Geographical area." } } }, "auth_ref": [ "r150", "r151", "r152", "r153", "r154", "r155", "r156", "r157", "r158", "r231", "r232", "r439", "r440", "r441", "r504", "r506", "r509", "r511", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r527", "r536", "r543", "r604", "r651" ] }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingPolicyPolicyTextBlock", "presentation": [ "http://brightgreen.us/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Segment Reporting", "documentation": "Disclosure of accounting policy for segment reporting." } } }, "auth_ref": [ "r216", "r217", "r218", "r219", "r220", "r221", "r231", "r533" ] }, "BGXX_SellersMember": { "xbrltype": "domainItemType", "nsuri": "http://brightgreen.us/20231231", "localname": "SellersMember", "presentation": [ "http://brightgreen.us/role/EquityMethodInvestmentInAlterolaDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Sellers [Member]", "documentation": "Sellers [Member]" } } }, "auth_ref": [] }, "BGXX_SeparationAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://brightgreen.us/20231231", "localname": "SeparationAgreementMember", "presentation": [ "http://brightgreen.us/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Separation Agreement [Member]", "documentation": "Separation Agreement [Member]" } } }, "auth_ref": [] }, "BGXX_SettlementAndReleaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://brightgreen.us/20231231", "localname": "SettlementAndReleaseAgreementMember", "presentation": [ "http://brightgreen.us/role/CommitmentsDetailsNarrative", "http://brightgreen.us/role/DepositsDetailsNarrative", "http://brightgreen.us/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Settlement And Release Agreement [Member]", "documentation": "Settlement And Release Agreement [Member]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://brightgreen.us/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://brightgreen.us/role/StatementsOfCashFlows", "http://brightgreen.us/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Stock-based compensation", "verboseLabel": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r7" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [ "http://brightgreen.us/role/Stock-basedCompensationDetailsNarrative", "http://brightgreen.us/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Restricted shares unit", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r300", "r301" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": [ "http://brightgreen.us/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Restricted stock vest, shares", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": [ "r304" ] }, "BGXX_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsControlPremium": { "xbrltype": "monetaryItemType", "nsuri": "http://brightgreen.us/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsControlPremium", "crdr": "credit", "presentation": [ "http://brightgreen.us/role/EquityMethodInvestmentInAlterolaDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Control premium", "documentation": "Share based compensation arrangement by share based payment award fair value assumptions control premium." } } }, "auth_ref": [] }, "BGXX_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsControlPremiumPercentage": { "xbrltype": "percentItemType", "nsuri": "http://brightgreen.us/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsControlPremiumPercentage", "presentation": [ "http://brightgreen.us/role/EquityMethodInvestmentInAlterolaDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Control premium percentage", "documentation": "Share based compensation arrangement by share based payment award fair value assumptions control premium percentage." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": [ "http://brightgreen.us/role/EquityMethodInvestmentInAlterolaDetailsNarrative", "http://brightgreen.us/role/ScheduleOfFairValueOfStockOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Dividend rate", "verboseLabel": "Expected dividend yield", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": [ "r312" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": [ "http://brightgreen.us/role/EquityMethodInvestmentInAlterolaDetailsNarrative", "http://brightgreen.us/role/ScheduleOfFairValueOfStockOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Volatility rate", "verboseLabel": "Expected stock volatility", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [ "r311" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": [ "http://brightgreen.us/role/EquityMethodInvestmentInAlterolaDetailsNarrative", "http://brightgreen.us/role/ScheduleOfFairValueOfStockOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Rist free rate", "verboseLabel": "Risk-free interest rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [ "r313" ] }, "BGXX_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice": { "xbrltype": "monetaryItemType", "nsuri": "http://brightgreen.us/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice", "crdr": "credit", "presentation": [ "http://brightgreen.us/role/EquityMethodInvestmentInAlterolaDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Stock price", "documentation": "Share based compensation arrangement by share based payment award fair value assumptions stock price." } } }, "auth_ref": [] }, "BGXX_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStrikePrice": { "xbrltype": "monetaryItemType", "nsuri": "http://brightgreen.us/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStrikePrice", "crdr": "credit", "presentation": [ "http://brightgreen.us/role/EquityMethodInvestmentInAlterolaDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Stock price", "documentation": "Share based compensation arrangement by share based payment award fair value assumptions strike price.", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStrikePrice" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://brightgreen.us/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": [ "http://brightgreen.us/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Number of shares authorized", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [ "r538" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "presentation": [ "http://brightgreen.us/role/ScheduleOfSummarizesStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Number of stock options expired", "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements." } } }, "auth_ref": [ "r299" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://brightgreen.us/role/RelatedPartyTransactionsDetailsNarrative", "http://brightgreen.us/role/ScheduleOfSummarizesStockOptionActivityDetails", "http://brightgreen.us/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Number of stock options granted", "verboseLabel": "Issuance of shares", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r296" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://brightgreen.us/role/ScheduleOfFairValueOfStockOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average fair value at grant date", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": [ "r306" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://brightgreen.us/role/ScheduleOfSummarizesStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Number of shares, outstanding beginning balance", "periodEndLabel": "Number of shares, outstanding ending balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r292", "r293" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://brightgreen.us/role/ScheduleOfSummarizesStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Weighted average exercise price beginning balance", "periodEndLabel": "Weighted average exercise price ending balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r292", "r293" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum", "presentation": [ "http://brightgreen.us/role/EquityMethodInvestmentInAlterolaDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Outstaanding common shares percentage", "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://brightgreen.us/role/RelatedPartyTransactionsDetailsNarrative", "http://brightgreen.us/role/Stock-basedCompensationDetailsNarrative", "http://brightgreen.us/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [ "http://brightgreen.us/role/ScheduleOfSummarizesStockOptionActivityDetails", "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Exercise price per share", "label": "Weighted average exercise price exercised", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": [ "r297" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://brightgreen.us/role/ScheduleOfSummarizesStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price expired", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired." } } }, "auth_ref": [ "r299" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://brightgreen.us/role/ScheduleOfSummarizesStockOptionActivityDetails", "http://brightgreen.us/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price granted", "verboseLabel": "Stock options exercise price", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r296" ] }, "us-gaap_SharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharePrice", "presentation": [ "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Share price", "documentation": "Price of a single share of a number of saleable stocks of a company." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [ "http://brightgreen.us/role/EquityMethodInvestmentInAlterolaDetailsNarrative", "http://brightgreen.us/role/ScheduleOfFairValueOfStockOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Expected term", "verboseLabel": "Expected life of options (years)", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r310" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "presentation": [ "http://brightgreen.us/role/ScheduleOfSummarizesStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average remaining life (years)", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r308" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares", "presentation": [ "http://brightgreen.us/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Stock options expiring, shares", "documentation": "Number of options vested." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue", "presentation": [ "http://brightgreen.us/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Stock options fair value", "documentation": "Weighted average grant-date fair value of options vested." } } }, "auth_ref": [] }, "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock", "presentation": [ "http://brightgreen.us/role/Stock-basedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Summarizes Stock Option Activity", "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP)." } } }, "auth_ref": [ "r112", "r118" ] }, "us-gaap_SharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesIssued", "presentation": [ "http://brightgreen.us/role/EquityMethodInvestmentInAlterolaDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Sellers transferred shares", "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury." } } }, "auth_ref": [ "r16" ] }, "us-gaap_SharesIssuedPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesIssuedPricePerShare", "presentation": [ "http://brightgreen.us/role/DescriptionOfBusinessAndOrganizationDetailsNarrative", "http://brightgreen.us/role/RelatedPartyLineOfCreditNoteDetailsNarrative", "http://brightgreen.us/role/StockholdersEquityDetailsNarrative", "http://brightgreen.us/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Shares issued price per share", "verboseLabel": "Common stock price per share", "terseLabel": "Issued price per share", "documentation": "Per share or per unit amount of equity securities issued." } } }, "auth_ref": [] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesOutstanding", "presentation": [ "http://brightgreen.us/role/StatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance, shares", "periodEndLabel": "Balance, shares", "label": "Shares, Outstanding", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://brightgreen.us/role/SummaryOfSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r102", "r182" ] }, "BGXX_SixConsultantsMember": { "xbrltype": "domainItemType", "nsuri": "http://brightgreen.us/20231231", "localname": "SixConsultantsMember", "presentation": [ "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Six Consultants [Member]", "documentation": "Six Consultants [Member]" } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://brightgreen.us/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r562" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://brightgreen.us/role/DescriptionOfBusinessAndOrganizationDetailsNarrative", "http://brightgreen.us/role/RelatedPartyTransactionsDetailsNarrative", "http://brightgreen.us/role/StatementsOfChangesInStockholdersEquity", "http://brightgreen.us/role/Stock-basedCompensationDetailsNarrative", "http://brightgreen.us/role/StockholdersEquityDetailsNarrative", "http://brightgreen.us/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r16", "r28", "r160", "r172", "r173", "r174", "r188", "r189", "r190", "r192", "r198", "r200", "r210", "r240", "r241", "r280", "r315", "r316", "r317", "r332", "r333", "r347", "r348", "r349", "r350", "r351", "r352", "r354", "r364", "r365", "r366", "r367", "r368", "r369", "r371", "r421", "r422", "r423", "r436", "r495" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementGeographicalAxis", "presentation": [ "http://brightgreen.us/role/PropertyPlantAndEquipmentDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]", "documentation": "Information by geographical components." } } }, "auth_ref": [ "r150", "r159", "r231", "r232", "r439", "r440", "r441", "r504", "r506", "r509", "r511", "r514", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r527", "r536", "r543", "r604", "r651" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://brightgreen.us/role/DescriptionOfBusinessAndOrganizationDetailsNarrative", "http://brightgreen.us/role/EquityMethodInvestmentInAlterolaDetailsNarrative", "http://brightgreen.us/role/ScheduleOfEquityMethodInvestmentInAlterolaDetails", "http://brightgreen.us/role/ScheduleOfFinancialStatementInformationDetails", "http://brightgreen.us/role/StatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r188", "r189", "r190", "r210", "r388", "r428", "r438", "r444", "r445", "r446", "r447", "r448", "r449", "r451", "r454", "r455", "r456", "r457", "r458", "r460", "r461", "r462", "r463", "r465", "r466", "r467", "r468", "r469", "r471", "r473", "r474", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r495", "r544" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementScenarioAxis", "presentation": [ "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]", "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts." } } }, "auth_ref": [ "r201", "r286", "r573", "r574", "r595" ] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://brightgreen.us/role/DescriptionOfBusinessAndOrganizationDetailsNarrative", "http://brightgreen.us/role/EquityMethodInvestmentInAlterolaDetailsNarrative", "http://brightgreen.us/role/ScheduleOfEquityMethodInvestmentInAlterolaDetails", "http://brightgreen.us/role/ScheduleOfFinancialStatementInformationDetails", "http://brightgreen.us/role/StatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r188", "r189", "r190", "r210", "r388", "r428", "r438", "r444", "r445", "r446", "r447", "r448", "r449", "r451", "r454", "r455", "r456", "r457", "r458", "r460", "r461", "r462", "r463", "r465", "r466", "r467", "r468", "r469", "r471", "r473", "r474", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r495", "r544" ] }, "us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants", "crdr": "credit", "presentation": [ "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrants estimate value", "documentation": "Value of preferred stock and warrants for common stock issued." } } }, "auth_ref": [] }, "BGXX_StockCancelledDuringPeriodValueIssuedForServices": { "xbrltype": "monetaryItemType", "nsuri": "http://brightgreen.us/20231231", "localname": "StockCancelledDuringPeriodValueIssuedForServices", "crdr": "credit", "presentation": [ "http://brightgreen.us/role/StatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Common stock cancelled that was issued for services (Note 11)", "documentation": "Stock cancelled during period value issued for services." } } }, "auth_ref": [] }, "BGXX_StockCancelledDuringSharesValueIssuedForServices": { "xbrltype": "sharesItemType", "nsuri": "http://brightgreen.us/20231231", "localname": "StockCancelledDuringSharesValueIssuedForServices", "presentation": [ "http://brightgreen.us/role/StatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Common stock cancelled that was issued for services (Note 11), shares", "documentation": "Stock cancelled during shares value issued for services." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "presentation": [ "http://brightgreen.us/role/StatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Common stock and warrants issued for cash in a private placement, net of issuance costs (Note 11), shares", "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities." } } }, "auth_ref": [ "r16", "r27", "r53", "r113", "r265" ] }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "presentation": [ "http://brightgreen.us/role/RelatedPartyTransactionsDetailsNarrative", "http://brightgreen.us/role/StatementsOfChangesInStockholdersEquity", "http://brightgreen.us/role/StockholdersEquityDetailsNarrative", "http://brightgreen.us/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common stock issued for services (Note 11), shares", "verboseLabel": "Common stock issued for services rendered", "terseLabel": "Common stock issued for service, shares", "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://brightgreen.us/role/DescriptionOfBusinessAndOrganizationDetailsNarrative", "http://brightgreen.us/role/StatementsOfChangesInStockholdersEquity", "http://brightgreen.us/role/Stock-basedCompensationDetailsNarrative", "http://brightgreen.us/role/StockholdersEquityDetailsNarrative", "http://brightgreen.us/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common stock issued for cash for EB-5 program (Note 11), shares", "verboseLabel": "Aggregate shares of common stock issued", "terseLabel": "Issuance of shares", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r16", "r86", "r87", "r113", "r430", "r495", "r512" ] }, "us-gaap_StockIssuedDuringPeriodSharesOther": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesOther", "presentation": [ "http://brightgreen.us/role/EquityMethodInvestmentInAlterolaDetailsNarrative", "http://brightgreen.us/role/StatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Common stock issued for a cashless conversion from related party LOC for EB-5 program (Notes 10 and 11), shares", "verboseLabel": "Number of shares transferred", "documentation": "Number of shares of stock issued attributable to transactions classified as other." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "presentation": [ "http://brightgreen.us/role/RelatedPartyTransactionsDetailsNarrative", "http://brightgreen.us/role/Stock-basedCompensationDetailsNarrative", "http://brightgreen.us/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Restricted stock, shares", "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards." } } }, "auth_ref": [ "r16", "r113" ] }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "presentation": [ "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Number of shares issued", "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r16", "r86", "r87", "r113" ] }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationForfeited", "presentation": [ "http://brightgreen.us/role/CommitmentsDetailsNarrative", "http://brightgreen.us/role/DepositsDetailsNarrative", "http://brightgreen.us/role/StockholdersEquityDetailsNarrative", "http://brightgreen.us/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Number of shares forfeited", "verboseLabel": "Shares Issued, Shares, Share-Based Payment Arrangement, Forfeited", "terseLabel": "Shares of common stock cancelled", "documentation": "Number of shares (or other type of equity) forfeited during the period." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://brightgreen.us/role/ScheduleOfSummarizesStockOptionActivityDetails", "http://brightgreen.us/role/Stock-basedCompensationDetailsNarrative", "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Stock options issued for services rendered, shares", "verboseLabel": "Number of stock options exercised", "terseLabel": "Stock options shares", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r16", "r86", "r87", "r113", "r297" ] }, "BGXX_StockIssuedDuringPeriodSharesWarrantsExercisedForCash": { "xbrltype": "sharesItemType", "nsuri": "http://brightgreen.us/20231231", "localname": "StockIssuedDuringPeriodSharesWarrantsExercisedForCash", "presentation": [ "http://brightgreen.us/role/StatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Warrants exercised for cash (Note 11), shares", "documentation": "Stock issued during period shares warrants exercised for cash." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "crdr": "credit", "presentation": [ "http://brightgreen.us/role/GoingConcernAndBasisOfPresentationDetailsNarrative", "http://brightgreen.us/role/StatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Common stock and warrants issued for cash in a private placement, net of issuance costs (Note 11)", "verboseLabel": "Warrants to purchase common stock", "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities." } } }, "auth_ref": [ "r16", "r28", "r113" ] }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueIssuedForServices", "crdr": "credit", "presentation": [ "http://brightgreen.us/role/StatementsOfChangesInStockholdersEquity", "http://brightgreen.us/role/Stock-basedCompensationDetailsNarrative", "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common stock issued for services (Note 11)", "verboseLabel": "Gross cash proceeds", "terseLabel": "Stock Issued During Period, Value, Issued for Services", "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://brightgreen.us/role/GoingConcernAndBasisOfPresentationDetailsNarrative", "http://brightgreen.us/role/RelatedPartyLineOfCreditNoteDetailsNarrative", "http://brightgreen.us/role/StatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Common stock issued for cash for EB-5 program (Note 11)", "verboseLabel": "Issuances of common stock", "terseLabel": "Number of shares issued", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [ "r16", "r86", "r87", "r113", "r436", "r495", "r512", "r550" ] }, "us-gaap_StockIssuedDuringPeriodValueOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueOther", "crdr": "credit", "presentation": [ "http://brightgreen.us/role/StatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Common stock issued for a cashless conversion from related party LOC for EB-5 program (Notes 10 and 11)", "documentation": "Value of shares of stock issued attributable to transactions classified as other." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValuePurchaseOfAssets", "crdr": "credit", "presentation": [ "http://brightgreen.us/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Number of shares purchase assets", "documentation": "Value of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination." } } }, "auth_ref": [] }, "BGXX_StockIssuedDuringPeriodValueWarrantsExercisedForCash": { "xbrltype": "monetaryItemType", "nsuri": "http://brightgreen.us/20231231", "localname": "StockIssuedDuringPeriodValueWarrantsExercisedForCash", "crdr": "credit", "presentation": [ "http://brightgreen.us/role/StatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Warrants exercised for cash (Note 11)", "documentation": "Stock issued during period value warrants exercised for cash." } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://brightgreen.us/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://brightgreen.us/role/BalanceSheets", "http://brightgreen.us/role/ScheduleOfFinancialStatementInformationDetails", "http://brightgreen.us/role/StatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders\u2019 equity", "periodStartLabel": "Balance", "periodEndLabel": "Balance", "label": "Equity (Deficit)", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r87", "r90", "r91", "r104", "r453", "r470", "r496", "r497", "r539", "r551", "r589", "r599", "r639", "r656" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": [ "http://brightgreen.us/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "STOCKHOLDERS\u2019 EQUITY" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://brightgreen.us/role/StockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 Equity", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r112", "r183", "r266", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r280", "r353", "r498", "r500", "r513" ] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventLineItems", "presentation": [ "http://brightgreen.us/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Line Items]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": [ "r370", "r381" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventMember", "presentation": [ "http://brightgreen.us/role/CommitmentsDetailsNarrative", "http://brightgreen.us/role/DepositsDetailsNarrative", "http://brightgreen.us/role/EquityMethodInvestmentInAlterolaDetailsNarrative", "http://brightgreen.us/role/PropertyPlantAndEquipmentDetailsNarrative", "http://brightgreen.us/role/RelatedPartyTransactionsDetailsNarrative", "http://brightgreen.us/role/Stock-basedCompensationDetailsNarrative", "http://brightgreen.us/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r370", "r381" ] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTable", "presentation": [ "http://brightgreen.us/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Table]", "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued." } } }, "auth_ref": [ "r370", "r381" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://brightgreen.us/role/CommitmentsDetailsNarrative", "http://brightgreen.us/role/DepositsDetailsNarrative", "http://brightgreen.us/role/EquityMethodInvestmentInAlterolaDetailsNarrative", "http://brightgreen.us/role/PropertyPlantAndEquipmentDetailsNarrative", "http://brightgreen.us/role/RelatedPartyTransactionsDetailsNarrative", "http://brightgreen.us/role/Stock-basedCompensationDetailsNarrative", "http://brightgreen.us/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r370", "r381" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://brightgreen.us/role/CommitmentsDetailsNarrative", "http://brightgreen.us/role/DepositsDetailsNarrative", "http://brightgreen.us/role/EquityMethodInvestmentInAlterolaDetailsNarrative", "http://brightgreen.us/role/PropertyPlantAndEquipmentDetailsNarrative", "http://brightgreen.us/role/RelatedPartyTransactionsDetailsNarrative", "http://brightgreen.us/role/Stock-basedCompensationDetailsNarrative", "http://brightgreen.us/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r370", "r381" ] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://brightgreen.us/role/SubsequentEvents" ], "lang": { "en-us": { "role": { "label": "Subsequent Events", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r380", "r382" ] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsidiarySaleOfStockAxis", "presentation": [ "http://brightgreen.us/role/DescriptionOfBusinessAndOrganizationDetailsNarrative", "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://brightgreen.us/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "CASH PAID FOR" } } }, "auth_ref": [] }, "BGXX_ThreeDirectorsMember": { "xbrltype": "domainItemType", "nsuri": "http://brightgreen.us/20231231", "localname": "ThreeDirectorsMember", "presentation": [ "http://brightgreen.us/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Three Directors [Member]", "documentation": "Three Directors [Member]" } } }, "auth_ref": [] }, "us-gaap_TimeDepositLiabilityAboveUsInsuranceLimit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TimeDepositLiabilityAboveUsInsuranceLimit", "crdr": "credit", "presentation": [ "http://brightgreen.us/role/ConcentrationOfCreditRiskDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Excess of FDIC insured limit", "documentation": "Amount of uninsured time deposit liability in excess of Federal Deposit Insurance Corporation (FDIC) insurance limit or similar state deposit insurance regime in United States of America (US). Excludes time deposit that is otherwise uninsured." } } }, "auth_ref": [ "r148" ] }, "BGXX_TitanAdvisoryServicesLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://brightgreen.us/20231231", "localname": "TitanAdvisoryServicesLLCMember", "presentation": [ "http://brightgreen.us/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Titan Advisory Services LLC [Member]", "documentation": "Titan Advisory Services LLC [Member]" } } }, "auth_ref": [] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualAxis", "presentation": [ "http://brightgreen.us/role/ContingenciesDetailsNarrative", "http://brightgreen.us/role/DescriptionOfBusinessAndOrganizationDetailsNarrative", "http://brightgreen.us/role/RelatedPartyTransactionsDetailsNarrative", "http://brightgreen.us/role/Stock-basedCompensationDetailsNarrative", "http://brightgreen.us/role/StockholdersEquityDetailsNarrative", "http://brightgreen.us/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]", "documentation": "Information by title of individual or nature of relationship to individual or group of individuals." } } }, "auth_ref": [ "r596", "r640" ] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [ "http://brightgreen.us/role/ContingenciesDetailsNarrative", "http://brightgreen.us/role/DescriptionOfBusinessAndOrganizationDetailsNarrative", "http://brightgreen.us/role/RelatedPartyTransactionsDetailsNarrative", "http://brightgreen.us/role/Stock-basedCompensationDetailsNarrative", "http://brightgreen.us/role/StockholdersEquityDetailsNarrative", "http://brightgreen.us/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Title of individual, or nature of relationship to individual or group of individuals." } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://brightgreen.us/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "BGXX_TransferFromDepositOnEquipmentToPrepaidExpensesAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://brightgreen.us/20231231", "localname": "TransferFromDepositOnEquipmentToPrepaidExpensesAndOtherAssets", "crdr": "credit", "presentation": [ "http://brightgreen.us/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Transfer from deposit on equipment to prepaid expenses and other assets" } } }, "auth_ref": [] }, "BGXX_TransferFromDueToRelatedPartyToRelatedPartyLOC": { "xbrltype": "monetaryItemType", "nsuri": "http://brightgreen.us/20231231", "localname": "TransferFromDueToRelatedPartyToRelatedPartyLOC", "crdr": "credit", "presentation": [ "http://brightgreen.us/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Transfer from due to related party to related party LOC", "documentation": "Transfer from dueto related party to related party loc." } } }, "auth_ref": [] }, "us-gaap_TransferOfInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TransferOfInvestments", "crdr": "credit", "presentation": [ "http://brightgreen.us/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Due to others for purchase of common stock in Alterola Biotech, Inc.", "documentation": "Value of investments transferred from the entity's investments in noncash transactions." } } }, "auth_ref": [ "r35", "r36", "r37" ] }, "us-gaap_TransferToInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TransferToInvestments", "crdr": "debit", "presentation": [ "http://brightgreen.us/role/RelatedPartyLineOfCreditNoteDetailsNarrative", "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Investment transfer for repayment of loan", "documentation": "Value of investments transferred to the entity's investments in noncash transactions." } } }, "auth_ref": [ "r35", "r36", "r37" ] }, "BGXX_TwoAccreditedInvestorMember": { "xbrltype": "domainItemType", "nsuri": "http://brightgreen.us/20231231", "localname": "TwoAccreditedInvestorMember", "presentation": [ "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Two Accredited Investor [Member]", "documentation": "Two Accredited Investor [Member]" } } }, "auth_ref": [] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TypeOfArrangementAxis", "presentation": [ "http://brightgreen.us/role/CommitmentsDetailsNarrative", "http://brightgreen.us/role/DepositsDetailsNarrative", "http://brightgreen.us/role/EquityMethodInvestmentInAlterolaDetailsNarrative", "http://brightgreen.us/role/PropertyPlantAndEquipmentDetailsNarrative", "http://brightgreen.us/role/Stock-basedCompensationDetailsNarrative", "http://brightgreen.us/role/StockholdersEquityDetailsNarrative", "http://brightgreen.us/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r342" ] }, "BGXX_UnsecuredLineOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://brightgreen.us/20231231", "localname": "UnsecuredLineOfCreditMember", "presentation": [ "http://brightgreen.us/role/RelatedPartyLineOfCreditNoteDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Unsecured Line of Credit [Member]", "documentation": "Unsecured Line of Credit [Member]" } } }, "auth_ref": [] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UseOfEstimates", "presentation": [ "http://brightgreen.us/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Use of Estimates", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r40", "r41", "r42", "r135", "r137", "r139", "r140" ] }, "BGXX_ValuationAllowancesOfIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://brightgreen.us/20231231", "localname": "ValuationAllowancesOfIncomeTaxExpenseBenefit", "crdr": "credit", "calculation": { "http://brightgreen.us/role/ScheduleOfIncomeTaxProvisionDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://brightgreen.us/role/ScheduleOfIncomeTaxProvisionDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Valuation allowance", "documentation": "Valuation allowance of income tax provision.", "label": "ValuationAllowancesOfIncomeTaxExpenseBenefit" } } }, "auth_ref": [] }, "us-gaap_VariableRateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableRateAxis", "presentation": [ "http://brightgreen.us/role/RelatedPartyLineOfCreditNoteDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Variable Rate [Axis]", "documentation": "Information by type of variable rate." } } }, "auth_ref": [] }, "us-gaap_VariableRateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableRateDomain", "presentation": [ "http://brightgreen.us/role/RelatedPartyLineOfCreditNoteDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index." } } }, "auth_ref": [] }, "BGXX_VenloStyleGreenHouseMember": { "xbrltype": "domainItemType", "nsuri": "http://brightgreen.us/20231231", "localname": "VenloStyleGreenHouseMember", "presentation": [ "http://brightgreen.us/role/PropertyPlantAndEquipmentDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Venlo Style Green House [Member]", "documentation": "Venlo Style Green House [Member]" } } }, "auth_ref": [] }, "BGXX_VotingAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://brightgreen.us/20231231", "localname": "VotingAgreementMember", "presentation": [ "http://brightgreen.us/role/EquityMethodInvestmentInAlterolaDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Voting Agreement [Member]", "documentation": "Voting Agreement [Member]" } } }, "auth_ref": [] }, "BGXX_WarrantAndSharePurchasePrice": { "xbrltype": "perShareItemType", "nsuri": "http://brightgreen.us/20231231", "localname": "WarrantAndSharePurchasePrice", "presentation": [ "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Purchase price", "documentation": "Warrant and share purchase price." } } }, "auth_ref": [] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantMember", "presentation": [ "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrant [Member]", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": [ "r541", "r542", "r545", "r546", "r547", "r548" ] }, "BGXX_WarrantRedeemedOrCalledDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://brightgreen.us/20231231", "localname": "WarrantRedeemedOrCalledDuringPeriodShares", "presentation": [ "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrants redeemed, shares", "documentation": "Warrant redeemed or called during period shares." } } }, "auth_ref": [] }, "BGXX_WarrantRedeemedOrCalledDuringPeriodValue": { "xbrltype": "monetaryItemType", "nsuri": "http://brightgreen.us/20231231", "localname": "WarrantRedeemedOrCalledDuringPeriodValue", "crdr": "debit", "presentation": [ "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrants redeemed, value", "documentation": "Warrant redeemed or called during period value." } } }, "auth_ref": [] }, "us-gaap_WarrantsAndRightsOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantsAndRightsOutstanding", "crdr": "credit", "presentation": [ "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrants fair value", "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price." } } }, "auth_ref": [] }, "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": { "xbrltype": "decimalItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantsAndRightsOutstandingMeasurementInput", "presentation": [ "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Dividend rate", "label": "Warrants and Rights Outstanding, Measurement Input", "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur." } } }, "auth_ref": [ "r358" ] }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantsAndRightsOutstandingTerm", "presentation": [ "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrants and rights outstanding term", "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r638" ] }, "BGXX_WarrantsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://brightgreen.us/20231231", "localname": "WarrantsPolicyTextBlock", "presentation": [ "http://brightgreen.us/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Warrants", "documentation": "Warrants [Policy Text Block]" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://brightgreen.us/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Weighted average common shares outstanding - diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r203", "r208" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://brightgreen.us/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Weighted average common shares outstanding - basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r202", "r208" ] }, "BGXX_WorkingCapitalDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://brightgreen.us/20231231", "localname": "WorkingCapitalDeficit", "crdr": "credit", "presentation": [ "http://brightgreen.us/role/GoingConcernAndBasisOfPresentationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Working capital deficit", "documentation": "Working capital deficit" } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://brightgreen.us/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r571" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482338/360-10-05-4" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "SubTopic": "20", "Topic": "940", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(f)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "21D", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-21D" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(g)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "825", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "20", "Topic": "715", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "20", "Topic": "835", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "405", "Topic": "942", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481047/942-405-50-1" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(2)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "60", "Paragraph": "1", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(19)", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-30)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "((a)(1),(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "450", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "450", "SubTopic": "20", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481573/470-10-45-13" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481573/470-10-45-14" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "710", "SubTopic": "10", "Section": "25", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483070/710-10-25-11" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-2" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-3" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-4" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(b),(f(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "15", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-16" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "940", "SubTopic": "820", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481753/940-820-50-1" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.10)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.12)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.15(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.15)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "944", "SubTopic": "825", "Section": "25", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479436/944-825-25-2" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205/tableOfContent" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205-30/tableOfContent" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 201.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 201.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 201.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4,6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//275/tableOfContent" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//360/tableOfContent" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.CC)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480091/360-10-S99-2" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-5" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//505/tableOfContent" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "710", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//710/tableOfContent" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "710", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483043/710-10-30-1" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "712", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//712/tableOfContent" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "715", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//715/tableOfContent" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//718/tableOfContent" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "9", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//810/tableOfContent" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-23" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//942/tableOfContent" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "210", "Topic": "946", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-20" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "35", "Topic": "720", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483406/720-35-50-1" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "20", "Topic": "910", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482332/910-20-50-1" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(1)", "Publisher": "SEC" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1406", "Paragraph": "(e)", "Publisher": "SEC" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1406", "Paragraph": "(f)", "Subparagraph": "(1)", "Publisher": "SEC" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1406", "Publisher": "SEC" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Footnote": "2", "Publisher": "SEC" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column B", "Publisher": "SEC" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column C", "Publisher": "SEC" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column D", "Publisher": "SEC" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column E", "Publisher": "SEC" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column F", "Publisher": "SEC" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column G", "Publisher": "SEC" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column H", "Publisher": "SEC" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column I", "Publisher": "SEC" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "29", "Footnote": "4", "Publisher": "SEC" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481664/323-10-45-1" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//350-30/tableOfContent" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450-20/tableOfContent" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450-30/tableOfContent" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483049/450-30-50-1" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "35", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483406/720-35-50-1" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//740/tableOfContent" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481839/830-10-45-17" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482014/830-20-35-1" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481956/830-20-45-1" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481926/830-20-50-1" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//850/tableOfContent" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//855/tableOfContent" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "920", "SubTopic": "350", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-1" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "920", "SubTopic": "350", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-1" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "920", "SubTopic": "350", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-4" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(h))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-21" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r527": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r528": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r529": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r530": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r531": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r532": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r533": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47" }, "r534": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r535": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r536": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r537": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r538": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r539": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r540": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r541": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r542": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r543": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r544": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r545": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r546": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r547": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r548": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r549": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r550": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, "r551": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r552": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r553": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r554": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r555": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r556": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r557": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r558": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r559": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r560": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r561": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r562": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r563": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r564": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r565": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r566": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r567": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r568": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w" }, "r569": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r570": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r571": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r572": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r573": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10" }, "r574": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3" }, "r575": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r576": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Topic": "321", "Publisher": "FASB", "URI": "https://asc.fasb.org//321/tableOfContent" }, "r577": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Topic": "325", "Publisher": "FASB", "URI": "https://asc.fasb.org//325/tableOfContent" }, "r578": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "11", "Subsection": "03", "Publisher": "SEC" }, "r579": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "04", "Paragraph": "(a)", "Publisher": "SEC" }, "r580": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r581": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r582": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r583": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r584": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r585": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r586": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(b)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r587": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r588": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r589": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r590": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r591": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r592": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r593": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r594": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r595": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r596": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13" }, "r597": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//320/tableOfContent" }, "r598": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r599": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r600": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r601": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r602": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r603": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r604": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r605": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r606": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r607": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r608": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r609": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r610": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r611": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r612": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r613": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r614": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r615": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r616": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r617": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r618": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r619": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r620": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r621": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r622": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r623": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r624": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r625": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r626": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r627": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r628": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r629": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r630": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r631": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r632": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r633": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6" }, "r634": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r635": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r636": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r637": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r638": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r639": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r640": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2" }, "r641": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r642": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r643": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r644": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r645": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r646": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r647": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r648": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r649": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r650": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r651": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B" }, "r652": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r653": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r654": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(k)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r655": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r656": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r657": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" } } } ZIP 80 0001493152-24-014864-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-24-014864-xbrl.zip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d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m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Î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form10-k_htm.xml IDEA: XBRL DOCUMENT 0001886799 2023-01-01 2023-12-31 0001886799 2023-06-30 0001886799 2024-04-11 0001886799 2023-12-31 0001886799 2022-12-31 0001886799 us-gaap:RelatedPartyMember 2023-12-31 0001886799 us-gaap:RelatedPartyMember 2022-12-31 0001886799 2022-01-01 2022-12-31 0001886799 us-gaap:CommonStockMember 2021-12-31 0001886799 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001886799 us-gaap:RetainedEarningsMember 2021-12-31 0001886799 2021-12-31 0001886799 us-gaap:CommonStockMember 2022-12-31 0001886799 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001886799 us-gaap:RetainedEarningsMember 2022-12-31 0001886799 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001886799 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001886799 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001886799 us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001886799 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-12-31 0001886799 us-gaap:RetainedEarningsMember 2023-01-01 2023-12-31 0001886799 us-gaap:CommonStockMember 2023-12-31 0001886799 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001886799 us-gaap:RetainedEarningsMember 2023-12-31 0001886799 srt:MaximumMember us-gaap:PrivatePlacementMember 2023-02-01 2023-02-01 0001886799 us-gaap:PrivatePlacementMember 2023-02-01 0001886799 BGXX:AccreditedInvestorAndExistingStockholderMember us-gaap:CommonStockMember 2023-05-20 2023-05-21 0001886799 BGXX:AccreditedInvestorAndExistingStockholderMember us-gaap:CommonStockMember 2023-05-21 0001886799 BGXX:AccreditedInvestorAndExistingStockholderMember us-gaap:PrivatePlacementMember 2023-05-21 0001886799 us-gaap:BuildingAndBuildingImprovementsMember 2023-12-31 0001886799 us-gaap:FurnitureAndFixturesMember 2023-12-31 0001886799 srt:MinimumMember 2023-12-31 0001886799 srt:MaximumMember 2023-12-31 0001886799 us-gaap:SubsequentEventMember BGXX:SettlementAndReleaseAgreementMember 2024-03-13 2024-03-13 0001886799 BGXX:AlterolaBiotechIncMember 2022-10-03 0001886799 BGXX:AlterolaBiotechIncMember BGXX:SellersMember 2022-10-03 0001886799 BGXX:AlterolaBiotechIncMember BGXX:SellersMember 2022-10-02 2022-10-03 0001886799 BGXX:SellersMember 2023-12-31 0001886799 BGXX:SellersMember 2022-12-31 0001886799 BGXX:AlterolaBiotechIncMember BGXX:SellersMember us-gaap:SubsequentEventMember 2024-03-13 2024-03-13 0001886799 BGXX:VotingAgreementMember 2023-01-01 2023-12-31 0001886799 BGXX:AlterolaBiotechIncMember 2023-12-31 0001886799 BGXX:AlterolaBiotechIncMember 2023-09-30 0001886799 BGXX:AlterolaBiotechIncMember 2022-12-31 0001886799 BGXX:AlterolaBiotechIncMember 2023-01-01 2023-09-30 0001886799 BGXX:AlterolaBiotechIncMember 2022-01-01 2022-12-31 0001886799 BGXX:AlterolaBiotechIncMember 2021-12-31 0001886799 BGXX:AlterolaBiotechIncMember 2022-01-01 2022-12-31 0001886799 BGXX:AlterolaBiotechIncMember 2022-12-31 0001886799 BGXX:AlterolaBiotechIncMember 2023-01-01 2023-12-31 0001886799 BGXX:NMMember BGXX:VenloStyleGreenHouseMember 2023-12-31 0001886799 BGXX:NMMember 2022-12-31 0001886799 us-gaap:ConstructionInProgressMember 2023-12-31 0001886799 us-gaap:ConstructionInProgressMember 2022-12-31 0001886799 us-gaap:SubsequentEventMember 2024-01-19 2024-01-19 0001886799 BGXX:RealEstateOptionAgreementOneMember BGXX:GrantGreenhouseGrowersIncMember 2020-10-05 2020-10-05 0001886799 BGXX:RealEstateOptionAgreementOneMember BGXX:GrantGreenhouseGrowersIncMember 2020-10-05 2021-06-30 0001886799 BGXX:RealEstateOptionAgreementOneMember BGXX:GrantGreenhouseGrowersIncMember 2021-07-01 2021-12-31 0001886799 BGXX:RealEstateOptionAgreementOneMember BGXX:GrantGreenhouseGrowersIncMember 2022-01-01 2022-01-01 0001886799 BGXX:RealEstateOptionAgreementOneMember BGXX:GrantGreenhouseGrowersIncMember 2022-01-01 0001886799 BGXX:RealEstateOptionAgreementTwoMember BGXX:GrantGreenhouseGrowersIncMember 2020-10-21 2020-10-21 0001886799 BGXX:RealEstateOptionAgreementTwoMember BGXX:GrantGreenhouseGrowersIncMember 2021-01-01 2021-12-31 0001886799 BGXX:RealEstateOptionAgreementTwoMember BGXX:GrantGreenhouseGrowersIncMember 2022-01-01 2022-01-01 0001886799 BGXX:RealEstateOptionAgreementTwoMember BGXX:GrantGreenhouseGrowersIncMember 2022-01-01 0001886799 us-gaap:EquipmentMember 2022-12-31 0001886799 us-gaap:EquipmentMember 2022-01-01 2022-12-31 0001886799 srt:MaximumMember BGXX:UnsecuredLineOfCreditMember BGXX:LDSCapitalLLCMember 2022-06-05 0001886799 BGXX:UnsecuredLineOfCreditMember BGXX:LDSCapitalLLCMember 2022-06-05 0001886799 BGXX:UnsecuredLineOfCreditMember BGXX:LDSCapitalLLCMember us-gaap:PrimeRateMember 2022-06-05 0001886799 BGXX:AmendedUnsecuredLineOfCreditMember 2022-11-14 0001886799 BGXX:UnsecuredLineOfCreditMember BGXX:LDSCapitalLLCMember 2023-01-01 2023-12-31 0001886799 BGXX:UnsecuredLineOfCreditMember BGXX:LDSCapitalLLCMember 2022-01-01 2022-12-31 0001886799 BGXX:UnsecuredLineOfCreditMember BGXX:LDSCapitalLLCMember us-gaap:ConstructionInProgressMember 2023-12-31 0001886799 BGXX:UnsecuredLineOfCreditMember BGXX:LDSCapitalLLCMember 2023-12-31 0001886799 BGXX:UnsecuredLineOfCreditMember BGXX:LDSCapitalLLCMember 2022-12-31 0001886799 2023-02-01 2023-02-01 0001886799 2023-02-06 2023-02-06 0001886799 2023-02-06 0001886799 2023-03-14 2023-03-14 0001886799 2023-08-31 0001886799 2023-08-31 2023-08-31 0001886799 2023-12-01 2023-12-01 0001886799 2023-12-01 0001886799 BGXX:OneAccreditedInvestorMember 2023-02-01 2023-02-28 0001886799 BGXX:OneAccreditedInvestorMember 2023-02-28 0001886799 BGXX:BoardMemberMember us-gaap:CommonStockMember 2023-02-01 2023-02-28 0001886799 BGXX:BoardMemberMember us-gaap:CommonStockMember 2023-02-28 0001886799 2023-02-01 2023-02-28 0001886799 BGXX:OneAccreditedInvestorMember us-gaap:CommonStockMember 2023-03-01 2023-03-31 0001886799 BGXX:OneAccreditedInvestorMember us-gaap:CommonStockMember 2023-03-31 0001886799 BGXX:ExecutiveChairmanMember us-gaap:CommonStockMember 2023-03-01 2023-03-31 0001886799 BGXX:ExecutiveChairmanMember us-gaap:CommonStockMember 2023-03-31 0001886799 srt:ChiefExecutiveOfficerMember us-gaap:CommonStockMember 2023-05-01 2023-05-31 0001886799 srt:ChiefExecutiveOfficerMember us-gaap:CommonStockMember 2023-05-31 0001886799 us-gaap:PrivatePlacementMember 2023-05-01 2023-05-31 0001886799 us-gaap:PrivatePlacementMember 2023-05-31 0001886799 BGXX:ExecutiveChairmanMember us-gaap:CommonStockMember 2023-06-01 2023-06-30 0001886799 BGXX:ExecutiveChairmanMember us-gaap:CommonStockMember 2023-06-30 0001886799 BGXX:ConsultantMember us-gaap:CommonStockMember 2023-07-01 2023-07-31 0001886799 BGXX:ConsultantMember us-gaap:CommonStockMember 2023-07-31 0001886799 2023-09-01 2023-09-30 0001886799 us-gaap:WarrantMember 2023-09-30 0001886799 us-gaap:CommonStockMember 2023-09-30 0001886799 BGXX:ConsultantMember us-gaap:CommonStockMember 2023-09-01 2023-09-30 0001886799 BGXX:ConsultantMember us-gaap:CommonStockMember 2023-09-30 0001886799 srt:ChiefFinancialOfficerMember us-gaap:CommonStockMember 2023-09-01 2023-09-30 0001886799 srt:ChiefFinancialOfficerMember us-gaap:CommonStockMember 2023-09-30 0001886799 BGXX:ExecutiveChairmanMember us-gaap:CommonStockMember 2023-09-01 2023-09-30 0001886799 BGXX:ExecutiveChairmanMember us-gaap:CommonStockMember 2023-09-30 0001886799 srt:DirectorMember us-gaap:CommonStockMember 2023-11-01 2023-11-30 0001886799 srt:DirectorMember us-gaap:CommonStockMember 2023-11-30 0001886799 BGXX:DirectorOneMember us-gaap:CommonStockMember 2023-11-01 2023-11-30 0001886799 BGXX:DirectorTwoMember us-gaap:CommonStockMember 2023-11-01 2023-11-30 0001886799 BGXX:DirectorThreeMember us-gaap:CommonStockMember 2023-11-01 2023-11-30 0001886799 BGXX:ExecutiveChairmanMember us-gaap:CommonStockMember 2023-12-01 2023-12-31 0001886799 BGXX:ExecutiveChairmanMember us-gaap:CommonStockMember 2023-12-31 0001886799 BGXX:OneAccreditedInvestorMember us-gaap:CommonStockMember 2022-01-01 2022-01-31 0001886799 BGXX:OneAccreditedInvestorMember us-gaap:CommonStockMember 2022-01-31 0001886799 srt:ChiefFinancialOfficerMember us-gaap:CommonStockMember 2022-04-01 2022-04-30 0001886799 srt:ChiefFinancialOfficerMember us-gaap:CommonStockMember 2022-04-30 0001886799 us-gaap:CommonStockMember us-gaap:PrivatePlacementMember 2022-04-30 0001886799 BGXX:SixConsultantsMember us-gaap:CommonStockMember 2022-04-01 2022-04-30 0001886799 BGXX:SixConsultantsMember us-gaap:CommonStockMember 2022-04-30 0001886799 BGXX:SixConsultantsMember us-gaap:CommonStockMember us-gaap:PrivatePlacementMember 2022-04-30 0001886799 BGXX:DirectorsMember us-gaap:CommonStockMember 2022-04-01 2022-04-30 0001886799 BGXX:DirectorsMember us-gaap:CommonStockMember 2022-04-30 0001886799 BGXX:TwoAccreditedInvestorMember us-gaap:CommonStockMember 2022-05-01 2022-05-31 0001886799 BGXX:TwoAccreditedInvestorMember us-gaap:CommonStockMember 2022-05-31 0001886799 BGXX:ConsultantsMember us-gaap:CommonStockMember 2022-06-01 2022-06-30 0001886799 BGXX:ConsultantsMember us-gaap:CommonStockMember 2022-06-30 0001886799 us-gaap:WarrantMember 2023-01-01 2023-09-30 0001886799 srt:ChiefExecutiveOfficerMember us-gaap:CommonStockMember 2022-12-01 2022-12-31 0001886799 srt:ChiefExecutiveOfficerMember BGXX:CommonStockOneMember 2022-12-01 2022-12-31 0001886799 srt:ChiefExecutiveOfficerMember BGXX:CommonStockOneMember 2022-12-31 0001886799 srt:ChiefExecutiveOfficerMember BGXX:CommonStockTwoMember 2022-12-01 2022-12-31 0001886799 srt:ChiefExecutiveOfficerMember BGXX:CommonStockTwoMember 2022-12-31 0001886799 srt:ChiefExecutiveOfficerMember BGXX:CommonStockThreeMember 2022-12-01 2022-12-31 0001886799 srt:ChiefExecutiveOfficerMember BGXX:CommonStockThreeMember 2022-12-31 0001886799 us-gaap:PrivatePlacementMember BGXX:SecuritiesPurchaseAgreementMember 2022-09-07 2022-09-07 0001886799 us-gaap:PrivatePlacementMember BGXX:SecuritiesPurchaseAgreementMember 2022-09-07 0001886799 us-gaap:PrivatePlacementMember 2022-09-07 2022-09-12 0001886799 2022-09-07 2022-09-07 0001886799 2022-09-21 2022-09-21 0001886799 2022-09-21 0001886799 BGXX:SecuritiesPurchaseAgreementMember 2023-05-21 0001886799 us-gaap:PrivatePlacementMember 2023-05-22 2023-05-24 0001886799 2023-05-01 2023-05-31 0001886799 us-gaap:PrivatePlacementMember 2022-09-07 0001886799 2022-09-06 0001886799 2022-09-12 0001886799 2022-09-07 2022-09-12 0001886799 us-gaap:WarrantMember us-gaap:PrivatePlacementMember 2023-05-01 2023-05-31 0001886799 us-gaap:WarrantMember us-gaap:PrivatePlacementMember 2023-05-31 0001886799 us-gaap:MeasurementInputExpectedTermMember us-gaap:WarrantMember us-gaap:PrivatePlacementMember 2023-05-31 0001886799 us-gaap:MeasurementInputOptionVolatilityMember us-gaap:WarrantMember us-gaap:PrivatePlacementMember 2023-05-31 0001886799 us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:WarrantMember us-gaap:PrivatePlacementMember 2023-05-31 0001886799 us-gaap:MeasurementInputExpectedDividendRateMember us-gaap:WarrantMember us-gaap:PrivatePlacementMember 2023-05-31 0001886799 srt:ScenarioForecastMember us-gaap:WarrantMember us-gaap:PrivatePlacementMember 2024-05-24 2024-05-24 0001886799 us-gaap:WarrantMember 2023-09-01 2023-09-30 0001886799 us-gaap:MeasurementInputExpectedTermMember us-gaap:WarrantMember 2023-09-30 0001886799 us-gaap:MeasurementInputOptionVolatilityMember us-gaap:WarrantMember 2023-09-30 0001886799 us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:WarrantMember 2023-09-30 0001886799 us-gaap:MeasurementInputExpectedDividendRateMember us-gaap:WarrantMember 2023-09-30 0001886799 us-gaap:WarrantMember 2023-09-01 2023-09-01 0001886799 BGXX:EquityCompensationPlanMember 2023-01-01 2023-12-31 0001886799 BGXX:EquityCompensationPlanMember 2022-01-01 2022-12-31 0001886799 us-gaap:RestrictedStockMember BGXX:EquityCompensationPlanMember 2023-12-31 0001886799 2023-09-20 2023-09-20 0001886799 2023-11-16 2023-11-16 0001886799 srt:ChiefExecutiveOfficerMember us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2024-03-31 2024-03-31 0001886799 srt:ChiefExecutiveOfficerMember us-gaap:SubsequentEventMember 2024-03-31 2024-03-31 0001886799 srt:ChiefExecutiveOfficerMember us-gaap:SubsequentEventMember BGXX:MutualAgreementMember 2024-03-31 2024-03-31 0001886799 us-gaap:DomesticCountryMember 2023-12-31 0001886799 us-gaap:DomesticCountryMember 2022-12-31 0001886799 BGXX:FormerExecutiveChairmanMember us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001886799 srt:ChiefExecutiveOfficerMember us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001886799 srt:ChiefFinancialOfficerMember us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001886799 BGXX:ThreeDirectorsMember 2023-01-01 2023-12-31 0001886799 srt:ChiefExecutiveOfficerMember us-gaap:RestrictedStockMember 2023-01-01 2023-12-31 0001886799 us-gaap:AccruedLiabilitiesMember BGXX:ExecutiveChairmanMember 2023-12-31 0001886799 us-gaap:AccruedLiabilitiesMember BGXX:ExecutiveChairmanMember 2022-12-31 0001886799 BGXX:FormerInterimChiefExecutiveOfficerMember us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2024-02-15 2024-02-15 0001886799 us-gaap:AccountsPayableMember BGXX:FormerChiefExecutiveOfficerMember 2023-12-31 0001886799 us-gaap:AccountsPayableMember srt:ChiefFinancialOfficerMember 2023-12-31 0001886799 us-gaap:AccountsPayableMember srt:ChiefFinancialOfficerMember 2022-12-31 0001886799 us-gaap:AccountsPayableMember srt:ChiefExecutiveOfficerMember 2023-12-31 0001886799 us-gaap:AccountsPayableMember srt:ChiefExecutiveOfficerMember 2022-12-31 0001886799 us-gaap:AccountsPayableMember BGXX:BoardOfDirectorsMember 2023-12-31 0001886799 us-gaap:AccountsPayableMember BGXX:BoardOfDirectorsMember 2022-12-31 0001886799 srt:ChiefExecutiveOfficerMember 2023-01-01 2023-12-31 0001886799 BGXX:FourConsultantsMember us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2024-01-30 2024-01-30 0001886799 BGXX:FourConsultantsMember us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2024-01-30 0001886799 us-gaap:SubsequentEventMember BGXX:OntarioLtdMember 2024-02-07 2024-02-07 0001886799 us-gaap:SubsequentEventMember 2024-02-08 2024-02-08 0001886799 BGXX:Mr.TerryRafihMember us-gaap:CommonStockMember us-gaap:SubsequentEventMember BGXX:SeparationAgreementMember 2024-02-15 2024-02-15 0001886799 BGXX:Mr.TerryRafihMember us-gaap:CommonStockMember us-gaap:SubsequentEventMember BGXX:SeparationAgreementMember 2024-02-15 0001886799 us-gaap:CommonStockMember us-gaap:SubsequentEventMember BGXX:SeparationAgreementMember 2024-02-15 2024-02-15 0001886799 BGXX:Mr.ElmasriMember us-gaap:SubsequentEventMember BGXX:CFOAgreementMember BGXX:TitanAdvisoryServicesLLCMember 2024-03-07 2024-03-07 0001886799 us-gaap:SubsequentEventMember BGXX:CreditAgreementMember 2024-03-14 0001886799 us-gaap:SubsequentEventMember 2024-03-25 2024-03-25 0001886799 us-gaap:SubsequentEventMember BGXX:ExecutiveEmploymentAgreementMember 2024-10-02 2024-10-02 0001886799 us-gaap:SubsequentEventMember BGXX:ExecutiveEmploymentAgreementMember 2024-10-03 2025-10-02 0001886799 us-gaap:SubsequentEventMember BGXX:ExecutiveEmploymentAgreementMember 2025-10-03 2026-10-02 0001886799 us-gaap:RestrictedStockMember us-gaap:SubsequentEventMember 2024-03-31 0001886799 us-gaap:SubsequentEventMember BGXX:ExecutiveEmploymentAgreementMember 2024-03-31 2024-03-31 0001886799 us-gaap:RestrictedStockUnitsRSUMember us-gaap:SubsequentEventMember BGXX:ExecutiveEmploymentAgreementMember 2024-03-31 2024-03-31 0001886799 us-gaap:SubsequentEventMember BGXX:ExecutiveEmploymentAgreementAgreementMember 2024-04-02 2024-04-02 0001886799 us-gaap:SubsequentEventMember BGXX:ExecutiveEmploymentAgreementAgreementMember 2024-03-31 2024-03-31 0001886799 us-gaap:SubsequentEventMember 2024-04-05 2024-04-05 0001886799 us-gaap:SubsequentEventMember 2024-04-09 2024-04-09 0001886799 us-gaap:SubsequentEventMember 2024-04-09 iso4217:USD shares iso4217:USD shares utr:acre pure false FY 0001886799 0 149 10-K true 2023-12-31 --12-31 2023 false 001-41395 BRIGHT GREEN CORPORATION DE 83-4600841 1033 George Hanosh Boulevard Grants NM 87020 (833) 658-1799 Common stock, $0.0001 par value per share BGXX NASDAQ No No Yes Yes Non-accelerated Filer true true false false false false 75060837 190166318 East Amherst, NY SRCO, C.P.A., Professional Corporation 6722 10059 414574 258230 77847 268289 492421 1157587 726343 3990960 16407415 17146325 1000 1000 17403047 22788293 4175220 5033831 411099 447325 1650000 1650000 392194 6236319 7523350 201783 3686107 201783 3686107 6438102 11209457 0.0001 0.0001 10000000 10000000 0 0 0 0 0.0001 0.0001 500000000 500000000 184758818 184758818 173304800 173304800 18476 17329 58149938 45637328 -47203469 -34075821 10964945 11578836 17403047 22788293 8252873 26609241 638507 704681 8891380 27313922 -8891380 -27313922 -1625 -970026 3045954 213000 4017605 213000 -12908985 -27526922 -12908985 -27526922 -218663 -135155 -13127648 -27662077 178574014 178574014 162058082 162058082 -0.07 -0.07 -0.17 -0.17 157544500 15754 14618389 -6413744 8220399 312500 31 3049969 3050000 863267 9523810 952 9135781 9136733 6036990 603 18850629 18851232 -113000 -11 -17440 -17451 -27662077 -27662077 173304800 17329 45637328 -34075821 11578836 173304800 17329 45637328 -34075821 11578836 395250 3684210 368 3104382 3104750 3684210 368 3104382 3104750 200000 20 209980 210000 22005 2 879998 880000 10000 2827960 283 3609506 3609789 22005 2 879998 880000 4697838 472 3234268 3234740 594478 594478 -13127648 -13127648 184758818 18476 58149938 -47203469 10964945 184758818 18476 58149938 -47203469 10964945 -13127648 -27662077 213000 -970026 3045954 218663 135155 638507 704681 3829218 18833781 40766 -90379 1823389 4883896 -36226 429298 223271 106117 -2455612 -2265770 1157587 2689115 2533653 10522242 -2533653 -14368944 400000 5191057 1611067 880000 3050000 3104750 9136733 10000 210000 4584750 15766723 -404515 -867991 414574 1282565 10059 414574 392194 139617 -880000 -3619789 -2682000 1650000 <p id="xdx_806_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zNUxxX1FRdS9" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_824_zSOSk9lh0R9a">Description of Business and Organization</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bright Green Corporation was incorporated on <span id="xdx_903_edei--EntityIncorporationDateOfIncorporation_dd_c20230101__20231231_zVoKefkVbrje" title="Date of incorporation">April 16, 2019</span>, under the Delaware General Corporation Law. The Company’s principal executive office is located in Grants, New Mexico. The Company holds the land, greenhouse, and patents required in the growth, production, and research of medicinal plants. When used herein, the terms the “Company,” “our,” “us,” “we,” or “Bright Green” refers to Bright Green Corporation and its consolidated subsidiary.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 29, 2022, the Company filed a registration statement pursuant to the Securities Act of 1933, as amended (the “Securities Act”) on Form S-1 with the Securities and Exchange Commission (“SEC”), which was declared effective May 13, 2022, (as amended, the “Registration Statement”), in connection with the direct listing of the Company’s common stock with the Capital Market of the Nasdaq Stock Market LLC (“Nasdaq”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 17, 2022, the Company’s common stock commenced trading on Nasdaq under the symbol “BGXX.”</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 1, 2023, the Company initiated a private placement offering of common stock, only to accredited or qualified institutional investors, in reliance upon Rule 506, Regulation D promulgated under the Securities Act, pursuant to the U.S. government’s EB-5 immigrant investor program. Under the EB-5 Program, the Company may issue up to an aggregate of <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230201__20230201__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__srt--RangeAxis__srt--MaximumMember_zI2pWKsJGeHi" title="Aggregate shares of common stock issued">12,609,152</span> shares of common stock at $<span id="xdx_90D_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230201__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zumMb9KZHJI6" title="Shares issued price per share">39.99</span> per share.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 21, 2023, the Company entered into a Securities Purchase Agreement with an accredited investor and existing stockholder of the Company for the sale by the Company of (i) <span id="xdx_90C_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230520__20230521__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorAndExistingStockholderMember_zhM65V0esaSg" title="Number of shares sold">3,684,210</span> shares of the Company’s common stock, par value $<span id="xdx_90C_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20230521__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorAndExistingStockholderMember_zi8UkAY1HpLe" title="Common stock, par value">0.0001</span> per share, and (ii) warrants to purchase up to an aggregate of <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230521__srt--TitleOfIndividualAxis__custom--AccreditedInvestorAndExistingStockholderMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_ziPJbzHQ06g4" title="Warrants to purchase shares">3,684,210</span> shares of the Company’s common stock, in a private placement offering. The combined purchase price of one share and accompanying warrant was $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230521__srt--TitleOfIndividualAxis__custom--AccreditedInvestorAndExistingStockholderMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_za6wG9kdFluk" title="Exercise price">0.95</span>. The shares and the warrants were sold and issued without registration under the Securities Act of 1933, in reliance on the exemptions provided by Section 4(a)(2) of the Securities Act as transactions not involving a public offering and Rule 506 of Regulation D promulgated under the Securities Act as sales to accredited investors, and in reliance on similar exemptions under applicable state laws.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 20, 2023, the Company formed Regional Center Bright Green, LLC (“RCBG”). RCBG is a wholly-owned subsidiary of the Company and is registered as a limited liability company in New Mexico. RCBG was created to assist foreign investors in obtaining permanent residency in the United States by investing in U.S. businesses, while adhering to the EB-5 Immigrant Investor Program guidelines. As of December 31, 2023, the subsidiary was not yet operational.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is a start-up company at December 31, 2023 and has <span id="xdx_908_eus-gaap--Revenues_do_c20230101__20231231_zkmxmR5edUyd" title="Revenue">no</span> revenue.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BRIGHT GREEN CORPORATION</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes to the Consolidated Financial Statements</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the Years Ended December 31, 2023 and 2022</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Expressed in United States Dollars)</span></p> <div style="margin-left: auto; margin-right: auto; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt"> </div></div> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 2019-04-16 12609152 39.99 3684210 0.0001 3684210 0.95 0 <p id="xdx_803_eus-gaap--LiquidationBasisOfAccountingTextBlock_zhHOP6mhoPMc" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_82C_zTPbCzJuoBp8">Going Concern and Basis of Presentation</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying consolidated financial statements have been prepared by the Company in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”). U.S. GAAP contemplates the continuation of the Company as a going concern. For the fiscal years ended December 31, 2023 and 2022, the Company had no revenues from product sales and incurred a net loss of $<span id="xdx_90A_eus-gaap--NetIncomeLoss_iN_di_c20230101__20231231_zMs5TvZztdD3">13,127,648 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_903_eus-gaap--NetIncomeLoss_iN_di_c20220101__20221231_zYBR5MNVbnJ7">27,662,077</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">, respectively. Net cash used in operations for the years ended 2023 and 2022 was $<span id="xdx_906_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_di_c20230101__20231231_zT8jzVNY3b8j">2,455,612 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_904_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_di_c20220101__20221231_zjYw0N1YNIcl">2,265,770</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">, respectively. The Company has incurred recurring losses from operations, and as of December 31, 2023, had an accumulated deficit of $<span id="xdx_90B_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_di_c20231231_zHGGYGQaaEGd">47,203,469 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(December 31, 2022 – $<span id="xdx_90D_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_di_c20221231_zhJkJIVzrPu6">34,075,821</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">) and had a negative working capital of $</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_ecustom--WorkingCapitalDeficit_iI_c20231231_z6MtCeBhfim4" title="Working capital deficit">5,968,030</span> (December 31, 2022 – $<span id="xdx_907_ecustom--WorkingCapitalDeficit_iI_c20221231_zr9f3zRVwYz6">7,030,929</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is in its initial stages of building facilities to grow, research, and distribute medical plants. The Company has historically financed its operations through the sale of equity securities and debt financing. The Company does not have sufficient working capital to pay its operating expenses for a period of at least 12 months from the date the consolidated financial statements were authorized to be issued. Therefore, the Company’s continued existence depends on its ability to continue executing its operating plan and obtaining additional debt or equity financing. The Company has developed plans to raise funds and continues to pursue sources of funding that management believes, if successful, would be sufficient to support the Company’s operating plan.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">In 2023, the Company raised $<span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_c20230101__20231231_zLR5YLMZv2L8" title="Warrants to purchase common stock">3,104,750</span> through the issuance of common stock and accompanying warrants to purchase shares of common stock from the Company’s private placement offering in May 2023, $<span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230101__20231231_zLefmRBPsmYa" title="Issuances of common stock">880,000</span> through common stock issuances from the Company’s EB-5 Program, and $<span id="xdx_906_eus-gaap--ProceedsFromWarrantExercises_c20230101__20231231_zlR8ror8cK7c" title="Exercise of warrants">210,000</span> through the exercise of warrants. The Company has drawn $<span id="xdx_900_eus-gaap--ProceedsFromLongTermLinesOfCredit_c20230101__20231231_zCRNDb8t1Dm3" title="Related party line of credit">400,000</span> from the Company’s $<span id="xdx_90F_eus-gaap--LineOfCredit_iI_pn6n6_c20231231_z9wpJlmsuOoi" title="Line of credit">15</span>,000,000 related party line of credit. The related party line of credit was used to pay in full the related party loan balance of $<span id="xdx_90F_eus-gaap--ProceedsFromPaymentsForLongTermLoansForRelatedParties_c20230101__20231231_zca9Da658qhg" title="Related party loan balance">392,194</span>. The related party line of credit was paid down $<span id="xdx_905_eus-gaap--RepaymentsOfLongTermLinesOfCredit_c20230101__20231231_zQVgnXnqDRCc" title="Line of credit paid down">880,000</span> in exchange for <span id="xdx_909_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20230101__20231231_zVltmtIr3eni" title="Line of credit paid down in exchange of shares">22,005</span> shares of the Company’s common stock valued at $<span id="xdx_90D_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pp2d_c20231231_zU83QoQ75c7b" title="Common stock value per share">39.99</span> per share pursuant to the Company’s EB-5 Program, and the related party line of credit was paid down $<span id="xdx_90D_eus-gaap--LineOfCredit_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z5A1wT7FM5hl" title="Related party line of credit paid down">3,619,789</span> in exchange for <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20231231_zN0U7gfH4PH1" title="Related party line of credit paid down in exchange of shares">2,827,960</span> shares of the Company’s common stock and accompanying warrants to purchase shares of common stock, leaving available $<span id="xdx_909_eus-gaap--LineOfCreditFacilityRemainingBorrowingCapacity_iI_c20231231_z2OivyQls4v5" title="Credit facility">14,800,000</span> to draw from that credit facility (Note 10). However, there is substantial doubt about the Company’s ability to continue as a going concern due to the necessity to generate positive cash flows from operations and/or obtain additional financing. There is no assurance that the Company will be able to generate positive cash flows from operations or obtain additional financing on terms acceptable to the Company, if at all.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition, the Company’s current and future operations are subject to various risks and uncertainties, including but not limited to general economic conditions, competition, and regulatory matters. Accordingly, the Company’s operation plan is predicated on various assumptions including, but not limited to, the level of product demand, cost estimates, its ability to continue raising additional financing, and the state of the general economic environment in which the Company operates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BRIGHT GREEN CORPORATION</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes to the Consolidated Financial Statements</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the Years Ended December 31, 2023 and 2022</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Expressed in United States Dollars)</span></p> <div style="margin-left: auto; margin-right: auto; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt"> </div></div> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Going Concern and Basis of Presentation (continued)</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These risks and uncertainties may have a material adverse effect on the Company’s financial condition and operating results. Management has taken actions to address the Company’s liquidity needs, including managing expenses, developing pathways to revenue, and pursuing additional financing, such as the EB-5 Program announced on February 1, 2023. However, there can be no assurance that such actions will be sufficient to enable the Company to continue as a going concern. There can be no assurance that these assumptions will prove accurate in all material respects or that the Company will be able to successfully execute its operating plan.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The consolidated financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. In addition, the Company does not have any short or long-term contractual purchases with suppliers for future purchases, capital expenditure commitments that cannot be canceled with minimal fees, noncancelable operating leases, or any commitment or contingency that would hinder management’s ability to scale down operations and management expenses until funding is raised.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s ability to continue as a going concern is dependent upon the outcome of the matters described above. The consolidated financial statements do not include any adjustments that might result from the outcome of these uncertainties.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This disclosure is intended to inform users of the consolidated financial statements about the Company’s current financial condition and its ability to continue as a going concern. The Company will continue to monitor its liquidity position and take appropriate actions as necessary to address any potential going concern issues.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> -13127648 -27662077 -2455612 -2265770 -47203469 -34075821 5968030 7030929 3104750 880000 210000 400000 15000000 392194 880000 22005 39.99 3619789 2827960 14800000 <p id="xdx_80E_eus-gaap--SignificantAccountingPoliciesTextBlock_zqS3m5sVOSx8" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_82A_zhpGTgTwyDQ1">Summary of Significant Accounting Policies</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84C_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zdu6S7UDPVv9" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_861_zRH2sMNvbxa2">Basis of Measurement</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The consolidated financial statements of the Company have been prepared on a historical cost basis except as indicated otherwise.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_843_eus-gaap--ConsolidationPolicyTextBlock_z9bxCIrHezc9" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_866_zFUoq66jo1d2">Principles of Consolidation</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, Regional Center Bright Green, LLC. Intercompany transactions and balances have been eliminated upon consolidation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BRIGHT GREEN CORPORATION</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes to the Consolidated Financial Statements</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the Years Ended December 31, 2023 and 2022</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Expressed in United States Dollars)</span></p> <div style="margin-left: auto; margin-right: auto; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt"> </div></div> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Summary of Significant Accounting Policies (continued)</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84B_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zUoI2ujdI254" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_868_zPP4cmmbGkv8">Property, Plant, and Equipment</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property, plant, and equipment are stated at cost less accumulated depreciation. Expenditures for maintenance and repairs are charged to earnings as incurred; additions, renewals, and betterments are capitalized. When property, plant, and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of property, plant, and equipment, except land, which is not depreciated, is provided using the declining balance method, or straight-line method, with estimated lives as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89E_ecustom--PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock_zGBZsE2JUbxj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 31.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_zN3puYFtZcAe" style="display: none">Summary of Estimated Useful Life</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 85%; margin-left: 1in"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 79%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Building and improvement - declining balance method</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 21%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--BuildingAndBuildingImprovementsMember_zwYPnzCLiPz5" title="Estimated useful life">10</span> year life</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furniture and fixtures - straight-line method</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zsERr6cek3X4" title="Estimated useful life">3</span> year life</span></td></tr> </table> <p id="xdx_8A3_zDw3MCtV0YL8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 31.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Construction in progress is not depreciated until the asset is placed in service.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_842_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_z84YwqZkd0Gi" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_863_zTx5cIt2NOYe">Long-lived Assets</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company applies the provisions of ASC Topic 360, Property, Plant, and Equipment, which addresses financial accounting and reporting for the impairment or disposal of long-lived assets. ASC Topic 360 requires that long-lived assets be reviewed annually for impairment whenever events or changes in circumstances indicate that the assets’ carrying amounts may not be recoverable; it further requires impairment losses to be recorded on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair value of the long-lived assets. Loss on long-lived assets to be disposed of is determined in a similar manner, except that fair values are reduced for the cost of disposal.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 31.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_842_eus-gaap--IntangibleAssetsFiniteLivedPolicy_z8k7Q63JrsSb" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">E.</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_863_z7z16V0hh5J7">Intangible Assets</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 31.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s intangible assets consist of certain licenses which will be amortized over the term of each license (Note 8). The intangible assets with finite useful lives are reviewed for impairment when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair value of the long-lived assets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 31.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BRIGHT GREEN CORPORATION</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes to the Consolidated Financial Statements</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the Years Ended December 31, 2023 and 2022</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Expressed in United States Dollars)</span></p> <div style="margin-left: auto; margin-right: auto; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt"> </div></div> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Summary of Significant Accounting Policies (continued)</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zC4NRDdAWH1b" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F.</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_866_zwYybh6VxsLl">Fair Value of Financial Instruments</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In accordance with ASC 820 (Topic 820, Fair Value Measurements and Disclosures), the Company uses a three-level hierarchy for fair value measurements of certain assets and liabilities for financial reporting purposes that distinguishes between market participant assumptions developed from market data obtained from outside sources (observable inputs) and our own assumptions about market participant assumptions developed from the best information available to us in the circumstances (unobservable inputs). The fair value hierarchy is divided into three levels based on the source of inputs as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 31.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="width: 1in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1 – inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets;</span></p></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2 – inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability other than quoted prices, either directly or indirectly including inputs in markets that are not considered to be active; and</span></p></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3 – inputs to the valuation methodology are unobservable and significant to the fair value measurement.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The carrying amounts of the Company’s cash, other assets, accounts payable, accrued liabilities, due to others, and due to related party approximated their fair values as of December 31, 2023 and 2022 due to their short-term nature. The Company’s Alterola investment is also accounted for at fair value and recorded in Other investment held at fair value on the consolidated balance sheets. In accordance with the levels defined above, Level 1, the fair value of the Company’s Alterola investment was $<span id="xdx_906_eus-gaap--Investments_iI_c20231231_zKQx0lJnJHr7" title="Investments">726,343</span> as of December 31, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_eus-gaap--EquityMethodInvestmentsPolicy_zG3MOkWtIOa6" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">G.</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_865_zivUBLQkVLh1">Investment Under the Equity Method</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When the Company does not have a controlling financial interest in an entity but can exert significant influence over the entity’s operating and financial policies, the investment is accounted for either (i) under the equity method of accounting or (ii) at fair value by electing the fair value option available under U.S. generally accepted accounting principles (“GAAP”). Significant influence generally exists when the Company owns <span id="xdx_908_ecustom--PercentageOfEntityCommonStock_iI_pid_dp_uPure_c20231231__srt--RangeAxis__srt--MinimumMember_zd3ArYqyJ1lf" title="Percentage of entity common stock">20</span>% to <span id="xdx_909_ecustom--PercentageOfEntityCommonStock_iI_pid_dp_uPure_c20231231__srt--RangeAxis__srt--MaximumMember_z4QrLnz2UnEc" title="Percentage of entity common stock">50</span>% of the entity’s common stock or in-substance common stock. In addition, the Company may recognize its share of an investee’s earnings based on an estimated amount for the investee’s earnings when the investee’s financial information is not sufficiently timely for the Company’s reporting period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 31.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BRIGHT GREEN CORPORATION</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes to the Consolidated Financial Statements</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the Years Ended December 31, 2023 and 2022</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Expressed in United States Dollars)</span></p> <div style="margin-left: auto; margin-right: auto; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt"> </div></div> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Summary of Significant Accounting Policies (continued)</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">G.</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Investment Under the Equity Method (continued)</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under the equity method of accounting, the investment is initially recorded at cost, including transaction costs incurred to acquire the investment, and thereafter adjusted for additional investments, distributions, and the proportionate share of earnings or losses of the investee. The Company’s equity method investment is reviewed for impairment whenever events or changes in circumstances indicate that an other-than-temporary decline in value may have occurred. If it is determined that a loss in value of the equity method investment is other than temporary, an impairment loss is measured based on the excess of the carrying amount of an investment over its estimated fair value. Impairment analyses are based on current plans, intended holding periods, and available information at the time the analysis is prepared.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Derivative Financial Instruments</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company evaluates all its financial instruments to determine if such instruments contain features that qualify as embedded derivatives. Embedded derivatives must be separately measured from the host contract if all the requirements for bifurcation are met. The assessment of the conditions surrounding the bifurcation of embedded derivatives depends on the nature of the host contract. Bifurcated embedded derivatives are recognized at fair value, with changes in fair value recognized in the consolidated statement of operations and comprehensive loss each period. Bifurcated embedded derivatives are classified with the related host contract in the Company’s consolidated balance sheets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p id="xdx_847_ecustom--OtherInvestmentsHeldAtFairValuePolicyTextBlock_z54CnFegcnY3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">H. <span style="text-decoration: underline"><span id="xdx_86F_zytKiRobR5Qk">Other Investment Held at Fair Value</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In accordance with ASC 825, the Company records its investment at fair value under the Other investment held at fair value in the Company’s consolidated balance sheets and changes in fair value are recognized as Change in fair value of assets, net, a component of Other expense in the consolidated statements of operations and comprehensive loss.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At the most recent remeasurement date, the Company evaluated its ability to continue to exercise significant influence over its investment and determined that it no longer had significant influence. The Company’s Alterola investment is accounted for at fair value under ASC 321 and recorded in Other investment held at fair value on the consolidated balance sheets and changes in fair value are recognized as Change in fair value of assets, a component of Other expense, net in the consolidated statements of operations and comprehensive loss (Note 6).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_849_eus-gaap--AdvertisingCostsPolicyTextBlock_zVrAq0yKIwp" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">I.</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_866_z1MD212o8zhc">Advertising Costs</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 31.5pt; text-align: justify; text-indent: -27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advertising costs are charged to operations when incurred. Advertising costs totaled $<span id="xdx_90A_eus-gaap--AdvertisingExpense_c20230101__20231231_zlZzpWWucqkf" title="Advertising cost">43,867</span> and $<span id="xdx_905_eus-gaap--AdvertisingExpense_c20220101__20221231_zk6g8tdTl3f1" title="Advertising cost">78,193</span> for the year ended December 31, 2023 and 2022, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 31.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_849_eus-gaap--IncomeTaxPolicyTextBlock_z2AQaPvppk42" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">J.</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_860_zoneuaJkriy2">Income Taxes</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for income taxes in accordance with ASC Topic 740, Income Taxes. ASC 740 requires a company to use the asset and liability method of accounting for income taxes, whereby deferred tax assets are recognized for deductible temporary differences, and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation </span>allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BRIGHT GREEN CORPORATION</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes to the Consolidated Financial Statements</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the Years Ended December 31, 2023 and 2022</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Expressed in United States Dollars)</span></p> <div style="margin-left: auto; margin-right: auto; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt"> </div></div> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Summary of Significant Accounting Policies (continued)</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">J.</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Income Taxes (continued)</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment. The Company has not changed its methodology for estimating the valuation allowance. A change in valuation allowance affects earnings in the period the adjustments are made and could be significant due to the large valuation allowance currently established.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 31.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under ASC 740, a tax position is recognized as a benefit only if it is “more likely than not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. <span id="xdx_909_eus-gaap--IncomeTaxExaminationDescription_c20230101__20231231_zJJfK51iLGJh" title="Income tax examination, description">The amount recognized is the largest amount of tax benefit that is greater than 50% likely to be realized on examination.</span> For tax positions not meeting the “more likely than not” test, no tax benefit is recorded. The Company has no material uncertain tax positions for any of the reporting periods presented (Note 13).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_849_eus-gaap--EarningsPerSharePolicyTextBlock_za0fY3Qb2IIi" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">K.</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_869_zJLfxad2j0Lc">Basic and Diluted Earnings (Loss) Per Share</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 4.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic earnings (loss) per share is calculated using the weighted average number of common shares outstanding during the period. The dilutive effect on earnings (loss) per share is calculated, presuming the exercise of outstanding stock options, warrants, and similar instruments. It assumes that the proceeds of such exercise would be used to repurchase common shares at the average market price during the period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 31.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the years ended December 31, 2023, and 2022, all outstanding stock options, warrants, and similar instruments were excluded from the computation of diluted net loss per share, because the exercise price of these instruments exceeded the average market price of the Company’s common stock, making them anti-dilutive.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 31.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zWh3xYzMTZ72" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">L.</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86B_zLY6vVWDzkX7">Segment Reporting</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 4.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC 280-10, “Disclosures about Segments of an Enterprise and Related Information”, establishes standards for how public business enterprises report information about operating segments in the Company’s consolidated financial statements. Operating segments are components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision-maker in deciding how to allocate resources and in assessing performance. Significantly all of the assets of the Company are located in the United States of America and the Company is a start-up company as at December 31, 2023 and 2022 and has no revenue. The Company’s reportable segments and operating segments will include its growth, production, and research of medicinal plants operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BRIGHT GREEN CORPORATION</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes to the Consolidated Financial Statements</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the Years Ended December 31, 2023 and 2022</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Expressed in United States Dollars)</span></p> <div style="margin-left: auto; margin-right: auto; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt"> </div></div> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Summary of Significant Accounting Policies (continued)</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_849_eus-gaap--UseOfEstimates_zEVwjjARRxh" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">M.</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_866_zA631o2Tb316">Use of Estimates</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 4.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions. The Company bases its estimates and assumptions on current facts, historical experience, various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities, and the accrual of costs and expenses that are not readily apparent from other sources. This applies in particular to valuation allowance for deferred tax assets, valuation of warrants, stock options, stock-based compensation, going concern assessment, impairment of non-current assets, and assignment of the useful lives of property, plant, and equipment. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_849_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zoGWKu9fUb4b" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N.</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_867_zMqNfFgMlsP1">Stock-Based Compensation</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 4.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for stock-based payments in accordance with the provision of ASC 718, which requires that all stock-based payments issued to acquire goods or services, including grants of employee stock options, be recognized in the consolidated statements of operations and comprehensive loss based on their fair values, net of estimated forfeitures. ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Compensation expense related to stock-based awards is recognized over the requisite service period, which is generally the vesting period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for stock-based compensation awards issued to non-employees for services, as prescribed by ASC 718-10, at either the fair value of the services rendered or the instruments issued in exchange for such services, whichever is more readily determinable, using the guidelines in ASC 505-50. The Company issues compensatory shares for services including, but not limited to, executive management, management, accounting, operations, corporate communication, and financial and administrative consulting services.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_849_ecustom--WarrantsPolicyTextBlock_zWbdDd1EYY4j" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">O.</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86C_z2QPQCRC79Na">Warrants</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in FASB, ASC 480 and ASC 815. The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own ordinary shares and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance, and each consolidated balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the consolidated statements of operations and comprehensive loss.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BRIGHT GREEN CORPORATION</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes to the Consolidated Financial Statements</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the Years Ended December 31, 2023 and 2022</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Expressed in United States Dollars)</span></p> <div style="margin-left: auto; margin-right: auto; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt"> </div></div> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> </p> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Summary of Significant Accounting Policies (continued)</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> </p> <p id="xdx_84D_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zR19BOEWm7T4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">P.</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86F_zacNcFigcxIj">Recently Adopted Accounting Standards</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In February 2016, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2016-02, <i>“Leases (Topic 842)”</i>, which establishes a right-of-use (ROU) model that requires a lessee to record an ROU asset and a lease liability on the statement of financial position for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the statement of activities. The new standard became effective for public business entities on January 1, 2019, with early adoption permitted. The new standard became effective for the Company on May 17, 2022, the date the Company became a public entity. The Company adopted this accounting policy as of May 17, 2022. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. While the Company continues to evaluate certain aspects of the new standard, including those still being revised by the FASB, the new standard does not have a material effect on the Company’s consolidated financial statements. As of December 31, 2023, the Company has one month to month lease, whereas the new standard does not apply.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In October 2023, the FASB issued ASU No. 2023-06, <i>Disclosure Improvements: Codification Amendments in Response to the SEC’s Disclosure Update and Simplification Initiative</i>. The amendments in this update modify the disclosure or presentation requirements of a variety of topics in the codification. Certain amendments represent clarifications to or technical corrections of the current requirements. Each amendment in the ASU will only become effective if the SEC removes the related disclosure or presentation requirement from its existing regulations by June 30, 2027. The Company is currently assessing the impact this standard will have on the Company’s future consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BRIGHT GREEN CORPORATION</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes to the Consolidated Financial Statements</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the Years Ended December 31, 2023 and 2022</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Expressed in United States Dollars)</span></p> <div style="margin-left: auto; margin-right: auto; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt"> </div></div> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Summary of Significant Accounting Policies (continued)</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"> </p> <p id="xdx_843_ecustom--RecentlyIssuedButNotAdoptedAccountingStandardsPolicyTextBlock_zBRoOdFYmul9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Q.</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_868_zPqlicFrf4Mh">Recently Issued but Not Adopted Accounting Standards</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 4.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In November 2023, the FASB issued ASU 2023-07, <i>Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</i>. The amendments in ASU 2023-07 are intended to enhance disclosures for significant segment expenses for all public entities required to report segment information in accordance with ASC 280. ASC 280 requires a public entity to report for each reportable segment a measure of segment profit or loss that its chief operating decision maker (“CODM”) uses to assess segment performance and to make decisions about resource allocations. The amendments in ASU 2023-07 improve financial reporting by requiring disclosure of incremental segment information on an annual and interim basis for all public entities to enable investors to develop more useful financial analyses. Currently, <i>Topic 280</i> requires that a public entity disclose certain information about its reportable segments. For example, a public entity is required to report a measure of segment profit or loss that the CODM uses to assess segment performance and make decisions about allocating resources. ASC 280 also requires other specified segment items and amounts, such as depreciation, amortization, and depletion expense, to be disclosed under certain circumstances. The amendments in ASU 2023-07 do not change or remove those disclosure requirements. The amendments in ASU 2023-07 also do not change how a public entity identifies its operating segments, aggregates those operating segments, or applies the quantitative thresholds to determine its reportable segments. The amendments in ASU 2023-07 are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. A public entity should apply the amendments in ASU 2023-07 retrospectively to all prior periods presented in the financial statements. The Company is currently assessing the impact this standard will have on the Company’s future consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2023, the FASB issued ASU 2023-09, <i>Income Taxes (Topic 740): Improvements to Income Tax Disclosures</i>. The amendments in ASU 2023-07 are intended to enhance the transparency and decision usefulness of income tax disclosures. The amendments in ASU 2023-09 require annual disclosures of specific categories in the rate reconciliation, additional information for reconciling items that meet a quantitative threshold, and a disaggregation of income taxes paid, net of refunds. The amendments in ASU 2023-09 also eliminate certain existing disclosure requirements related to uncertain tax positions and unrecognized deferred tax liabilities. The amendments in ASU 2023-09 are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The amendments in ASU 2023-09 should be applied prospectively. The Company is currently assessing the impact this standard will have on the Company’s future consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management does not believe that other recently issued, but not yet effective, accounting standards could have a material effect on the Company’s consolidated financial statements. As new accounting pronouncements are issued, the Company will adopt those that are applicable under the circumstances.</span></p> <p id="xdx_853_z6xyHi7wENS2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BRIGHT GREEN CORPORATION</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes to the Consolidated Financial Statements</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the Years Ended December 31, 2023 and 2022</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Expressed in United States Dollars)</span></p> <div style="margin-left: auto; margin-right: auto; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt"> </div></div> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84C_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zdu6S7UDPVv9" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_861_zRH2sMNvbxa2">Basis of Measurement</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The consolidated financial statements of the Company have been prepared on a historical cost basis except as indicated otherwise.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_843_eus-gaap--ConsolidationPolicyTextBlock_z9bxCIrHezc9" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_866_zFUoq66jo1d2">Principles of Consolidation</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, Regional Center Bright Green, LLC. Intercompany transactions and balances have been eliminated upon consolidation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BRIGHT GREEN CORPORATION</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes to the Consolidated Financial Statements</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the Years Ended December 31, 2023 and 2022</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Expressed in United States Dollars)</span></p> <div style="margin-left: auto; margin-right: auto; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt"> </div></div> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Summary of Significant Accounting Policies (continued)</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84B_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zUoI2ujdI254" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_868_zPP4cmmbGkv8">Property, Plant, and Equipment</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property, plant, and equipment are stated at cost less accumulated depreciation. Expenditures for maintenance and repairs are charged to earnings as incurred; additions, renewals, and betterments are capitalized. When property, plant, and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of property, plant, and equipment, except land, which is not depreciated, is provided using the declining balance method, or straight-line method, with estimated lives as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89E_ecustom--PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock_zGBZsE2JUbxj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 31.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_zN3puYFtZcAe" style="display: none">Summary of Estimated Useful Life</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 85%; margin-left: 1in"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 79%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Building and improvement - declining balance method</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 21%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--BuildingAndBuildingImprovementsMember_zwYPnzCLiPz5" title="Estimated useful life">10</span> year life</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furniture and fixtures - straight-line method</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zsERr6cek3X4" title="Estimated useful life">3</span> year life</span></td></tr> </table> <p id="xdx_8A3_zDw3MCtV0YL8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 31.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Construction in progress is not depreciated until the asset is placed in service.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89E_ecustom--PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock_zGBZsE2JUbxj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 31.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_zN3puYFtZcAe" style="display: none">Summary of Estimated Useful Life</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 85%; margin-left: 1in"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 79%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Building and improvement - declining balance method</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 21%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--BuildingAndBuildingImprovementsMember_zwYPnzCLiPz5" title="Estimated useful life">10</span> year life</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furniture and fixtures - straight-line method</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zsERr6cek3X4" title="Estimated useful life">3</span> year life</span></td></tr> </table> P10Y P3Y <p id="xdx_842_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_z84YwqZkd0Gi" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_863_zTx5cIt2NOYe">Long-lived Assets</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company applies the provisions of ASC Topic 360, Property, Plant, and Equipment, which addresses financial accounting and reporting for the impairment or disposal of long-lived assets. ASC Topic 360 requires that long-lived assets be reviewed annually for impairment whenever events or changes in circumstances indicate that the assets’ carrying amounts may not be recoverable; it further requires impairment losses to be recorded on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair value of the long-lived assets. Loss on long-lived assets to be disposed of is determined in a similar manner, except that fair values are reduced for the cost of disposal.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 31.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_842_eus-gaap--IntangibleAssetsFiniteLivedPolicy_z8k7Q63JrsSb" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">E.</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_863_z7z16V0hh5J7">Intangible Assets</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 31.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s intangible assets consist of certain licenses which will be amortized over the term of each license (Note 8). The intangible assets with finite useful lives are reviewed for impairment when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair value of the long-lived assets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 31.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BRIGHT GREEN CORPORATION</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes to the Consolidated Financial Statements</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the Years Ended December 31, 2023 and 2022</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Expressed in United States Dollars)</span></p> <div style="margin-left: auto; margin-right: auto; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt"> </div></div> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Summary of Significant Accounting Policies (continued)</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zC4NRDdAWH1b" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F.</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_866_zwYybh6VxsLl">Fair Value of Financial Instruments</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In accordance with ASC 820 (Topic 820, Fair Value Measurements and Disclosures), the Company uses a three-level hierarchy for fair value measurements of certain assets and liabilities for financial reporting purposes that distinguishes between market participant assumptions developed from market data obtained from outside sources (observable inputs) and our own assumptions about market participant assumptions developed from the best information available to us in the circumstances (unobservable inputs). The fair value hierarchy is divided into three levels based on the source of inputs as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 31.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="width: 1in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1 – inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets;</span></p></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2 – inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability other than quoted prices, either directly or indirectly including inputs in markets that are not considered to be active; and</span></p></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3 – inputs to the valuation methodology are unobservable and significant to the fair value measurement.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The carrying amounts of the Company’s cash, other assets, accounts payable, accrued liabilities, due to others, and due to related party approximated their fair values as of December 31, 2023 and 2022 due to their short-term nature. The Company’s Alterola investment is also accounted for at fair value and recorded in Other investment held at fair value on the consolidated balance sheets. In accordance with the levels defined above, Level 1, the fair value of the Company’s Alterola investment was $<span id="xdx_906_eus-gaap--Investments_iI_c20231231_zKQx0lJnJHr7" title="Investments">726,343</span> as of December 31, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 726343 <p id="xdx_847_eus-gaap--EquityMethodInvestmentsPolicy_zG3MOkWtIOa6" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">G.</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_865_zivUBLQkVLh1">Investment Under the Equity Method</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When the Company does not have a controlling financial interest in an entity but can exert significant influence over the entity’s operating and financial policies, the investment is accounted for either (i) under the equity method of accounting or (ii) at fair value by electing the fair value option available under U.S. generally accepted accounting principles (“GAAP”). Significant influence generally exists when the Company owns <span id="xdx_908_ecustom--PercentageOfEntityCommonStock_iI_pid_dp_uPure_c20231231__srt--RangeAxis__srt--MinimumMember_zd3ArYqyJ1lf" title="Percentage of entity common stock">20</span>% to <span id="xdx_909_ecustom--PercentageOfEntityCommonStock_iI_pid_dp_uPure_c20231231__srt--RangeAxis__srt--MaximumMember_z4QrLnz2UnEc" title="Percentage of entity common stock">50</span>% of the entity’s common stock or in-substance common stock. In addition, the Company may recognize its share of an investee’s earnings based on an estimated amount for the investee’s earnings when the investee’s financial information is not sufficiently timely for the Company’s reporting period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 31.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BRIGHT GREEN CORPORATION</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes to the Consolidated Financial Statements</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the Years Ended December 31, 2023 and 2022</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Expressed in United States Dollars)</span></p> <div style="margin-left: auto; margin-right: auto; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt"> </div></div> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Summary of Significant Accounting Policies (continued)</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">G.</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Investment Under the Equity Method (continued)</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under the equity method of accounting, the investment is initially recorded at cost, including transaction costs incurred to acquire the investment, and thereafter adjusted for additional investments, distributions, and the proportionate share of earnings or losses of the investee. The Company’s equity method investment is reviewed for impairment whenever events or changes in circumstances indicate that an other-than-temporary decline in value may have occurred. If it is determined that a loss in value of the equity method investment is other than temporary, an impairment loss is measured based on the excess of the carrying amount of an investment over its estimated fair value. Impairment analyses are based on current plans, intended holding periods, and available information at the time the analysis is prepared.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Derivative Financial Instruments</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company evaluates all its financial instruments to determine if such instruments contain features that qualify as embedded derivatives. Embedded derivatives must be separately measured from the host contract if all the requirements for bifurcation are met. The assessment of the conditions surrounding the bifurcation of embedded derivatives depends on the nature of the host contract. Bifurcated embedded derivatives are recognized at fair value, with changes in fair value recognized in the consolidated statement of operations and comprehensive loss each period. Bifurcated embedded derivatives are classified with the related host contract in the Company’s consolidated balance sheets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> 0.20 0.50 <p id="xdx_847_ecustom--OtherInvestmentsHeldAtFairValuePolicyTextBlock_z54CnFegcnY3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">H. <span style="text-decoration: underline"><span id="xdx_86F_zytKiRobR5Qk">Other Investment Held at Fair Value</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In accordance with ASC 825, the Company records its investment at fair value under the Other investment held at fair value in the Company’s consolidated balance sheets and changes in fair value are recognized as Change in fair value of assets, net, a component of Other expense in the consolidated statements of operations and comprehensive loss.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At the most recent remeasurement date, the Company evaluated its ability to continue to exercise significant influence over its investment and determined that it no longer had significant influence. The Company’s Alterola investment is accounted for at fair value under ASC 321 and recorded in Other investment held at fair value on the consolidated balance sheets and changes in fair value are recognized as Change in fair value of assets, a component of Other expense, net in the consolidated statements of operations and comprehensive loss (Note 6).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_849_eus-gaap--AdvertisingCostsPolicyTextBlock_zVrAq0yKIwp" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">I.</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_866_z1MD212o8zhc">Advertising Costs</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 31.5pt; text-align: justify; text-indent: -27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advertising costs are charged to operations when incurred. Advertising costs totaled $<span id="xdx_90A_eus-gaap--AdvertisingExpense_c20230101__20231231_zlZzpWWucqkf" title="Advertising cost">43,867</span> and $<span id="xdx_905_eus-gaap--AdvertisingExpense_c20220101__20221231_zk6g8tdTl3f1" title="Advertising cost">78,193</span> for the year ended December 31, 2023 and 2022, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 31.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 43867 78193 <p id="xdx_849_eus-gaap--IncomeTaxPolicyTextBlock_z2AQaPvppk42" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">J.</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_860_zoneuaJkriy2">Income Taxes</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for income taxes in accordance with ASC Topic 740, Income Taxes. ASC 740 requires a company to use the asset and liability method of accounting for income taxes, whereby deferred tax assets are recognized for deductible temporary differences, and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation </span>allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BRIGHT GREEN CORPORATION</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes to the Consolidated Financial Statements</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the Years Ended December 31, 2023 and 2022</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Expressed in United States Dollars)</span></p> <div style="margin-left: auto; margin-right: auto; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt"> </div></div> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Summary of Significant Accounting Policies (continued)</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">J.</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Income Taxes (continued)</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment. The Company has not changed its methodology for estimating the valuation allowance. A change in valuation allowance affects earnings in the period the adjustments are made and could be significant due to the large valuation allowance currently established.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 31.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under ASC 740, a tax position is recognized as a benefit only if it is “more likely than not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. <span id="xdx_909_eus-gaap--IncomeTaxExaminationDescription_c20230101__20231231_zJJfK51iLGJh" title="Income tax examination, description">The amount recognized is the largest amount of tax benefit that is greater than 50% likely to be realized on examination.</span> For tax positions not meeting the “more likely than not” test, no tax benefit is recorded. The Company has no material uncertain tax positions for any of the reporting periods presented (Note 13).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> The amount recognized is the largest amount of tax benefit that is greater than 50% likely to be realized on examination. <p id="xdx_849_eus-gaap--EarningsPerSharePolicyTextBlock_za0fY3Qb2IIi" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">K.</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_869_zJLfxad2j0Lc">Basic and Diluted Earnings (Loss) Per Share</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 4.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic earnings (loss) per share is calculated using the weighted average number of common shares outstanding during the period. The dilutive effect on earnings (loss) per share is calculated, presuming the exercise of outstanding stock options, warrants, and similar instruments. It assumes that the proceeds of such exercise would be used to repurchase common shares at the average market price during the period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 31.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the years ended December 31, 2023, and 2022, all outstanding stock options, warrants, and similar instruments were excluded from the computation of diluted net loss per share, because the exercise price of these instruments exceeded the average market price of the Company’s common stock, making them anti-dilutive.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 31.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zWh3xYzMTZ72" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">L.</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86B_zLY6vVWDzkX7">Segment Reporting</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 4.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC 280-10, “Disclosures about Segments of an Enterprise and Related Information”, establishes standards for how public business enterprises report information about operating segments in the Company’s consolidated financial statements. Operating segments are components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision-maker in deciding how to allocate resources and in assessing performance. Significantly all of the assets of the Company are located in the United States of America and the Company is a start-up company as at December 31, 2023 and 2022 and has no revenue. The Company’s reportable segments and operating segments will include its growth, production, and research of medicinal plants operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BRIGHT GREEN CORPORATION</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes to the Consolidated Financial Statements</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the Years Ended December 31, 2023 and 2022</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Expressed in United States Dollars)</span></p> <div style="margin-left: auto; margin-right: auto; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt"> </div></div> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Summary of Significant Accounting Policies (continued)</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_849_eus-gaap--UseOfEstimates_zEVwjjARRxh" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">M.</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_866_zA631o2Tb316">Use of Estimates</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 4.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions. The Company bases its estimates and assumptions on current facts, historical experience, various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities, and the accrual of costs and expenses that are not readily apparent from other sources. This applies in particular to valuation allowance for deferred tax assets, valuation of warrants, stock options, stock-based compensation, going concern assessment, impairment of non-current assets, and assignment of the useful lives of property, plant, and equipment. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_849_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zoGWKu9fUb4b" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N.</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_867_zMqNfFgMlsP1">Stock-Based Compensation</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 4.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for stock-based payments in accordance with the provision of ASC 718, which requires that all stock-based payments issued to acquire goods or services, including grants of employee stock options, be recognized in the consolidated statements of operations and comprehensive loss based on their fair values, net of estimated forfeitures. ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Compensation expense related to stock-based awards is recognized over the requisite service period, which is generally the vesting period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for stock-based compensation awards issued to non-employees for services, as prescribed by ASC 718-10, at either the fair value of the services rendered or the instruments issued in exchange for such services, whichever is more readily determinable, using the guidelines in ASC 505-50. The Company issues compensatory shares for services including, but not limited to, executive management, management, accounting, operations, corporate communication, and financial and administrative consulting services.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_849_ecustom--WarrantsPolicyTextBlock_zWbdDd1EYY4j" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">O.</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86C_z2QPQCRC79Na">Warrants</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in FASB, ASC 480 and ASC 815. The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own ordinary shares and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance, and each consolidated balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the consolidated statements of operations and comprehensive loss.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BRIGHT GREEN CORPORATION</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes to the Consolidated Financial Statements</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the Years Ended December 31, 2023 and 2022</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Expressed in United States Dollars)</span></p> <div style="margin-left: auto; margin-right: auto; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt"> </div></div> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> </p> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Summary of Significant Accounting Policies (continued)</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> </p> <p id="xdx_84D_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zR19BOEWm7T4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">P.</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86F_zacNcFigcxIj">Recently Adopted Accounting Standards</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In February 2016, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2016-02, <i>“Leases (Topic 842)”</i>, which establishes a right-of-use (ROU) model that requires a lessee to record an ROU asset and a lease liability on the statement of financial position for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the statement of activities. The new standard became effective for public business entities on January 1, 2019, with early adoption permitted. The new standard became effective for the Company on May 17, 2022, the date the Company became a public entity. The Company adopted this accounting policy as of May 17, 2022. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. While the Company continues to evaluate certain aspects of the new standard, including those still being revised by the FASB, the new standard does not have a material effect on the Company’s consolidated financial statements. As of December 31, 2023, the Company has one month to month lease, whereas the new standard does not apply.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In October 2023, the FASB issued ASU No. 2023-06, <i>Disclosure Improvements: Codification Amendments in Response to the SEC’s Disclosure Update and Simplification Initiative</i>. The amendments in this update modify the disclosure or presentation requirements of a variety of topics in the codification. Certain amendments represent clarifications to or technical corrections of the current requirements. Each amendment in the ASU will only become effective if the SEC removes the related disclosure or presentation requirement from its existing regulations by June 30, 2027. The Company is currently assessing the impact this standard will have on the Company’s future consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BRIGHT GREEN CORPORATION</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes to the Consolidated Financial Statements</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the Years Ended December 31, 2023 and 2022</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Expressed in United States Dollars)</span></p> <div style="margin-left: auto; margin-right: auto; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt"> </div></div> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Summary of Significant Accounting Policies (continued)</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"> </p> <p id="xdx_843_ecustom--RecentlyIssuedButNotAdoptedAccountingStandardsPolicyTextBlock_zBRoOdFYmul9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Q.</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_868_zPqlicFrf4Mh">Recently Issued but Not Adopted Accounting Standards</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 4.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In November 2023, the FASB issued ASU 2023-07, <i>Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</i>. The amendments in ASU 2023-07 are intended to enhance disclosures for significant segment expenses for all public entities required to report segment information in accordance with ASC 280. ASC 280 requires a public entity to report for each reportable segment a measure of segment profit or loss that its chief operating decision maker (“CODM”) uses to assess segment performance and to make decisions about resource allocations. The amendments in ASU 2023-07 improve financial reporting by requiring disclosure of incremental segment information on an annual and interim basis for all public entities to enable investors to develop more useful financial analyses. Currently, <i>Topic 280</i> requires that a public entity disclose certain information about its reportable segments. For example, a public entity is required to report a measure of segment profit or loss that the CODM uses to assess segment performance and make decisions about allocating resources. ASC 280 also requires other specified segment items and amounts, such as depreciation, amortization, and depletion expense, to be disclosed under certain circumstances. The amendments in ASU 2023-07 do not change or remove those disclosure requirements. The amendments in ASU 2023-07 also do not change how a public entity identifies its operating segments, aggregates those operating segments, or applies the quantitative thresholds to determine its reportable segments. The amendments in ASU 2023-07 are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. A public entity should apply the amendments in ASU 2023-07 retrospectively to all prior periods presented in the financial statements. The Company is currently assessing the impact this standard will have on the Company’s future consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2023, the FASB issued ASU 2023-09, <i>Income Taxes (Topic 740): Improvements to Income Tax Disclosures</i>. The amendments in ASU 2023-07 are intended to enhance the transparency and decision usefulness of income tax disclosures. The amendments in ASU 2023-09 require annual disclosures of specific categories in the rate reconciliation, additional information for reconciling items that meet a quantitative threshold, and a disaggregation of income taxes paid, net of refunds. The amendments in ASU 2023-09 also eliminate certain existing disclosure requirements related to uncertain tax positions and unrecognized deferred tax liabilities. The amendments in ASU 2023-09 are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The amendments in ASU 2023-09 should be applied prospectively. The Company is currently assessing the impact this standard will have on the Company’s future consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management does not believe that other recently issued, but not yet effective, accounting standards could have a material effect on the Company’s consolidated financial statements. As new accounting pronouncements are issued, the Company will adopt those that are applicable under the circumstances.</span></p> <p id="xdx_806_eus-gaap--ConcentrationRiskDisclosureTextBlock_zwW0K2hlPyN" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span><span id="xdx_828_zc5SYZCQWWsf">Concentration of Credit Risk</span></span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash deposits. Accounts at each institution are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $<span id="xdx_902_eus-gaap--CashFDICInsuredAmount_iI_c20231231_zlzCm3Bqw0Y7" title="Cash FDIC insured amount">250,000</span>. The Company had $<span id="xdx_909_eus-gaap--TimeDepositLiabilityAboveUsInsuranceLimit_iI_dxL_c20231231_zJeC0WeO4n69" title="Excess of FDIC insured limit::XDX::0"><span style="-sec-ix-hidden: xdx2ixbrl0603">nil</span></span> and $<span id="xdx_90F_eus-gaap--TimeDepositLiabilityAboveUsInsuranceLimit_iI_c20221231_zzlvreXfcNCj" title="Excess of FDIC insured limit">187,821</span>in excess of the FDIC insured limit at December 31, 2023 and 2022, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 250000 187821 <p id="xdx_800_eus-gaap--DepositLiabilitiesDisclosuresTextBlock_zyLCJdwO6nkl" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_824_zpYOUcVokiy5">Deposits</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2022, deposits were comprised of two down payments. One was for a construction of equipment contract for which the Company had not yet taken title. The other was for a construction contract for which the work had not started. As of December 31, 2023, the Company has still not taken title of the equipment and the construction contract was completed (Note 9).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">On March 13, 2024, the Company entered into and signed a Settlement and Release Agreement, in which the deposit was forfeited, leased equipment was returned, and <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_c20240313__20240313__us-gaap--TypeOfArrangementAxis__custom--SettlementAndReleaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zQf1ss3OFgk5" title="Number of shares forfeited">118,535,168</span> shares of common stock of Alterola was transferred to the vendor in lieu of payment. Additionally, all parties involved mutually released, relieved, acquitted, remised, and discharged each other as per the Settlement and Release Agreement (Notes 9 and 16).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 118535168 <p id="xdx_804_eus-gaap--InvestmentTextBlock_z0Mi6d0fVEAe" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_821_zJbqODfTKWp4">Equity Method Investment in Alterola</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October 3, 2022, the Company entered into a Secondary Stock Purchase Agreement and Release (the “Secondary SPA”) with Phytotherapeutix Holdings Ltd., a United Kingdom entity, Equipped4 Holdings Limited, a United Kingdom entity, TPR Global Limited, a United Kingdom entity (each, a “Seller” and collectively, the “Sellers”) and Alterola Biotech Inc., a Nevada corporation (“Alterola”) providing for the purchase by Bright Green of shares of Common Stock of Alterola from the Sellers (the “Transferred Shares”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Secondary SPA provided that, as of the date thereof, the authorized shares of Alterola consisted of <span id="xdx_900_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20221003__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--AlterolaBiotechIncMember_zIR6xqeltsSd" title="Common stock, shares authorized">2,000,000,000</span> shares of common stock, $<span id="xdx_907_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20221003__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--AlterolaBiotechIncMember_zoHlnxJZ7Ei8" title="Common stock, par value">0.001</span> par value, of which <span id="xdx_900_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20221003__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--AlterolaBiotechIncMember_zPhfzCzZhxec" title="Common stock, shares outstanding">807,047,948</span> shares were issued and outstanding. The Sellers held <span id="xdx_906_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20221003__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--AlterolaBiotechIncMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SellersMember_zQbZavDH9V26" title="Debt instrument, stated percentage">67</span>% of Alterola’s total outstanding shares prior to the closing of the Secondary SPA. As a result of this transaction, the Company obtained ownership or voting power of approximately <span id="xdx_908_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20221003__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--AlterolaBiotechIncMember_ziDXrTJyhmH3" title="Debt instrument, stated percentage">25</span>% of the total outstanding shares of Alterola. The Sellers Transferred Shares consisted of, in aggregate, <span id="xdx_900_eus-gaap--SharesIssued_iI_pid_c20221003__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--AlterolaBiotechIncMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SellersMember_z2LteV64EqJe" title="Sellers transferred shares">201,761,982</span> shares of Common Stock, which were sold to the Company for a purchase price of $<span id="xdx_90A_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20221002__20221003__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--AlterolaBiotechIncMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SellersMember_zHd5aTJ23FT3" title="Number of shares sold, value">3,999,999</span>, pursuant to the payment schedule set forth in the Secondary SPA. Following the receipt of each installment payment, the Sellers agreed to loan to Alterola the proceeds such Seller received from the foregoing sale of its Transferred Shares, pursuant to a loan agreement. As of December 31, 2023 and 2022, the Company has a liability to the Sellers of $<span id="xdx_90D_eus-gaap--LiabilitiesRelatedToInvestmentContractsFairValueDisclosure_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SellersMember_zG4lRvNr03yd" title="Liability to the sellers"><span id="xdx_90B_eus-gaap--LiabilitiesRelatedToInvestmentContractsFairValueDisclosure_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SellersMember_z95GhYlaBBg1" title="Liability to the sellers">1,650,000</span></span>, which is in default as of December 31, 2023. The liability is not interest-bearing and not secured.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 13, 2024, the Company entered into and signed a Settlement Agreement with the Sellers, in which the Company transferred <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesOther_c20240313__20240313__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--AlterolaBiotechIncMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SellersMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zJQ3e2oa4ZUi" title="Number of shares transferred">27,742,273</span> of the Transferred Shares to </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">each of the Sellers. Additionally, all parties involved mutually released, relieved, acquitted, remised, and discharged each other from any further claims as outlined in the Release Agreement (Note 16).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Voting Agreement</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Concurrently with the signing of the Secondary SPA, Bright Green and the Sellers entered into a voting agreement (the “Voting Agreement”) whereby the Sellers agreed to vote in <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">favor of the adoption of an agreement to effect Bright Green’s acquisition of Alterola or the Alterola’s merger into Bright Green or a subsidiary of Bright Green, as the case may be, pursuant to additional terms set forth in the Voting Agreement.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BRIGHT GREEN CORPORATION</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes to the Consolidated Financial Statements</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the Years Ended December 31, 2023 and 2022</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Expressed in United States Dollars)</span></p> <div style="margin-left: auto; margin-right: auto; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt"> </div></div> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Equity Method Investment in Alterola (continued)</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Voting Agreement was initially measured at fair value utilizing the Black-Scholes option pricing model based on the following assumptions: dividend rate of <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--VotingAgreementMember_ztPwc4LgFACg" title="Dividend rate">0.0</span>%, risk free rate of <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--VotingAgreementMember_zW818ZycJYGe" title="Rist free rate">4.0</span>%, term of <span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--VotingAgreementMember_zIYQcZrshZl2" title="Expected term">0.5</span> years, volatility of <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--VotingAgreementMember_zl4VDKQ8ZTA1" title="Volatility rate">66.0</span>%, the stock price of $<span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--VotingAgreementMember_zNhzhuKNmZf" title="Stock price">26,400,000</span>, inclusive of a Control Premium of <span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsControlPremiumPercentage_pid_dp_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--VotingAgreementMember_zlVI48cUxoVe" title="Control premium percentage">65</span>% valued at $<span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsControlPremium_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--VotingAgreementMember_zpDFiTA90Tae" title="Control premium">10,400,000</span>, determined using the Recent Transaction Method as the transaction was determined to be arms-length, and a strike price of $<span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStrikePrice_pn5n6_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--VotingAgreementMember_zVAz5MFEOHF2" title="Stock price">61.3</span> million reflecting the option to purchase the remaining <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_pid_dp_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--VotingAgreementMember_zc8vSUEN8VM1" title="Outstaanding common shares percentage">75</span>% of the outstanding shares of common stock for $<span id="xdx_90D_eus-gaap--PaymentsToAcquireBusinessesAndInterestInAffiliates_pn5n6_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--VotingAgreementMember_z1S9oJEFosCk" title="Oustanding common shares value">46.0</span> million. The issuance date fair value of the Voting Agreement was determined to be $<span id="xdx_902_ecustom--FairValueOfAgreement_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--VotingAgreementMember_zXcwRdCZFNP1" title="Fair value of agreement">213,000</span> of the gross payment to the Sellers of $<span id="xdx_90F_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--VotingAgreementMember_zYPFT1PMbCt8" title="Number of shares sold, value">3,999,999</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2022, the value of the option was impaired to $nil to reflect the likelihood that the option would be exercised according to the terms set forth. As of December 31, 2023, the option has expired.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Equity Method Accounting Treatment</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s <span id="xdx_903_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20231231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--AlterolaBiotechIncMember_zv4tRDx20Ynf" title="Ownership percentage">25</span>% ownership of Alterola allowed the Company to have significant influence over the operations and decision-making at Alterola. Accordingly, the Company accounted for the transaction under the equity method and recorded the carrying value of the Company’s investment in Alterola common shares at cost, including the transaction costs incurred to obtain the equity method investment, in the consolidated balance sheets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></p> <p id="xdx_89D_esrt--ScheduleOfCondensedFinancialStatementsTableTextBlock_zJIEmM10bhq" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table provides summarized balance sheet information for Alterola as of September 30, 2023 and December 31, 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_zbtQDRNhYp3b" style="display: none">Schedule of Financial Statement Information</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_495_20230930__dei--LegalEntityAxis__custom--AlterolaBiotechIncMember_zosYG8aHzCH6" style="border-bottom: Black 1.5pt solid; text-align: center">September 30, 2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49E_20221231__dei--LegalEntityAxis__custom--AlterolaBiotechIncMember_zv8k1GLU80y" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40B_eus-gaap--AssetsCurrent_iI_zPZT0BtBRUch" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Current assets</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">197,208</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">192,011</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--AssetsNoncurrent_iI_z2LxBF1hKQBk" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Non-current assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">300,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,018,147</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--LiabilitiesCurrent_iI_zZaQbNhtKy14" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Current liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,519,231</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,822,696</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--LiabilitiesNoncurrent_iI_zPCzjDTQqxM9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Non-current liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0670">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">151,255</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--StockholdersEquity_iI_zqRE5rBKGFT9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Equity (Deficit)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(2,022,023</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">10,236,207</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table provides summarized income statement information for Alterola for the nine months ended September 30, 2023 and the year ended December 31, 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_490_20230101__20230930_zM3eicmVP3N" style="border-bottom: Black 1.5pt solid; text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_493_20220101__20221231_ziSAayXFcd4f" style="border-bottom: Black 1.5pt solid; text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">Nine Months Ended</td><td> </td><td> </td> <td colspan="2" style="text-align: center"> Year Ended</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">September 30, 2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_408_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hdei--LegalEntityAxis__custom--AlterolaBiotechIncMember_z9zddC9ddYC2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Total revenues</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0676">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0677">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--NetIncomeLoss_hdei--LegalEntityAxis__custom--AlterolaBiotechIncMember_zOSxGdAXf0li" style="vertical-align: bottom; background-color: White"> <td style="width: 56%; text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 18%; text-align: right">874,653</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 18%; text-align: right">4,980,510</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AD_zZYuVgydPPT3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BRIGHT GREEN CORPORATION</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes to the Consolidated Financial Statements</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the Years Ended December 31, 2023 and 2022</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Expressed in United States Dollars)</span></p> <div style="margin-left: auto; margin-right: auto; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt"> </div></div> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Equity Method Investment in Alterola (continued)</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the year ended December 31, 2022 and the period through October 16, 2023, the Company maintained significant influence through its ownership interest and accounted for its Alterola investment under the equity method. For the year ended December 31, 2022, the Company recorded a loss of $<span id="xdx_90A_ecustom--IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterestEquityInNetLossesOfAffiliate_iN_di_c20220101__20221231_zDmwnSrbfzgg" title="Noncontrolling interest equity in net losses of affiliate">135,155</span> to account for its 25% share of Alterola’s net loss from October 3, 2022, through the year ended December 31, 2022. As of December 31, 2022, the equity method investment balance was $<span id="xdx_90C_eus-gaap--EquityMethodInvestments_iI_c20221231_zCpM9ez11ari" title="Equity method investments">3,990,960</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the year ended December 31, 2023, the Company recorded a loss of $<span id="xdx_90A_ecustom--IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterestEquityInNetLossesOfAffiliate_iN_di_c20230101__20231231_zUICKpMy3Xk7" title="Noncontrolling interest equity in net losses of affiliate">218,663</span> to account for its 25% share of Alterola’s net loss for the period ended October 16, 2023. On October 16, 2023, Alterola issued shares of its common stock in exchange for forgiveness of debt diluting the Company’s 25% share to approximately 15%. The Company evaluated its ability to continue to exercise significant influence over its investment and determined that it no longer had significant influence. Subsequent to this remeasurement date, the Company’s Alterola investment is accounted for at fair value under ASC 321 and recorded in Other investment held at fair value on the consolidated balance sheets. Any changes in fair value of the Company’s Alterola investment are recorded as a Change in fair value of assets in its consolidated statements of operations and comprehensive loss. Based on quoted market prices, the fair value of the Company’s Alterola investment was $<span id="xdx_906_eus-gaap--Investments_iI_c20231231_zzOzB89bhi2i" title="Investments">726,343</span> as of December 31, 2023. For the year ended December 31, 2023, the Company recorded $<span id="xdx_901_ecustom--ChangeInFairValueOfAssetsAndLiabilitiesNet_c20230101__20231231_zxz8MJ7UoUgl" title="Change in fair value of assets and liabilities net">3,045,954</span> of Change in fair value of assets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_894_eus-gaap--EquityMethodInvestmentsTextBlock_zG8ff4UpS8Lk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes the activity of the Company’s equity method investment in Alterola:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B0_zifFHfBvKj02" style="display: none">Schedule of Equity Method Investment in Alterola</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" id="xdx_4BE_srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_custom--AlterolaBiotechIncMember_zzz7O8odJbJf" style="text-align: center">Equity Method</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Investment in Alterola</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_435_c20220101__20221231_eus-gaap--EquityMethodInvestments_iS_zGNeAqniMv73" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance at December 31, 2021</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0694">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--MinorityInterestPeriodIncreaseDecrease_zRsbO8k02Q9e" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 80%; text-align: left">Company’s initial investment in Alterola</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">4,126,115</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_iN_di_zIWUCH2vqjk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Company’s 25% share in net loss recognized in 2022</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(135,155</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_43D_c20230101__20231231_eus-gaap--EquityMethodInvestments_iS_zQk0IF3ho22d" style="vertical-align: bottom; background-color: White"> <td>Balance at December 31, 2022</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,990,960</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_iN_di_ztFiqZ8V8fPi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Company’s 25% share in net loss recognized through October 16, 2023</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(218,663</td><td style="text-align: left">)</td></tr> <tr id="xdx_405_eus-gaap--NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_iN_di_zulomTSqRjVj" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Company’s 25% share in net loss</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(218,663</td><td style="text-align: left">)</td></tr> <tr id="xdx_40F_ecustom--ChangeInFairValueOfAssetsAndLiabilitiesNet_iN_di_z7qIxukv57eg" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Change in fair value of assets</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,045,954</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_430_c20230101__20231231_eus-gaap--EquityMethodInvestments_iE_zYEnQoO4w7Ok" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance at December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">726,343</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_8AD_zu7y3l2oYLH5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 2000000000 0.001 807047948 0.67 0.25 201761982 3999999 1650000 1650000 27742273 0.000 0.040 P0Y6M 0.660 26400000 0.65 10400000 61300000 0.75 46000000.0 213000 3999999 0.25 <p id="xdx_89D_esrt--ScheduleOfCondensedFinancialStatementsTableTextBlock_zJIEmM10bhq" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table provides summarized balance sheet information for Alterola as of September 30, 2023 and December 31, 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_zbtQDRNhYp3b" style="display: none">Schedule of Financial Statement Information</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_495_20230930__dei--LegalEntityAxis__custom--AlterolaBiotechIncMember_zosYG8aHzCH6" style="border-bottom: Black 1.5pt solid; text-align: center">September 30, 2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49E_20221231__dei--LegalEntityAxis__custom--AlterolaBiotechIncMember_zv8k1GLU80y" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40B_eus-gaap--AssetsCurrent_iI_zPZT0BtBRUch" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Current assets</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">197,208</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">192,011</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--AssetsNoncurrent_iI_z2LxBF1hKQBk" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Non-current assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">300,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,018,147</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--LiabilitiesCurrent_iI_zZaQbNhtKy14" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Current liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,519,231</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,822,696</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--LiabilitiesNoncurrent_iI_zPCzjDTQqxM9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Non-current liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0670">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">151,255</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--StockholdersEquity_iI_zqRE5rBKGFT9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Equity (Deficit)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(2,022,023</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">10,236,207</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table provides summarized income statement information for Alterola for the nine months ended September 30, 2023 and the year ended December 31, 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_490_20230101__20230930_zM3eicmVP3N" style="border-bottom: Black 1.5pt solid; text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_493_20220101__20221231_ziSAayXFcd4f" style="border-bottom: Black 1.5pt solid; text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">Nine Months Ended</td><td> </td><td> </td> <td colspan="2" style="text-align: center"> Year Ended</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">September 30, 2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_408_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hdei--LegalEntityAxis__custom--AlterolaBiotechIncMember_z9zddC9ddYC2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Total revenues</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0676">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0677">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--NetIncomeLoss_hdei--LegalEntityAxis__custom--AlterolaBiotechIncMember_zOSxGdAXf0li" style="vertical-align: bottom; background-color: White"> <td style="width: 56%; text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 18%; text-align: right">874,653</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 18%; text-align: right">4,980,510</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 197208 192011 300000 12018147 2519231 1822696 151255 -2022023 10236207 874653 4980510 -135155 3990960 -218663 726343 3045954 <p id="xdx_894_eus-gaap--EquityMethodInvestmentsTextBlock_zG8ff4UpS8Lk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes the activity of the Company’s equity method investment in Alterola:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B0_zifFHfBvKj02" style="display: none">Schedule of Equity Method Investment in Alterola</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" id="xdx_4BE_srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_custom--AlterolaBiotechIncMember_zzz7O8odJbJf" style="text-align: center">Equity Method</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Investment in Alterola</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_435_c20220101__20221231_eus-gaap--EquityMethodInvestments_iS_zGNeAqniMv73" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance at December 31, 2021</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0694">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--MinorityInterestPeriodIncreaseDecrease_zRsbO8k02Q9e" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 80%; text-align: left">Company’s initial investment in Alterola</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">4,126,115</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_iN_di_zIWUCH2vqjk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Company’s 25% share in net loss recognized in 2022</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(135,155</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_43D_c20230101__20231231_eus-gaap--EquityMethodInvestments_iS_zQk0IF3ho22d" style="vertical-align: bottom; background-color: White"> <td>Balance at December 31, 2022</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,990,960</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_iN_di_ztFiqZ8V8fPi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Company’s 25% share in net loss recognized through October 16, 2023</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(218,663</td><td style="text-align: left">)</td></tr> <tr id="xdx_405_eus-gaap--NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_iN_di_zulomTSqRjVj" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Company’s 25% share in net loss</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(218,663</td><td style="text-align: left">)</td></tr> <tr id="xdx_40F_ecustom--ChangeInFairValueOfAssetsAndLiabilitiesNet_iN_di_z7qIxukv57eg" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Change in fair value of assets</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,045,954</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_430_c20230101__20231231_eus-gaap--EquityMethodInvestments_iE_zYEnQoO4w7Ok" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance at December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">726,343</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 4126115 135155 3990960 218663 218663 3045954 726343 <p id="xdx_80F_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zL1wlTCObN48" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_82E_za7PP12jBg87">Property, Plant, and Equipment</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company owns an expansive <span id="xdx_907_eus-gaap--AreaOfLand_iI_uAcre_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--VenloStyleGreenHouseMember__srt--StatementGeographicalAxis__custom--NMMember_zP9i48tywcDd" title="Area of land owned">22</span>-acre modern Dutch “Venlo style” glass greenhouse situated on <span id="xdx_905_eus-gaap--AreaOfLand_iI_uAcre_c20221231__srt--StatementGeographicalAxis__custom--NMMember_zl6jsYJfDlkg" title="Area of land">70</span> acres in Grants, New Mexico. It is being retrofitted for growing, processing and distribution of medicinal plants, including Marijuana, for medical researchers licensed by the Drug Enforcement Administration.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_891_eus-gaap--PropertyPlantAndEquipmentTextBlock_zcdDsGlt844l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property, plant, and equipment at December 31, 2023 and 2022, consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_zbWwmFUfKE41" style="display: none">Schedule of Property Plant and Equipment</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49B_20231231_zpX60kO1vHr1" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_495_20221231_zhHfPCq9u9Y8" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_400_eus-gaap--FurnitureAndFixturesGross_iI_maPPAEGzv61_maPPAEGzOAj_zfusB1sbMBS7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: justify">Furniture and fixtures</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">88,690</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">88,690</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--Land_iI_maPPAEGzv61_maPPAEGzOAj_zlBVXXJcT5xi" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Land</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">260,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">260,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--ConstructionInProgressGross_iI_maPPAEGzv61_maPPAEGzOAj_zIwdguSVPsjg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Construction in progress</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,635,866</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,736,269</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--BuildingsAndImprovementsGross_iI_maPPAEGzv61_maPPAEGzOAj_zaItLmKj5H5e" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Building and improvements</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,883,851</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,883,851</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentGross_iTI_pp0p0_maPPAENzAvU_mtPPAEGzOAj_zydZCzCCsZJb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Property, plant and equipment gross</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">19,868,407</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">19,968,810</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzAvU_z2DmbDzbl2ae" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Accumulated depreciation</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,460,992</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,822,485</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzAvU_zRZO2NdzY0Ub" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Net property, plant, and equipment</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">16,407,415</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">17,146,325</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A8_zHgAlnNgdyI2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BRIGHT GREEN CORPORATION</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes to the Consolidated Financial Statements</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the Years Ended December 31, 2023 and 2022</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Expressed in United States Dollars)</span></p> <div style="margin-left: auto; margin-right: auto; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt"> </div></div> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Property, Plant, and Equipment (continued)</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The amount of interest expense capitalized and included in construction in progress was $<span id="xdx_900_eus-gaap--AccumulatedCapitalizedInterestCosts_iI_pp0p0_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember_zgjTTS2H1nc" title="Interest costs capitalized">223,271</span> and $<span id="xdx_90C_eus-gaap--AccumulatedCapitalizedInterestCosts_iI_pp0p0_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember_zwVfKoDtH9uk" title="Interest costs capitalized">106,117</span> for the years ended December 31, 2023 and 2022, respectively (Note 10).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 19, 2024, the Company reached an agreement with the vendor to cancel approximately $<span id="xdx_90E_eus-gaap--ConstructionInProgressExpendituresIncurredButNotYetPaid_c20240119__20240119__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z2lYN5Wh5tJl" title="Agreement with vendor to cancel">2,650,000</span> of construction in progress. As part of the agreement, the vendor also agreed to cancel the related accounts payable and completion of the project. The project was being constructed at the vendor’s location. The adjustment is reflected in the construction in progress balance as of December 31, 2023 (Note 16).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Real Estate Options </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In 2020, the Company entered into a merger agreement with Grants Greenhouse Growers, Inc. and acquired the following two land options:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">A Real Estate Option Agreement dated October 5, 2020, and expiring on <span id="xdx_906_eus-gaap--LeaseExpirationDate1_c20201005__20201005__dei--LegalEntityAxis__custom--GrantGreenhouseGrowersIncMember__us-gaap--TypeOfArrangementAxis__custom--RealEstateOptionAgreementOneMember_zhW803C9U2o4" title="Expiration date">December 31, 2021</span>, for $<span id="xdx_906_eus-gaap--DebtInstrumentPeriodicPayment_c20201005__20210630__dei--LegalEntityAxis__custom--GrantGreenhouseGrowersIncMember__us-gaap--TypeOfArrangementAxis__custom--RealEstateOptionAgreementOneMember_zNZ9zQGfgiA4" title="Monthly payments">1,500</span> monthly payments up until June 30, 2021, and $<span id="xdx_90B_eus-gaap--PaymentsToAcquireLand_c20210701__20211231__dei--LegalEntityAxis__custom--GrantGreenhouseGrowersIncMember__us-gaap--TypeOfArrangementAxis__custom--RealEstateOptionAgreementOneMember_zcW4aeZyYRR4" title="Payments to acquire land">1,750</span> monthly payments from July 1, 2021 to December 31, 2021, with a one-year extension starting on January 1, 2022 for $<span id="xdx_90B_eus-gaap--DebtInstrumentPeriodicPayment_c20220101__20220101__dei--LegalEntityAxis__custom--GrantGreenhouseGrowersIncMember__us-gaap--TypeOfArrangementAxis__custom--RealEstateOptionAgreementOneMember_zwLnvGhylnd8" title="Monthly payments">2,000</span> monthly payments, with the option to purchase <span id="xdx_908_eus-gaap--AreaOfLand_iI_pid_uAcre_c20220101__dei--LegalEntityAxis__custom--GrantGreenhouseGrowersIncMember__us-gaap--TypeOfArrangementAxis__custom--RealEstateOptionAgreementOneMember_zofsdfgnthIj" title="Area of land">330</span> acres for $<span id="xdx_903_ecustom--LeasePaymentMadePerAcre_c20220101__20220101__dei--LegalEntityAxis__custom--GrantGreenhouseGrowersIncMember__us-gaap--TypeOfArrangementAxis__custom--RealEstateOptionAgreementOneMember_z1H443xAvGc4" title="Expense made">5,000</span> per acre.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A Real Estate Option Agreement dated October 21, 2020, and expiring on <span id="xdx_902_eus-gaap--LeaseExpirationDate1_c20201021__20201021__dei--LegalEntityAxis__custom--GrantGreenhouseGrowersIncMember__us-gaap--TypeOfArrangementAxis__custom--RealEstateOptionAgreementTwoMember_zlFU5EYmo93d" title="Expiration date">December 31, 2021</span>, for $<span id="xdx_906_eus-gaap--PaymentsToAcquireLand_c20210101__20211231__dei--LegalEntityAxis__custom--GrantGreenhouseGrowersIncMember__us-gaap--TypeOfArrangementAxis__custom--RealEstateOptionAgreementTwoMember_zKBcmjEVrDg1" title="Monthly payments for land">1,000</span> monthly payments, with a one-year extension starting on January 1, 2022 for $<span id="xdx_90E_eus-gaap--DebtInstrumentPeriodicPayment_c20220101__20220101__dei--LegalEntityAxis__custom--GrantGreenhouseGrowersIncMember__us-gaap--TypeOfArrangementAxis__custom--RealEstateOptionAgreementTwoMember_z8pXowgrMIR9" title="Monthly payments">1,500</span> monthly payments, with the option to purchase <span id="xdx_90B_eus-gaap--AreaOfLand_iI_uAcre_c20220101__dei--LegalEntityAxis__custom--GrantGreenhouseGrowersIncMember__us-gaap--TypeOfArrangementAxis__custom--RealEstateOptionAgreementTwoMember_zvGvs5R8dskk" title="Area of land for purchase">175</span> acres for $<span id="xdx_90C_ecustom--LeasePaymentMadePerAcre_c20220101__20220101__dei--LegalEntityAxis__custom--GrantGreenhouseGrowersIncMember__us-gaap--TypeOfArrangementAxis__custom--RealEstateOptionAgreementTwoMember_ziQOzOKDH07g" title="Expense made">5,000</span> per acre.</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2022, the Company notified the two landowners of the Company’s intention to exercise the two Real Estate Option Agreements. The Company is in the process of negotiating final terms of the two acquisitions. As of December 31, 2023, the acquisitions have not been completed.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 22 70 <p id="xdx_891_eus-gaap--PropertyPlantAndEquipmentTextBlock_zcdDsGlt844l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property, plant, and equipment at December 31, 2023 and 2022, consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_zbWwmFUfKE41" style="display: none">Schedule of Property Plant and Equipment</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49B_20231231_zpX60kO1vHr1" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_495_20221231_zhHfPCq9u9Y8" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_400_eus-gaap--FurnitureAndFixturesGross_iI_maPPAEGzv61_maPPAEGzOAj_zfusB1sbMBS7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: justify">Furniture and fixtures</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">88,690</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">88,690</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--Land_iI_maPPAEGzv61_maPPAEGzOAj_zlBVXXJcT5xi" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Land</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">260,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">260,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--ConstructionInProgressGross_iI_maPPAEGzv61_maPPAEGzOAj_zIwdguSVPsjg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Construction in progress</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,635,866</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,736,269</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--BuildingsAndImprovementsGross_iI_maPPAEGzv61_maPPAEGzOAj_zaItLmKj5H5e" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Building and improvements</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,883,851</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,883,851</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentGross_iTI_pp0p0_maPPAENzAvU_mtPPAEGzOAj_zydZCzCCsZJb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Property, plant and equipment gross</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">19,868,407</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">19,968,810</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzAvU_z2DmbDzbl2ae" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Accumulated depreciation</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,460,992</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,822,485</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzAvU_zRZO2NdzY0Ub" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Net property, plant, and equipment</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">16,407,415</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">17,146,325</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 88690 88690 260000 260000 10635866 10736269 8883851 8883851 19868407 19968810 3460992 2822485 16407415 17146325 223271 106117 2650000 2021-12-31 1500 1750 2000 330 5000 2021-12-31 1000 1500 175 5000 <p id="xdx_807_eus-gaap--IntangibleAssetsDisclosureTextBlock_zRzf7ohsKedd" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_82B_zaZdd2SXTuTh">Intangible Assets</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_891_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zJqy8sGKSrI8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible assets at December 31, 2023 and 2022, consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BE_zQgb8hsWnWqe" style="display: none">Schedule of Intangible Assets</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_492_20231231_zcEobocmtqIf" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20221231_zk4j6xvM3eYf" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40D_eus-gaap--FiniteLivedLicenseAgreementsGross_iI_maIANEGzAKK_zYnrWdBkK8va" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Licenses</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_msIANEGzAKK_zT1GTURK2fzk" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Accumulated amortization</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0774">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0775">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iTI_maAzyIt_mtIANEGzAKK_zYmflCCfIQa4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Net intangible assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AD_zEbe5cYfswab" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_891_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zJqy8sGKSrI8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible assets at December 31, 2023 and 2022, consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BE_zQgb8hsWnWqe" style="display: none">Schedule of Intangible Assets</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_492_20231231_zcEobocmtqIf" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20221231_zk4j6xvM3eYf" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40D_eus-gaap--FiniteLivedLicenseAgreementsGross_iI_maIANEGzAKK_zYnrWdBkK8va" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Licenses</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_msIANEGzAKK_zT1GTURK2fzk" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Accumulated amortization</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0774">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0775">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iTI_maAzyIt_mtIANEGzAKK_zYmflCCfIQa4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Net intangible assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 1000 1000 1000 1000 <p id="xdx_808_eus-gaap--CommitmentsDisclosureTextBlock_zgNLBs7D1Qrk" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_820_zr9piqFQJ8l7">Commitments</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In 2022, the Company entered a contract to purchase equipment for $<span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zlsWMoSlHln3" title="Purchase price">2,219,285</span>. The Company made a deposit totaling $<span id="xdx_904_eus-gaap--Deposits_iI_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zweNJU24jzm7" title="Deposits">1,109,643</span> as of December 31, 2022. The remaining balance of $<span id="xdx_90C_eus-gaap--PaymentsForPurchaseOfOtherAssets1_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zAD0Fmz0WfDd" title="Remaining payment">1,109,642</span> is due upon delivery of the equipment. In addition, the Company entered into and paid in full a construction contract for $<span id="xdx_903_eus-gaap--ConstructionContractCostProgressPaymentOffset_iI_c20221231_zgiFiSIH87I8" title="Construction contract paid">47,944</span> as of December 31, 2022. The construction was completed in March 2023, and the contract was fulfilled (Note 5).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-size: 10pt">On March 13, 2024, the Company entered into and signed a Settlement and Release Agreement, in which the deposit was forfeited, leased equipment was returned, and <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_c20240313__20240313__us-gaap--TypeOfArrangementAxis__custom--SettlementAndReleaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zJbODQ10Rly6">118,535,168</span></span><span style="font-size: 10pt"> shares of common stock of Alterola was transferred to the vendor in lieu of payment. Additionally, all parties involved mutually released, relieved, acquitted, remised, and discharged each other as per the Settlement and Release Agreement </span><span style="font-size: 8pt"> </span><span style="font-size: 10pt">(Notes 5 and 16).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BRIGHT GREEN CORPORATION</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes to the Consolidated Financial Statements</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the Years Ended December 31, 2023 and 2022</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Expressed in United States Dollars)</span></p> <div style="margin-left: auto; margin-right: auto; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt"> </div></div> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 2219285 1109643 1109642 47944 118535168 <p id="xdx_80B_ecustom--RelatedPartyLineOfCreditTextBlock_z9eoQdfJLKji" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_824_zlmyBd9klVbf">Related Party Line of Credit Note</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 35.1pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">On June 5, 2022, the Company and LDS Capital LLC (“Lender”), whose managing member is a member of the Company’s Board of Directors (the “Board”), entered into an unsecured line of credit in the form of a note (the “June Note”). The June Note provides that the Company may borrow up to $<span id="xdx_90F_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_c20220605__us-gaap--CreditFacilityAxis__custom--UnsecuredLineOfCreditMember__us-gaap--LineOfCreditFacilityAxis__custom--LDSCapitalLLCMember__srt--RangeAxis__srt--MaximumMember_zCLbCSR9D65i" title="Line of credit loan amount">5,000,000</span>, including an initial loan of $<span id="xdx_900_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_c20220605__us-gaap--CreditFacilityAxis__custom--UnsecuredLineOfCreditMember__us-gaap--LineOfCreditFacilityAxis__custom--LDSCapitalLLCMember_z5IjHAnbqrD" title="Line of credit loan amount">3,000,000</span>, through June 4, 2025 (the “June Note Maturity Date”) from Lender. Prior to the June Note Maturity Date, the Company may borrow up to an additional $<span id="xdx_905_ecustom--LineOfCreditFacilityIncreaseInBorrowingCapacity_iI_c20220605__us-gaap--CreditFacilityAxis__custom--UnsecuredLineOfCreditMember__us-gaap--LineOfCreditFacilityAxis__custom--LDSCapitalLLCMember_zhd9mUmg7Ya1" title="Additional borrowing capacity">2,000,000</span> under the June Note, at Lender’s sole discretion, and subject to the Company’s request of such additional funds from Lender (each loan furnished under the June Note individually, a “Loan,” and collectively, the “Loans”). The Company has the right, but not the obligation, to prepay any Loan, in whole or in part, prior to the June Note Maturity Date. Interest on the unpaid principal amount of any Loan accrues through the earlier of the June Note Maturity Date or the date of prepayment on such Loan, at a rate of <span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220605__us-gaap--CreditFacilityAxis__custom--UnsecuredLineOfCreditMember__us-gaap--VariableRateAxis__us-gaap--PrimeRateMember__us-gaap--LineOfCreditFacilityAxis__custom--LDSCapitalLLCMember_zkQ3X8bJ99o6" title="Interest rate stated percentage">2</span>% per annum plus the Prime Rate (the rate of interest per annum announced from time to time by JP Morgan Chase Bank as its prime rate). If the principal and interest, if any, of any Loan is not paid in full on the June Note Maturity Date, additional penalty interest will accrue on such Loan in the amount of <span id="xdx_901_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220605__us-gaap--CreditFacilityAxis__custom--UnsecuredLineOfCreditMember__us-gaap--LineOfCreditFacilityAxis__custom--LDSCapitalLLCMember_zFlpf6LxWf5k" title="Interest rate stated percentage">2</span>% per annum. The Company amended the line of credit on November 14, 2022, to increase the capacity by $<span id="xdx_906_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_c20221114__us-gaap--CreditFacilityAxis__custom--AmendedUnsecuredLineOfCreditMember_zzldGYjBtR49" title="Increase in the line of credit capacity amount">10,000,000</span>. On January 31, 2023, LDS Capital LLC assigned the note to its sole member, Lynn Stockwell, who is the Company’s Chairwoman and majority shareholder.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2023, the Lender has funded the Company $<span id="xdx_902_eus-gaap--IncreaseDecreaseInSecuritiesLendingPayable_c20230101__20231231__us-gaap--CreditFacilityAxis__custom--UnsecuredLineOfCreditMember__us-gaap--LineOfCreditFacilityAxis__custom--LDSCapitalLLCMember_znHrGHMZUJwd" title="Lender committed funds">5,983,250</span> (December 31, 2022 – $<span id="xdx_901_eus-gaap--IncreaseDecreaseInSecuritiesLendingPayable_c20220101__20221231__us-gaap--CreditFacilityAxis__custom--UnsecuredLineOfCreditMember__us-gaap--LineOfCreditFacilityAxis__custom--LDSCapitalLLCMember_zMFJwlEi8ftc" title="Lender committed funds">5,191,057</span>), with the Company paying back $<span id="xdx_90A_eus-gaap--RepaymentsOfOtherDebt_pp0p0_c20230101__20231231__us-gaap--CreditFacilityAxis__custom--UnsecuredLineOfCreditMember__us-gaap--LineOfCreditFacilityAxis__custom--LDSCapitalLLCMember_z9iFZMvBJYYh" title="Repayments of other debt">6,110,855</span> (December 31, 2022 – $<span id="xdx_905_eus-gaap--RepaymentsOfOtherDebt_pp0p0_c20220101__20221231__us-gaap--CreditFacilityAxis__custom--UnsecuredLineOfCreditMember__us-gaap--LineOfCreditFacilityAxis__custom--LDSCapitalLLCMember_z8YYfc2oO47" title="Repayments of other debt">1,611,067</span>) of those funds, which includes $<span id="xdx_900_eus-gaap--InterestPayableCurrent_iI_pp0p0_c20231231__us-gaap--CreditFacilityAxis__custom--UnsecuredLineOfCreditMember__us-gaap--LineOfCreditFacilityAxis__custom--LDSCapitalLLCMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember_zOebIEYv62ph" title="Interest payable">327,605</span> in interest. As of December 31, 2023, there was accrued interest of $<span id="xdx_905_eus-gaap--InterestPayableCurrent_iI_c20231231__us-gaap--CreditFacilityAxis__custom--UnsecuredLineOfCreditMember__us-gaap--LineOfCreditFacilityAxis__custom--LDSCapitalLLCMember_zuIsKdgbum64" title="Accrued interest">1,783</span> (December 31, 2022 – $<span id="xdx_909_eus-gaap--InterestPayableCurrent_iI_c20221231__us-gaap--CreditFacilityAxis__custom--UnsecuredLineOfCreditMember__us-gaap--LineOfCreditFacilityAxis__custom--LDSCapitalLLCMember_ztecvKM362v9" title="Accrued interest">106,117</span>). The funds have been used for the construction in progress, and during the year ended December 31, 2023, interest expense of $<span id="xdx_901_eus-gaap--InterestCostsCapitalized_c20230101__20231231__us-gaap--CreditFacilityAxis__custom--UnsecuredLineOfCreditMember__us-gaap--LineOfCreditFacilityAxis__custom--LDSCapitalLLCMember_zaNfN6PgZ0wf" title="Interest costs capitalized">223,271</span> (December 31, 2022 – $<span id="xdx_902_eus-gaap--InterestCostsCapitalized_c20220101__20221231__us-gaap--CreditFacilityAxis__custom--UnsecuredLineOfCreditMember__us-gaap--LineOfCreditFacilityAxis__custom--LDSCapitalLLCMember_zaWf2ooeWI9j" title="Interest costs capitalized">106,117</span>) has been capitalized (Note 7).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 1, 2023, through a cashless conversion, the related party line of credit note was used to pay the related party loan balance of $<span id="xdx_900_eus-gaap--RepaymentsOfRelatedPartyDebt_pp0p0_c20230201__20230201_zXIapxktIxmi" title="Payment of related party loan">392,194</span> in full.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 6, 2023, through a cashless conversion, the related party line of credit note was paid down $<span id="xdx_906_eus-gaap--RepaymentsOfLongTermLinesOfCredit_pp0p0_c20230206__20230206_ziBrSAHavSD6" title="Related party line of credit paid">880,000</span> in exchange for an $<span id="xdx_901_eus-gaap--TransferToInvestments_c20230206__20230206_zYJqpP3TJ3S" title="Investment transfer for repayment of loan">880,000</span> investment for <span id="xdx_902_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20230206__20230206_zEbjUoxjdVY4" title="Debt conversion, shares issued">22,005</span> shares of the Company’s common stock valued at $<span id="xdx_904_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20230206_zJ1IhkY2nFk9" title="Conversion price">39.99</span> per share pursuant to the Company’s EB-5 Program (Note 11).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 14, 2023, the Company drew an additional $<span id="xdx_90B_eus-gaap--ProceedsFromRelatedPartyDebt_c20230314__20230314_zlQd5v2W6fTa" title="Drew from related party line of credit">200,000</span> on the related party line of credit note.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BRIGHT GREEN CORPORATION</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes to the Consolidated Financial Statements</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the Years Ended December 31, 2023 and 2022</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Expressed in United States Dollars)</span></p> <div style="margin-left: auto; margin-right: auto; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt"> </div></div> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Related Party Line of Credit Note (continued)</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 35.1pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At August 31, 2023, the amount of principal, interest, and other costs outstanding under the related party line of credit note was $<span id="xdx_906_eus-gaap--LineOfCredit_iI_c20230831_zVuH0UkkXPSj" title="Line of credit">3,619,789</span> (the “Repayment Obligation”). On September 1, 2023, the Company and the Lender entered into an agreement (the “Repayment Agreement”) pursuant to which, in consideration for the cancellation and full satisfaction of the Repayment Obligation, the Company issued to the Lender (i) <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230831__20230831_z3pA5XxXUWif" title="Number of shares issued">2,827,960</span> shares (the “Shares”) of the Company’s common stock, par value $<span id="xdx_904_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20230831_zcGkuQDCHf6k" title="Common stock, par value">0.0001</span> per share (the “Common Stock”), representing a conversion of outstanding principal at $<span id="xdx_903_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20230831_zIJZucKcBC4a" title="Conversion of principal price per share">1.15</span> per Share, and (ii) warrants representing a conversion of outstanding principal at $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230831_z9XYJnOW46Uc" title="Warrants price per share">0.13</span> per warrant to purchase up to <span id="xdx_90E_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20230831__20230831_z1VeMRGenWjc" title="Debt conversion, shares issued">2,827,960</span> shares of Common Stock at a price of $<span id="xdx_902_eus-gaap--SharesIssuedPricePerShare_iI_c20230831_zYzprkV4uX5a" title="Common stock price per share">3.00</span> per share (Note 11).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company determined the Repayment Agreement should be accounted for as an extinguishment in accordance ASC 405, Liabilities, and ASC 470-50, Debt. The Company measured the difference between the fair value of the equity interests granted and the carrying value of the obligation, determining that the carrying value exceeded the fair value of the interests granted. The Company determined that a gain would be recorded; however, the Company recorded the $<span id="xdx_90A_ecustom--CapitalTransactionDueToRelatedParty_iI_c20231231_zrOzEBwRqmPb" title="Capital transaction due to related party">2,090,564</span> gain as a capital transaction due to the related party nature of the Lender.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 1, 2023, the Company drew an additional $<span id="xdx_90C_eus-gaap--ProceedsFromRelatedPartyDebt_c20231201__20231201_z64XT83JQ7Ok" title="Additional related party line of credit">200,000</span> on the related party line of credit note, leaving available $<span id="xdx_90B_eus-gaap--LineOfCreditFacilityRemainingBorrowingCapacity_iI_c20231201_zbqHUVnOQwJ2" title="Credit facility">14,800,000</span> to draw from that credit facility.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 5000000 3000000 2000000 0.02 0.02 10000000 5983250 5191057 6110855 1611067 327605 1783 106117 223271 106117 392194 880000 880000 22005 39.99 200000 3619789 2827960 0.0001 1.15 0.13 2827960 3.00 2090564 200000 14800000 <p id="xdx_80C_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zehP16xEy543" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_82F_zTmtcrBHl7n">Stockholders’ Equity</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has authorized <span id="xdx_90A_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20231231_zj8dd2EOfqed" title="Common stock, shares authorized">500,000,000</span> shares of $<span id="xdx_902_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20231231_zIVyfYdm0E7e" title="Common stock, par value">0.0001</span> par value common stock and <span id="xdx_901_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20231231_zTiPacxBQNUe" title="Preferred stock, shares authorized">10,000,000</span> shares of $<span id="xdx_90D_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20231231_zUoMiyTcbso8" title="Preferred stock par value">0.0001</span> par value preferred stock. As of December 31, 2023, and 2022, there were <span id="xdx_900_eus-gaap--CommonStockSharesIssued_iI_c20231231_zuXaHohfV4Zd" title="Common stock, shares issued"><span id="xdx_90E_eus-gaap--CommonStockSharesOutstanding_iI_c20231231_zy7AdjBCUem1" title="Common stock, shares outstanding">184,758,818</span></span> and <span id="xdx_90D_eus-gaap--CommonStockSharesIssued_iI_c20221231_zceSJxu1yOF1" title="Common stock, shares issued"><span id="xdx_901_eus-gaap--CommonStockSharesOutstanding_c20221231_pdd" title="Common stock, shares outstanding">173,304,800</span></span>, respectively, of common shares issued and outstanding. The Company has not issued any preferred shares to date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2023, the Company issued the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_ecustom--NumberOfWarrantsExercised_pid_c20230201__20230228__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OneAccreditedInvestorMember_zm2wozsES7F9" title="Number of warrants exercised">200,000</span> warrants exercised in exchange for <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20230201__20230228__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OneAccreditedInvestorMember_zM1HCTnNZhfd" title="Number of shares issued">200,000</span> shares of common stock issued for cash at $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230228__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OneAccreditedInvestorMember_zSkOHWUDyI65" title="Exercised price">1.05</span> per share, to one accredited investor in February 2023;</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230201__20230228__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--BoardMemberMember_zYYrw1vxmlHk" title="Common stock issued for cash, shares">22,005</span> shares of common stock issued at $<span id="xdx_90C_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230228__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--BoardMemberMember_zqAf6Kz6Qb13" title="Shares issued, price per share">39.99</span> per share, to the Company’s Chairwoman in February 2023, through a cashless conversion; the related party line of credit note was paid down $<span id="xdx_90B_eus-gaap--RepaymentsOfLongTermLinesOfCredit_pp0p0_c20230201__20230228_zw8pikCwo4Qk" title="Related party line of credit paid">880,000</span> in exchange for an $<span id="xdx_904_eus-gaap--TransferToInvestments_c20230201__20230228_z1MQwXVSr971" title="Investments exchanged for payment of credit">880,000</span> investment, pursuant to the Company’s EB-5 Program (Note 10);</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230301__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--OneAccreditedInvestorMember_zoG7NFlyKC36" title="Common stock issued for cash, shares">22,005</span> shares of common stock issued at $<span id="xdx_904_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--OneAccreditedInvestorMember_zZDq8KVNOrx1" title="Shares issued, price per share">39.99</span> per share, to one accredited investor in March 2023, pursuant to the Company’s EB-5 Program;</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BRIGHT GREEN CORPORATION</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes to the Consolidated Financial Statements</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the Years Ended December 31, 2023 and 2022</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Expressed in United States Dollars)</span></p> <div style="margin-left: auto; margin-right: auto; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt"> </div></div> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Stockholders’ Equity (continued)</span></span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20230301__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--ExecutiveChairmanMember_zlxCMJQg5ER7" title="Common stock issued for service, shares">875,000</span> shares of common stock for services rendered, at a fair value of $<span id="xdx_902_eus-gaap--SharesIssuedPricePerShare_iI_c20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--ExecutiveChairmanMember_zVNHDWBMEWMa" title="Issued price per share">0.9416</span> per share, to the Company’s former Executive Chairman, in March 2023 (Note 14);</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20230501__20230531__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_z1dm3q45Fcpl" title="Common stock issued for service, shares">500,000</span> shares of common stock for services rendered, at a fair value of $<span id="xdx_90B_eus-gaap--SharesIssuedPricePerShare_iI_c20230531__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zlo41q15nMWd" title="Issued price per share">1.13</span> per share, to the Company’s former Chief Executive Officer, in May 2023 (Note 14);</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230501__20230531__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_z6N1cTuHd6wh" title="Common stock issued for cash, shares">3,684,210</span> shares of common stock and warrants to purchase up to an aggregate of <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230531__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zEwlT27usRfl" title="Warrants to purchase common stock">3,684,210</span> shares of common stock, at a combined purchase price of $<span id="xdx_903_ecustom--WarrantAndSharePurchasePrice_iI_pid_c20230531__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zpJQYioQEXm4" title="Purchase price">0.95</span> per share and accompanying warrant, in a private placement offering, in May 2023 (the “May 2023 Private Placement”);</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20230601__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--ExecutiveChairmanMember_zj88UhzeYW52" title="Common stock issued for service, shares">875,000</span> shares of common stock for services rendered, at a fair value of $<span id="xdx_90F_eus-gaap--SharesIssuedPricePerShare_iI_c20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--ExecutiveChairmanMember_zkWK3N1k6pI6" title="Issued price per share">1.01</span> per share, to the Company’s former Executive Chairman, in June 2023 (Note 14);</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20230701__20230731__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_z81rfL8aFEed" title="Common stock issued for service, shares">137,838</span> shares of common stock for services rendered, at a fair value of $<span id="xdx_902_eus-gaap--SharesIssuedPricePerShare_iI_c20230731__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_zbghl0Du0Zo3" title="Issued price per share">0.74</span> per share, to a consultant of the Company, in July 2023;</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20230901__20230930_z98OzxacsGEd" title="Debt conversion, shares issued">2,827,960</span> shares of common stock and warrants to purchase up to an aggregate of <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_znd3JJ4t8QCg" title="Warrants to purchase common stock">2,827,960</span> shares of common stock at an exercise price of $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zhBMEurN9v74" title="Exercise price per share">3.00</span> per share, issued at a combined price of $<span id="xdx_903_ecustom--ExercisePriceOfWarrants_iI_pid_c20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_znhmuseHwol7" title="Exercise price per share">1.28</span> per share and accompanying warrant, to the Company’s Chairwoman, through a cashless conversion; the related party line of credit note was paid in full $<span id="xdx_90D_eus-gaap--ProceedsFromRepaymentsOfRelatedPartyDebt_c20230901__20230930_ztfMpulbj6V5" title="Related party line of credit paid">3,619,789</span> in exchange for a $<span id="xdx_902_eus-gaap--TransferToInvestments_c20230901__20230930_zjzxN853nGh7" title="Investment transfer for repayment of loan">3,619,789</span> investment, in September 2023 (Note 10);</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20230901__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_zHZ6arxaW16f" title="Common stock issued for service, shares">60,000</span> shares of common stock for services rendered, at a fair value of $<span id="xdx_902_eus-gaap--SharesIssuedPricePerShare_iI_c20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_zqeIImYRlkV8" title="Issued price per share">0.4015</span> per share, to a consultant of the Company, in September 2023;</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20230901__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zpU73Lkr8uJf" title="Common stock issued for service, shares">500,000</span> shares of common stock for services rendered, at a fair value of $<span id="xdx_908_eus-gaap--SharesIssuedPricePerShare_iI_c20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_ztWFKqSuO5s2" title="Issued price per share">0.4015</span> per share, to the Company’s Chief Financial Officer, in September 2023 (Note 14);</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20230901__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--ExecutiveChairmanMember_zcAd8TBZLQe6" title="Common stock issued for service, shares">875,000</span> shares of common stock for services rendered, at a fair value of $<span id="xdx_905_eus-gaap--SharesIssuedPricePerShare_iI_c20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--ExecutiveChairmanMember_zMtdydy7Nuha" title="Issued price per share">0.3959</span> per share, to the Company’s former Executive Chairman, in September 2023 (Note 14);</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20231101__20231130__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zA3b39UFu85f" title="Stock options issued for services rendered, shares">1,800,000</span> shares of stock options for services rendered, at a fair value of $<span id="xdx_904_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20231130__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zcbDhoUXLCac" title="Issued price per share">0.3303</span> per share, an exercise price of $<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20231101__20231130__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zO11PUjD5SM9" title="Exercise price per share">0.3353</span> per share, which vest immediately, expire on November 16, 2033, with <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20231101__20231130__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--DirectorOneMember_z6CMy6p1jBW8" title="Stock options issued for services rendered, shares"><span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20231101__20231130__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--DirectorTwoMember_zaOmZTZ8XLdf" title="Stock options issued for services rendered, shares"><span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20231101__20231130__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--DirectorThreeMember_z2zYNNkFO6O7" title="Stock options issued for services rendered, shares">600,000</span></span></span> each to three Directors of the Company, in November 2023 (Notes 12 and 14); and</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BRIGHT GREEN CORPORATION</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes to the Consolidated Financial Statements</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the Years Ended December 31, 2023 and 2022</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Expressed in United States Dollars)</span></p> <div style="margin-left: auto; margin-right: auto; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt"> </div></div> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Stockholders’ Equity (continued)</span></span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20231201__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--ExecutiveChairmanMember_z7ju5Ma6MZfl" title="Common stock issued for service, shares">875,000</span> shares of common stock for services rendered, at a fair value of $<span id="xdx_900_eus-gaap--SharesIssuedPricePerShare_iI_c20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--ExecutiveChairmanMember_z8qyRgy6lBL3" title="Issued price per share">0.3301</span> per share, to the Company’s former Executive Chairman, in December 2023 (Note 14).</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 2.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year December 31, 2022, the Company issued the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220101__20220131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--OneAccreditedInvestorMember_z7HmOSTjFotb" title="Shares of common stock">12,500</span> shares of common stock at a purchase price of $<span id="xdx_90B_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20220131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--OneAccreditedInvestorMember_zXekJceoBvij" title="Purchase price">4.00</span> per share, for gross cash proceeds of $<span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_c20220101__20220131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--OneAccreditedInvestorMember_zP5SZ0P1Rryh" title="Gross cash proceeds">50,000</span>, to one accredited investor in January 2022;</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20220401__20220430__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zChC5Jj339Mf" title="Shares of common stock for services">500,000</span> shares of common stock for services rendered, at a fair value of $<span id="xdx_90C_eus-gaap--SharesIssuedPricePerShare_iI_pip0_c20220430__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zij1jweY1Ab8" title="Shares issued price per share">4.00</span> per share determined using the per share purchase price of the latest $<span id="xdx_90E_eus-gaap--SharesIssuedPricePerShare_iI_pip0_c20220430__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_ztjyXXzbOeU4" title="Shares issued price per share">4.00</span> private placement Round, to the Chief Financial Officer of the Company, in April 2022;</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20220401__20220430__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--SixConsultantsMember_zPB889o349Zj" title="Shares of common stock for services">1,574,490</span> shares of common stock for services rendered, at a fair value of $<span id="xdx_90F_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20220430__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--SixConsultantsMember_zfivKcukYjFb" title="Shares issued price per share">8.00</span> per share determined using the per share purchase price of the latest $<span id="xdx_903_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20220430__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__srt--TitleOfIndividualAxis__custom--SixConsultantsMember_zKbHj4Vk68oj" title="Shares issued price per share">8.00</span> private placement Round, to six consultants in April 2022;</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_pid_c20220401__20220430__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--DirectorsMember_z7yI8UWZjA22" title="Shares of common stock cancelled">5,000</span> shares of common stock that were issued in January 2021 to a director of the Company, for services valued at $<span id="xdx_90B_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20220430__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--DirectorsMember_zk3ZquXYdCtd" title="Purchase price">2.00</span> per share determined using the per share purchase price of the $<span id="xdx_906_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20220430__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--DirectorsMember_zs5nAdAJEn36" title="Purchase price">2.00</span> Round, were canceled in April 2022;</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220501__20220531__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--TwoAccreditedInvestorMember_zsWI1aiHWP99" title="Shares of common stock issued">300,000</span> shares of common stock at a purchase price of $<span id="xdx_906_eus-gaap--SharesIssuedPricePerShare_iI_c20220531__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--TwoAccreditedInvestorMember_zDpPLfDukVmk" title="Purchase price">10.00</span> per share, for gross cash proceeds of $<span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20220501__20220531__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--TwoAccreditedInvestorMember_zb0rSrIt9fLl" title="Gross cash proceeds">3,000,000</span>, to two accredited investors in May 2022;</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_pid_c20220601__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--ConsultantsMember_zQKY9yh6eZNd" title="Shares of common stock cancelled">108,000</span> shares of common stock that were issued in June 2019 to a consultant of the Company, for services valued at $<span id="xdx_908_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--ConsultantsMember_zkXzdDwed9c7" title="Shares issued price per share">0.069</span> per share determined using an asset approach, were canceled in June 2022;</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zCgizaP6CnFf">9,523,810</span> shares of common stock and warrants to purchase up to an aggregate of <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zHH3eEWtI4E6" title="Stock issued for cash">9,523,810</span> shares of common stock, at a combined purchase price of $<span id="xdx_908_eus-gaap--SharesIssuedPricePerShare_iI_c20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zA4iWod8Anib" title="Purchase price">1.05</span> per share and accompanying warrant, in a private placement offering, in September 2022 (the “September 2022 Private Placement”); and</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 2.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20221201__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zzxCFZwxZeBi" title="Common stock issued for services rendered">3,962,500</span> shares of common stock for services rendered, with (i) <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_pid_c20221201__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockOneMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zFCigQV8WfX4" title="Number of shares issued">3,000,000</span> shares issued at a fair value of $<span id="xdx_907_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockOneMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_ztsuOXpfoDy7" title="Issued price per share">1.25</span> per share, (ii) <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_pid_c20221201__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockTwoMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zLGRunpXAn6a" title="Number of shares issued">87,500</span> shares at a fair value of $<span id="xdx_90B_eus-gaap--SharesIssuedPricePerShare_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockTwoMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zySOPILN8Rqd" title="Issued price per share">1.08</span> per share, and (iii) <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_pid_c20221201__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockThreeMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zH7gCGPct4O7" title="Number of shares issued">875,000</span> shares at a fair value of $<span id="xdx_90A_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockThreeMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zvG5umWVjqPg" title="Issued price per share">0.4695</span> per share, to the former Chief Executive Officer of the Company, in December 2022.</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Private Placement Offerings</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>September 2022 Private Placement</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 7, 2022, the Company entered into a Securities Purchase Agreement with investors for the sale by the Company of <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220907__20220907__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z9LB0Sg1ubb" title="Issuance of shares">9,523,810</span> shares of common stock and warrants to purchase up to an aggregate of <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20220907__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zKTzl7yt3Phi" title="Warrants to purchase common stock">9,523,810</span> shares of common stock. The combined purchase price of one share and the accompanying warrant (“September 2022 Warrants”) was $<span id="xdx_90F_ecustom--WarrantAndSharePurchasePrice_iI_pid_c20220907__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zBgKzkuV1Vxl" title="Purchase price">1.05</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BRIGHT GREEN CORPORATION</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes to the Consolidated Financial Statements</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the Years Ended December 31, 2023 and 2022</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Expressed in United States Dollars)</span></p> <div style="margin-left: auto; margin-right: auto; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt"> </div></div> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Stockholders’ Equity (continued)</span></span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject to certain ownership limitations, the September 2022 Warrants are exercisable immediately after issuance at an exercise price equal to $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220907__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zcU8YTU0vgZ9" title="Warrants exercise price">1.05</span> per share of Common Stock, subject to adjustments as provided under the terms of the September 2022 Warrants. The September 2022 Warrants have a term of <span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_pid_dc_c20220907__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zWpN6dni5TD9" title="Warrants term">five years</span> from the date of issuance. The September 2022 Private Placement closed on September 12, 2022. The Company received gross proceeds of approximately $<span id="xdx_90D_ecustom--GrossProceedsFromIssuanceOfPrivatePlacement_pn6n6_c20220907__20220912__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zojsrdLTJTOj" title="Gross proceeds from private placement">10</span> million before deducting transaction-related fees and expenses payable by the Company. As of December 31, 2023, <span id="xdx_904_ecustom--WarrantRedeemedOrCalledDuringPeriodShares_c20230101__20231231_zWnORThZLErc" title="Warrants redeemed, shares">200,000</span> of the September 2022 Warrants have been redeemed for $<span id="xdx_90C_ecustom--WarrantRedeemedOrCalledDuringPeriodValue_c20220907__20220907_zfxhgcVdFtCf" title="Warrants redeemed, value">210,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with the September 2022 Private Placement, the Company entered into a Registration Rights Agreement with the investors. The Company’s registration statement on Form S-1 to register the securities issued in the September 2022 Private Placement went effective on September 21, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transaction costs incurred related to the September 2022 Private Placement include the following: (i) placement agent fees of $<span id="xdx_901_eus-gaap--ProfessionalFees_c20220921__20220921_zEp0bNtmS678" title="Placement agent fees">800,000</span>, (ii) legal expenses of $<span id="xdx_90F_eus-gaap--LegalFees_c20220921__20220921_zR1ajlTqKV3f" title="Legal fees">55,617</span>, and (iii) escrow agent expenses of $<span id="xdx_906_eus-gaap--EscrowDeposit_iI_c20220921_zK0tjHJHNygd" title="Escrow deposit">7,650</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>May 2023 Private Placement</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 21, 2023, the Company entered into a Securities Purchase Agreement with an accredited investor and existing stockholder of the Company. The combined purchase price of one share and the accompanying warrant (“May 2023 Warrants”) was $<span id="xdx_906_ecustom--WarrantAndSharePurchasePrice_iI_pid_c20230521__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zcnlyqcmk2Ui" title="Purchase price">0.95</span>. Subject to certain ownership limitations, the May 2023 Warrants are exercisable immediately after issuance at an exercise price equal to $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230521__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zsUeJpPegITh" title="Warrants exercise price">0.95</span> per share of Common Stock, subject to adjustments as provided under the terms of the May 2023 Warrants. The May 2023 Warrants have a term of <span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_pid_dc_c20230521__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zfuItS4PuuF9" title="Warrants term">five years</span> from the date of issuance. The May 2023 Private Placement closed on May 24, 2023. The Company received gross proceeds of approximately $<span id="xdx_904_ecustom--GrossProceedsFromIssuanceOfPrivatePlacement_pn5n6_c20230522__20230524__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zmdoC0gn1j2a" title="Gross proceeds from private placement">3.5</span> million before deducting transaction related fees and expenses payable by the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with the May 2023 Private Placement, the Company entered into a Registration Rights Agreement with the investor. The Company’s registration statement on Form S-3 to register the securities issued in the May 2023 Private Placement went effective on June 5, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transaction costs incurred related to the May 2023 Private Placement include the following: (i) placement agent fees of $<span id="xdx_90D_eus-gaap--ProfessionalFees_c20230501__20230531_zevUKPBVtyg2" title="Placement agent fees">316,850</span>, and (ii) legal expenses of $<span id="xdx_902_eus-gaap--LegalFees_c20230501__20230531_zmrOjtQcvajl" title="Legal fees">78,400</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Warrants</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>September 2022 Warrants</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the Company’s September 2022 Private Placement, Warrants to purchase up to <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20220907__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zigTB1RKAf62" title="Warrants to purchase common stock">9,523,810</span> shares of Common Stock were issued (“September 2022 Warrants”). The September 2022</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BRIGHT GREEN CORPORATION</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes to the Consolidated Financial Statements</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the Years Ended December 31, 2023 and 2022</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Expressed in United States Dollars)</span></p> <div style="margin-left: auto; margin-right: auto; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt"> </div></div> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Stockholders’ Equity (continued)</span></span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants were initially exercisable at a price of $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220907__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zyljyz7I72Ie" title="Exercise price">1.05</span> per share, subject to adjustment as set forth in the September 2022 Warrants, at any time after September 12, 2022 and will expire on September 13, 2027. In connection with the May 2023 Private Placement, the exercise price of the September 2022 Warrants issued in the September 2022 Private Placement was reduced to $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230521__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zR7pUBgPPoI6" title="Warrants exercise price">0.95</span> per share.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of the September 2022 Warrants immediately prior to the modification was $<span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstanding_iI_c20220906_zxmPLSWpMPV3" title="Warrants prior modification">7,399,000</span>, and the fair value of the September 2022 Warrants immediately after the modification was $<span id="xdx_900_eus-gaap--WarrantsAndRightsOutstanding_iI_c20220912_zj036G3ka7xj" title="Warrants fair value">6,901,000</span>, representing a decrease in fair value of $<span id="xdx_900_ecustom--DecreaseInFairValueOfWarrants_c20220907__20220912_zlgpd7QgmWzg" title="Decrease in fair value of warrants">498,000</span>. In accordance with ASU 2021- 04, as the modification was a result of issuing equity and there was no increase in fair value, the Company accounted for the adjustment as a reduction of additional paid-in capital with a corresponding offset recorded to additional paid-in capital.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>May 2023 Warrants</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the Company’s May 2023 Private Placement, Warrants to purchase up to <span id="xdx_90E_ecustom--CommonStockAndWarrantsIssuedSharesForCashInPrivatePlacements_c20230501__20230531__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zib9CUosh5Se" title="Shares of warrants to purchase">3,684,210</span> shares of Common Stock were issued (“May 2023 Warrants”). The fair value of the May 2023 Warrants was determined utilizing a Black-Scholes model considering all relevant assumptions current at the date of issuance (i.e., share price of $<span id="xdx_905_eus-gaap--SharePrice_iI_pid_c20230531__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_z11tXbThucLe" title="Share price">0.78</span>, exercise price of $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230531__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zeQZYgvF6HK1" title="Warrant exercise price">0.95</span>, term of <span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20230531__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zK3qui2m3Bqj" title="Warrants and rights outstanding term">five years</span>, volatility of <span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20230531__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zOl8RKWiCemf" title="Volatility rate">165.0%</span>, risk-free rate of <span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20230531__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zQzc4tk1NT37" title="Risk-free rate">3.8%</span>, and dividend rate of <span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_dp_uPure_c20230531__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_z7koGhxWrU61" title="Dividend rate">0.0%</span>). The grant date fair value of the May 2023 Warrants was estimated to be $<span id="xdx_900_eus-gaap--StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_c20240524__20240524__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__srt--StatementScenarioAxis__srt--ScenarioForecastMember_zRiuflghj1t1" title="Warrants estimate value">1,600,000</span> on May 24, 2024 and is reflected within additional paid-in capital as of December 31, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>September 2023 Warrants</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with the Repayment Obligation disclosed in Note 10, Warrants to purchase up to <span id="xdx_90C_ecustom--CommonStockAndWarrantsIssuedSharesForCashInPrivatePlacements_c20230901__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zW53LgP72Ej8">2,827,960</span> shares of Common Stock were issued (“September 2023 Warrants”). The fair value of the September 2023 Warrants was determined utilizing a Monte Carlo simulation considering all relevant assumptions current at the date of issuance (i.e., share price of $<span id="xdx_90E_eus-gaap--SharePrice_iI_pid_c20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zOLpNPAvvCz7">0.46</span>, exercise price of $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zbqrTeojxNa9">3.00</span>, expected life of <span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20230930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z4ydwqwAGqq7" title="Warrants and rights outstanding term">one year</span>, volatility of <span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20230930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zjfFvfWde1Wc"><span style="-sec-ix-hidden: xdx2ixbrl1072">149%</span></span>, risk-free rate of <span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20230930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmau1PTBOQie">5.36%</span>, and dividend rate of <span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_dp_uPure_c20230930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zVkHLWl6CAh4">0.0%</span>). The grant date fair value of the September 2023 Warrants was estimated to be approximately $<span id="xdx_901_eus-gaap--StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_c20230901__20230901__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zMf5eE3PDgz6">149,180</span> on September 1, 2023, and is reflected within additional paid-in capital as of December 31, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BRIGHT GREEN CORPORATION</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes to the Consolidated Financial Statements</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the Years Ended December 31, 2023 and 2022</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Expressed in United States Dollars)</span></p> <div style="margin-left: auto; margin-right: auto; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt"> </div></div> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 500000000 0.0001 10000000 0.0001 184758818 184758818 173304800 173304800 200000 200000 1.05 22005 39.99 880000 880000 22005 39.99 875000 0.9416 500000 1.13 3684210 3684210 0.95 875000 1.01 137838 0.74 2827960 2827960 3.00 1.28 3619789 3619789 60000 0.4015 500000 0.4015 875000 0.3959 1800000 0.3303 0.3353 600000 600000 600000 875000 0.3301 12500 4.00 50000 500000 4.00 4.00 1574490 8.00 8.00 5000 2.00 2.00 300000 10.00 3000000 108000 0.069 9523810 9523810 1.05 3962500 3000000 1.25 87500 1.08 875000 0.4695 9523810 9523810 1.05 1.05 P5Y 10000000 200000 210000 800000 55617 7650 0.95 0.95 P5Y 3500000 316850 78400 9523810 1.05 0.95 7399000 6901000 498000 3684210 0.78 0.95 P5Y 165.00 3.08 0.000 1600000 2827960 0.46 3.00 P1Y 5.36 0.000 149180 <p id="xdx_801_eus-gaap--CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock_zfJwqqMyMiV2" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_82E_z3xPZJMWw2p9">Stock-Based Compensation</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In 2022, the Company adopted the Bright Green Corporation 2022 Omnibus Equity Compensation Plan, which allows for various types of stock-based awards. These awards can be in the form of stock options (including non-qualified and incentive stock options), SARs, restricted shares, performance shares, deferred stock, restricted stock units (“RSUs”), dividend equivalents, bonus shares, or other types of stock-based awards.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2023 and 2022, there were <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityCompensationPlanMember_zHd5DwJct4B7" title="Stock issued during period, shares, new issues">3,050,000</span> and <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_dxL_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityCompensationPlanMember_zHy53odrk634" title="Stock issued during period, shares, new issues::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl1081">nil</span></span>, respectively, of awards granted under the Plan. The awards consisted of <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityCompensationPlanMember_zEcTFw6RA2h3" title="Stock options, shares">2,425,000</span> shares of stock options and <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--PlanNameAxis__custom--EquityCompensationPlanMember_z6v6tdr2g8E6" title="Restricted shares unit">625,000</span> shares of RSUs.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s stock-based compensation costs for the years ended December 31, 2023, and 2022 were $<span id="xdx_90F_eus-gaap--ShareBasedCompensation_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityCompensationPlanMember_zfxk5cd3qkS2">3,829,218 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_90F_eus-gaap--ShareBasedCompensation_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityCompensationPlanMember_zneFW6EJyB3c">18,833,781</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">, respectively, with the costs allocated to general and administrative expenses. Stock options accounted for $<span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityCompensationPlanMember_zLZVzY2FZW6k">594,478 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of the total stock-based compensation costs for the year ended December 31, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Stock Options</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company uses the Black-Scholes option pricing model to value stock option grants to employees, non-employees, and directors. The fair value of the Company’s common stock is used to determine the fair value of stock options. The Black-Scholes option pricing model requires inputs based on certain subjective assumptions, including (i) the expected stock price volatility, (ii) the expected term of the award, (iii) the risk-free interest rate, and (iv) expected dividends. The historical volatility is calculated based on a period of time commensurate with the expected term assumption. The Company uses the simplified method to calculate the expected term for options granted to employees whereby the expected term equals the arithmetic average of the vesting term and the original contractual term of the options due to its lack of sufficient historical data. The risk-free interest rate is based on U.S. Treasury securities with a maturity date commensurate with the expected term of the associated award. The expected dividend yield is assumed to be zero as the Company has never paid dividends and has no current plans to pay any dividends on its common stock. The Company recognizes forfeitures as they occur.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_898_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zOFXSR7w9Lqc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of the stock options was estimated using the following assumptions:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_zEoCdvFL15U9">Schedule of Fair Value of The Stock Options</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Weighted average fair value at grant date</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20230101__20231231_zAioT8xOFDTb" title="Weighted average fair value at grant date">0.3303</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20220101__20221231_zk6XWyQzZvue" title="Weighted average fair value at grant date"><span style="-sec-ix-hidden: xdx2ixbrl1094">-</span></span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Valuation assumptions:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected life of options (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231_zLynFD7IN4ke" title="Expected life of options (years)">5.00</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_c20220101__20221231_zCxOVJ0nqbYl" title="Expected life of options (years)"><span style="-sec-ix-hidden: xdx2ixbrl1098">-</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected stock volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20231231_z8W8J8tkgNKi" title="Expected stock volatility">213.90</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20221231_zyzEzOZQtiae" title="Expected stock volatility"><span style="-sec-ix-hidden: xdx2ixbrl1102">-</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20231231_z9xm21UW3Fq4" title="Risk-free interest rate">4.42</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20221231_z2hONp60WW7d" title="Risk-free interest rate"><span style="-sec-ix-hidden: xdx2ixbrl1106">-</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20231231_z40Z7AxNjFfb" title="Expected dividend yield">0.00</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220101__20221231_zWDnSBGHGYj" title="Expected dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl1110">-</span></span></td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A9_z7hveFTzT1G1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BRIGHT GREEN CORPORATION</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes to the Consolidated Financial Statements</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the Years Ended December 31, 2023 and 2022</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Expressed in United States Dollars)</span></p> <div style="margin-left: auto; margin-right: auto; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt"> </div></div> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Stock-Based Compensation (continued)</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2023, the Company granted the following stock options:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 20, 2023, the Company granted <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20230920__20230920_zeR6eABpuh4c" title="Stock options, shares">625,000</span> shares of stock options with an exercise price of $<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230920__20230920_zVA5SPVIZio1" title="Stock options exercise price">0.385</span>, which vest in thirty equal monthly installments beginning April 1, 2024, to the Chief Executive Officer of the Company (Note 14); and</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 16, 2023, the Company granted <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20231116__20231116_zg03gyIkmRn7" title="Stock options, shares">1,800,000</span> shares of stock options with an exercise price of $<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20231116__20231116_z31qFGhEBved" title="Stock options exercise price">0.3353</span>, a fair value of $<span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_c20231116__20231116_zefHoHIV5bpl" title="Stock options fair value">0.3303</span>, vesting immediately, and expiring on November 16, 2033, with <span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20231116__20231116_zT2fH3CpYoKl" title="Stock options expiring, shares">600,000</span> each to three Directors of the Company (Notes 11 and 14).</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During year ended December 31, 2022, the Company did <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_do_c20220101__20221231_zmFOYfmjtoxg" title="Stock options shares">no</span>t issue any stock options.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89A_eus-gaap--ShareholdersEquityAndShareBasedPaymentsTextBlock_zdwSLaVfUU2k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes stock option activity for the year ended December 31, 2023:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 8pt; text-indent: 40pt"><span id="xdx_8B4_z4H14THHthfa" style="display: none">Schedule of Summarizes Stock Option Activity</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center">Stock Options Outstanding &amp; Exercisable</td><td style="text-align: center; padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center"> </td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center"> </td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center">Weighted Average</td><td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center">Number of</td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center">Weighted Average</td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center">Remaining Life</td><td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Stock Options</td><td style="text-align: center; padding-bottom: 1.5pt"> </td><td style="text-align: center; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Exercise Price</td><td style="text-align: center; padding-bottom: 1.5pt"> </td><td style="text-align: center; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">(Years)</td><td style="text-align: center; padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance, December 31, 2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20230101__20231231_z7B6kvbqPry2" style="text-align: right" title="Number of shares, outstanding beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1128">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20230101__20231231_zLVQLGAL8Du9" style="text-align: right" title="Weighted average exercise price beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1130">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 40%">Granted</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20231231_zb3fYpoipjcg" style="width: 16%; text-align: right" title="Number of stock options granted">2,425,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230101__20231231_zOvkvrz3VaWf" style="width: 16%; text-align: right" title="Weighted average exercise price granted">0.3353</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20230101__20231231_zIa0Fz3yRTI3" style="text-align: right" title="Number of stock options exercised"><span style="-sec-ix-hidden: xdx2ixbrl1136">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20230101__20231231_zPa4y5GTebP8" style="text-align: right" title="Weighted average exercise price exercised"><span style="-sec-ix-hidden: xdx2ixbrl1138">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c20230101__20231231_zrO5hfAyz3Sl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of stock options expired"><span style="-sec-ix-hidden: xdx2ixbrl1140">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20230101__20231231_zp1jfvMjE1W" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price expired"><span style="-sec-ix-hidden: xdx2ixbrl1142">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance, December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20230101__20231231_z5ScvjP23Azl" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, outstanding ending balance">2,425,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20230101__20231231_z7k9mxlpjnqk" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price ending balance">0.3353</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231_zxUzybqANd2f" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average remaining life (years)">9.90</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A3_zT88osX025m9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 31, 2024, the <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240331__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zEIjYYjo8vZ6" title="Issuance of shares">625,000</span> shares of stock options granted to the Chief Executive Officer of the Company were canceled by mutual agreement between the Company and the Chief Executive Officer (Notes 14 and 16).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Restricted Stock Units</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for the fair value of restricted stock units (“RSUs”) using the closing market price of the Company’s common stock on the date of the grant. Stock-based compensation cost for RSUs is measured at the grant date based on the estimated fair value of the award and is recognized as expense over the requisite service period (generally the vesting period), net of forfeitures.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2023, the Company granted the following RSUs:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 20, 2023, the Company granted <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20230920__20230920_z3RD2i0WjI3j" title="Restricted stock, shares">625,000</span> shares of RSUs, which vest in thirty equal monthly installments beginning April 1, 2024, to the Chief Executive Officer of the Company (Note 14).</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2022, the Company did <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_do_c20220101__20221231_znnZv3bXtJAe" title="Restricted stock, shares">no</span>t issue any RSUs.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 31, 2024, the <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20240331__20240331__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zp0snUCwMIke" title="Restricted stock, shares">625,000</span> shares of RSUs granted to the Chief Executive Officer of the Company were canceled and replaced with <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20240331__20240331__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--MutualAgreementMember_zINqvTWWlj9i" title="Restricted stock, shares">5,500,000</span> RSUs by mutual agreement between the Company and the Chief Executive Officer (Notes 14 and 16).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BRIGHT GREEN CORPORATION</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes to the Consolidated Financial Statements</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the Years Ended December 31, 2023 and 2022</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Expressed in United States Dollars)</span></p> <div style="margin-left: auto; margin-right: auto; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt"> </div></div> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 3050000 2425000 625000 3829218 18833781 594478 <p id="xdx_898_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zOFXSR7w9Lqc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of the stock options was estimated using the following assumptions:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_zEoCdvFL15U9">Schedule of Fair Value of The Stock Options</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Weighted average fair value at grant date</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20230101__20231231_zAioT8xOFDTb" title="Weighted average fair value at grant date">0.3303</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20220101__20221231_zk6XWyQzZvue" title="Weighted average fair value at grant date"><span style="-sec-ix-hidden: xdx2ixbrl1094">-</span></span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Valuation assumptions:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected life of options (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231_zLynFD7IN4ke" title="Expected life of options (years)">5.00</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_c20220101__20221231_zCxOVJ0nqbYl" title="Expected life of options (years)"><span style="-sec-ix-hidden: xdx2ixbrl1098">-</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected stock volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20231231_z8W8J8tkgNKi" title="Expected stock volatility">213.90</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20221231_zyzEzOZQtiae" title="Expected stock volatility"><span style="-sec-ix-hidden: xdx2ixbrl1102">-</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20231231_z9xm21UW3Fq4" title="Risk-free interest rate">4.42</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20221231_z2hONp60WW7d" title="Risk-free interest rate"><span style="-sec-ix-hidden: xdx2ixbrl1106">-</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20231231_z40Z7AxNjFfb" title="Expected dividend yield">0.00</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220101__20221231_zWDnSBGHGYj" title="Expected dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl1110">-</span></span></td><td style="text-align: left"> </td></tr> </table> 0.3303 P5Y 2.1390 0.0442 0.0000 625000 0.385 1800000 0.3353 0.3303 600000 0 <p id="xdx_89A_eus-gaap--ShareholdersEquityAndShareBasedPaymentsTextBlock_zdwSLaVfUU2k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes stock option activity for the year ended December 31, 2023:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 8pt; text-indent: 40pt"><span id="xdx_8B4_z4H14THHthfa" style="display: none">Schedule of Summarizes Stock Option Activity</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center">Stock Options Outstanding &amp; Exercisable</td><td style="text-align: center; padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center"> </td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center"> </td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center">Weighted Average</td><td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center">Number of</td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center">Weighted Average</td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center">Remaining Life</td><td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Stock Options</td><td style="text-align: center; padding-bottom: 1.5pt"> </td><td style="text-align: center; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Exercise Price</td><td style="text-align: center; padding-bottom: 1.5pt"> </td><td style="text-align: center; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">(Years)</td><td style="text-align: center; padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance, December 31, 2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20230101__20231231_z7B6kvbqPry2" style="text-align: right" title="Number of shares, outstanding beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1128">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20230101__20231231_zLVQLGAL8Du9" style="text-align: right" title="Weighted average exercise price beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1130">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 40%">Granted</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20231231_zb3fYpoipjcg" style="width: 16%; text-align: right" title="Number of stock options granted">2,425,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230101__20231231_zOvkvrz3VaWf" style="width: 16%; text-align: right" title="Weighted average exercise price granted">0.3353</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20230101__20231231_zIa0Fz3yRTI3" style="text-align: right" title="Number of stock options exercised"><span style="-sec-ix-hidden: xdx2ixbrl1136">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20230101__20231231_zPa4y5GTebP8" style="text-align: right" title="Weighted average exercise price exercised"><span style="-sec-ix-hidden: xdx2ixbrl1138">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c20230101__20231231_zrO5hfAyz3Sl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of stock options expired"><span style="-sec-ix-hidden: xdx2ixbrl1140">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20230101__20231231_zp1jfvMjE1W" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price expired"><span style="-sec-ix-hidden: xdx2ixbrl1142">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance, December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20230101__20231231_z5ScvjP23Azl" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, outstanding ending balance">2,425,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20230101__20231231_z7k9mxlpjnqk" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price ending balance">0.3353</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231_zxUzybqANd2f" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average remaining life (years)">9.90</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 2425000 0.3353 2425000 0.3353 P9Y10M24D 625000 625000 0 625000 5500000 <p id="xdx_804_eus-gaap--IncomeTaxDisclosureTextBlock_zkszSgyr4BW7" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_825_zwI81akp1jm2">Income Taxes</span></span> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. A full valuation allowance is established against all net deferred tax assets as of December 31, 2023 and 2022, based on estimates of recoverability. While the Company has optimistic plans for its business strategy, it determined that such a valuation allowance was necessary given the current and expected near term losses and the uncertainty with respect to its ability to generate sufficient profits from its business model.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The current and deferred income tax expenses for the year December 31, 2023 and 2022, was $<span id="xdx_908_eus-gaap--IncomeTaxExpenseBenefit_dxL_c20230101__20231231_z7xDAo7JWmX4" title="Current and deferred income tax expenses::XDX::-"><span id="xdx_90B_eus-gaap--IncomeTaxExpenseBenefit_dxL_c20220101__20221231_zGZwqZ2F3O7a" title="Current and deferred income tax expenses::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl1162"><span style="-sec-ix-hidden: xdx2ixbrl1164">nil</span></span></span></span>. The provision for income taxes differs from that computed at combined corporate tax rate of approximately <span id="xdx_908_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_pid_dp_uPure_c20230101__20231231_zOrr3DJ4M4oe" title="Tax rate">25.8</span>% (2022 – <span id="xdx_903_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_pid_dp_uPure_c20220101__20221231_zUlRbo0Ywp5h" title="Tax rate">25.8</span>%) as follows:</span></p> <p id="xdx_89E_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zJyhqQrV23C6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B7_zz8lpdIXdYp" style="display: none">Schedule of Income Tax Provision</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20230101__20231231_z1IfKqywWbSj" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_492_20220101__20221231_zR0nbAZMQH55" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 60%"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--NetIncomeLoss_zVjixg8pSKld" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Loss before income taxes</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(13,127,648</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(27,662,077</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The (benefit) provision for income taxes for 2023 and 2022 consists of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40A_eus-gaap--CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB_zoxAj7P6DBZh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Current:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--CurrentFederalTaxExpenseBenefit_i01_maCITEBzz1e_zEJClpEPDUcl" style="vertical-align: bottom; background-color: White"> <td>Federal</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1178">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1179">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_i01_maCITEBzz1e_zUqfGZuS38F9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">State</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1181">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1182">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--CurrentIncomeTaxExpenseBenefit_i01T_mtCITEBzz1e_maITEBzG4H_z8lPAy0Z6TV4" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total current (benefit) provision</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1184">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1185">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB_zUx3PeKeWl17" style="vertical-align: bottom; background-color: White"> <td>Deferred:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_i01_maDITEBzmoD_maDITEBzRXu_zZu7w8002Dcl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Federal</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">(2,520,309</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">(5,727,839</td><td style="width: 1%; text-align: left">)</td></tr> <tr id="xdx_404_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_i01_maDITEBzmoD_maDITEBzRXu_zS6oOkIISrP5" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">State</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(576,071</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,309,220</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40E_eus-gaap--DeferredIncomeTaxExpenseBenefit_i01T_maITEBzG4H_mtDITEBzRXu_zJxSp0E46fH6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total current (benefit) provision</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,096,380</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7,037,059</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_402_ecustom--ValuationAllowancesOfIncomeTaxExpenseBenefit_i01N_di_msITEBzG4H_z0xaiG9251Ab" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Valuation allowance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,096,380</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,037,059</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzG4H_zpiMvYe2Twgk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total (benefit) expense</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1202">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1203">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A3_zMf2Xgf1ibVa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89B_ecustom--ScheduleOfFederalAndStateTaxEffectsOfTemporaryDifferenceAndCarryforwardsTableTextBlock_z05iE8bXmmze" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The federal and state tax effects of the temporary differences and carry forwards that give rise to deferred tax assets consists of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BE_zondO0ivgfLg" style="display: none">Schedule of Federal and State Tax Effects of Temporary Differences and Carryforwards</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20231231_zTIl5mIa1Ndg" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_490_20221231_zJ0OpeI8IA83" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_405_eus-gaap--DeferredTaxAssetsOther_iI_maDTAGzqzZ_zm4lab9nS3Ph" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Other</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">1,401,963</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">728,201</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGzqzZ_zPmpikojWYwi" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Net operating loss carry over</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,716,764</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,294,146</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGzqzZ_z10xS6XxMBl8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Total deferred tax assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11,118,727</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,022,347</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_znpBDFHNq6U4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: valuation allowance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(11,118,727</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(8,022,347</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsNet_iTI_zGnYlwZoaz61" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Deferred tax assets, net of valuation allowance</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1219">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1220">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A6_zLwTHK2hKjR3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BRIGHT GREEN CORPORATION</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes to the Consolidated Financial Statements</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the Years Ended December 31, 2023 and 2022</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Expressed in United States Dollars)</span></p> <div style="margin-left: auto; margin-right: auto; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt"> </div></div> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Income Taxes (continued)</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2023 and 2022, the Company decided that a valuation allowance relating to the above deferred tax assets of the Company was necessary, largely based on the negative evidence represented by losses incurred and a determination that it is not more likely than not to realize these assets, such that, a corresponding valuation allowance, for each respective period, was recorded to offset deferred tax assets. Management has based its assessment on the Company’s lack of profitable operating history. As of December 31, 2023 and 2022, the Company has approximately $<span id="xdx_90E_eus-gaap--OperatingLossCarryforwards_iI_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zuufQHQ9Dzob" title="Operating loss carryforwards">37,661,876</span> and $<span id="xdx_90D_eus-gaap--OperatingLossCarryforwards_iI_c20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zQ2C5I4nlfa5" title="Operating loss carryforwards">28,577,832</span> respectively, of Federal net of operating losses available to reduce taxable income of future years. The federal loss carryforward expires indefinitely. The benefit from the non-capital loss carry-forward balance has not been recorded in the consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is subject to U.S. federal jurisdiction and the state of New Mexico income taxes. Management has not filed federal or state income tax returns due to incurring cumulative losses. Therefore, the Company’s actual tax position may differ from their book position. In the event that the Company is assessed interest or penalties at some point in the future, it will be classified in the consolidated financial statements as tax expense.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 0.258 0.258 <p id="xdx_89E_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zJyhqQrV23C6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B7_zz8lpdIXdYp" style="display: none">Schedule of Income Tax Provision</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20230101__20231231_z1IfKqywWbSj" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_492_20220101__20221231_zR0nbAZMQH55" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 60%"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--NetIncomeLoss_zVjixg8pSKld" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Loss before income taxes</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(13,127,648</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(27,662,077</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The (benefit) provision for income taxes for 2023 and 2022 consists of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40A_eus-gaap--CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB_zoxAj7P6DBZh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Current:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--CurrentFederalTaxExpenseBenefit_i01_maCITEBzz1e_zEJClpEPDUcl" style="vertical-align: bottom; background-color: White"> <td>Federal</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1178">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1179">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_i01_maCITEBzz1e_zUqfGZuS38F9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">State</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1181">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1182">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--CurrentIncomeTaxExpenseBenefit_i01T_mtCITEBzz1e_maITEBzG4H_z8lPAy0Z6TV4" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total current (benefit) provision</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1184">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1185">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB_zUx3PeKeWl17" style="vertical-align: bottom; background-color: White"> <td>Deferred:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_i01_maDITEBzmoD_maDITEBzRXu_zZu7w8002Dcl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Federal</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">(2,520,309</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">(5,727,839</td><td style="width: 1%; text-align: left">)</td></tr> <tr id="xdx_404_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_i01_maDITEBzmoD_maDITEBzRXu_zS6oOkIISrP5" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">State</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(576,071</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,309,220</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40E_eus-gaap--DeferredIncomeTaxExpenseBenefit_i01T_maITEBzG4H_mtDITEBzRXu_zJxSp0E46fH6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total current (benefit) provision</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,096,380</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7,037,059</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_402_ecustom--ValuationAllowancesOfIncomeTaxExpenseBenefit_i01N_di_msITEBzG4H_z0xaiG9251Ab" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Valuation allowance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,096,380</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,037,059</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzG4H_zpiMvYe2Twgk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total (benefit) expense</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1202">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1203">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> -13127648 -27662077 -2520309 -5727839 -576071 -1309220 -3096380 -7037059 -3096380 -7037059 <p id="xdx_89B_ecustom--ScheduleOfFederalAndStateTaxEffectsOfTemporaryDifferenceAndCarryforwardsTableTextBlock_z05iE8bXmmze" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The federal and state tax effects of the temporary differences and carry forwards that give rise to deferred tax assets consists of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BE_zondO0ivgfLg" style="display: none">Schedule of Federal and State Tax Effects of Temporary Differences and Carryforwards</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20231231_zTIl5mIa1Ndg" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_490_20221231_zJ0OpeI8IA83" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_405_eus-gaap--DeferredTaxAssetsOther_iI_maDTAGzqzZ_zm4lab9nS3Ph" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Other</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">1,401,963</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">728,201</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGzqzZ_zPmpikojWYwi" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Net operating loss carry over</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,716,764</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,294,146</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGzqzZ_z10xS6XxMBl8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Total deferred tax assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11,118,727</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,022,347</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_znpBDFHNq6U4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: valuation allowance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(11,118,727</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(8,022,347</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsNet_iTI_zGnYlwZoaz61" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Deferred tax assets, net of valuation allowance</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1219">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1220">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 1401963 728201 9716764 7294146 11118727 8022347 11118727 8022347 37661876 28577832 <p id="xdx_80B_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zPhZjn3V3zNk" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_82C_zFydGwIbfubd">Related Party Transactions</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other than the transactions disclosed elsewhere in the consolidated financial statements, the following are the other significant related party transactions and balances:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Included in common stock issued for services during the year ended December 31, 2023, were <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--FormerExecutiveChairmanMember_z5aVIVavD6D6" title="Issuance of shares">3,500,000</span> shares of common stock issued to the former Executive Chairman of the Company (Note 11).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Included in common stock issued for services during the year ended December 31, 2023, were <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_z2hmcGBvMVh9" title="Issuance of shares">500,000</span> shares of common stock issued to the former Chief Executive Officer of the Company (Note 11).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Included in common stock issued for services during the year ended December 31, 2023, were <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_z6KKfy3UGB5e" title="Issuance of shares">500,000</span> shares of common stock issued to the Chief Financial Officer of the Company (Note 11).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Included in stock options issued for services during the year ended December 31, 2023, were <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20230101__20231231__srt--TitleOfIndividualAxis__custom--ThreeDirectorsMember_zaAW5yz9wIvh" title="Issuance of service shares">1,800,000</span> shares of stock options issued to three Directors of the Company (Notes 11 and 12).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Included in stock-based awards granted during the year ended December 31, 2023, were <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zXPcY38azvKd" title="Issuance of shares">625,000</span> shares of stock options and <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20231231__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zt0p3zQyBDje" title="Issuance of shares">625,000</span> shares of RSUs issued to the Chief Executive Officer of the Company. On March 31, 2024, both the <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240331__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zpVLaGVvyGuh" title="Issuance of shares">625,000</span> shares of stock options and <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20240331__20240331__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zJMorcl7tVz6" title="Restricted stock, shares">625,000</span> shares of RSUs were canceled by mutual agreement between the Company and the Chief Executive Officer (Notes 12 and 16).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BRIGHT GREEN CORPORATION</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes to the Consolidated Financial Statements</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the Years Ended December 31, 2023 and 2022</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Expressed in United States Dollars)</span></p> <div style="margin-left: auto; margin-right: auto; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt"> </div></div> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Related Party Transactions (continued)</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At December 31, 2023 and 2022, $<span id="xdx_90B_eus-gaap--OtherLiabilities_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ExecutiveChairmanMember__us-gaap--BalanceSheetLocationAxis__us-gaap--AccruedLiabilitiesMember_z47YgOQ3MR2j" title="Due from officers or stockholders">400,000</span> and $<span id="xdx_90C_eus-gaap--OtherLiabilities_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ExecutiveChairmanMember__us-gaap--BalanceSheetLocationAxis__us-gaap--AccruedLiabilitiesMember_z45hD1zPSJIi" title="Due from officers or stockholders">400,000</span>, respectively, was due to the Company’s former interim Chief Executive Officer, who is also the Company’s former Executive Chairman. The amounts, which includes $<span id="xdx_904_eus-gaap--AccruedBonusesCurrentAndNoncurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ExecutiveChairmanMember__us-gaap--BalanceSheetLocationAxis__us-gaap--AccruedLiabilitiesMember_z2WHMV4NJAfg" title="Accrued bonus">200,000</span> and $<span id="xdx_90D_eus-gaap--AccruedBonusesCurrentAndNoncurrent_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ExecutiveChairmanMember__us-gaap--BalanceSheetLocationAxis__us-gaap--AccruedLiabilitiesMember_zxzQrPKZThl7" title="Accrued bonus">300,000</span>, respectively, in accrued bonus, is included in accrued liabilities in the consolidated balance sheet. On February 15, 2024, the Company issued <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20240215__20240215__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--FormerInterimChiefExecutiveOfficerMember_z4JJlMGogTgc" title="Common stock issued for service, shares">2,420,000</span> shares of common stock as a final settlement for the unpaid remuneration and bonus compensation (Notes 11 and 16).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At December 31, 2023 and 2022, $<span id="xdx_90E_eus-gaap--OtherLiabilities_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FormerChiefExecutiveOfficerMember__us-gaap--BalanceSheetLocationAxis__us-gaap--AccountsPayableMember_zwYJPYVX3W68" title="Accounts payable">23,460</span> and $<span id="xdx_90B_eus-gaap--OtherLiabilities_iI_d0_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FormerChiefExecutiveOfficerMember__us-gaap--BalanceSheetLocationAxis__us-gaap--AccountsPayableMember_z2jmc8i4ggE6" title="Accounts payable">nil</span>, respectively, was due to a company majority owned by the Company’s former Chief Executive Officer. The amount is included in accounts payable in the consolidated balance sheets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At December 31, 2023 and 2022, $<span id="xdx_900_eus-gaap--OtherLiabilities_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--ChiefFinancialOfficerMember__us-gaap--BalanceSheetLocationAxis__us-gaap--AccountsPayableMember_zj3qccOx1Vue">68,037 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and <span style="background-color: white">$<span id="xdx_90D_eus-gaap--OtherLiabilities_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--ChiefFinancialOfficerMember__us-gaap--BalanceSheetLocationAxis__us-gaap--AccountsPayableMember_zduYsvpKbru6">65,856</span>, respectively, </span>was due to a company wholly owned by the Company’s Chief Financial Officer, who also is a shareholder. The amount is included in accounts payable in the consolidated balance sheets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At December 31, 2023 and 2022, $<span id="xdx_902_eus-gaap--OtherLiabilities_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--ChiefExecutiveOfficerMember__us-gaap--BalanceSheetLocationAxis__us-gaap--AccountsPayableMember_zn8v2pBB5Zf4" title="Due to related party"><span id="xdx_903_eus-gaap--OtherLiabilities_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--ChiefExecutiveOfficerMember__us-gaap--BalanceSheetLocationAxis__us-gaap--AccountsPayableMember_zVRE6ulluCe5" title="Due to related party">66,667</span></span> and $nil, respectively, was due to a company wholly owned by the Company’s Chief Executive Officer. The amount is included in accounts payable in the consolidated balance sheets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At December 31, 2023 and 2022, $<span id="xdx_901_eus-gaap--OtherLiabilities_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BoardOfDirectorsMember__us-gaap--BalanceSheetLocationAxis__us-gaap--AccountsPayableMember_zDCWo6dEBMkj" title="Due to related party">400,000</span> and $<span id="xdx_90E_eus-gaap--OtherLiabilities_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BoardOfDirectorsMember__us-gaap--BalanceSheetLocationAxis__us-gaap--AccountsPayableMember_zCMAgTvu9e2j" title="Due to related party">143,900</span>, respectively, was due to a firm that has one of its partners serving on the Company’s Board of Directors. The amount is included in accounts payable in the consolidated balance sheets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At December 31, 2023 and 2022, the outstanding balance on the line of credit of $<span id="xdx_90E_eus-gaap--LongTermLineOfCredit_iI_c20231231_z5pPY3vP0T6e" title="Long-term line of credit">201,783</span> and <span style="background-color: white">$<span id="xdx_901_eus-gaap--LongTermLineOfCredit_iI_c20221231_zCRgPvt3S7b7" title="Long-term line of credit">3,686,107</span>, respectively, </span> was due to a Lender, who is the Company’s Chairwoman and majority shareholder (Note 10).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 3500000 500000 500000 1800000 625000 625000 625000 625000 400000 400000 200000 300000 2420000 23460 68037 65856 66667 66667 400000 143900 201783 3686107 <p id="xdx_804_eus-gaap--LossContingencyDisclosures_zKb0iAEDdHjl" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_821_zSy4PmN6JTwk">Contingencies</span> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the ordinary course of business, the Company is routinely defendants in, or parties to a number of pending and threatened legal actions including actions brought on behalf of various classes of claimants. In view of the inherent difficulty of predicting the outcome of such matters, the Company cannot state what the eventual outcome of such matters will be. Legal provisions are established when it becomes probable that the Company will incur an expense related to a legal action and the amount can be reliably estimated. Such provisions are recorded at the best estimate of the amount required to settle any obligation related to these legal actions as at the consolidated balance sheet date, taking into account the risks and uncertainties surrounding the obligation. Management and internal and external experts are involved in estimating any amounts that may be required. The actual costs of resolving these claims may vary significantly from the amount of the legal provisions. The Company’s estimate involves significant judgement, given the varying stages of the proceedings, the fact that the Company’s liability, if any, has yet to be determined and the fact that the underlying matters will change from time to time. Other than as set forth below, the Company is not presently a party to any <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">litigation. The Company is not able to make a reliable assessment of the potential losses as these matters are at an early stage, accordingly, no amounts have been accrued in the consolidated financial statements.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BRIGHT GREEN CORPORATION</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes to the Consolidated Financial Statements</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the Years Ended December 31, 2023 and 2022</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Expressed in United States Dollars)</span></p> <div style="margin-left: auto; margin-right: auto; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt"> </div></div> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Contingencies (continued)</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Bright Green Corporation v. John Fikany, State of New Mexico, County of Cibola, Thirteenth Judicial District</i>. In this matter, the Company filed a complaint for declaratory judgment against a consultant of the <span id="xdx_900_eus-gaap--LossContingencyActionsTakenByDefendant_c20230101__20231231__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zL8tvlOr0Wph" title="Contingency, taken by defendant description">Bright Green Group of Companies, an entity unrelated to the Company, to determine if defendant is entitled to 5,000,000 shares of the Company’s common stock, based on a failure to fulfill agreed upon conditions precedent to earning such shares from the Company.</span> Defendant counterclaimed and filed a third-party claim against a director of the Company, and her spouse, for claims including wrongful termination and breach of contract. The Company denies defendants allegations and have set forth arguments refuting defendant’s counterclaims and third-party claims. The trial date for the case has been scheduled for April 22, 2024.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Bright Green Corporation v. Jerry Capussi, State of New Mexico, County of Cibola, Thirteenth Judicial District</i>. In this matter, the Company and defendant, a former consultant of Sunnyland Farms Inc., an entity unrelated to the Company, have each filed claims for declaratory judgment seeking to determine by court order whether defendant is entitled to <span id="xdx_90F_eus-gaap--LossContingencyActionsTakenByDefendant_c20230101__20231231_zrKNWwmYc6Cd" title="Contingency, taken by defendant description">(i) shares of common stock in the Company (amounting to no more than 108,000 shares) or (ii) fair market value of defendant’s equity ownership of BGGI.</span> The lawsuit is in early discovery stages, and the Company is preparing arguments for a summary judgment motion. There are no claims for specific monetary liability against either party.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> Bright Green Group of Companies, an entity unrelated to the Company, to determine if defendant is entitled to 5,000,000 shares of the Company’s common stock, based on a failure to fulfill agreed upon conditions precedent to earning such shares from the Company. (i) shares of common stock in the Company (amounting to no more than 108,000 shares) or (ii) fair market value of defendant’s equity ownership of BGGI. <p id="xdx_804_eus-gaap--SubsequentEventsTextBlock_zeb1IGOy4UR6" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_827_z8msiwKOT9yk">Subsequent Events</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s management has evaluated the subsequent events up to April 16, 2024. The date the consolidated financial statements were issued, pursuant to the requirements of ASC 855, and has determined the following constitute material subsequent events:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 19, 2024, the Company reached an agreement with a vendor to cancel approximately $<span id="xdx_901_eus-gaap--ConstructionInProgressExpendituresIncurredButNotYetPaid_c20240119__20240119__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zAonzRnFnxWj" title="Agreement with vendor to cancel">2,650,000</span> of construction in progress. As part of the agreement, the vendor also agreed to cancel the related accounts payable and completion of the project (Note 7).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 30, 2024, the Company issued <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20240130__20240130__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--FourConsultantsMember_zznQXvNXWhG5" title="Shares of common stock for services">450,000</span> shares of common stock for services rendered, at a fair value of $<span id="xdx_901_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20240130__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--FourConsultantsMember_zjNtCAvwm7Z9" title="Shares issued price per share">0.2116</span> per share, to four consultants of the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">On February 7, 2024, the Company entered into a short-term note with 1401330 Ontario Ltd. (the “Bridge Lender”), a Company owned and controlled by a member of the Board of Directors, for $<span id="xdx_900_eus-gaap--InterestAndDebtExpense_c20240207__20240207__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__dei--LegalEntityAxis__custom--OntarioLtdMember_zOONdq9rZxtc" title="Owned interest expenses">150,000</span>. Additionally, the Company agreed to pay the Bridge Lender $<span id="xdx_907_eus-gaap--InterestExpenseShortTermBorrowings_c20240207__20240207__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__dei--LegalEntityAxis__custom--OntarioLtdMember_z9xToNKNwN5a" title="Interest expense short term borrowings">15,000</span> as interest. The note is personally guaranteed by the Company’s Chairwoman.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 8, 2024, the Company drew an additional $<span id="xdx_90F_eus-gaap--ProceedsFromRelatedPartyDebt_c20240208__20240208__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zjJHx0LXLrxf" title="Proceeds from related party debt">100,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">on the related party line of credit note.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BRIGHT GREEN CORPORATION</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes to the Consolidated Financial Statements</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the Years Ended December 31, 2023 and 2022</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Expressed in United States Dollars)</span></p> <div style="margin-left: auto; margin-right: auto; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt"> </div></div> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Subsequent Events (continued)</span></span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 15, 2024, Mr. Terry Rafih, the former Executive Chairman, resigned. Mr. Rafih and the Company entered into a Memorandum of Understanding (the “Separation Agreement”). The Separation Agreement provided that the Company (i) issue to Mr. Rafih <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240215__20240215__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SeparationAgreementMember__srt--TitleOfIndividualAxis__custom--Mr.TerryRafihMember_zU5bs1FYq3H1" title="Number of shares issued">2,537,500</span> shares of the Company’s common stock, representing the acceleration of the vesting of the balance of shares of common stock issuable pursuant to a one-time award of <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pn6n6_c20240215__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SeparationAgreementMember__srt--TitleOfIndividualAxis__custom--Mr.TerryRafihMember_zvzjSnYC78xa" title="Number of shares authorized">10</span> million shares of common stock approved by the stockholders of the Company at the 2022 Special Meeting of Stockholders, and (ii) further issue to Mr. Rafih <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20240215__20240215__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SeparationAgreementMember__srt--TitleOfIndividualAxis__custom--Mr.TerryRafihMember_zepvt4M0pU22" title="Number of shares issued for services">2,420,000</span> shares of common stock, in lieu of an aggregate of $<span id="xdx_90B_eus-gaap--CompensationExpenseExcludingCostOfGoodAndServiceSold_pid_c20240215__20240215__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SeparationAgreementMember__srt--TitleOfIndividualAxis__custom--Mr.TerryRafihMember_zpQbE4rYj3D3" title="Unpaid cash renumeration and bonus compensation">450,000</span> of unpaid cash renumeration and bonus compensation during his tenure with the Company. The <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240215__20240215__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SeparationAgreementMember_zutwvF8ToJ95" title="Number of shares issued">4,957,000</span> shares of common stock were issued on February 15, 2024.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 7, 2024, the Company entered into a scope of work agreement with Titan Advisory Services, LLC, a limited liability company controlled by Saleem Elmasri, Chief Financial Officer of the Company, through which Mr. Elmasri provides services to the Company (the “CFO Agreement”). The CFO Agreement is effective as of March 1, 2024. Pursuant to the CFO Agreement, Mr. Elmasri shall continue to act as Chief Financial Officer of the Company through February 28, 2025, and provides Mr. Elmasri with a $<span id="xdx_909_eus-gaap--OfficersCompensation_c20240307__20240307__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--CFOAgreementMember__srt--TitleOfIndividualAxis__custom--Mr.ElmasriMember__dei--LegalEntityAxis__custom--TitanAdvisoryServicesLLCMember_zXYC1cPRDD3h" title="Monthly cash fee">25,000</span> monthly cash fee, and <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20240307__20240307__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--CFOAgreementMember__srt--TitleOfIndividualAxis__custom--Mr.ElmasriMember__dei--LegalEntityAxis__custom--TitanAdvisoryServicesLLCMember_zJGzVzl230Ch" title="Number of restricted stock units issued">600,000</span> restricted stock units, which were issued on March 7, 2024 and vest in equal monthly installments over a period of one year beginning one month from the date of grant.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-size: 10pt">On March 13, 2024, the Company entered into and signed a Settlement and Release Agreement</span><span style="font-size: 8pt"> </span> <span style="font-size: 10pt">with United Science, LLC (“United”) and Alterola, in which a deposit made to United was forfeited, leased equipment was returned to United, <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_c20240313__20240313__us-gaap--TypeOfArrangementAxis__custom--SettlementAndReleaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_znvFBLD6iOai" title="Number of shares forfeited">118,535,168</span> shares of common stock of Alterola was transferred to United in lieu of payment of outstanding invoices, and <span id="xdx_90B_ecustom--PaymentOfLieuOutstandingSharesOfCommonStock_c20240313__20240313__us-gaap--TypeOfArrangementAxis__custom--SettlementAndReleaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zbIbU2HyRsQi" title="Payment of lieu Outstanding shares of common stock">83,226,820</span> shares of common stock of Alterola was returned to the three shareholders (Equipped4 Holdings Limited (“Equipped”), Phytotherapeutix Holdings Ltd. (“Phyto”), and TPR Global Limited (“TPR”)) who initially sold the shares to the Company for settlement of the $<span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValuePurchaseOfAssets_c20240313__20240313__us-gaap--TypeOfArrangementAxis__custom--SettlementAndReleaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zQU2qNUzd3F1" title="Number of shares purchase assets">1,650,000</span> outstanding balance on the share purchase. Equipped, Phyto, and TPR each received <span id="xdx_90B_ecustom--EquippedPurchaseSharesOfCommonStock_c20240313__20240313__us-gaap--TypeOfArrangementAxis__custom--SettlementAndReleaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zmWCcCnGGP64" title="Equipped purchase shares of common stock">27,742,273</span> shares of common stock of Alterola</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">On March 14, 2024, the Company entered into a credit agreement with JVR Holdings, pursuant to which JVR Holdings agreed to provide the Company with a line of credit facility up to a maximum amount of $<span id="xdx_904_eus-gaap--LineOfCredit_iI_pn6n6_c20240314__us-gaap--TypeOfArrangementAxis__custom--CreditAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z8I2I1Bsfjeh" title="Line of credit">60</span> million, to be drawn in tranches. The line of credit is contingent on the Company formalizing a JVR Holdings approved plan for a construction project to expand the Company’s current research, production and extraction processing facility Grants, New Mexico.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">On March 25, 2024, the Company drew an additional $<span id="xdx_90C_eus-gaap--ProceedsFromRelatedPartyDebt_c20240325__20240325__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z6R4X7HXRVE3" title="Proceeds from related party debt">10,000</span> on the related party line of credit note.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 31, 2024, the Company entered into an Amended Executive Employment Agreement with the Company’s Chief Executive Officer (the “CEO”), which replaced in its entirety the executive employment agreement entered into between the Company and the CEO on October 2, 2023. The Agreement provides the CEO a monthly base salary of $<span id="xdx_903_eus-gaap--SalariesAndWages_pp2d_c20241002__20241002__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--ExecutiveEmploymentAgreementMember_zp8DcopllKH" title="Salaries and wages">35,833.33</span> through October 2, 2024, a monthly base salary of $<span id="xdx_90E_eus-gaap--SalariesAndWages_pp2d_c20241003__20251002__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--ExecutiveEmploymentAgreementMember_zHzEuN0BmCfj" title="Salaries and wages">38,333.00</span> from October 2, 2024 to October 2, 2025, and a monthly base salary of $<span id="xdx_900_eus-gaap--SalariesAndWages_pp2d_c20251003__20261002__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--ExecutiveEmploymentAgreementMember_z4vHThhWsvEb" title="Salaries and wages">41,667.00</span> from October 2, 2025 to October 2, 2026. The agreement provides for customary reimbursement for certain expenses, and eligibility to participate in the Company’s benefit plans and executive compensation programs generally. Additionally, the <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20240331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zDgHgBmNalAe" title="Restricted shares unit">625,000</span> shares of stock options and <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--PlanNameAxis__custom--EquityCompensationPlanMember_zN67rCCBMcc" title="Restricted shares unit">625,000</span> shares of RSUs that were issued in September 2023, under the original Executive Employment Agreement, were canceled and replaced with <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20240331__20240331__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--MutualAgreementMember_zG50elNK4CK2" title="Restricted stock, shares">5,500,000</span> RSUs. The Agreement provides for the award of up to an aggregate of <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c20240331__20240331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--ExecutiveEmploymentAgreementMember_zMC68iC2kBn3" title="Restricted stock vest, shares">5,500,000</span> restricted stock units, which vest in accordance with the terms provided in the Agreement, with <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c20240331__20240331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--ExecutiveEmploymentAgreementMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zHxDZwdM0Ijh" title="Restricted stock vest, shares">500,000</span> RSUs vested on March 31, 2024, <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c20240402__20240402__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--ExecutiveEmploymentAgreementAgreementMember_z1n8zbpSwP0c" title="Restricted stock vest, shares">3,000,000</span> RSUs vesting ratably over a period of twenty-four 24 months beginning April 2, 2024, and the remaining <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c20240331__20240331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--ExecutiveEmploymentAgreementAgreementMember_z7OMOjFPIc81" title="Restricted stock vest, shares">2,000,000</span> RSUs, along with cash bonuses, vesting upon the achievement of certain milestones as outlined in the Amended Executive Employment Agreement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">On April 5, 2024, the Company drew an additional $<span id="xdx_90D_eus-gaap--ProceedsFromRelatedPartyDebt_c20240405__20240405__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zLOVlFLgGmDc" title="Proceeds from related party debt">20,000</span> on the related party line of credit note.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">On April 9, 2024, the Company drew an additional $<span id="xdx_905_eus-gaap--ProceedsFromRelatedPartyDebt_c20240409__20240409__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zIVgwJJ07Lwf" title="Proceeds from related party debt">40,000</span> on the related party line of credit note, leaving available $<span id="xdx_900_eus-gaap--LineOfCreditFacilityRemainingBorrowingCapacity_iI_pn5n6_c20240409__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z4vMqEBh87p9" title="Credit facility">14.6</span> million to draw from that credit facility.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p> 2650000 450000 0.2116 150000 15000 100000 2537500 10000000 2420000 450000 4957000 25000 600000 118535168 83226820 1650000 27742273 60000000 10000 35833.33 38333.00 41667.00 625000 625000 5500000 5500000 500000 3000000 2000000 20000 40000 14600000